Pathophysiological effects of fatty acids by Gibbons, Janay
 
   
 
ANGLIA RUSKIN UNIVERSITY 
 
FACULTY OF SCIENCE AND TECHNOLOGY 
 
PATHOPHYSIOLOGICAL EFFECTS OF FATTY 
ACIDS 
 
JANAY GIBBONS 
 
A thesis in partial fulfilment of the requirements of 
Anglia Ruskin University for the degree of 
DOCTOR OF PHILOSOPHY 
 
 
 
 
Submitted: April 2018 
 
i 
 
Acknowledgements 
 
I would like to thank my supervisors, Dr. Linda King, Dr. Nick Pugh and Dr. Havovi Chichger 
for their support and wisdom. Furthermore, I would like to thank my family for believing in 
me and pushing me to achieve my best. A massive thanks also goes out to Cambridge 
University Officers’ Training Corps, who have kept me sane over the past few years, and I 
don’t know where I’d be without them (definitely having less fun). And finally, thank you to 
Mimi, Bridget, Nadya, Lucy and the Hashemite Kingdom of Jordan for a memorable week 
before submission (promises are promises). 
 
ii 
 
ANGLIA RUSKIN UNIVERSITY 
 
ABSTRACT 
 
FACULTY OF SCIENCE AND TECHNOLOGY 
 
DOCTOR OF PHILOSOPHY 
 
PATHOPHYSIOLOGICAL EFFECTS OF FATTY 
ACIDS 
 
JANAY GIBBONS 
April 2018 
 
Elevated plasma free fatty acid levels have been associated with the development of type II 
diabetes and cardiovascular diseases, and are thought to be present in the obese state. 
Studies suggest that cellular exposure to free fatty acids can result in intracellular lipid 
accumulation and lipotoxicity, leading to cellular dysfunction and cell death. In turn, this can 
promote a range of systemic consequences. 
 
This project employed a multifactorial approach to better understand the pathophysiological 
effects of fatty acids. The effects of the two most common circulating fatty acids, palmitic 
acid and oleic acid, were investigated on hepatocyte, skeletal myocyte and washed platelet 
models in vitro. In addition, a systematic review and meta-analysis was conducted to 
calculate average circulating concentrations of plasma lipid species. This was to determine 
whether plasma free fatty acids and other lipid species are in fact elevated in obesity.  
In vitro studies determined that palmitic acid induced cell death in both the hepatocyte and 
skeletal myocyte models, whilst oleic acid caused intracellular lipid accumulation. However, 
there was no correlation between lipid accumulation and cell death. In platelets, palmitic 
acid had no effect. In contrast, oleic acid evoked platelet aggregation that was not 
characteristic of platelet activation. The meta-analysis determined that circulating plasma 
free fatty acids are higher in obese subjects than in non-obese subjects and higher yet in 
type II diabetics. 
 
In conclusion, fatty acids exert deleterious effects on a range of cells in vitro, and are raised 
in the obese state. This lends weight to the proposed association between elevated plasma 
free fatty acids and comorbidities of obesity, further highlighting the importance of future 
work to understand the mechanisms responsible. 
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1 Introduction 
The purpose of this project was to investigate the pathophysiological effects of fatty acids 
as elevated plasma free fatty acid levels, which have been reported in the obese state, 
have been associated with the development of type II diabetes and cardiovascular 
diseases. In vitro studies were designed to establish the effects of palmitic acid and oleic 
acid in cell death and lipid accumulation in two cell models: hepatocytes and skeletal 
myocytes, and activation and aggregation in washed human platelets. A meta-analysis was 
planned to calculate normal levels of different circulating plasma lipids in the general 
population and subpopulations for the creation of normal reference ranges. The final 
analysis aimed to identify associations between plasma lipid species and different 
subpopulations, especially diseased states and obesity. 
Research in this area is vital as obesity is a growing epidemic associated with a plethora of 
co-morbidities. Currently more than one billion people worldwide are overweight or obese 
(Aguilera, et al., 2013) with obesity worldwide tripling within the last 30 years. As of 2016, 
39% of the world’s adults were overweight and 13% were obese (World Health 
Organization, 2018). This is putting strain on healthcare services across the globe, but 
especially on state run services such as the NHS.  
 
1.1 The pathology of obesity 
Obesity is the accumulation of excess body fat, which may impact health negatively. 
Obesity is characterised by increased visceral and subcutaneous adiposity, and 
accumulation of lipids in non-adipose tissue, in a phenomenon called ectopic lipid 
accumulation (van Herpen & Schrauwen-Hinderling, 2008).  
The universally accepted measurement of adiposity is body mass index (BMI), assessing 
weight relative to height regardless of age or sex. BMI is divided into categories (Table 1.1). 
As BMI increases above 25 kg/m2 , the associated health risks increase exponentially, with 
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risk of developing type II diabetes increasing over 40-fold with a BMI of >35 kg/m2 (Day & 
Bailey, 2011). 
𝐵𝑀𝐼 =
𝑊𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔)
𝐻𝑒𝑖𝑔ℎ𝑡2 (𝑚)
 
 
Studies on the comorbidities of obesity indicate that abdominal adiposity is a greater risk 
factor than the overall extent of obesity, due to increased visceral fat (Chang, et al., 2012; 
Day, et al., 2011; Faria, et al., 2015). Visceral fat stored in the abdominal cavity, is more 
harmful than subcutaneous fat, stored beneath the skin, in the development of 
comorbidities of obesity including hypertension, atherosclerosis, hyperlipidaemia and type II 
diabetes mellitus (Farb & Gokce, 2015). Furthermore, obesity affects not only physical but 
also psychological wellbeing (Table 1.2) (Ogunbode, et al., 2009), and as such access to 
clinical psychologists for people struggling with obesity is a fundamental part of Tier 3 
weight management services, recommended by NICE and the British Psychological 
Society. However, this service is tremendously limited within the current NHS provisions 
(Atter, et al., 2011; NICE, 2014) 
Table 1.1 Clinically accepted categories of BMI 
 BMI (kg/m2) 
Underweight <18.5 
Healthy 18.5 – 24.9 
Overweight 25.0 – 29.9 
Obese 30.0 – 39.9 
Morbidly obese ≥40 
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Table 1.2 Risks associated with obesity 
Categories of problems Health risks of obesity 
Medical ● Hypertension (Landsberg, et al., 2013) 
● Cerebrovascular accident, otherwise known as stroke 
(Kwon, et al., 2016) 
● Hypertriglyceridaemia and hyperlipidaemia (Taskinen, et 
al., 2011) 
● Coronary heart disease (Logue, et al., 2011) 
● Non-alcoholic fatty liver disease (NAFLD) (Chang, et al., 
2016) 
● Obesity hypoventilation syndrome (Piper & Grunstein, 
2011) 
● Gastro-oesophageal reflux disease (Friedenberg, et al., 
2008) 
● Type II diabetes mellitus (Eckel, et al., 2011; Sharma & 
Lau, 2013)  
● Osteoarthritis (Thijssen, et al., 2015) 
● Gout (Juraschek, et al., 2013) 
● Cholethiasis, otherwise known as gall stones (Erlinger, 
2000) 
● Obstructive sleep apnoea (Romero-Corral, et al., 2010) 
● Cancer (De Pergola & Silvestris, 2013) 
● Cutaneous infections including: cellulitis, folliculitis, 
candidiasis, impertigo, furunculosis, erythrasma and tinea 
cruris (Scheinfeld, 2004) 
● Dermatological issues including, eczema, psoriasis, 
dermatitis, skin ulcers, acanthosis nigricans, 
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hyperandrogenism and hirsutism (Silverberg & Simpson, 
2014; Yosipovitch, et al., 2007) 
● Fluid retention (Sartorio, et al., 2005) 
● Stretch marks (Cho, et al., 2006) 
● Low back pain (Shiri, et al., 2010) 
Surgical ● Difficult intravenous access (Guss & Bhattacharyya, 
2006; Nafiu, et al., 2010)  
● Altered wound healing (Mitchell & Fantasia, 2016; 
Pierpont, et al., 2014) 
● Longer operation time (Silber, et al., 2013) 
● Increased risk of wound infection (Guss, et al., 2006; 
Thelwall, et al., 2015) 
● Greater intraoperative blood loss (Triantafyllopoulos, et 
al., 2015) 
● Wound dehiscence (Pierpont, et al., 2014) 
● Increased risk of deep vein thrombosis (Guss, et al., 
2006; Klovaite, et al., 2015) 
Reproductive ● Menstrual irregularities (Zhang, et al., 2012) 
● Reduced fertility in males and females (Katib, 2015) 
● Polycystic ovary syndrome (Álvarez-Blasco, et al., 2006) 
● Gestational diabetes mellitus (Chu, et al., 2007) 
● Gestational hypertension (Gaillard, et al., 2011) 
● Pre-eclampsia (Roberts, et al., 2011) 
● Difficult labour with increased risk of maternal and foetal 
complications (Gupta & Faber, 2011) 
● Stress incontinence (Mishra, et al., 2008) 
● Erectile dysfunction (Skrypnik, et al., 2014) 
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Social and psychological ● Poor self-esteem (Griffiths, et al., 2010; O’Dea, 2006) 
● Depression and anxiety (Fox, et al., 2016; Gariepy, et al., 
2010)  
● Social disadvantage and discrimination (Cawley, 2004) 
● Decreased libido (Kolotkin, et al., 2012; Nackers, et al., 
2015; Østbye, et al., 2011) 
● Reduced cognitive function (van den Berg, et al., 2009) 
Table adapted from Kelly, et al., (2013) listing possible medical, surgical, reproductive, 
social and psychological consequences of obesity. 
 
1.2 Mechanisms of obesity  
Obesity occurs gradually when a person’s total energy intake regularly exceeds their total 
energy expenditure causing an energy imbalance. The chronic state of surplus energy in 
obesity is thought to saturate the normal triacylglycerol storage capacity of adipose tissue 
by increasing fatty acid uptake (Kusminski, et al., 2009). This is initially contained by 
hypertrophy and hyperplasia of adipocytes within the adipose tissue (Kusminski, et al., 
2009). However, when adipose tissue can no longer accommodate excess fatty acids and 
lipid products, the adipose tissue goes into a state of dysfunction and surplus is deposited 
in non-adipose tissue, such as the liver and skeletal muscle, and named ectopic fat (Blüher, 
2009; Blüher, 2013; Kusminski, et al., 2009). Ectopic fat is defined as occurring when more 
than 5% of an organ’s volume is made of fat or the presence of lipid droplets exceeds 5% of 
the organ’s cells (Snel, et al., 2012). The accumulation of ectopic fat and the dysfunction of 
the adipose tissue are thought to cause pathological responses associated with a number 
of sequelae (Carobbio, et al., 2011)  
As shown in Table 1.2, obesity has been linked to a number of potentially fatal conditions 
such as type II diabetes mellitus (T2DM) (Hu, et al., 2001), cardiovascular diseases (CVD) 
(Ortega, et al., 2016) and hypertension (Jiang, et al., 2016; Re, 2009). Despite the 
consensus about the positive correlation between obesity and these conditions, the 
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association between them has yet to be fully understood. Studies have identified links 
between obesity and these comorbidities involving altered fatty acid metabolism (Abel, 
2010; Blaak, 2003; Fukushima & Lopaschuk, 2016), insulin resistance (Kahn & Flier, 2000; 
Ye, 2013), proinflammatory cytokines (interleukin-6 and tumor necrosis factor) (Redinger, 
2007; Sulistyoningrum, et al., 2017; Yudkin, et al., 2000), endoplasmic reticulum stress 
(Cnop, et al., 2012) and mitochondrial dysfunction (Højlund, et al., 2008; Parish & Petersen, 
2005). However, these interactions are complex and their importance vaguely defined 
(Eckel, et al., 2011). 
 
1.2.1 Obesity and type II diabetes 
Type II diabetes mellitus (T2DM) is a chronic metabolic disorder characterised by 
hyperglycaemia (Olokoba, et al., 2012). T2DM develops as a result of insulin resistance in 
peripheral tissues including muscle, liver, and adipose, followed by impaired insulin 
secretion by the pancreatic β-cells (Pratley, 2013). Insulin resistance and decreased 
circulating insulin leads to decreased glucose uptake into cells and, thus, elevated blood 
glucose levels. This hyperglycaemia can cause serious chronic sequelae including 
cardiovascular disease, diabetic retinopathy, neuropathy and diabetic nephropathy, in 
addition to acute sequelae that can lead to a diabetic coma and death (Zimmet, et al., 
2001). The aetiology of T2DM is complex. Several risk factors that play a role in the 
pathophysiology of T2DM have been recognised, including gender, ethnicity, age, history of 
smoking, generalised obesity and central obesity, low fibre and high saturated fat diets, 
family history, low physical activity, dyslipidaemia, elevated blood pressure and use of 
certain drug treatments including diuretics (Lyssenko & Laakso, 2013). Whilst evidence 
suggests genetics have a strong influence over the development of type II diabetes with 
studies of monozygotic twins exhibiting ~70% concordance for T2DM as opposed to ~25% 
for dizygotic twins (Barnett, et al., 1981; Kaprio, et al., 1992; Newman, et al., 1987). In 
addition to a 3.5-fold greater risk of developing type II diabetes than the general population, 
if one parent has the disorder (Groop, et al., 1996; Köbberling, 1982; Scott, et al., 2007) 
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with inheritance more commonly from the mother (Cox, 1994; Groop, et al., 1996). Much 
evidence supports a causal relationship between obesity and the development of T2DM, 
including molecular (Kadowaki, et al., 2003), epidemiological (Chan, et al., 1994), genetical 
(McCarthy, 2010; Morris, et al., 2012) and clinical studies (Dixon, et al., 2008; Lim, et al., 
2011). Furthermore, Type II diabetes is potentially reversible by implementing a substantial 
negative energy balance by either dietary intervention or bariatric surgery (Taylor, 2013), 
with one study finding that bariatric surgery reversed type II diabetes in 73% of patients 
(Ferrannini & Mingrone, 2009). Following bariatric surgery, daily calorie intake is 
dramatically reduced thereby diminishing pressure on lipid metabolism pathways, which in 
turn profoundly alters intracellular concentrations of lipid metabolites, including those found 
to be toxic.  
Three distinct mechanisms have been offered to connect obesity to insulin resistance and 
predisposition to T2DM. 1) mitochondrial dysfunction, due to decreased mitochondrial 
biogenesis and/or reduced functional capacity (Bournat & Brown, 2010; Højlund, et al., 
2008). 2) increased production of adipokines/cytokines, including retinol-binding protein 4 
tumor necrosis factor-α and interleukin-6, that contribute to insulin resistance (Deng & 
Scherer, 2010). 3) ectopic fat accumulation, particularly in the liver and skeletal muscle, 
leading to dysmetabolic sequelae (Cusi, 2010; Eckel, et al., 2011; Levelt, et al., 2016) 
Decreases in mitochondrial oxidative activity and mitochondrial adenosine triphosphate 
(ATP) synthesis were found in subjects with severely insulin resistant muscle. This finding 
supports the theory that insulin resistance can arise from defects in mitochondrial fatty acid 
oxidation. These defects likely increase intracellular fatty acid metabolites such as fatty acyl 
CoA and diacylglyerol, thereby disrupting insulin signalling (Lowell, 2005). 
Other papers have published the presence of low-grade chronic inflammation in obesity 
(Koca, 2017) with the adipose tissue secreting higher levels of proinflammatory cytokines 
such as interleukin 6 and tumor necrosis factor-alpha (Greenberg & Obin, 2006; 
Hotamisligil, et al., 1995; Monteiro & Azevedo, 2010). These cytokines are potential 
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mediators that link obesity-derived low-grade chronic inflammation with insulin resistance 
(Kim, et al., 2009). 
 
1.2.2 Obesity and cardiovascular diseases 
Obesity can cause physical dysfunction of the heart and vasculature via lipid accumulation. 
For example, obesity can lead to an almost 2-fold increase in the fat pads around the base 
of ventricles (Montani, et al., 2004), which causes diastolic and systolic dysfunction 
(Christoffersen, et al., 2003; Szczepaniak, et al., 2003), and deposition of fat along major 
blood vessels, which can lead to alterations in blood pressure (Dwyer, et al., 1995). 
However, the main links between obesity and CVD are thought to encompass many of the 
same mechanisms as with obesity and T2DM, sharing similar chronic inflammatory 
processes and oxidative injury (Vincent, et al., 2001; Witztum & Lichtman, 2014), however, 
these associations are less clear. In fact, the question of whether obesity is an individual 
risk factor for coronary heart disease (CHD) is currently under debate. This does not 
suggest that obesity is not a causative risk factor for CHD. It is agreed that in the least 
obesity is a contributing cause of directly atherogenic risk factors, so must be in the chain of 
causality somewhere. Moreover, the induction of several major risk factors by obesity may 
actually make it a more significant in the development of atherosclerotic disease than if it 
were an individual risk factor (Grundy, 2002). 
Research indicates that the relationship between obesity and CVD is mediated through 
major risk factors including total cholesterol (Xu, et al., 2007), HDL (Mahdy Ali, et al., 2012; 
Wilkins, et al., 2014), hypertension (Artham, et al., 2009; Montani, et al., 2004), and T2DM 
(Hanley, et al., 2002; Wilson, et al., 1998; Xun, et al., 2012), all of which are affected by 
obesity (Grundy, 2002; Wilson, et al., 1998). In spite of this, obesity is thought to play a 
more active role in the development of atherosclerosis, which encompasses complex 
interactions between serum lipids, platelets inflammatory cells and the vascular 
endothelium (Williams, et al., 2002). Atherosclerosis is initiated by endothelial cell 
dysfunction, which is induced by a reduction in the bioavailability of nitric oxide (Ross, 
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1999). Obesity has been found to reduce the biosynthesis of nitric oxide in endothelial cells 
causing dysfunction (Joost & Tschöp, 2007; Toda & Okamura, 2013), vasoconstriction and 
reduced inhibition of thrombocyte aggregation (Joost, et al., 2007; Leite, et al., 2016; 
Vignini, et al., 2008). Furthermore, impaired sensitivity of platelets to inhibition by nitric 
oxide has been found in obesity, all of which combine to increase the risk of atherosclerosis 
(Russo, et al., 2010). 
 
1.3 The physiological role of platelets 
Platelets are the smallest cells of the body and yet vital for the maintenance of the 
cardiovascular system, especially following vascular injury. In normal conditions, platelet 
function is regulated by three types of signal; inhibitory signals which encourage platelet 
quiescence in healthy vasculature, activatory signals that trigger adhesion and aggregation 
at sites of vascular injury, and negative regulatory signals that provide feedback in order to 
control thrombus formation following platelet activation (Bye, et al., 2016).  
Platelets, otherwise known as thrombocytes, are activated when they come into contact 
with a damaged blood vessel wall. The process of activation involves the reorganisation of 
the cytoskeleton to facilitate rapid shape change, granule release to promote activation 
through soluble agonists, and integrin activation to enable platelet-platelet and platelet-
endothelium interactions. However, this is a process that requires strict regulation in order 
to prevent dysfunction resulting in mortalities from haemorrhagic or thrombotic pathologies. 
Therefore, understanding the causes and mechanisms of platelet activation is instrumental 
in the fight against cardiovascular disease (CVD). Platelet signalling and their role in 
haemostasis will be discussed in more detail in this chapter.  
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1.3.1 Platelet formation  
Platelets are formed from megakaryocytes (MKs), derived from haematopoietic stem cells 
of the myeloid lineage. As megakaryocytes differentiate they lose their ability to proliferate, 
whereby the normal mitotic cycle is arrested at anaphase B and re-enters in G1 phase in a 
process called endomitosis (Geddis, 2010; Patel, et al., 2005). Multiple cycles of 
endomitosis occur causing the replication of chromosomes and the beginnings of cleavage 
furrow formation without telophase and cytokinesis (Geddis, 2010; Patel, et al., 2005), 
resulting in the production of megakaryocytes each with a multilobulated, polyploid nucleus 
containing up to 512N chromosomes (Malherbe, et al., 2016). Differentiated 
megakaryocytes then undergo maturation involving the development on an extensive 
membrane system known as the demarcation membrane system (DMS) (Eckly, et al., 
2014; Kautz & Demarsh, 1954). The DMS divides the cytoplasm of the megakaryocyte into 
membrane-delineated platelet territories that ultimately forms the cell membrane of the 
platelets produced (Eckly, et al., 2014; Kautz, et al., 1954). 
Two hypotheses exist to explain platelet formation from mature megakaryocytes; the 
fragment model and the proplatelet model (Geddis, 2010). The fragment model suggests 
that mature megakaryocytes leave the bone marrow and travel to the lungs to be 
fragmented into platelets in the microvasculature, which has been found in infants (Sharnoff 
& Scardino, 1960). The proplatelet model asserts that within the bone marrow, 
megakaryocytes form long branching processes called proplatelets that extend into 
sinusoids of the bone marrow and shed platelets into the vasculature (Machlus & Italiano, 
2013). The proplatelet model has more support including live cell microscopy showing 
elaborate proplatelet networks extending from megakaryocytes in culture (Italiano, et al., 
1999) and in vivo imaging of fluorescently-labelled megakaryocytes releasing particles, 
presumed to be platelets, into sinusoids of the marrow vasculature (Junt, et al., 2007).  
The platelet formation process takes approximately 10 days and leads to the release of 
approximately 4000 platelets per megakaryocyte, and is an important step in understanding 
the structure and function of platelets (Hoffbrand & Moss, 2015). 
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1.3.2 Platelet structure  
Platelets are anuclear, biconvex discoid cells with an average diameter of 2.5 µm. They 
contain two types of granules α-granules and dense granules that store clotting factors and 
mediators to platelet activation, respectively. These granules are released via the canicular 
system upon platelet activation. This system also serves as a pathway of transport into the 
platelet (Figure 1.10). Inactivated platelets circulate in a biconvex discoid shape, but upon 
activation undergo rapid morphological changes by extending pseudopodia which increase 
surface area and aid in the formation of a stable platelet plug (Figure 1.11).  
 
 
Figure 1.1 Scanning electron microscopy image of a platelet 
The image demonstrates the structure and organelles of a platelet. The platelet’s 
phospholipid bilayer is encased in an outer membrane called the glycocalyx. The structure 
of the platelet is maintained by the cytoskeleton consisting of microtubular coils and actin 
filaments. The cytoplasm contains numerous components required for their role in 
thrombosis such as α-and dense granules. Adapted from (White, 2007).  
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Table 1.3 Components of platelet granules 
α-Granules  Dense Granules  Lysosomes  
Albumin  Serotonin  Cathepsin D  
Fibrinogen  ATP  Cathepsin E  
Fibronectin  ADP  Carboxypeptidase A  
Vitronectin  Calcium  Carboxypeptidase B  
Osteonectrin  Pyrophosphate  Proline Carboxypeptidase  
Von Willebrand Factor  
 
β-N-acetyl-D-hexosaminidase  
Von Willebrand antigen II  
 
β-D-Glucuronidase  
Thrombospondin  
 
β-D-Galactosidase  
Platelet Factor 4  
 
α-D-Mannosidase  
IgG, IgA, IgM  
 
α-L-Arabinofuranosidase  
C1 Inhibitor  
 
α-D-Galactosidase  
Plasminogen  
 
α-L-Fucosidase  
Plasminogen Activator Inhibitor-1  
 
β-D-Fucosidase  
Platelet-Derived Collagenase Inhibitor  
 
β-D-Glucosidase  
High Molecular Weight Kininogen  
 
α-D-Glucosidase  
Protein S  
 
Acid Phosphatase  
α2-antitrypsin  
 
Arylsulphatase  
α2-macroglobulin  
  
α2-antiplasmin  
  
Multimerin  
  
Platelet Basic Protein  
  
β-thromboglobulin  
  
Histidine-Rich Glycoprotein  
  
Connective Tissue-Activation Protein III  
  
Neutrophil-Activation Protein II  
  
Platelet-Derived Growth Factor  
  
Transforming Growth Factor β  
  
Vascular Endothelial Cell Growth Factor  
  
Coagulation Factor V  
  
Coagulation Factor VIII  
  
A table listing the contents of α-granules, dense granules and lysosomes of platelets. 
Taken from (McNicol & Israels, 1999). 
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Figure 1.2 Platelet shape change  
Scanning electron microscope images of platelets. (A) An unstimulated platelet with the 
normal round discoid morphology with the surface having a convoluted appearance. (B) 
Protrusions called “pseudopodia” burst from the surface of the platelet during early shape 
change triggered by activation. (C) Lamellipodia spread between the pseudopodia after 
adherence to a surface. (D) The platelet achieves a fully spread morphology approximately 
20 minutes after adhering to a surface, thereby increasing surface area (Bearer, et al., 
2002). Adapted from (White, 2007).
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1.3.3 Formation of the platelet plug 
Exposure of vWF in the sub-endothelium transiently tethers platelets through interactions 
with the platelet membrane receptor glycoprotein (GP) complex GPIb-V-IX (Gibbins, 2004) 
However, vWF-dependant interactions are insufficiently stable to support thrombus 
formation and are superseded by the binding of collagen via integrin α2β1 and GPVI 
receptors on the platelet surface (Clemetson, 2012). Ca2+ release, degranulation and shape 
change are triggered downstream of GPVI, which in turn amplifies platelet activation 
(Nieswandt, et al., 2001). Platelets contain two types of granule with distinct cargos and 
function (Table 1.4). Alpha (α)-granules contain a plethora of proteins that comprise the 
majority of the platelet secretome, whilst dense granules mainly contain small molecules 
(Whiteheart, 2011). α-granules contain coagulation factors, angiogenic factors, anti-
angiogenic factors, proteases, growth factors, necrotic factors, other cytokines, fibrinogen 
and adhesion molecules (Blair & Flaumenhaft, 2009; Whiteheart, 2011). Dense granules 
contain serotonin, ATP, ADP and Ca2+ (King & Reed, 2002; Whiteheart, 2011). ADP-
induced platelet activation stimulates the synthesis and release of the secondary agonist 
TxA2 (Paul, et al., 1999). ATP and ADP are also secondary mediators of aggregation that 
perpetuate platelet activation and, thus, aggregation (Fung, et al., 2007). Shape change is 
caused by the reorganisation of the actin cytoskeleton following stimulation by an agonist. 
The platelets lose their discoid shape, increasing surface area and facilitate the recruitment 
of passing platelets to the forming thrombus by becoming rounded and extending 
pseudopodia out (Paul, et al., 1999). With interactions between GPIb-V-IX and vWF being 
too weak to mediate platelet adhesion, additional, more robust interactions between 
collagen and α5β1, α2β1 and α6β1 receptors and collagen, laminin and fibronectin are formed 
(Gibbins, 2004; Grüner, et al., 2003; Inoue, et al., 2006; Maurer, et al., 2016). In vivo 
interactions between platelets and multiple endothelial matrix proteins were shown to be 
necessary to form a stable foundation for subsequent thrombus formation (Kuijpers, et al., 
2007; Schaff, et al., 2013). Intraplatelet adhesion is then facilitated by the binding of 
fibrinogen to integrin αIIbβ3 (Bennett, 1996). Furthermore, phosphatidylserine (PS) is 
exposed on the surface of a subset of platelets, which provides the membrane surface for 
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thrombin formation (Munnix, et al., 2007). The thrombin generated activates other platelets 
and coagulation factors, and generates an insoluble mesh by cleaving fibrinogen to fibrin, 
thereby further stabilising the thrombus (Binnie & Lord, 1993). 
 
1.3.4 Thrombosis and Haemostasis  
Damage to the sub-endothelium of a blood vessel exposes matrix proteins which upon 
contact with platelets cause them to activate and undergo dynamic shape change (Figure 
1.11), adherence and aggregation to prevent blood loss, in a process called haemostasis. 
However, thrombosis, the dysregulation of this process can restrict blood flow to vital 
organs such as the heart and brain, and can be fatal. A reduction in blood flow causes 
decreased oxygenation of these vital organs causing ischaemia. Severe reduction to the 
heart and brain cause anoxia and ultimately myocardial infarction and cerebrovascular 
accident (stroke), respectively. Diseases associated with thrombosis are the leading cause 
of cardiovascular-related mortality globally (ISTH Steering Committee for World Thrombosis 
Day, 2014). 
Major haemorrhage resultant from traumatic injury or a medical condition is fatal in the 
absence of an adequate haemostatic response. However, dysregulated haemostasis 
through excessive stimulation or insufficient inhibition can be equally life threatening. In a 
balanced haemostatic state, the endothelial cells of vasculature express heparin 
proteoglycans (de Agostini, et al., 1990) and thrombomodulin (Esmon & Esmon, 2011), and 
release nitric oxide and prostacyclin (PGI2) to maintain platelet quiescence thereby 
preventing activation of the coagulation cascade (Gryglewski, et al., 2001). Haemostasis is 
instigated via exposure to sub-endothelial matrix proteins such as collagen (Roberts, et al., 
2004), exogenous agonists such as ADP and ATP (Born & Cross, 1964) or by mechanical 
deformation from shear stress (Goncalves, et al., 2005), all of which promote procoagulant 
activity and thrombus formation. However, a fine balance between activation and inhibition 
exists as excessive stimulation or insufficient inhibition of these processes can lead to 
occlusion and may end in myocardial infarction, cerebrovascular and pulmonary embolism. 
 16 
 
Injury to the vessel endothelium exposes von Willebrand factor (vWF) and matrix proteins 
such as collagen, laminin and fibronectin which bind to platelets and initiate activation 
pathways (Gibbins, 2004; Grüner, et al., 2003; Schaff, et al., 2013). Platelet activation is 
further induced in response to thrombin, ADP and thromboxane A2 (TxA2) that are produced 
or secreted by platelets. These inside-out signalling pathways lead to activation of integrin 
αIIbβ3 receptors, which bind to fibrinogen forming bridges to cross-link platelets, developing 
a stable platelet plug (Ye, et al., 2011). 
In cases of dysfunction, such as in the rupture of lipid-rich atherosclerotic plaques, the 
formation of thrombi may lead to myocardial infarction and/ or ischemic stroke. 
 
1.3.5 Atherosclerotic plaques 
Atherosclerosis is a potentially serious condition in which arteries are narrowed due to the 
formation of lipid-rich plaques (Bentzon, et al., 2014). These plaques can be caused by an 
increased concentration of low-density lipoproteins (LDL) in the blood, or they may develop 
at lower concentrations of LDL in combination with other risk factors such as hypertension 
and smoking (Bentzon, et al.,2014; Riccioni, et al., 2003).  
The LDL accumulates in the intima where it is oxidised. Monocytes-macrophages are 
recruited to the area where macrophage scavenger receptors uptake the oxidised LDL and 
transform into foam cells. A fibrous cap containing smooth muscle cells is then formed over 
the plaque to stabilise it. Each stage of the process is also mediated by inflammatory 
cytokines (Tegui & Mallat, 1999). 
Atherosclerosis and obesity share common pathophysiological features with lipids 
contributing critically to both conditions. Both oxidized LDL associated with atherosclerotic 
disease and free fatty acids associated with obesity can trigger inflammation and initiate 
disease (Rocha & Libby, 2009). 
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1.4 Lipids 
1.4.1 Triacylglycerol digestion and transport 
The most common form of lipid in the human diet is triacylglycerol (TAG), a 3C alcohol with 
three fatty acids conjugated to glycerol (Figure 1.5), which is insoluble in the aqueous 
environment of the gastrointestinal tract and must be solubilised to be absorbed.  
 
 
Figure 1.3 Generic triacylglycerol structure 
Glycerol backbone depicted in black with three generic fatty acids in mauve attached to 
hydroxyl groups. These fatty acids vary, but all three are usually different and contain 16, 
18 or 20 carbons.  
 
 
The absorption process starts in the stomach, where mechanical digestion exposes lipids to 
hydrolysis by gastric lipase which breaks down up to 20% of the fatty acids (Lowe, 2002). 
Expulsion of chyme from the stomach into the duodenum follows, where bile acids from the 
gall bladder, are released to emulsify the lipid components (Favé, et al., 2004). Emulsion is 
achieved through hydrophobic domains of bile acids intercalating into the lipids, which 
forms a complex oil interface with the aqueous environment that achieves maximal lipase 
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activity (Lowe, 2002). This oil interface is fluid in its composition and physical properties, 
and continuously changes as lipolysis proceeds, increasing the surface area by breaking 
down large aggregates into smaller droplets. The increase in surface area allows greater 
accessibility of pancreatic lipase and pancreatic phospholipase A2 (PLA2) to degrade 
dietary triacylglycerols into their acylglycerol and free fatty acid components (Mun, et al., 
2007). The products then enter enterocytes lining the intestine via simple diffusion or 
facilitated by fatty acid binding protein (FABP) (Favé, et al., 2004). Within the endoplasmic 
reticulum (ER) of enterocytes triacylglycerols are reformed and passed through the Golgi 
apparatus where they are packaged with fatty acids, cholesterol and lipoproteins to form 
chylomicrons (Lambert, et al., 2001). Chylomicrons are exuded from the Golgi and 
exocytosed in vesicles into the lymphatic system, from which they flow into the systemic 
circulation (Figure 1.5). Nascent chylomicrons consist of 85% TAG and some cholesterol, 
with apolipoptein B-48 as the main apolipoprotein (Table 1.3). As chylomicrons circulate, 
they exchange components with high-density lipoproteins (HDL). As the chylomicrons 
circulate, components are delivered to various parts of the body, and the remnant is then 
returned to the liver for endocytosis and breakdown.  
VLDL are synthesised in the liver, and their function is to deliver TAG to the body. As they 
circulate, VLDL particles are stripped of TAG and become less dense, thus, transforming 
into LDL (Table 1.3). The function of LDL (so called ‘bad’ cholesterol) is to deliver 
cholesterol to the cells, which is required for plasma membrane function or synthesis into 
steroid hormones. Cells take up cholesterol via receptor-mediated endocytosis. HDL (so 
called ‘good’ cholesterol) is involved in reverse cholesterol transport, and the function of the 
liver is to remove LDL from the circulation. Familial hypercholesterolaemia, a dominant 
gene disorder resulting in early heart attack and stroke, results from a defect in the LDL 
receptor.  
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Figure 1.4 Uptake, transport and distribution of lipids in the body 
In the intestine TG is broken down by lipase to produce MG and FA, which are absorbed by 
enterocytes and re-esterified to TG. This reformed TG is packaged into chylomicrons and 
released into the lymph system then the circulation. The TG is taken up by hepatocytes and 
metabolised into FA, which is released into the circulation and bound to albumin. 
Simultaneously, lipoprotein lipases within blood vessels metabolise TG to FA. This FA is 
delivered to parenchymal cells for storage and use, and to adipocytes for storage. 
(abbreviations: TG – triacylglyceride, MG – monoacylglyceride, FA – fatty acids, PL - 
phospholipid)  
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Table 1.4 Lipoproteins: their composition and associated apolipoproteins 
 Chylomicron VLDL IDL LDL HDL 
Density (g/mL) <0.950 0.950-
1.006 
1.006-
1.019 
1.019-
1.063 
1.063-
1.090 
Diameter (nm) 80-1000 30-80 25-30 20-22 9-15 
Apolipoproteins B48, A1, A2, 
C, E 
B100, C, E B100, C, E B100 A1, A2, C, 
E 
Protein (%) ~1 ~10 ~18 ~20 ~50 
Triglyceride (%) ~90 ~65 ~34 ~10 ~20 
Cholesterol (%) ~5 ~13 ~22 ~45 ~18 
Phospholipids 
(%) 
~4 ~13 ~22 ~23 ~30 
 
 
Adults consume approximately 70g of fat per day, most of this in the form of triacylglycerol 
(TAG). TAG is digested in the gastrointestinal tract to release free fatty acids (FFA), 
diacylglycerol (DAG) and monoacylglycerol (MAG), which are then absorbed in the small 
intestine. FFAs are re-esterified to triacylglycerols in the intestinal epithelial cells, which are 
transported in chylomicrons via the lymph system and into the circulation (Figure 1.5). Due 
to their low solubility, FFAs are bound to albumin in order to be transported in the 
circulation, from where they are taken up by cells via protein transporters in the cell 
membrane. Once inside the cell, FFAs are transported via fatty acid-binding proteins 
(FABP) to the endoplasmic reticulum (ER) and the outer mitochondrial membrane for 
activation with CoA to form fatty acyl-CoA. Afterwards they are transported to the 
mitochondria, peroxisomes, and ER via acyl-CoA-binding protein (ACBP). In the 
mitochondria and peroxisomes they are broken down via β-oxidation to produce ATP, whilst 
in the ER they are esterified to different lipid species. 
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1.5 Fatty Acids 
Fatty acids (FAs) are energy-rich long hydrocarbon chain molecules that exist both in a free 
state and as part of complex lipids, usually forming either triglycerides (three fatty acids + 
glycerol) or phospholipids (two fatty acids plus glycerol plus phosphate and a changed head 
group). They play vital roles in metabolism, are essential components of cell membranes, 
and are important in signal transduction and gene regulation (Rustan & Drevon, 2005; van 
der Vusse, 2009).  
Fatty acids are defined as carboxylic acids with a long unbranched aliphatic chain and 
share a common structure with diversity based on chain length and degree of saturation 
(Duplus, et al., 2000). The general formula for fatty acids is CH3(CH2)nCOOH, where n is the 
chain length (Figure 1.1), although the chain length of biological fatty acids is usually an 
even number between 4 and 28. Fatty acids are synthesised from 2C acetyl CoA, thus, the 
even number of carbons. Fatty acids have trivial names, as well as using systematic 
nomenclature. FAs over 16 carbons in length can be either saturated, monounsaturated 
(MUFA) or polyunsaturated (PUFA) depending upon the presence of none, one or more 
double bonds respectively, in the carbon chain (Duplus, et al., 2000).  
 
 
Figure 1.5 Nomenclature for fatty acids 
Fatty acids are commonly named by systematic or colloquial nomenclature. The systematic 
approach is to describe fatty acids in relation to the methyl (ω) end. It is from this end that 
the position of double bonds are described the position of double bonds from the end of the 
fatty acid. The letter n may also be used to denote the position of the double bond. 
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Fatty acids have a low solubility in water in their undissociated (acidic) form. Their solubility 
is dramatically influenced by temperature and pH, and they have a strong tendency to 
associate in lamellar structures and micelles thereby reducing their bioavailability. The 
formation of micelles occurs over a limited range of concentrations and conditions with the 
point of association known as the critical micellar concentration (CMC). The CMC is not a 
fixed value, but rather represents a concentration range at which the conditions of a 
solution strongly affect the lipids and cause them to exhibit a tendency to associate rather 
than remain as single molecules (Rustan, et al., 2005) (Figure 1.2). Therefore, in the 
circulation FFAs are bound to the transporter protein albumin to increase solubility. 
The unbound FFA at pH 7.4 in the final concentrations used in this study may form lamellar 
fatty acid/soap or crystalline 1:1 acid-soap aggregates, but not micelles, as fatty acids do 
not form micelles in solutions below pH 9 (Figure 1.2) (Cistola, et al., 1988). Furthermore, 
the melting point for palmitic acid is 62.20°c and oleic acid is 12.82°c, which further support 
this assumption (Figure 1.2) (Knothe & Dunn, 2009). A ratio of FFA:BSA greater than a 7:1 
also increases the chances of unbound fatty acid crystallising (Cistola, et al., 1987). All 
stock solutions contained 1% w/v BSA, which equates to approximately 151 μM, therefore, 
the upper limit of FFA concentration before crystallisation was 1057 μM. Thus, 
concentrations used in this study were below this threshold. 
The structure of a fatty acid plays a significant role in the manifestation of its physical 
properties. For example, fatty acids with odd numbers of carbon atoms have higher melting 
points, whilst monounsaturated fatty acids with a cis double bond have lower melting points 
due to their inability to pack closely. The complete saturation of saturated fatty acids makes 
them very stable, whereas unsaturated fatty acids are more susceptible to oxidation due to 
instability caused by their double bonds. The more double bonds, the greater their instability 
(Cistola, et al., 1988).  
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Figure 1.6 Formation of fatty acids in aqueous solutions 
The aqueous phase is a saturated solution of fatty acid, acid-soap, or soap, and the 
concentration of these molecules varies with ionization state and hydrocarbon chain length. 
The closed circles represent ionized (anionic) carboxylate groups and the open circles 
protonated carboxyl groups. The straight lines represent ordered hydrocarbon chains and 
the curved lines disordered (liquid) hydrocarbon chains. 
 
1.5.1 Saturated fatty acids 
Saturated fatty acids (SFAs) derive their name from the fact that all of their carbon atoms 
are fully saturated with hydrogen. Most SFA are linear hydrocarbon chains with an even 
number of carbons, with the most abundant containing between 12-22 carbon atoms 
(Rustan, et al., 2005). 
 
1.5.2 Unsaturated fatty acids 
Unsaturated fatty acids are not fully saturated with carbon atoms due to the presence of 
one or more double bonds. Monounsaturated fatty acids (MUFAs) have one carbon-carbon 
double bond, which can occur at different carbon positions and produce different 
configurations, namely cis and trans isomers. In cis isomers the carbon atoms are present 
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on the same side of the double bond, whilst in trans isomers the carbon atoms are on 
opposite sides of the double bond (Figure 1.2). The presence of a double bond not only 
alters the structure and stability of fatty acids, but also has important physiological 
implications. The double bond in cis isomers causes a kink in the molecular shape and 
reduces the thermodynamic stability, this kink reduces the ability of cis fatty acids to pack 
tightly thereby causing lower melting points than their saturated or trans unsaturated 
counterparts (Rustan, et al., 2005). The most common monounsaturated fatty acids are 
between 16-22 carbons in length and exist in the cis configuration. If the double bond is 
present between the seventh and eighth carbon atoms, these are called ω-7 fatty acids, 
and if the double bond is between the ninth and tenth carbon atoms, these are called ω-9 
fatty acid. Trans fatty acids are less common as they are produced via the industrial 
process of hydrogenation or by biohydrogenation in the gastrointestinal tract of ruminants 
(Iqbal, 2014). Furthermore, trans monounsaturated fatty acids have similar effects in 
organisms as saturated fatty acids due to their similarity in shape (Doyle, 1997).  
Polyunsaturated fatty acids (PUFAs) have two or more double bonds and are categorised 
based on the position of the first double bond. If the first double bond is present between 
the third and fourth carbons, these are called ω-3 fatty acids, and if the first double bond 
exists between the sixth and seventh carbon atoms, these are called ω-6 fatty acids. 
PUFAs are produced by plants and are metabolised in the human body by the addition of 
carbons, and the extraction of hydrogen in a process called desaturation. Fatty acids are 
also broken down by β-oxidation in the mitochondria. 
 
 
 25 
 
 
 
 
Figure 1.7 Fatty acid formulae and example molecular shapes 
Double bonds are represented by two parallel lines. Cis isomers are bent as the carbon 
atoms are present on the same side of the double bond causing repulsion between 
electrons. 
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1.5.3 Palmitic acid and oleic acid 
Two of the most populous circulating fatty acids are palmitic acid (PA) and oleic acid (OA), 
and, thus, their common use in research. Palmitic acid has a lipid number of 16:0, and is 
classified as a saturated fatty acid due to all of its 16 carbon atoms being fully saturated 
with hydrogen atoms (Figure 1.3). Oleic acid is a fatty acid classified as a monounsaturated 
omega-9 fatty acid with the lipid number 18:1 cis-9, meaning it is 18 carbon atoms in length 
with a double bond at the 9th carbon, with the chain continuing on the same side of the 
double bond (Figure 1.3).  
 
 
Figure 1.8 The structure of palmitic acid and oleic acid 
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1.5.4 Lipid uptake, storage and utilisation 
Fatty acids are transported around the body in the vasculature and lymphatic system, in 
which they are transported as triacylglycerols in lipoproteins (Guo, et al., 2009) and 
chylomicrons (see below), or as non-esterified fatty acids (NEFA) (van der Vusse, 
2009)(van der Vusse, 2009). NEFA is another term for free fatty acids, meaning the fatty 
acids have not been incorporated into other lipid species.  
Upon reaching cells, fatty acids are released from the triacylglycerol component of 
lipoproteins by lipoprotein lipase and from albumin. Free fatty acid uptake into cells occurs 
via two routes -passive diffusion, and via specific membrane-bound transport proteins, 
namely fatty acid transport protein (FATP) and CD36 (Bonen, et al., 2004; Ehehalt, et al., 
2006; Glatz, et al., 2002). Following uptake, fatty acids are hydrolysed to produce acyl 
groups, which bind to hydroxyl groups in glycerol esterification, forming acylglycerols. 
Monoacylglycerol (MAG), diacylglycerol (DAG) and triacylglycerol (TAG) (also known at 
triglyceride TG) are produced following the addition of one, two and three fatty acids 
respectively to the three hydroxyl groups of glycerol (Figure 1.6) (Gunstone & Herslöf, 
2000). 
The TAG pool is in constant flux, termed the glycerolipid/free fatty acid cycle (Karpe, et al., 
2011). At normal levels of free fatty acid uptake, cells convert surplus, unoxidised fatty 
acids into neutral triacylglycerol. The production of TAG occurs via the glycerol-3-
phosphate pathway and/or the monoaclyglycerol pathway, dependant on the tissue type 
(Figure 1.8). When there is a short-term increase in demand for ATP due to low-intensity 
exercise or short-term fasting, TAG turnover increases without an effect on the overall TAG 
content of the pool, indicating a matched rate of synthesis to lipolysis (Figure 1.7) (Karpe, et 
al., 2011). 
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Figure 1.9 The glycerolipid/free fatty acid cycle 
The intracellular lipid pool is in constant flux. At normal levels of fatty acid uptake into cells, 
TAG is formed. Once storage has reached capacity the pathways are reversed, leading to 
the formation of toxic lipid species. However, high intensity exercise also causes the 
breakdown of TAG in muscle cells, fatty acid products from which are neutralised by 
oxidation (Karpe, et al., 2011). (abbreviations: Gly-3-p – glycerol-3-phosphate, otherwise 
known as Gro3P) 
 
 
Once formed these acylglycerols along with sterol esters are stored in lipid droplets (LD) as 
an energy reservoir with high ATP-generating capacity as part of normal lipid accumulation 
(Thiam, et al., 2013). The lipid droplets are localised to the endoplasmic reticulum and 
mitochondria, bound in a phospholipid monolayer expressing a variety of proteins involved 
in lipolysis and esterification (Thiam, et al., 2013). The main repository of fat is the adipose 
tissue, with skeletal muscle and liver playing a key role. It is said that skeletal muscle 
contains ~300g of tryglyceride in adults with a normal BMI, whilst the liver contains ~100g 
(Frayn, et al., 2006; Frayn & Blaak, 2007). 
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Figure 1.10 Normal pathway of lipid accumulation 
Normal levels of free fatty acid uptake lead to the production of TAG via the glycerol-3-
phosphate pathway and/or the monoacylglycerol pathway, neutralising unoxidised fatty 
acids (Karpe, et al., 2011). TAG turnover increases when demand for ATP increases 
without affecting the TAG pool, indicating a matched rate of synthesis to lipolysis. However, 
intracellular TAG content is reduced by high-intensity exercise by favouring fatty acid 
oxidation over fatty acid esterification and production of TAG (Karpe, et al., 2011). 
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1.5.5 Lipid droplets 
Neutral lipids, such as TG, found in lipid droplets (LDs) are synthesised in the endoplasmic 
reticulum, however, the mechanism of formation is largely unknown. One hypothesis, the 
ER-budding model, postulates that a layer of oil forms in the ER membrane, from which 
sections of lipid bilayer ‘bud’. This model has significant backing, but no direct evidence 
supporting it (Walther, et al., 2009; Zhang & Zhang, 2012). A variation on this, the ER-
domain model, theorises that lipid droplets are essentially protrusions of specialised ER 
domain containing lipids, however, little research supports it (Raghunathan, et al., 2017). 
Other theories for the formation of LDs have been offered. The bicelle model (Ploegh, 
2007) suggests that accumulation of neutral lipids occurs between the leaflets of the ER 
bilayer and that upon excision from the membrane they remove phospholipids from the 
luminal and cytosolic leaflets (Walther, et al., 2009). Another model, vesicular-budding, 
posits that small bilayer vesicles form in the ER membrane and remain tethered, whilst 
neutral lipids fill the intermembrane space until the internal bilayer is overwhelmed (Farese, 
et al., 2009; Walther, et al., 2009). More research is required to shed light on LD formation.  
 
1.5.6 Normal fat metabolism in adipose tissue 
Adipose tissue is a connective tissue mainly composed of adipocytes, specialised to 
synthesise and store TG. The storage of TG varies greatly between individuals with ~ 30% 
of the ‘standard’ adult female body weight accounted for by fat. This number is lower in 
males at ~20% (Gallagher, et al., 2000). Adipocytes are highly specialised for the storage of 
fat, but plays an important role in the secretion of hormones such as adiponectin and leptin, 
and a cytokines termed ‘adipokines’. The composition of fatty acids stored in the adipose 
tissue directly reflects dietary intake with most arising from the TG fraction of plasma lipids, 
whilst a minority are from the direct uptake of circulating FFAs (Coppack, et al., 1999). 
However, the control of uptake by adipocytes is unclear.  
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Adipocytes synthesise lipoprotein lipase (LPL) and export it to the surface of endothelial 
cells in the lumen of capillaries. However, a pool remains within the adipose tissue to 
degrade TG in the fasting state, with only a percentage becoming active endothelial-bound 
LPL (Gonzales & Orlando, 2007). Upon feeding, LPL is diverted away from the degradative 
pathway within the adipose tissue and the secretory pathway is up-regulated (Bergö, et al., 
1996). Chylomicrons are the main substrate for secreted LPL as chylomicron-TG is 
hydrolysed more rapidly than VLDL-TG. The FAs liberated by LPL in the lumen migrate 
across the capillary endothelium and into adipocytes beneath by a proposed combination of 
diffusion- and protein-mediated uptake, likely involving CD36 (Thompson, et al., 2010; 
Wiczer, et al., 2006). Inside the adipocyte, FAs are esterified to CoA in an ATP-dependent 
process. 
Adipose tissue LPL produce an excess of FAs, a proportion of which are taken up by 
adipocytes, subject to their nutritional state. However, there is always a surplus or ‘overspill’ 
of fatty acids that are release into the plasma. The uptake of LPL-derived FAs is regulated 
by insulin, which increases the percentage taken up. Nonetheless, even in the postprandial 
state ~50% are released as NEFA, making them available for uptake by parenchymal cells 
of other tissues including the liver and skeletal muscle (Koutsari, et al., 2008). It is thought 
that insulin stimulation controls FA uptake via recruitment of FA transporters FATP1, 
ACSL1 and CD36 to the cell surface (Lobo & Bernlohr, 2007; Wiczer, et al., 2006). Insulin 
also stimulates the esterification of FAs to produce TG within adipocytes. Despite 
consensus that insulin stimulates intracellular TG synthesis, the regulation of enzymes 
involved in this process is not fully understood (Czech, et al., 2013; Holm, 2003). 
Furthermore, insulin is possibly the stimulant for glucose uptake and glycolysis, supplying 
the Gro3P required for FA esterification as the direct uptake of acylglycerols is very limited 
in adipocytes (Frayn, et al., 2006).  
Within adipocytes TG hydrolysis is regulated by two enzymes, hormone-sensitive lipase 
(HSL), which is active against two fatty acid chains on a TG molecule, and monoglycerol 
lipase to catalyse the final stage of TG hydrolysis (Fredrikson, et al., 1986). Long-term 
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regulation of HSL is by transcriptional control with starvation causing an increase in HSL 
mRNA abundance, whilst obesity causes a reduction. But on a daily basis, HSL is regulated 
via reversible phosphorylation by protein kinase A at its three phosphorylation sites (Holm, 
2003). Phosphorylation rapidly increases the activity of HSL via signalling that increases 
cAMP concentrations, thereby increasing adipocyte fat mobilisation. On the other hand, 
insulin suppresses HSL activity via signalling that reduces cAMP concentration. Concurrent 
to HSL phosphorylation, a protein that coats the intracellular lipid droplet, perilipin, is also 
phosphorylated. This enables the translocation of HSL from the cytosol to the lipid droplet 
surface in order to achieve lipolysis (Miyoshi, et al., 2006), without which HSL would be 
excluded.  
HSL as the main enzyme for lipolysis in adipocytes was challenged by results in HSL-
deficient mice finding relatively normal adipose tissue mass with functional lipolysis 
(Haemmerle, et al., 2002; Kraemer & Shen, 2006). This led to the discovery of adipose 
triglyceride lipase (ATGL) which has a specificity for triacylglycerols and not di- or mono-
acylglycerols (Kershaw, et al., 2006). ATGL is now considered to be responsible for basal 
adipose lipolysis with HSL responsible for catecholamine- stimulated lipolysis (Rydén, et al., 
2007). 
 
1.5.7 Normal fat metabolism in the liver  
The normal TG content of the liver is up to 10% by weight, but can enlarge significantly in 
non-alcoholic fatty liver disease. The liver obtains FAs from the uptake of lipoprotein 
remnants and the hydrolysis of circulating TG with uptake of FAs through diffusion- and 
protein-mediated process involving FAT/CD36, FATP2 and FATP5 (Wilson, et al., 2016). 
LPL is not normally expressed in adult liver, instead hepatic lipase (HL), a related enzyme 
is employed. HL acts preferentially on smaller lipoprotein particles than LPL, removing TG 
from VLDL particles, HDL particles and from particles forming LDL (Carr, et al., 2002). The 
liver is the main site for uptake of remnant lipoprotein particles formed by the LPL removal 
of TG from TG-rich chylomicrons and VLDL. These remnants typically contain about one-
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third of the original TG content, which is considerable as chylomicron particles comprise 
~106 molecules of TG (Frayn, et al., 2006). These processes deliver 20–30 g/day of dietary 
TG to the liver.  
Additionally, the liver has the enzymatic ability for de novo lipogenesis (DNL), the synthesis 
of FAs from glucose and other carbohydrate precursors. This process makes a small 
contribution in people consuming high fat diets, but is activated when intake of 
carbohydrate exceeds energy requirements (Hellerstein, et al., 1996). Isotopic data 
indicates that ~10% of adipose tissue FAs arise from DNL (Strawford, et al., 2004). DNL 
involves the formation acetyl-CoA in mitochondria followed by conversion to malonyl-CoA 
by acetyl-CoA carboxylase, and finally elongation by the sequential addition of two carbon 
groups by fatty acid synthase (Sanders & Griffin, 2016).  
FAs taken up into hepatocytes are esterified to CoA. Acyl-CoA may then be oxidised in the 
mitochondria or act as a substrate for TG and phospholipid synthesis, in a process called 
glycerolipid synthesis. This is the vital regulatory point, regulated by entry into the 
mitochondria, via carnitine palmitoyltransferase 1 (CPT1), which is allosterically controlled 
by the concentration of cytosolic malonyl-CoA due to inhibitory properties. The 
concentration of malonyl-CoA is linked to insulin levels and is increased when glucose is 
readily available, essentially during conditions when FA synthesis is required over FA 
oxidation. FA oxidation is favoured when insulin is low in the fasting state (Lee, et al., 
2016). The cytosolic TG stores within hepatocytes are precursors for VLDL-TG. The 
generation of FAs via lipolysis of the cytosolic pool is required for esterification into new TG, 
occurring in the ER where VLDL is assembled. However, the regulation and lipase involved 
remain unclear. Insulin acutely inhibits the secretion of VLDL-TG, causing the storage of 
hepatic FAs as TG when insulin levels are high. Thus, intracellular TG stores fluctuate, 
accumulating following meals and depleting during fasting due to the secretion of VLDL. It 
is approximated that 10% of fat consumed is stored in the liver within a few hours of 
consumption (Ravikumar, et al., 2005). 
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1.6 Normal fat metabolism in skeletal muscle  
The total TG content throughout skeletal muscle is ~300 g across two main sites (Frayn & 
Blaak, 2007). In muscle TG is stored interleaved between muscle fibres in adipocytes and 
within skeletal myocytes themselves (intramyocellular TG). Intramyocellular TG form lipid 
droplets in close proximity with mitochondria. Skeletal myocytes contain many of the same 
enzymatic processes for TG and FA metabolism as adipocytes. FA uptake is from the 
hydrolysis of circulating TG by LPL, and from albumin-bound plasma FFA with uptake via 
facilitated diffusion utilising FATP1, FABPpm and CD36 expressed in skeletal muscle 
(Harasim, et al., 2008). The TG present in skeletal muscle arises exclusively from plasma 
FAs (NEFA or TG). The regulation of FA oxidation is via malonyl-CoA, in the same manner 
as described above for liver, however, skeletal muscle is unable to synthesise FAs (Foster, 
2012; Saha, et al., 1997).  
Intramyocellular TG is hydrolysed to make FAs for oxidation with hormone-sensitive lipase 
(HSL) the likely enzyme controlling the process. No direct evidence exists to support this 
other than the expression of HSL in skeletal muscle and its activation upon muscle 
contraction (Donsmark, et al., 2005), which is reinforced by the formation of large 
intramyocellular lipid droplets in HSL-deficient mice (Hansson, et al., 2005). FAs released 
from TG lipolysis are substrates for oxidation after activation into CoA and transit into the 
mitochondria. This lipolysis is not as sensitive to hormone regulation as lipolysis in 
adipocytes. Insulin is ineffective at stimulating muscle lipolysis, whilst catecholamines are 
effective (Donsmark, et al., 2005; Moberg, et al., 2002; Qvisth, et al., 2006).  
It remains unclear whether, skeletal muscle releases FAs into the circulation as adipocytes 
do, however, it is agreed that the muscle never gives a net contribution, always extracting 
from the circulating FFA pool overall. Adipose tissue is the only tissue that is a net 
contributor to circulating plasma FFAs.  
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1.6.1 Fatty acid oxidation 
1.6.1.1 Carnitine transport 
Within the cytosol, fatty acids are converted into fatty acyl-CoA by acyl-CoA synthetases, 
which enable the formation of a thioester bond between the carboxyl group of the fatty acid 
and the thiol group of coenzyme A (CoA) in an ATP-dependent reaction. Fatty acyl-CoA 
then attaches to the hydroxyl group of carnitine in the presence of carnitine 
palmitoyltransferase I (CPT1), forming fatty acyl-carnitine. Fatty acyl-carnitine is transported 
across the outer mitochondrial membrane in exchange for carnitine via carnitine-
acylcarnitine translocase facilitated diffusion. Inside the mitochondrial matrix, carnitine 
acyltransferase II (CPT2) on the inner mitochondrial membrane catalyses the transfer of the 
acyl group from fatty acyl-carnitine to a different CoA, thus, forming fatty acyl-CoA and free 
carnitine. Fatty acyl-CoA is then ready for β-oxidation (Longo, et al., 2016). 
 
1.6.1.2 Beta oxidation of fats  
Within the mitochondrial matrix, fatty acyl-CoA is dehydrogenated in the presenceof acyl-
CoA dehydrogenase to form trans-Δ2-enoyl-CoA with a trans double bond between the two 
carbons closest to the carboxyl end. Electrons from this reaction are transferred to FAD 
reducing it to FADH2, which is converted to ATP via the electron transport system. Trans-
Δ2-enoyl-CoA is then hydrated via enoyl-CoA hydrase to form β-hydroxyacyl-CoA, which is 
dehydrogenated in the presence of β-hydroxyacyl-CoA dehydrogenase to form β-ketoacyl-
CoA. This results in the transfer of electrons to NAD+ to form NADH + H+ which enters the 
electron transport system to produce ATP. The final step is the thiolysis of β-ketoacyl-CoA; 
in the presence of acyl-CoA acetyltransferase and CoA, acetyl-CoA and a fatty acid CoA 
with n-2 carbons. This process is repeated for the new fatty acyl-CoAuntil the entire 
molecule has been converted to acetyl-CoA. Acetyl-CoA molecules enter the Kreb’s cycle 
(Longo, et al., 2016). 
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1.6.2 Ectopic fat accumulation and lipotoxicity 
In 2003, Roger Unger proposed the ‘lipid overflow’ to explain the accumulation of ectopic fat 
accumulation (Unger, 2003). This hypothesis suggests that obesity causes adipose tissue 
to expand to capacity, and upon continuation of excess energy intake surplus lipids 
spillover into non-adipose tissues for storage, whereby ‘lipotoxicity’ is induced. This, in 
combination with leptin resistance causes the metabolic dysfunction associated with obesity 
(Farooqi & O’Rahilly, 2009). Lipotoxicity is the accumulation of intracellular lipids in non-
adipose tissue, causing cellular dysfunction and/or cell death. 
However, the flaw in this hypothesis is that there is no evidence for a limit to subcutaneous 
adipose tissue expansion. Furthermore, this theory is completely contradicted by findings 
that endurance trained athletes have markedly high insulin sensitivity, despite elevated 
intramyocellular lipid content that often exceeds that of obese, diabetic subjects 
(Goodpaster, et al., 2001; van Loon, et al., 2004). 
Perhaps, a more fitting hypothesis is the theory of adiposopathy, or sick fat. In 2004, Harold 
Bays suggested that metabolic disease may be caused by dysfunctional adipose tissue and 
its interaction with the body, in a condition termed ‘adiposopathy’ (Bays, et al., 2004). This 
concept has been further discussed and enhanced over the past decade (Bays, 2014; 
Bays, et al., 2005; Bays, 2011; Dalamaga & Christodoulatos, 2015; McCrindle, 2014). 
According to this hypothesis, increase in adiposity leads to metabolic disease when the 
adipose tissue expands via hypertrophy rather than hyperplasia due to adipocyte 
dysfunction, which impairs adipogenesis (Klöting, et al., 2010). This dysfunction leads to 
excess free fatty acid release, and ultimately systemic inflammation and insulin resistance 
via apoptosis, ER stress, hypoxia, macrophage infiltration and inflammation, and peripheral 
insulin resistance (Mittendorfer, 2011). Moreover, the dysfunctional adipose tissue not only 
releases excess free fatty acids, but also down-regulates uptake (McQuaid, et al., 2011), 
through decrease fatty acid transporter expression (Fabbrini, et al., 2009). Both of which 
lead to increased levels of plasma free fatty acid and, therefore, increased availability to 
non-adipose tissues (McQuaid, et al., 2011).  
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Healthy humans store surplus energy in adipose tissue in the form of triglycerides. 
However, in an obese state, the storage capacity of adipose tissue is exceeded leading to 
the formation of ectopic fat in non-adipose tissues. Triglycerides in themselves are 
considered neutral and, therefore, not toxic, although they act as a reservoir for metabolites 
of non-oxidative pathways that cause toxic effects (Samuel, et al., 2010). Furthermore, 
excess triacylglycerol production eventually surpasses storage capacity of the cell and 
drives hydrolysis of neutral TAG back into fatty-acyl CoAs and glycerol (Figure 1.9).  
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Figure 1.11 Triacylglycerol breakdown and accumulation of fatty acid species 
When capacity of TAG storage is reached, hydrolysis back into fatty-acyl coA is favoured. 
This in turn strains the oxidative capacity of the cell and drives reactions towards non-
oxidative pathways of fatty acid metabolism (Unger & Zhou, 2001). These pathways lead to 
the production of toxic lipid species such as ceramide. 
 
 
 
 
 
 
The increase in fatty-acyl CoA strains the cell's oxidative capacity, causing spillover into 
non-oxidative pathways of fatty acid metabolism that produce toxic lipid intermediates 
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(Unger, et al., 2001). It is these lipid intermediates from lipolysis and esterification in the 
glycerolipid/fatty acid cycle that are hypothesised to initiate signalling that alters insulin 
sensitivity (Samuel, et al., 2010) (Figure 1.9). The de novo ceramide pathway is one such 
pathway feeding into the pool of reactive lipid species with deleterious effects (Summers, 
2010).  
Lipotoxicity describes cellular dysfunction caused by chronically elevated intracellular lipid 
accumulation in non-adipose tissue. Lipotoxic effects are reported to occur via several 
mechanisms, including the production of reactive oxygen species (ROS), disruption to 
intracellular signalling pathways, damage to organelles, release of proinflammatory factors 
and lipoapoptosis, and lipid-induced apoptosis. Lipotoxicity has been found to cause cell 
death and insulin resistance and is a possible link between obesity, insulin resistance and 
type II diabetes (Day, et al., 2011). It is proposed that reactive lipid metabolites rather than 
FA themselves are deleterious in terms of insulin signalling and cell death. Such species 
include fatty acyl-CoAs (especially long-chain), diacylglycerol (DAG) (Shmueli, et al., 1993), 
phosphatidic acids (Zhang, et al., 2013) and ceramides (Górski, 2012; Reali, et al., 2017). 
Ceramide accumulation is thought to hinder insulin action by activating Akt inhibition, and 
inducing mitochondrial dysfunction and ER stress (Stratford, et al., 2004).  
These metabolites induce chronic activation of a serine/threonine kinase cascade, leading 
to altered insulin signalling through serine phosphorylation of IRS (Morino, et al., 2006). The 
serine-phosphorylated IRS1 is then unable to activate downstream signalling, leading to 
decreased GLUT4 translocation and hence decreased glucose uptake. Excess intracellular 
fatty acids and toxic lipid species such as fatty acyl-coA, ceramide and DAG have been 
shown to promote insulin resistance and exert deleterious effects on a range of tissues 
(Samuel, et al., 2010). DAG activates both novel and conventional protein kinases C (PKC), 
which are serine/threonine kinases shown to inhibit IRS via serine phosphorylation leading 
to insulin resistance (Erion & Shulman, 2010; Huang, 1989; Wang, 2006). 
Lipotoxicity also results in the induction of apoptosis with many mechanisms such as; 
synthesis of nitric oxide and reactive oxygen species (Gehrmann, et al., 2010), ceramide 
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production (Lupi, et al., 2002), endoplasmic reticulum stress (Cui, et al., 2013), being 
implicated. Furthermore, a one study indicates that lipotoxicity may cause cell death by 
necrosis via the mitochondrial necrotic pathway (Rockenfeller, et al., 2010). Many studies 
suggest that ectopic fat accumulation in insulin-sensitive tissues is linked to insulin 
resistance, however, understanding of the mechanisms by which the reactive lipid species 
alter insulin signalling and induce apoptosis, in liver and skeletal muscle is limited (Yki-
Järvinen, 2002). 
 
1.7 Adipose stress in obesity 
When adipocytes become too large a number of stress pathways are triggered casuing 
adipose dysfunction. This includes stress of the endothelial reticulum (ER), which increases 
the number of misfolded proteins and leads to an unfolded protein response (UPR) (Gregor 
& Hotamisligil, 2007). Under normal conditions, the ER is an important site of protein 
synthesis and is involved in the transport and release of proteins. Under acute ER stress 
the UPR is activated to increases protein folding, degradation, protein ubiquitination and 
various post-translational protein modifications in order to combat the ER stress (Ron & 
Walter, 2007). However under chronic ER stress conditions, UPR induces apoptosis. The 
ER demonstrates a state of chronic stress in obese and insulin resistant patients. The 
involvement of the UPR is thought to trigger the activation of inflammatory pathways, 
causing the release of chemokines and cytokines able to interfere with insulin signalling 
(Snel, et al., 2012). However, an increase in circulating insulin has been shown to 
upregulate the UPR (Boden, et al., 2014). Furthermore, UPR activation has been implicated 
in the development of insulin resistance via an array of mechanisms, including activation of 
c-jun N-terminal kinase (JNK), oxidative stress and inflammation (Cnop, et al., 2012). 
The dysfunction of adipose tissue results in adipocyte hypertrophy and apoptosis, both of 
which have the potential to induce the secretion of pro-inflammatory adipokines leading to 
the recruitment of pro-inflammatory immune cells to the site of dysfunction causing chronic, 
low-grade inflammation. In turn, this is associated with the activation of stress-signalling 
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pathways, insulin resistance and increases in autophagy and apoptosis resulting in a 
vicious cycle (Cancello, et al., 2005; Cinti, et al., 2005; Harman-Boehm, et al., 2007). 
 
1.7.1 Ectopic fat accumulation in liver 
Obesity, especially central obesity associated with increased visceral fat plays a primary 
role in ectopic fat accumulation and the pathogenesis of non-alcoholic fatty liver disease 
(NAFLD) (Marchesini, et al., 2008). Intrahepatocellular fat accumulation varies with the 
degree of obesity; small changes to weight are evident in changes in steatosis (Hamaguchi, 
et al., 2005). Compared with individuals of a normal weight, obese people have a 4.6-fold 
increased risk of developing NAFLD (Bellentani, et al., 2000). NAFLD is associated with 
metabolic abnormalities linked with excess adiposity and is a risk factor for type II diabetes 
mellitus, cardiovascular disease, and subsequent mortality (Anstee, et al., 2013). More than 
90% of obese type II diabetic patients also have non-alcoholic fatty liver disease (NAFLD) 
(Perry, et al., 2014), but weight loss is capable of normalising metabolic abnormalities 
responsible for the pathogenesis of NAFLD (Klein, et al., 2006). 
Accumulation of fat in the liver is mostly dependent on levels of free fatty acids (FFAs) 
recirculating from the adipose tissue with an estimated 59% of liver triglycerides from this 
source (Donnelly, et al., 2005). It is these FFAs rather than circulating triglycerides that 
promote hepatocellular injury (Yamaguchi, et al., 2007). Furthermore, the lipolytic potential 
of visceral adipose tissue is greater than that of the more abundant subcutaneous adipose 
tissue, and it deposits FFAs directly into the portal circulation adding more significantly to 
hepatic injury and steatosis (Björntorp, 1990; Jensen, 2008). Studies have shown that a 1% 
increase in subcutaneous fat increases intrahepatocellular lipids by 20%, whereas an 
increase of 1% in visceral fat increases intrahepatocellular lipids by 50% (Thomas, et al., 
2005). 
NAFLD leads to localised hepatic insulin resistance, caused by decreased tyrosine 
phosphorylation of IRS-2 and, thus, the inability to suppress hepatic glucose production and 
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active glycogen synthesis (Kubota, et al., 2016). Increased levels of hepatic DAG is thought 
to be the vehicle by which insulin signalling is hindered with the link being attributed to the 
activation of novel PKC-ε, which binds directly to and inhibits insulin receptor kinase activity 
(Erion, et al., 2010; Perry, et al., 2014; Schmitz-Peiffer & Biden, 2008). In turn, this causes 
a reduction in downstream phosphorylation and consequently Akt activation; thereby 
impairing insulin stimulation of glycogen synthesis and insulin inhibition of gluconeogenesis 
(Perry, et al., 2014). Furthermore, Kumashiro, et al., (2011) showed that increased hepatic 
DAG levels in obese, non-diabetic subjects was associated with insulin resistance via PKC-
ε activation. 
Additionally, hepatocellular carcinoma (HCC) has been associated with obesity (Ioannou, et 
al., 2003) with obesity-related metabolic abnormalities considered to initiate hepatic 
neoplasm (Yang, et al., 2001). In comparison with people of a normal weight, people with a 
BMI greater than 35 kg/m2 have a 4.52 relative risk of dying from HCC (Calle, et al., 2003). 
Exposure of the liver to high levels of FFAs can also lead to acute lipotoxicity, causing 
oxidative stress, ER stress (Pardo, et al., 2015), disturbances to the cell membrane, 
apoptosis and necrosis and can ultimately result in chronic liver injury and end-stage liver 
disease (Akazawa & Nakao, 2016; Marra, et al., 2008; Trauner, et al., 2010; Zámbó, et al., 
2013). However, mechanisms of lipotoxicity are not fully understood. 
In vitro studies on hepatocytic cell lines suggest that FFAs induce cell death mediated by 
ER stress, and mitochondrial dysfunction (Egnatchik, et al., 2014; Han & Kaufman, 2016; 
Yao, et al., 2011). Many studies suggest that cell death is via apoptosis (Akazawa, et al., 
2016; Malhi, et al., 2006; Zámbó, et al., 2013), however, further research is required to 
understand the mechanisms and consequences involved. 
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1.7.2 Ectopic lipid accumulation in skeletal muscle 
In skeletal muscle, lipids are present as extracellular lipids (EMCL) and intramyocellular 
lipids (IMCL). EMCL are lipids located in adipocytes between myofibers and IMCL are lipids 
located in droplets within muscle cells (Boesch, et al., 2006). In obese individuals, excess 
lipids are capable of accumulating as intramyocellular lipids (Unger, et al., 2010). This lipid 
overload affects not only insulin sensitivity, but also muscle repair and regeneration 
(Akhmedov & Berdeaux, 2013). 
Skeletal muscle is an important insulin-sensitive tissue heavily involved in glucose 
metabolism and, therefore, plays a crucial role in the pathogenesis of insulin resistance. 
Exposure to FFAs and intramyocellular lipid accumulation is able to cause lipotoxicity 
associated with localised insulin resistance, an indicator of systemic insulin resistance in 
non-obese offspring of type II diabetic patients (Guebre-Egziabher, et al., 2013). The 
relationship between the accumulation of intramyocellular triglycerides and insulin 
sensitivity was well established by Kelley & Goodpaster (2001). Intramyocellular 
accumulation of DAG was found to activate novel PKC-θ and in turn inhibit insulin signalling 
(Schmitz-Peiffer, et al., 2008; Szendroedi, et al., 2014).  
Another mechanism of lipotoxicity is the reduction in mitochondrial oxidative capacity 
caused either by a defect in the respiratory pathway or by a decrease in mitochondrial 
content. Much research suggests impairment in mitochondrial fatty acid oxidation causes 
an accumulation of toxic lipid intermediates. However, contradictory research indicates that 
insulin resistance is unlikely to be a consequence of diminished mitochondrial oxidative 
capacity caused by lipid accumulation (Summers, 2010; Turner, et al., 2007; Unger, et al., 
2001). A less common idea is that increased passage of fatty acids through mitochondria 
promotes incomplete oxidation and/or oxidative stress, resulting in a compensatory 
impairment in glucose utilisation (Guebre-Egziabher, et al., 2013). However, evidence 
indicates that mitochondrial dysfunction is not a primary defect, but rather a consequence of 
insulin resistance (Sleigh, et al., 2012). Therefore, it is interesting that although endurance-
trained athletes have high intramyocellular lipid content they also exhibit high insulin 
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sensitivity (Goodpaster, et al., 2001). Thus, it is thought that the cell’s oxidative capacity 
determines whether the accumulated lipids play a pathological or physiological role (van 
Loon & Goodpaster, 2006). 
In vitro studies on skeletal muscle cell lines indicate that exposure to FFAs causes 
irreversible impairments to cellular functions by inducing ER stress, mitochondrial 
dysfunction and ultimately apoptosis, and/or necrosis (Brøns & Vaag, 2009; Han, et al., 
2016; Martins, et al., 2012; Turpin, et al., 2009).  
 
1.7.3 Mechanisms of cell death  
Apoptosis is defined as programmed cell death and is a normal physiological process that 
removes damaged cells and aids in the homeostasis of tissue. However, apoptosis is also 
involved in the pathological progression of a number of diseases (Favaloro, et al., 2012) 
including type II diabetes mellitus (Butler, et al., 2003). The process of apoptosis involves 
characteristic morphological changes (Saraste & Pulkki, 2000), including shrinkage of the 
cytoplasm (Bortner & Cidlowski, 2002), cleavage of chromatin into internucleosomal 
fragments (Hughes & Cidlowski, 1997; Iglesias-Guimarais, et al., 2012), and damage to the 
cell membrane such as blebbing and asymmetry (Coleman, et al., 2001). Asymmetry of the 
membrane is an early feature of apoptosis and is accompanied by the translocation of 
phospholipid phosphatidylserine (PS) from the internal surface of the phospholipid bilayer to 
the external surface (Fadok, et al., 2001; Rysavy, et al., 2014).  
On the other hand necrosis was once considered as a passive, unregulated form of cell 
death usually resulting from insult to the cell. However, research over the past decade has 
found links between apoptosis and necrosis, indicating the involvement of signalling 
pathways (Hitomi, et al., 2008), yet much is left to be understood. The characteristics of 
necrosis are undefined, but can be distinguished from apoptosis by the rapid loss of 
membrane integrity early in the death process resulting in leakage of cellular content 
(Ziegler & Groscurth, 2004).  
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1.7.4 Fats as signalling molecules 
The capacity of lipids to act as signalling molecules was first acknowledged in the 1930s 
upon the discovery of cysteinyl leukotrienes and prostaglandins as muscle stimulants 
(Feldberg, et al., 1938; von Euler, 1936). The major breakthrough in lipid signalling was the 
identification of arachidonic acid as the source of prostaglandins and leukotrienes, which 
has resulted in our present understanding of eicosanoid signalling. This proved that a single 
lipid signalling molecule could induce a range of cell type- and pathway-dependent 
responses.  
Eicosanoids are a family of lipid signalling molecules including leukotrienes, prostaglandins 
and lipoxins, most of which are derived from arachidonic acid (AA) oxidation. These 
molecules modulate a vast array of physiological processes such as cell differentiation, 
migration, proliferation, antibody production, antigen presentation and cytokine formation 
(Harizi, et al., 2008). Cells of innate immunity are significant manufacturers of eicosanoids, 
which play a vital role in innate immunity by eliciting their effects locally in a paracrine and 
autocrine manner. Furthermore, they interact with cytokines and chemokines in the 
regulation of both inflammatory and homeostatic disorders. AA and its bioactive 
metabolites, thromboxane A2 and/or prostaglandin H2 are also potent activators of platelet 
aggregation (Hornberger & Patscheke, 1989; Parise, et al., 1984; Rao & White, 1985; 
Sangkuhl, et al., 2011). 
Research into lipid bilayers uncovered that phospholipase C could hydrolyse 
phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) to DAG and inositol-1,4,5-
trisphosphate (Ins(1,4,5)P3). Both of which were determined to be secondary messengers, 
triggering PKC activation and Ca2+ release from the internal pool, respectively. 
Phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) was also discovered as a 
signalling molecule regulating cell proliferation, growth, migration and survival (Leslie, et al., 
2007; Wymann, et al., 2003).  
The anti-proliferative and pro-apoptotic properties of ceramides and sphingosines have 
been well published (Futerman & Hannun, 2004; Pettus, et al., 2002; Woodcock, 2006). 
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Yet, sphingosine-1-phosphate (S1P) is involved in the promotion of cell proliferation, 
growth, survival and mobility via G protein-coupled receptors (GPCRs) and an unknown 
intracellular mechanism (An, et al., 2000; Goetzl, et al., 2004). 
Lysophosphatidic acid (LPA) is yet another signalling lipid that regulates gene expression 
through lipid-sensing transcription activators (Oyesanya, et al., 2008; Semple, et al., 2006). 
Furthermore, LPA induces platelet aggregation via an unclear mechanism that is thought to 
rely on the release of intracellular Ca2+ (Gerrard, et al., 1979).  
The contribution of lipid signalling dysregulation to the progression of many diseases has 
been established including allergic reactions, cancer, and cardiovascular, degenerative, 
and metabolic diseases to name a few (Wymann, et al., 2003). 
 
1.8 Physiological fatty acid concentrations 
Circulating fatty acids have been associated with a number of diseases including 
cardiovascular disease (Imamura, et al., 2012) and type II diabetes (Eckel, et al., 2005). 
Moreover, different groups within the subpopulation are said to have different levels of 
circulating FAs with studies indicating that circulating plasma FFAs are increased in obesity 
(Arner & Rydén, 2015; Ni, et al., 2015). As levels of circulating FAs may predispose subsets 
of the population to specific pathologies, it is important to understand natural variation in 
circulating lipid species and to find associations with disease. Especially as established 
references ranges for the concentration of each fatty acid for healthy individuals have yet to 
be standardised (Abdelmagid, et al., 2015).  
A review of the literature uncovered a handful of studies reporting average PA and OA in 
plasma phospholipids (De Vriese, et al., 2003; Song, et al., 2016). Many of the studies 
reviewed published relative percentages of fatty acid fractions rather than absolute 
concentrations (Bermúdez-Cardona & Velásquez-Rodríguez, 2016; Glaser, et al., 2010; 
Imamura, et al., 2017; Phillips & Dodges, 1967; Saadatian-Elahi, et al., 2008). Song, et al., 
(2016) measured the concentration of fatty acid fractions in phospholipids and their relative 
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percentages in 279 participants. Average PA in phospholipids was reported as 36.49 
mg/dL, and OA as 1.67 mg/dL. Most absolute values correlated with relative values, 
however, correlation between the concentration of PA in phospholipids and the relative 
weight percentage of PA in phospholipids was low (Song, et al., 2016). Another paper 
found 36.8 ± 8.3 mg/dL of PA and 10.5 ± 3.4 mg/dL (Yeh, et al., 1994).  
Most papers reporting average PA and OA in cholesterol esters also published relative 
values rather than absolute concentrations (Lewis-Barned, et al., 2000; Lindeberg, et al., 
1996; Salomaa, et al., 1990). Additionally, studies commonly omit whether the relative 
value is based on weight or concentration, which could lead to confusion (Lindeberg, et al., 
1996). Papers reporting absolute concentrations were exceedingly difficult to find. Yeh, et 
al., (1994) measured fatty acids fractions in plasma cholesterol esters in 104 
postmenopausal women and found 11.2 ± 2.6 mg/dL of PA and 14.8 ± 3.9 mg/dL of OA.  
Average PA and OA in plasma TG was more commonly published as a percentage relative 
to weight or concentration than absolute concentration (Koletzko & Decsi, 1994; Peterson, 
et al., 1994), with papers containing concentrations difficult to find. However, Yeh, et al., 
(1994) measured 17.9 ± 13.5 mg/dL of PA in plasma TG and 20.0 ± 13.5 mg/dl of OA in 
plasma TG.  
Once again, average circulating free palmitic acid and oleic acid were more frequently 
measured as a molar percentage (Laaksonen, et al., 2002; Raatz, et al., 2001; Yli-Jama, et 
al., 2002). A moderate number of papers publishing concentrations were also found, 
however, the range of reported values was large. Itakura et al., (2011) established 
circulating free fatty acid concentrations in 8076 participants, uncovering an average PA 
concentration of 74.8 ± 31.3 mg/dL and average OA concentration of 69.1 ± 37.0 mg/dL. 
Han, et al., (2011) found an average free PA of 25.6 ± 4.6 mg/dL and free OA of 47.9 ± 9.0 
mg/dl in 30 subjects. However, previous research has found that levels of plasma FFA 
increase during extended periods of fasting (Gjesdal, et al., 1976) and in states of 
increased stress (Taggart & Carruthers, 1971). 
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Relative measures and absolute concentrations of PA and OA in total plasma lipids were 
published equally in the literature (Abdelmagid, et al., 2015; Risé, et al., 2007; Yeh, et al., 
1994). However, the usage of the units mmol/L were more common than mg/dL. 
Abdelmagid, et al., (2015) studied concentrations in 826 subjects. Average total PA and OA 
were 1.63 ± 0.46 mmol/L and 1.29 ± 0.42 mmol/L, respectively. Concentrations ranged as 
high as 4.1 mmol/L for PA and 3.2 mmol/L for OA. From this paper ‘normal ranges’ (2.5th -
97.5th percentile) of PA were found to be 0.71 -2.5 mM, whilst for OA this was slightly 
lower, 0.45 -2.1 mM.  
 
1.8.1 Dietary effects of saturated versus unsaturated fatty acids 
The issue of dietary fat intake is particularly relevant considering the extensive intake of 
saturated fats in the western ‘McDonald’s’ diet. The recommendation (based on an 
average-sized woman doing an average amount of exercise) for total fat intake is less than 
70g, with saturates less than 20g (NHS, 2017). While the average total fat intake for the UK 
population is close to recommended values, that for saturated fats remains about 1.7% over 
the recommended limit (British Nutrition Foundation, 2018). Morever, there is a proportion 
of the population with a significantly higher intake of fat, with 1 in 4 adults and 1 in 4 
children aged 10-11 classified as obese. 
The fat composition of dietary intake is important as the diet is able to alter circulating fatty 
acid compositions (Ahrens, et al., 1957; Liu, et al., 2015; Raatz, et al., 2001). Furthermore, 
the composition of TG in the adipose tissue is directly related to composition of ingested 
fats (Coppack, et al., 1999).  
For the past few decades, controversy regarding ‘good’ fats and ‘bad’ fats has led to 
sensational stories in the media, and an increase in the number of meta-analysis and 
cohort studies being published. It is claimed that the consumption of dietary SFA is bad and 
leads to the development of T2DM, CVD and CHD. Whereas both unsaturated fatty acids, 
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MUFA and PUFA, are considered ‘good’ with their consumption decreasing these risk 
factors.  
The majority of large-scale studies concluded that the consumption of SFA was not 
associated with the development of CHD (de Souza, et al., 2015; Li, et al., 2015; Nettleton, 
et al., 2017; Siri-Tarino, et al., 2010), CVD (de Souza, et al., 2015; Siri-Tarino, et al., 2010), 
stroke (de Souza, et al., 2015; Li, et al., 2015; Nettleton, et al., 2017), T2DM (de Souza, et 
al., 2015; Guasch-Ferré, et al., 2017; Liu, et al., 2018) or all—cause mortality (de Souza, et 
al., 2015). However, Zong, et al., (2016) found that high dietary intake of SFA was 
associated with CHD, whilst Paquet, et al., (2014) discovered a link between dietary SFA 
and T2DM. Some studies concluded that the total intake of SFA is not as important as the 
source of those SFA (Praagman, et al., 2016), for example Guasch-Ferré, et al., (2017) 
found no association between baseline dietary SFA intake and T2DM, but did find a 
significant association between the consumption of cheese and butter and its development. 
In contrast, the consumption of whole yoghurt was found to reduce the risk of developing 
T2DM. Additionally, a link between the consumption of SFA from processed foods and the 
development of CVD was uncovered (Guasch-Ferré, et al., 2015). 
Conversely to SFA, the dietary intake of PUFA and MUFA was inversely associated with 
all-cause mortality (Guasch-Ferré, et al., 2015) and omega-3 fatty acids were negatively 
associated with the development of T2DM (Paquet, et al., 2014). Furthermore, it was 
established that the replacement of dietary SFA with PUFA decreased the risk of 
developing CHD (Jakobsen, et al., 2009; Li, et al., 2015; Nettleton, et al., 2017; Siri-Tarino, 
et al., 2010). Additionally, the replacement of SFA with PUFA or MUFA decreased the risk 
of CVD (Guasch-Ferré, et al., 2017). 
The consumption of trans fats was also linked with CHD and all-cause mortality (de Souza, 
et al., 2015). The replacement of which with MUFA was found to decrease the risk of CVD 
(Guasch-Ferré, et al., 2015). 
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1.9 Models 
1.9.1 Solubility of fatty acids in solutions 
The fact that long-chain fatty acids have low solubility in aqueous solutions presents as the 
main limitation for in vitro studies. However, this may be bridged by conjugating FFAs to 
albumin, which in turn enhances the physiological relevance of the FFA solutions. Plasma 
albumin has 7 binding sites for fatty acids ranging from high to moderate affinity, and also 
acts to facilitate fatty acid uptake at cells (van der Vusse, 2009). Albumin makes up about 
60% of the total protein in blood. The reference range for albumin in serum is approximately 
35-50 g/L, with a serum half-life of approximately 20 days. Ratios greater than 7 exceed 
solubility, potentially inducing artefacts. Therefore, the FFA/albumin molar ratio is an 
important factor in determining cellular responses.  
Unbound FFAs are considered accessible for cellular uptake, the concentration of which is 
reliant on the ratio of albumin to total FFAs (Spector, 1975). This suggests that biological 
effects can be augmented to mimic pathological conditions by reducing the concentration of 
bovine serum albumin (BSA) present, thereby increasing bioavailable FFA. Despite albumin 
having 7 FA-binding sites (van der Vusse, 2009), only 2 FA molecules are conjugated to 
each albumin in the circulation (Oliveira, et al., 2015). It is said that the FFA:albumin ratio 
can rise to 6 in certain disease states (Kleinfeld, et al., 1996; Nehra, et al., 2001), however, 
many studies use higher ratios to study mechanisms of lipotoxicity. 
Experimentally, FFA to BSA molar ratios between 8:1 and 2:1 were used in lipotoxicity 
studies. 8:1 (Hatanaka, et al., 2014), 7:1 (Mei, et al., 2011; Song, et al., 2007), 6.6:1 (Hall, 
et al., 2014; Lai, et al., 2008; Listenberger, et al., 2003a; Mantzaris, et al., 2011), 6:1 (Chu, 
et al., 2010; Martinez, et al., 2008; Nagaoka, et al., 2015; Schulz, et al., 2013), 5:1 (Briaud, 
et al., 2001; Laurens, et al., 2016), 3.5:1 (Lou, et al., 2014) and 2:1 (Cacicedo, et al., 2011; 
He, et al., 2016; Hetherington, et al., 2016; Stoianov, et al., 2015). The FFA to BSA used in 
this study was guided by the literature and did not exceed 7:1 (Table 2.2).  
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1.9.2 HepG2 
HepG2 are a widely used hepatocellular carcinoma cell line that are highly differentiated, 
displaying many genotypical traits of normal liver cells (Gerets, et al., 2012; Sassa, et al., 
1987). Yet, they have a basal gene expression profile distinct from primary human 
hepatocytes (Jennen, et al., 2010). This may be due to oncogenic transformation from their 
origin as hepatocellular carcinoma cells, but may also be a result of extensive passaging 
leading to genetic mutations (Marx, 2014).  
The metabolic capacity of HepG2 is also low in comparison to primary hepatocytes (Xu, et 
al., 2004), meaning they are more suited to testing the toxicity of molecules than their 
metabolites. Additionally, HepG2 cells are partially deficient in cytochromes whilst levels of 
phase II enzymes, excluding UDP-glucuronosyl transferases, are expressed in normal 
levels (Westerink & Schoonen, 2007). 
Regardless of these drawbacks, the sensitivity of HepG2 in the detection of hepatotoxic 
treatments was established to be 90% (O’Brien, et al., 2006). 
 
1.9.3 L6 
Most established immortalised skeletal muscle cell lines exhibit little insulin-dependent 
glucose uptake and GLUT4 translocation, except for rat L6 and mouse C2C12 myotubes 
(Nedachi & Kanzaki, 2006). However, L6 myotubes exhibit greater glucose uptake following 
insulin stimulation than C2C12 cells (Sarabia, et al., 1990), thereby highlighting L6 
myotubes as the most promising in vitro skeletal muscle cell model for this project. 
Furthermore, L6 maintain many of the same characteristics as mature skeletal muscle cells 
and grow in a monolayer, thus, allowing even accessibility to substrates (Klip, et al., 1986). 
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1.9.4 3T3-L1 
3T3-L1 is an immortalised cell line developed from murine Swiss 3T3 cells (Mehra, et al., 
2007). The cells are morphologically indistinguishable from fibroblasts yet are already 
committed to the adipocyte lineage (Mehra, et al., 2007). Differentiation is achieved through 
treatment with pro-differentiation agents for approximately 5 days followed by a period of 
maintenance, which results in the development of mature adipocytes characterised by the 
formation of intracellular lipid droplets (Zebisch, et al., 2012). 
3T3-L1 are used extensively as a model for insulin signalling studies as they utilise two 
isoforms of glucose transporters; a constitutive glucose transporter, GLUT1 and an insulin-
sensitive transporter, GLUT4 (Thomson, et al., 1997). The fibroblast phenotype expresses 
only GLUT1, whilst upon differentiation the adipocyte phenotype additionally expresses 
GLUT4 (Thomson, et al., 1997). 3T3-L1 are thought to represent a valid model for insulin 
signalling studies as evidence indicates their metabolism mimics that of adipocytes isolated 
from adipose tissue (Macdougald, et al., 1995; Mehra, et al., 2007). 
 
1.9.5 Washed human platelets 
Three platelet models exist for in vitro studies: whole blood, platelet rich plasma (PRP) and 
washed platelets. Despite being more physiologically relevant, whole blood and PRP still 
contain many components of the blood that could potentially interfere and/or mask the 
effects being studied. The plasma in whole blood and PRP contain fluctuating FFA 
concentrations which would make the study of the effects of individual fatty acids 
impossible. Therefore, a washed platelet model was selected.  
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2 Materials and methods 
2.1 Chemicals and reagents 
Palmitic acid ≥99% (catalogue no. P0500) and oleic acid ≥99% (catalogue no. O1008) were 
purchased from Sigma-Aldrich (Dorset, UK). 
Human hepatocellular carcinoma cells (HepG2 -ATCC® HB-8065™) were purchased from 
American Type Culture Collection (ATCC) (Virginia, USA), cultured in Roswell Park 
Memorial Institute (RPMI, catalogue no. 21875-034) medium from Thermo Fisher 
(Massachusetts, USA) and used between passage 6-15. Rat skeletal muscle cells (L6 -
ATCC® CRL-1458™) were purchased from ATCC (Virginia, USA), cultured in Dulbecco’s 
Modified Eagle Medium (DMEM, catalogue no. 41965-039) from Thermo Fisher 
(Massachusetts, USA) and used between passage 4-15. Mouse fibroblasts (3T3-L1 -
ATCC® CL-173™) were purchased from ATCC (Virginia, USA), cultured in Dulbecco 
Modified Eagle Medium (DMEM, catalogue no. 41965-039) from Thermo Fisher 
(Massachusetts, USA) and used between passage 4-6. All medium contained 10% foetal 
bovine serum (catalogue no. F2442) and 1% penicillin/streptomycin (catalogue no. P4333) 
from Sigma-Aldrich (Dorset, UK). FITC Annexin V Apoptosis Detection Kit (catalogue no. 
556419) was purchased from BD Pharmingen (Wokingham, UK) and EnzChek® Caspase-3 
Assay Kit #1 (catalogue no. E13183) was obtained from Thermo Fisher (Massachusetts, 
USA). All other reagents were purchased from Sigma Aldrich (Dorset, UK). 
Human platelets were obtained from volunteers. Thrombin (catalogue no. T9326) was 
obtained from Sigma-Aldrich (Dorset, UK) and CRP-XL was donated by the Department of 
Pharmacology at Cambridge University, UK. Antibodies against markers of activation, anti-
CD62P (catalogue no. MCA2420PE) and anti-CD63 (catalogue no. MCA4754) were 
obtained from Bio-Rad (California, USA). Anti-PAC1 (catalogue no. MABT893) was 
purchased from Merck Millipore (Massachusetts, USA). Pierce™ LDH Cytotoxicity Assay 
Kit (catalogue no. 88953) was acquired from Thermo Fisher (Massachusetts, USA). All 
other reagents were purchased from Sigma Aldrich (Dorset, UK). 
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2.1.1 Fatty acid solutions 
Fatty acid stock solutions were created by dissolving palmitic acid (PA) or oleic acid (OA) in 
100% methanol (catalogue no. 34860, Sigma Aldrich, Dorset UK) to a concentration of 100 
mM. These stock solutions were diluted in cell culture medium containing 1% w/v BSA 
(catalogue no. A7030, Sigma Aldrich, Dorset UK) to produce the final working 
concentrations prior to treatment of the cells. Treatment medium was dispensed onto the 
cells for 24 hours. Final treatment concentrations are shown in Tables 2.1 and 2.3. 
Concentrations of free fatty acids in the medium prior to the addition of PA and/or OA could 
not be ascertained due to the use of a proprietary formula of Thermo Fisher Scientific, 
however, they were said to be low. 
1% w/v BSA was added to each treatment solution (151 µM). BSA: FFA molar ratios are 
presented in Table 2.2. 
 
 
Table 2.1 Final concentrations of fatty acids used in cell culture experiments in 
medium containing 1% BSA 
 
Concentration (mM) 
PA OA PA OA PA OA PA OA 
Palmitic acid  
0.17 - 0.33 - 0.67 - 1.0 - 
Oleic acid 
 
- 0.17 - 0.33 - 0.67 - 1.0 
2 : 1 
combination 
OA : PA 
0.17 0.33 0.67 1.0 
0.06 0.11 0.11 0.22 0.22 0.45 0.33 0.67 
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Table 2.2 BSA : fatty acid molar ratio in final concentrations 
Concentration (mM) FFA to BSA molar ratio 
0.06 0.38:1 
0.11 0.73:1 
0.17 1.13:1 
0.22 1.46:1 
0.33 2.19:1 
0.45 2.98:1 
0.67 4.44:1 
1.00 6.62:1 
 
Fatty acids in platelet experiments were added to calcium free Tyrode’s solution (Table 2.4) 
without BSA as its addition altered the turbidity of washed platelets thereby preventing 
analysis by light transmission aggregometry. Initial concentrations are shown below in 
Table 2.3. A wide range of concentrations were used as lower levels of unbound FFA are 
present in the plasma than bound to albumin. Eventually, only the effects of 0.1 mM oleic 
acid were investigated. 
 
 
Table 2.3 Final concentrations of fatty acids used in platelet experiments using a 
logarithmic scale 
 Concentration (mM) 
Palmitic 
acid 
0.001 0.003 0.01 0.03 0.1 0.3 1 
Oleic 
acid 
0.001 0.003 0.01 0.03 0.1 0.3 1 
 
 56 
 
2.1.2 Calcium Free Tyrode’s (CFT) buffer 
CFT buffer is the most commonly used buffer in platelet research and was selected as the 
presence of above normal levels of calcium can inhibit platelet aggregation, thus, 
invalidating results (Herrmann, et al., 1970). The formulation can be found in Table 2.4. 
NaCl (catalogue no. S7653), KCl (catalogue no. P9333), HEPES (catalogue no. H3375), 
NaH2PO4 (catalogue no. S8282), NaHCO3 (catalogue no. S5761), MgCl2 (catalogue no. 
M8266) and glucose (catalogue no. D9434) were all ordered from Sigma Aldrich, Dorset 
UK. The pH of the solution was adjusted to pH 7.4 and checked every morning before use. 
 
 
Table 2.4 Calcium-free Tyrode’s (CFT) buffer formulation 
(500 ml of 1 mM stock) 
CFT buffer Mass (g) 
NaCl 68.5 
KCl 1.35 
HEPES 5.0 
NaH2PO4 0.2 
NaHCO3 5.95 
MgCl2 0.55 
Glucose 2.8 
 
2.1.3 Oil Red O solution 
350 mg of Oil Red O was dissolved in 100 ml of 100 % isopropanol and filtered with 5-8 µm 
pore filter paper. The stock solution was stored at room temperature. Oil Red O working 
solution was freshly prepared by mixing the stock solution in a 3:2 ratio with double distilled 
water (ddH20), and vortexed prior to use. 
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2.2 Cell culture methods 
2.2.1 Cell culture 
HepG2 (ATCC® HB-8065™) cells were purchased from ATCC. Upon arrival the vial was 
thawed by gentle agitation in a 37°C water bath, transferred to a centrifuge tube containing 
9 ml of Roswell Park Memorial Institute medium (RPMI) and spun at 125 x g for 5 minutes. 
The pellet was resuspended in 20 ml of pre-incubated, supplemented RPMI and transferred 
into a 75 cm2 flask (T-75). 
L6 (ATCC® CRL-1458™) cells were purchased from ATCC. Upon arrival the vial was 
thawed by gentle agitation in a 37°C water bath and transferred into a T-75 containing 20 
ml of pre-incubated, supplemented Dulbecco’s Modified Eagle’s Medium supplemented 
(DMEM). The myocytes were differentiated to form multinucleated myotubes and striated 
fibres by allowing them to mature at a high confluence over 5 days (Figure 2.1). Cell fusion 
gradually declined with passage, so cells with a passage higher than 15 were not used in 
this study. 
3T3-L1 (ATCC® CL-173™) cells were purchased from ATCC. Upon receipt the vial was 
thawed by gentle agitation in a 37°C water bath, transferred to a centrifuge tube containing 
9 ml of DMEM and spun at 125 x g for 5 minutes. The pellet was resuspended in 10 ml of 
pre-incubated, supplemented DMEM and transferred into a 25 cm2 flask (T-25). 
All cells were incubated in a humidified incubator with an atmosphere of 5% CO2 at 37°C. 
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Figure 2.1 Image of differentiated L6 myotubes 
A) Inverted microscopy image of L6 myotubes following differentiation at 1000x 
magnification. B) Image of differentiated L6 myotubes supplied in ATCC literature (ATCC, 
2017). 
 
2.2.1.1 Subculturing Procedure 
Cells were subcultured before reaching 70% confluence. The culture medium was removed 
and discarded, and cells were washed gently with phosphate-buffered saline (PBS). 1 ml of 
trypsin-EDTA solution was added per 25 cm2 of flask and observed under an inverted 
microscope until the cell layer dispersed. Dispersal was often facilitated by placing flasks in 
an incubator at 37°C. Upon detachment, medium was added to neutralise the trypsin-EDTA 
and cells were aspirated via pipette. Appropriate aliquots of the cell suspension were 
transferred to new culture vessels. A subcultivation ratio of between 1:4 and 1:6 was used 
for HepG2 (ATCC, 2018b), whilst a ratio of between 1:20 and 1:40 was used for L6 (ATCC, 
2017). For 3T3-L1, new flasks were inoculated with 2 X 103 cells/cm2 (ATCC, 2018a). 
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2.2.2 Assessment of cell viability  
2.2.2.1 Cell Counting Kit 8  
For experimental conditions, a 96 well-plate was plated with 100 µl/well of 16,000 cells/ml 
cell suspension. The plate was incubated in a humidified incubator at 37°C with 5% CO2 for 
24 hours. Cells were treated with control and fatty acid solutions and returned to the 
incubator for a further 24 hours. 10 µl CCK-8 reagent was added to each well, and the plate 
was returned to the incubator for 2 hours. Following this incubation period, the absorbance 
was measured at 450 nm (Tecan Sunrise absorbance microplate reader). 
Initially, a standard curve (Figure 2.2A) was created to assess the linearity of absorbance, 
by diluting a cell suspension of 100,000 cells/well in increments of 2000 cells/well in a 96-
well plate. The above method was used and and the results used to select a seeding 
density for the following experimentation.  
The confidence interval for the line of best-fit was defined by the confidence bands on either 
side. The curved nature of the dashed confidence bands indicate the boundaries of all 
possible lines of best-fit, rather than indicating that the line of best-fit may be a curve. Given 
the assumptions of linear regression, the confidence bands encapsulated the true best-fit 
line of non-linear regression with a 95% certainty (Figure 2.2A). They indicated a consistent 
linear relationship between number of cells and absorbance below 20000 cells, therefore, 
allowing use of the line of best-fit to calculate percentage viability. 
The slight inverted u-shaped distribution on the residuals plot indicated that a non-linear 
regression was preferable over linear regression. However, the spread appeared to be 
random and, thus, did not allow the prediction of error, indicating that only random error 
remained and the non-linear regression model was a good fit (Figure 2.2B). 
A non-linear relationship was found between the number of cells and absorbance above 
22,000 cells per well, where the curve plateaued and standard error increased due to 
saturation of the solution in the wells. Therefore, a final cell density of ~16,000 cells per well 
were utilised to maximise effect size without invalidating results by reaching saturation.  
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Figure 2.2 CCK-8 produced a linear relationship between the number of cells and 
absorbance 
A) Up to 20000 cells per well, the absorbance of CCK-8 was directly proportional to the 
number of cells present. B) The random distribution of points on the residuals plot indicated 
that the model used for the line of best-fit was correct. 
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2.2.3 Stages of cell death determined by flow cytometric analysis 
2.2.3.1 Annexin V/propidum iodide assay  
Flow cytometric apoptosis assays exploit exposed phosphatidylserine (PS) via the use of 
fluorophore conjugated annexin V, a phospholipid-binding protein with high affinity for PS. 
The translocation of PS precedes the loss of plasma membrane integrity, which is evident 
in the subsequent stages of apoptotic and necrotic progression. Therefore, the use of a 
nuclear counter stain such as propidium iodide (PI) with annexin V is vital for flow 
cytometric analysis of cell states ranging from viable to apoptotic, necrotic and dead. The 
intact, but damaged membranes of early apoptotic cells are targeted by the annexin V, but 
are impermeable to PI, however, as apoptosis and/or necrosis progress the membrane is 
further damaged, becoming permeable to PI allowing for the identification of the later 
stages of cell death. 
Flow cytometric analysis of annexin V/PI stained cells is divided into 4 quadrants (Figure 
2.4). Annexin V-and PI-negative cells are considered viable, as PS is not located 
extracellularly. Annexin V-positive and PI-negative cells are classified as early apoptotic 
due to the translocation of PS to the external surface of the cell membrane. Annexin V-
negative and PI-positive cells are late apoptotic/necrotic, portraying external cellular 
damage as PS has not translocated to the extracellular surface of the cell membrane, yet 
nuclear content is leaking. Annexin V-and PI-positive cells are considered to be dead as 
both PS and nuclear material can be accessed by the antibodies. 
Cells were grown in T-25 flasks and treated with fatty acids for 24 hours once 70% 
confluent. After treatment the cells were trypsinised, neutralised with medium and 
transferred to 15 ml centrifuge tubes. 
A FITC Annexin V Apoptosis Detection Kit was used to assess cell death. Binding buffer 
supplied in the kit was diluted 1:9 with ddH2O. The cells were washed with 5 ml of chilled 
cell wash then centrifuged, twice. The pellets were resuspended in 300 µl of binding buffer 
solution and 150 µl of each sample was transferred to a 5 ml Falcon tube. 5 µl of annexin V 
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and 5 µl of PI was added to each Falcon tube. The cells were gently vortexed and 
incubated in the dark, at room temperature for 15 minutes. 300 µl of binding buffer solution 
was then added to each tube and agitated prior to analysis. 
Samples were analysed on a BD Accuri™ C6 (BD Biosciences), with 10,000 events per 
sample acquired. Control flow cytometry plots were used to gate the cell population and 
exclude debris from further analysis. A forward scatter vs. side scatter plot included in a 
template supplied by BD Biosciences for the FITC Annexin V Apoptosis Detection Kit was 
used to gate the visible cell population (Figure 2.3).The template was also used with the 
gated flow cytometry results to separate plots into four quadrants; live, dead, early apoptotic 
and late apoptotic/necrotic (Figure 2.4). Raw data and the percentage of events in each 
quadrant was collected and analysed in conjunction with visual analysis of the plots. 
Forward scattered light and side scattered light were measured and converted to 
percentage change from the control. 
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Figure 2.3 Exclusion of debris using the BD Bioscience kit template 
A gate drawn around the visible cell population in the control samples excluded low FSC 
and SSC events, which were likely to be debris. 
 
 
Figure 2.4 BD Biosciences template used to gate different stages of cell death  
A) Annexin V-negative/PI-positive quadrant where late apoptotic/necrotic events were 
recorded. B) Annexin V-and PI-negative quadrant where live cells were logged. C) Annexin 
V-and PI-positive quadrant where dead cells were measured. D) Annexin V-positive/PI 
negativequadrant where apoptotic events were counted. 
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2.2.4 Determination of apoptosis by caspase 3/7 assay 
Apoptosis, a form of programmed cell death, plays a vital role in many disease states and 
disorders (Favaloro, et al., 2012). Apoptosis is distinct from necrosis, both biochemically 
and morphologically and, thus, can be distinguished from one another. Apoptosis causes 
condensation of the nuclear chromatin and shrinkage of the cytoplasm whilst fragmenting 
the genome and degrading a number of cellular proteins including cytokeratins, alpha-
fodrin, poly (ADP-ribose) polymerase (PARP), and nuclear mitotic apparatus protein 
(NuMA) (Slee, et al., 2001). The caspase CED-3/ICE family of proteases are thought to be 
crucial mediators of these detrimental biochemical processes. Caspase-3 cleaves a range 
of proteins, a number of which are important in the initiation of apoptosis through its 
specificity for the amino acid sequence Asp-Glu-Val-Asp (DEVD) (Asakura, et al., 1999; 
Shiah, et al., 1999; Wolf, et al., 1999). 
 
2.2.4.1 EnzChek® Caspase-3 Assay Kit #1 
The EnzChek® Caspase-3 Assay Kit #1 enables the detection of apoptosis by measuring 
increases in caspase-3 activity and the activity of other DEVD-specific proteases such as 
caspase-7. The assay capitalises on the use of Z-DEVD–AMC substrate which is mildly 
fluorescent in its native state (excitation/emission ~330/390 nm), but which produces a 
strong blue fluorescent product (excitation/emission ~342/441 nm) upon proteolytic 
cleavage (Thermo Fisher, 2003). Fluorescence measured via a fluorescence microplate 
reader is directly proportional to caspase-like activity. Furthermore, this activity can be 
quantified with the use of a reference standard and the result verified with the use of an 
inhibitor (Blaak, et al., 2007).  
The EnzChek® Caspase-3 Assay Kit #1 (Thermo Fisher) was utilised to assess apoptosis 
in L6 cells. The assay was not used for HepG2 cells as these cells were found to clump in 
culture, thereby risking high levels of background cell death.  
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Cells were cultured in T-25 flasks following the aforementioned procedure until 60% 
confluent, and differentiated in to myotubes prior to treatment. Cells were incubated for 24 
hours with the fatty acid solutions at 37oC with 5% CO2. Negative controls were also 
prepared by treating cells with medium containing 1% BSA, but no fatty acids. 
Following treatment, cells were harvested by trypsinisation via the aforementioned method 
and washed in ice cold phosphate-buffered saline (PBS) three times prior to use of the 
EnzChek® Caspase-3 Assay Kit #1. Cell pellets were resuspended in 50 µL of cell lysis 
buffer, frozen in a dry ice-ethanol bath for 5 minutes and then thawed. The lysed cells were 
centrifuged at 5000 rpm for 5 minutes in a micro-centrifuge to pellet cell debris, and 50 µL 
of each supernatant aliquoted into individual wells of a 96-well plate. 50 µL of cell lysis 
buffer was used to determine background fluorescence as a no-enzyme control. 1 µL of 1 
mM Ac-DEVD-CHO inhibitor was added to specific samples. These samples were covered 
with foil and incubated at room temperature for 10 minutes. Meanwhile, 1 µL of DMSO was 
added to another set of samples without the inhibitor and incubated under the same 
conditions, whilst the remaining samples were stored on ice for 10 minutes. 50 µL of 
substrate working solution, containing Z-DEVD–AMC substrate and reaction buffer was 
added to each sample and control. The microplate was covered with foil and incubated at 
room temperature for 30 minutes. Meanwhile, a 7-amino-4-methylcoumarin (AMC) standard 
curve was created. 10 mM AMC stock solution was diluted in reaction buffer to yield a 
concentration range between 0-100 µM. 100 µL of each concentration was dispensed into 
empty microplate wells. Fluorescence was measured using a PerkinElmer fluorescence 
plate reader at an excitation of 342 nm and emission of 441 nm every 10 minutes for 5 
hours. 
The reference standard, AMC was used to enable the quantitation of AMC released, and, 
thus, caspase activity (Figure 2.6B). A reversible aldehyde inhibitor, Ac-DEVD-CHO was 
employed to confirm that caspase-3-like proteases were responsible for the observed 
fluorescence signal in control and treated cell populations.  
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Figure 2.5 Fluorescence of the reference standard, AMC, over time at increasing 
concentrations 
The reference samples did not increase in fluorescence over time and produced a linear 
line of best-fit. A) Plotted over time, the fluorescence produced by all concentrations of the 
reference did not increase over time. B) At 5 hours, there was a linear relationship between 
concentration of the reference standard and fluorescence. C) A residuals plot showed 
random distribution indicating the correct model for the line of best-fit was selected. 
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Readings were taken every 10 minutes for 5 hours to find the optimum time point at which 
the samples were adequately fluorescent for statistical analysis of the data (Figure 2.6). 
The AMC reference standard was also read every 10 minutes for 5 hours to ensure 
evaporation was not occurring (Figure 2.5A). The 5 hour time point was selected. 
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Figure 2.6 Fluorescence produced by all treatments increased linearly over time 
Fluorescence produced by palmitic acid treated cells (A), oleic acid treated cells (B) and 
combination treated cells (C) increased linearly over time and produced maximal 
fluorescence at the 5 hour time point. 
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2.2.5 Intracellular lipid accumulation 
2.2.5.1 Oil Red O assay 
Cells were seeded at 8 x 104/ml onto coverslips in 6 well plates. Cells were treated at 60% 
confluence for 24 hours. After 24 hours, the medium was removed and the cells were 
washed with PBS. 2 ml of 10% formalin was dispensed into each well and incubated at 
room temperature for 10 minutes. The formalin was discarded and replaced with 2 ml of 
fresh 10% formalin and incubated at room temperature for a further 2 hours. The formalin 
was then removed and the cells were washed twice with ddH20. 2 ml of 60% isopropanol 
was dispensed into the wells and the cells were incubated at room temperature for 5 
minutes. The isopropanol was removed and the cells were left to dry. 1 ml of Oil Red O 
working solution was added to the cells and incubated at room temperature for 10 minutes. 
Following incubation the Oil Red O was removed and the cells were immediately washed 4 
times with ddH20. 
Intracellular Oil Red O was eluted out of the cells by 1 ml of 100% isopropanol and 
incubated on an agitator for 10 minutes. The solution was mixed via pipette and transferred 
to glass cuvettes for spectrophotometric analysis. The absorbance was measured at 500 
nm with 100% isopropanol as a blank (Tecan Sunrise absorbance microplate reader). 
 
2.2.5.2 ImageJ analysis of intracellular lipid accumulation 
Cells were grown to 60% confluence and treated in T-75 flasks as described above. 
Medium was discarded and cells studied via inverted microscopy at 1000x magnification. A 
camera was attached to the microscope and photos were taken of random fields for ImageJ 
analysis. 
A review of the literature identified two methods for the identification of lipid droplets via 
open-source ImageJ software (National Institutes of Health), using Macros MorphoLibJ 
morphological segmentation (INRA-IJPB Modeling and Digital Imaging lab) and MRI Lipid 
Droplets Tool (MRI). The ability of these two tools to count and/or measure lipid droplets in 
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unstained L6 cell images were assessed. However, neither method was capable of 
distinguishing lipid droplets to a high enough degree of accuracy (Figure 2.7 and 2.8, 
respectively). Therefore, a new method was developed to count lipid droplets in unstained 
images. 
 
2.2.5.3 Method development for ImageJ analysis of unstained intracellular lipid 
droplets 
Images from inverted microscopy were assigned unique identifiers and analysed blind. 
Their identity was revealed after all data collection had taken place. The image to be 
analysed was randomly selected from the pool of images, without knowing to which 
treatment or concentration it belonged. The photograph was opened, viewed at 100% size, 
converted to an 8-bit greyscale image, and the contrast increased using the sharpen tool. 
The area of interest was randomly selected by dragging the image across the field aperture, 
and then cropped (Figure 2.9A).The image was thresholded by eye to include the maximum 
number of lipid droplets without introducing artefacts (Figure 2.9B). This was performed on 
the acquired images to segment background from lipid droplets, which was possible as the 
edge of lipid droplets were more highly saturated than other structures within the cell. The 
images were converted to binary images and processed to fill holes and view outlines. Lipid 
droplets that had not been adequately captured by thresholding were corrected using the 
ImageJ pencil tool. The watershed feature was also used to separate adjoining outlines 
(Figure 2.9C). The images were manually compared against the original image to ensure 
consistency and correct binary conversion prior to measuring the number of lipid droplets 
present per field. Finally, the image was analysed using the ‘analyse particles’ feature with 
limits set at 10 pixels to infinity, to include all levels of sphericity, and to produce an image 
of outlines including holes along with the number of lipid droplets present (Figure 2.9D). 
Data was loaded into GraphPad Prism 7 for statistical analysis. 
Note that the limits for the final analysis of particles could have been lowered from 10, 
however, this would likely have included artefacts in the results. 
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Figure 2.7 MorphoLibJ morphological segmentation analysis of lipid accumulation 
did not produce acceptable results 
A) Normal 8-bit image analysed as a ‘Border Image’. Watershedding identified whole cells 
not lipid droplets. B) Normal 8-bit image analysed as an ‘Object Image’. Watershedding 
outlined miscellaneous areas of the image, not lipid droplets. C) Inverted colour 8-bit image 
analysed as a ‘Border Image’. Watershedding was unable to identify any structures. D) 
Inverted colour 8-bit image analysed as an ‘Object Image’. Watershedding outlined 
miscellaneous areas of the image, not lipid droplets. 
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Figure 2.8 MRI Lipid Droplets Tool did not identify lipid droplets 
A) Normal 8-bit image following analysis. Watershedding identified few structures, mainly 
interfaces between cells and not lipid droplets. B) Inversed colour 8-bit image following 
analysis. Watershedding outlined cells not intracellular lipid droplets. 
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Figure 2.9 Visual representation of novel method to count unstained intracellular 
lipid droplets using ImageJ 
A) 8-bit sharpened and cropped image. B) Thresholded lipid droplets. C) Binarised image 
containing only lipid droplets and background. D) The counted lipid droplets. 
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2.3 Platelet methods 
2.3.1 Blood collection 
The use of human blood in this project was granted ethical approval by the Research Ethics 
Panel of the Faculty of Science and Technology, Anglia Ruskin University, UK. Donors 
were selected at random from a pool of healthy adult volunteers, with no exclusion criteria 
for smokers and/or consumers of alcohol. Before donation, the volunteers provided 
informed consent and confirmed that medication, such as aspirin, that may affect platelet 
function, had not been taken within 14 days prior to blood donation. Blood was drawn by 
venepuncture of the median cubital vein in the cubital fossa using a 21G butterfly needle. 
Blood was collected into 50 ml syringes containing trisodium citrate (11 mM) in a 1:5 (v/v) 
concentration. 
 
2.3.1.1 Isolation of platelets from donor blood 
Following collection, blood was transferred into 15 ml Falcon tubes and centrifuged at 125 x 
g at room temperature for 15 minutes. Centrifugation separated the blood into three layers, 
the bottom-most red layer of erythrocytes, the cloudy middle layer of leukocytes (buffy coat) 
and the upper layer of platelet-rich plasma (PRP). The PRP was gently aspirated off and 
dispensed into clean 15 ml Falcon tubes, with care taken to leave the buffy coat 
undisturbed. Prostaglandin E1 (PGE1), a reversible inhibitor of platelet activation, was 
added at a concentration of 1 µM and gently inverted to mix before centrifugation at 200 x g 
for 15 minutes. The supernatant, otherwise known as platelet-poor plasma (PPP), was 
aspirated off and discarded. The platelet pellet was gently resuspended in CFT (Table 2.4) 
and incubated in a water bath at 37 °C for 1 hour before being counted and adjusted to 
achieve the required platelet count.  
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2.3.2 Methodology for the investigation of platelet aggregatory responses 
2.3.2.1 Light transmission aggregometry  
Platelet aggregation was measured in a Helena Biosciences AggRam, light transmission 
aggregometer (Helena Biosciences Europe). Washed platelet preparations (250 μl) were 
aliquoted from stock stored in a water bath at 37°C into glass cuvettes, and incubated in the 
AggRam for 2 minutes without stirring to allow the platelets to equilibrate prior to 
stimulation. The program was then initiated, and the appropriate agonists were introduced 
at the 30-second time point, under stirred conditions (1000 rpm). Aggregatory responses 
were measured for 15 minutes. 
In order to study pathways of platelet activation in isolation, a number of inhibiting agents 
were utilised. In experiments to investigate secondary-mediated signalling, washed 
platelets were pre-treated with aspirin (1 mM), Prostaglandin E1 (PGE1) (2 μM) and 
N,N,N',N'-tetrakis(2-pyridylmethyl)ethane-1,2-diamine (TPEN) (50 μM), and incubated in a 
water bath at 37°C for 15 minutes prior to light transmission aggregometry. Aspirin was 
utilised to prevent the generation of thromboxane A2 (TxA2); PGE1 was employed to inhibit 
adenosine diphosphate (ADP) signalling; and TPEN, a Zn2+ chelating agent, was used to as 
a general inhibitor of secondary aggregation. To investigate protein kinase C (PKC)-
mediated signalling, platelet suspensions were pre-incubated with GF109203X (10 μM) for 
15 minutes prior to aggregometry, to inhibit PKC. To study integrin ɑIIbβ3-dependent 
signalling, washed platelets were pre-incubated with GR144053 (10 μM) and 1,2-Bis(2-
aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA) (10 μM) for 15 minutes 
preceding aggregation analysis. GR144053 was used to competitively inhibit integrin ɑIIbβ3, 
whilst BAPTA, a Ca2+ chelator, was employed to inhibit the activation of ɑIIbβ3.  
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2.3.2.2 Fixation of platelets 
To explore the reliance of platelet aggregation on intracellular signalling, washed platelets 
were fixed prior to LTA. 
Washed platelets were fixed with the addition of paraformaldehyde in order to determine 
whether oleic acid-induced aggregation was dependent on intracellular signalling. A final 
concentration of 4% (v/v) paraformaldehyde was added to washed platelets and incubated 
in a water bath at 37oC for thirty minutes. After incubation aggregometry studies were 
performed as mentioned above. 
 
2.3.3 Flow cytometric analysis of platelet activation markers 
The exposure of markers of platelet activation following stimulation was investigated using 
PE anti-CD62P, Alexa Fluor 647® anti-CD63, FITC anti-PAC1. Anti-CD62P is an antibody 
against P-selectin, and anti-CD63 is directed against CD63, both of which are expressed on 
the outer platelet membrane following α-granule release and dense granule release, 
respectively. Anti-PAC1 is directed against activated integrin ɑIIbβ3, the vital product of 
platelet activation. PE, FITC and Alexa Fluor 647® conjugated antibodies were chosen to 
enable simultaneous analysis via different FL channels. The excitation/emission 
wavelengths of FITC are 495/519 nm, and, thus, anti-PAC1 was analysed via the FL1 
channel using a laser at 488 nm and a filter at 533 nm with a band pass of 30 nm. The 
excitation/emission wavelengths of PE are 496/576 nm. Therefore, anti-CD62P was 
measured using the FL2 channel with a 488 nm laser and a filter at 585 nm with a band 
pass of 40 nm. Alexa Fluor 647® is excited at 650 nm and emits at 665 nm, consequently 
anti-CD63 was analysed via the FL4 channel using a laser at 640 nm and a filter at 675 nm 
with a band pass of 25 nm (Abcam, 2012; BD Biosciences, 2011). 
Tubes containing CFT (50 μl) and 1.5μl of each antibody were prepared once the washed 
platelets had been rested. The washed platelets (50μl) were added to each tube and mixed 
gently by flicking. Samples were incubated for 20 minutes at room temperature before 
being analysed continuously over 5 minutes. After 30 seconds, 1.5 μl of agonist or 
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treatment was added and mixed via pipette, to assess platelet activation in real-time for 5 
minutes. Samples were analysed on a BD Accuri™ C6. 
FITC annexin V was used separately to study the exposure of phosphatidylserine (PS) on 
the outer platelet membrane, which occurs following platelet activation. It was measured 
using the FL1 channel due to the conjugated FITC, using the method above. 
Prior to experimentation, unstained platelets, isotype controls, untreated platelets with 
primary antibody only, untreated platelets with secondary antibody only, and untreated 
platelets with both primary and secondary antibodies were used to control background 
fluorescence. 
 
2.3.4 Methodology for the investigation of platelet death 
2.3.4.1 LDH assay  
Platelet cell death was quantified using a Pierce™ LDH Cytotoxicity Assay Kit (Thermo 
Fisher Scientific), following a modified version of the manufacturer’s protocol. Platelets were 
stimulated in the aggregometer for 15 then centrifuged at 125 x g to remove the CFT 
containing released LDH. Aliquots of the supernatant (50 μl) were dispensed into a 96 well 
microplate, 50 μl reaction mixture was added and the plate was incubated at room 
temperature for 30 minutes, protected from light. Following incubation 50 μl of Stop Solution 
was added to each sample and mixed by gentle tapping. The absorbance was measured at 
490 nm and 680 nm. The 680 nm value was subtracted from the 490 nm value to remove 
background signal from the instrument. 
A standard curve was created to ascertain the optimum number of platelets required to 
produce a level of absorbance measurable with acceptable levels of error and without 
saturating the absorbance (Figure 2.10). The above method was used to measure LDH 
release in up to 2 x 107 platelets that had been lysed with lysis buffer. The optimum number 
of platelets for the LDH assay was assessed to be 2 x 106, which was used for the samples 
treated with fatty acids. 
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Figure 2.10 LDH standard curve demonstrated the absorbance produced by lysed 
platelets 
The standard curve demonstrated the absorbance and hence total LDH released from 
platelets destroyed using lysis buffer. This was used to assess the optimum number of 
platelets required for the LDH assay to detect a significant increase in absorbance upon 
platelet death. This was determined to be 2 x 106 platelets. 
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2.3.4.2 Calcein determination of viability 
Platelet viability was established using calcein AM, a cell-permeant, non-fluorescent dye 
that is hydrolysed by intracellular esterases in viable cells, thereby becoming fluorescent.  
Calcein was added to freshly washed platelets to a final concentration of 2 μg/mL and 
incubated for 1 hour in a water bath at 30°C. After incubation, 1 μM PGE1 was added to the 
platelets and centrifuged at 1,000 × g for 10 minutes. The supernatant was discarded and 
the platelets washed with PBS supplemented with 1% BSA (w/v) and 1 μM PGE1. The 
platelets were centrifuged again at 1,000 g for 10 minutes, the supernatant discarded and 
resuspended in CFT. Calcein AM fluorescence has excitation and emission wavelengths of 
495/515 nm respectively, so was measured using the FL1 channel on the BD Accuri™ C6 
flow cytometer due to the appropriate laser and filter setup. Before experimentation, 
unstained platelets and stained untreated platelets were used as controls to determine 
background fluorescence.  
 
2.3.5 Confocal microscopy 
Confocal microscopy was performed to ensure platelets were in fact aggregating and not 
producing artefactual results via light transmission aggregometry.  
Washed platelets were prepared and treated as aforementioned. The cuvettes were placed 
in the aggregometer and testing initiated. Cuvettes were removed at time points of 1, 2, 5, 
10 and 15 minutes and 1 μL as immediately pipetted on to a cover slip. Samples were 
studied on a confocal microscope (Zeiss Axiovert 200M) at 600X magnification. Images 
were taken of random fields. 
 
2.3.6 Analysis of competing hypotheses 
Analysis of competing hypothesis software (ACH) was used to determine which hypothesis 
was mostly likely following experimentation and statistical analysis. 
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Analysis of competing hypotheses (ACH) is an analytical process that aims to provide an 
unbiased methodology for evaluating competing hypotheses through systematic evaluation 
of whether data is consistent or inconsistent with each hypothesis. This enables the 
rejection of hypotheses that are too inconsistent with the data. The concept works on the 
principle that data consistent with a hypothesis does not prove said hypothesis, as it may 
be consistent with multiple hypotheses and further research could reveal inconsistencies in 
the future. On the other hand, even a single piece of inconsistent data may be enough to 
disprove said hypothesis, and allow for its rejection (Heuer Jr., 1999). 
ACH was performed with the help of ACH software (Palo Alto Research Center). 
Competing hypotheses present in this study were entered into the software, along with 
primary evidence collected in this project, and secondary evidence in the form of key pieces 
of literature. Each piece of evidence was individually assessed for its relevance to this study 
and its credibility as a source of evidence. Each piece of evidence was then judged against 
each hypothesis for inconsistences and marked as CC for very consistent, C for consistent, 
N for neutral, I for inconsistent and II for very inconsistent. Upon completion, the software 
computed weighted inconsistency scores based upon the relevance and credibility ratings.  
 
2.4 Systematic review and meta-analysis 
2.4.1 Search Strategy 
Primary research articles and meta-analysis reviews were identified through electronic 
searches of the following databases: PubMed, Web of Knowledge, MEDLINE, SCOPUS 
and Google Scholar. Search terms included: free fatty acids, non-esterified fatty acids, 
palmitic acid, oleic acid, plasma, serum, phospholipids, cholesterol esters, triglycerides. The 
full list of search terms can be found in Appendix F. Articles identified through databases 
were supplemented by reviewing reference lists of review articles to identify additional 
eligible articles. All databases were searched by one reviewer, initially in April 2016, and 
again in January/February 2018.   
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2.4.2 Inclusion Criteria 
Any study of adult plasma regardless of the date of publication, methodology or number of 
participants was included. The data must also have been presented in mol%, mass%, 
mg/L, mg/dL, mmol/L or µmol/L. Multiple articles from a single dataset were included when 
minimal overlap between factors existed.  
No restrictions were imposed on publication date or methodology used for lipid 
measurement, although studies in adolescents, and those studying specific medical 
conditions were excluded.  
 
2.4.3 Exclusion criteria 
For the analysis of average concentrations of plasma lipid species and the comparison of 
lipid species between subpopulations, studies were excluded if they were missing 
information such as BMI, and SD or SEM. Also, groups of subjects with any reported 
medical condition, smokers, BMI below 20 kg/m2 or following a specific diet were also 
excluded. 
 
2.4.4 Data extraction 
Articles were reviewed by one reviewer on two separate occasions. Those not meeting the 
eligibility criteria were discarded as were duplicates. 
Data meeting the eligibility criteria was collated using the standard BMI measures of obesity 
(20-24.9 for normal, 25-29.9 for overweight and over 30 for obese). However, authors often 
broadened the standard BMI categories, using a BMI of up to 25 for lean participants. Many 
authors also used morbidly obese participants with a BMI of over 40. The categories for this 
meta-analysis were adjusted accordingly with non-obese including BMIs between 20-27.9, 
and overweight/obese using BMIs over 28. In studies that arranged the results by health 
condition or smoking status, only the control groups were used for analysis of average 
concentrations of plasma lipid species.  
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Data was extracted into a Microsoft Excel 2010 spreadsheet and separated by lipid species 
and unit of measurement, BMI, and subpopulation i.e. sex, medical condition, smoking 
status, etc 
For analysis of average plasma triglycerides all data was converted to mmol/L, whilst all 
data of average plasma FFAs was convered to µmol/L using the average molecular weight 
calculated in Table 5.3. 
All data included in this study can be found in Appendix F. 
 
2.5 Data analysis 
The software used for statistical analysis throughout this project was GraphPad Prism 7. 
For all chapters, P<0.05 was accepted as statistically significant with a single asterisk on 
graphs to represent significance. The minimum number of times an experiment was 
repeated was three, with the exact n number provided in the figure legend or text. All data 
in chapters 3 and 4 were presented as mean ± SEM. All data presented in chapter 5 is 
mean ± SD, as this was more suitable for a meta-analysis. 
 
2.5.1 Chapter 3 specific data analysis  
One-way ANOVAs with Dunnett’s multiple comparisons test were used to analysis data with 
a single variable. Two-way ANOVAs were performed with Dunnett’s multiple comparisons 
test to analyse two factors concurrently. Correlation coefficients were used to assess the 
relationship between lipid accumulation and alterations in cell viability. The Oil Red O data 
was plotted on the X-axis against data from one of the cell viability experiments on the Y-
axis, to establish whether any associations existed between lipid accumulation and cell 
death, apoptosis or late apoptosis. 
Pearson correlation coefficient was calculated to analyse the relationship between 
intracellular lipid accumulation and HepG2 viability measured by CCK-8 assay. Pearson 
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correlation coefficient, a parametric test, was judged as suitable for this analysis as n=16. 
However, non-parametric testing was used to study the remaining associations because 
normality was uncertain due to small sample sizes which would have affected the validity of 
parametric testing had the data not had a Gaussian distribution. In particular, Spearman's 
rho (also known as Spearman’s rank correlation coefficient) was selected to examine the 
correlation between variables. Spearman's rho is a measure of rank correlation, which 
determines the direction of the monotonic relationship between two variables.  
Both correlation coefficients result in an r value between 1 and -1. A positive number 
indicates positive correlation and a negative number indicates a negative correlation. The 
closer the r value is to 1 or -1, the stronger the correlation. P values were also calculated as 
a measure of the statistical strength of the correlation. 
Datasets were normalised relative to the control and presented as either fold change or 
percentage change. The formulas below were used for these calculations. 
Fold change was calculated with the following formula: 
𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 = (
𝑡𝑒𝑠𝑡 𝑟𝑒𝑠𝑢𝑙𝑡 − 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝑐𝑜𝑛𝑡𝑟𝑜𝑙
) 
 
Percentage change was calculated using the following formula: 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑐ℎ𝑎𝑛𝑔𝑒 = (
𝑡𝑒𝑠𝑡 𝑟𝑒𝑠𝑢𝑙𝑡 − 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝑐𝑜𝑛𝑡𝑟𝑜𝑙
) × 100 
 
 
2.5.2 Chapter 4 specific data analysis 
One-way ANOVAs with Dunnett’s multiple comparisons test were performed for the 
analysis of all data. Helena AggRAM (Helena Biosciences Europe, UK) software was used 
to graph aggregation traces. ACH software was used to calculate inconsistency scores. 
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2.5.3 Chapter 5 specific data analysis 
Averages were calculated of Microsoft Office Excel 2010. An average for each set of data 
was calculated without weighting the average of each study, and, thus, the number of 
participants per study had no influence. In addition, a weighted average was calculated for 
each set of data by weighting the average of each study based on the number of 
participants included. Weighted standard deviations were calculated using the following 
formula: 
 
 
Simple T-tests were performed on GraphPad Prism 7 to compare the average and 
weighted means of the data. GraphPad Prism 7 was also used to analyse Gaussian 
distribution by fitting Gaussian distribution non-linear regressions to % frequency 
histograms of the data. The frequency histograms plotted the percentage of data points 
falling within a certain interval in order to show the distribution of data. 
Residual plots of the non-linear regression lines were also produced and assessed to 
determine the ability to create reference ranges from the data. A residual is the difference 
between the observed value of the dependent variable and the value predicted by the 
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regression model. A residual plot graphs these differences on the Y-axis against the 
independent variable on the X-axis in order to assess the fit of the regression model. 
Results from the non-linear regression were presented as an adjusted R2 value. A value of 
1 indicates a model that perfectly predicts values in within that subpopulation and a value 
that is less than or equal to 0 indicates a model that has no predictive value. In the real 
world, adjusted R2 lies between these values. 
 
Reference range between the 2.5th and 97.5th percentile were calculated with the formula: 
𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑟𝑎𝑛𝑔𝑒 =  𝑀𝑒𝑎𝑛 ± 2 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛𝑠 
 
RevMan 5 was used to statistically compare the levels of lipid species between different 
subpopulations. Tau2, Chi2 and I2 were automatically calculated by the RevMan software 
and were used in combination to assess heterogeneity. 
The unit molar percentage (mol%) is the percentage of moles of a particular component 
within the total moles in a mixture. Whereas the unit mass percentage (mass%) is the 
percentage of mass of a particular component within the total mass in a mixture. 
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3  The effects of palmitic acid and oleic acid on cell viability 
3.1 Background 
Obesity worldwide has tripled within the last 30 years with 39% of the world’s adults 
overweight and 13% obese as of 2016 (World Health Organization, 2018). The increasing 
incidence of obesity, and more specifically its associated health burden, continues to place 
strain on healthcare systems across the world. It is hypothesised that a key factor in 
obesity-associated sequelae is the elevation of circulating plasma free fatty acid levels 
(Guenther Boden, 2008; Karpe, et al., 2011). Therefore, it is essential that we understand 
how metabolic changes cause cellular changes, and play a role in the pathologies 
associated with this condition.  
The central importance of fatty acids in nutrition and disease is widely agreed, and yet, 
surprisingly few comprehensive studies have been conducted to assess how fatty acids 
directly affect cell viability, intracellular lipid accumulation and the link between the two. 
Alterations in fatty acid metabolism have been widely linked with development of insulin 
resistance (Karpe, et al., 2011), amongst other diseases such as cancer (Saavedra-García, 
et al., 2018). Thus, an understanding of how fatty acids affect different insulin-sensitive cells 
is crucial.  
Two cell lines, HepG2 (human hepatocarcinoma) and L6 myotubes (rat myoblasts), were 
selected to expand current knowledge regarding the differential effects of palmitic acid and 
oleic acid on insulin-sensitive cells. Treatments with palmitic acid and oleic acid were 
selected as they are the most abundant saturated fatty acid and monounsaturated fatty acid 
in the plasma, respectively (Abdelmagid, et al., 2015). The cells were treated with these 
fatty acids alone and combined, in a 2:1 molar ratio of oleic acid:palmitic acid, as suggested 
by previous studies. 
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Yao, et al., (2011) showed that treatment of HepG2 cells with a 2:1 ratio of oleic acid to 
palmitic acid at concentrations between 1-3 mM caused intracellular lipid accumulation and 
cell death. Lipid accumulation and cell death occurred in a dose-dependent manner and led 
to apoptosis and necrosis (Yao, et al., 2011). However, the research demonstrated the 
effects of these fatty acids in combination, not in isolation, and only studied their effects in 
HepG2 cells, which provides a limited view of the differential effects of palmitic acid and 
oleic acid on insulin-sensitive cells. Furthermore, the 3 mM concentration of fatty acids is 
above physiological concentrations as demonstrated by the systematic review performed in 
this study (Chapter 5). Thus, this project investigated these results and studied the effects 
of palmitic acid up to 1 mM, oleic acid up to 2 mM and the combined treatment up to 3 mM 
(see appendix). The treatments were refined to more physiologically relevant 
concentrations up to 1 mM as the systematic review found that normal plasma free fatty 
acid levels are between 0.2 – 0.9 mM (Figure 5.5A). At these concentrations, a combination 
of oleic acid and palmitic acid (2:1 ratio, respectively) caused intracellular lipid accumulation 
and apoptosis in HuH7 (human hepatocarcinoma cells) (Chavez-Tapia, et al., 2012), 
however, the study’s range of concentrations was limited and only hepatocarcinoma cells 
were studied.  
Moravcová, et al., (2015) also found that PA exhibited a dose-dependent cytotoxic effect in 
primary rat hepatocytes, whilst OA caused cytoplasmic membrane damage at 
concentrations above 1 mM. Yet, in combination OA:PA induced lower cytotoxicity than 
palmitic acid alone. Furthermore, both oleic acid and palmitic acid were found to increase 
intracellular triacylglycerol content in hepatocytes, however the purposes of the study was 
to identify the best model for steatosis, and as such did not study the link between lipid 
accumulation and cytotoxicity. 
Many studies investigating the effects of fatty acids across a range of cell lines report a 
decrease in cell viability following treatment with palmitic acid (Cheon & Cho, 2014; El-
Assaad, et al., 2003; Listenberger, et al., 2003). For example, 0.5 mM of PA caused 
apoptosis in Chinese Hamster Ovary (CHO) cells (Listenberger, et al., 2003b), and 0.3 mM 
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of PA induced endoplasmic reticulum stress in cardiomyocytes leading to cell death (Haffar, 
et al., 2015). In β-pancreatic cells, 0.4 mM PA was found to synergise with high levels of 
glucose to cause cell death (El-Assaad, et al., 2003) and the same concentration induced 
membrane phase separation in HeLa cells (Shen, et al., 2017). However, all such studies 
would not be directly comparable to hepatocytes and skeletal myocytes due to different 
functional outputs and signalling pathways.  
More relevant to this study, palmitic acid induced cell death in C2C12 skeletal myocytes in 
a dose dependent manner up to 1.5 mM with death occurring via apoptosis as a result of 
mitochondrial membrane potential loss (Cheon & Cho, 2014). Ricchi, et al., (2009) studied 
the differential effects of PA on three hepatocytic cell lines (HepG2, HuH7, WRL68), and 
demonstrated that palmitic acid induced apoptosis in all three at concentrations of 0.66 mM.  
Research indicates that toxicity may result from intracellular accumulation (Chavez-Tapir, et 
al., 2012). It is widely agreed that obesity leads to elevated levels of circulating free fatty 
acids, which cause adipose dysfunction and lead to the accumulation of lipids outside of the 
adipose tissue, in and around other tissues. Previous papers indicate that palmitic acid is 
poorly incorporated into neutral lipids and is, thus, free to exert its lipotoxic effects 
(Listenberger, et al., 2003b). Others report that PA accumulates intracellularly as 
diacylglycerol (DAG) and triacylglycerol (TAG) (Gaster, et al., 2005); the accumulation of 
DAG is considered toxic in many cells (Akoumi, et al., 2017; Erion, et al., 2010). Whilst Lee, 
et al., (2017) found that treatment with palmitic acid increases exosome production in LX-2 
cells, and alters the exosomal miRNA profile which could act as a mediator of toxicity. 
On the other hand, research across a range of different cell lines reported no decrease in 
cell viability following treatment with oleic acid (El-Assaad, et al., 2003; Listenberger, et al., 
2003b; Ricchi, et al., 2009), yet this finding was not consistently observed with one study 
noting oleic acid-induced cell death. This study demonstrated that 0.2 mM OA caused 
modest levels of apoptosis in HepG2 and primary mouse hepatocytes MRH 7777 (Malhi, et 
al., 2006). However, at concentrations of 1.32 mM OA was not found to induce cell death in 
three hepatocytic cell lines (HepG2, HuH7, WRL68) (Ricchi, et al., 2009). It is thought that 
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the lack of toxicity exerted by OA is due to its intracellular accumulation as neutral TAG 
which is well tolerated (Listenberger, et al., 2003b), however, Gaster, et al., (2005) reported 
that oleic acid accumulates as intracellular free fatty acids (FFA).  
Interestingly, researchers claim that the addition of oleic acid is able to reduce palmitic acid-
induced cell death (Cheon & Cho, 2014; Haffar, et al., 2015; Listenberger, et al., 2003). For 
example, the addition of 0.2 mM OA to 0.5 mM PA protected CHO cells from cell death 
induced by 0.5 mM PA alone (Listenberger, et al., 2003b). In cardiomyocytes it was found 
that the addition of just 0.05 mM of OA rescued ER stress induced by 0.3mM PA (Haffar, et 
al., 2015), whilst 0.0625 mM of oleic acid reduced palmitic acid-induced cell death in 
HepG2 cells (Cheon & Cho, 2014). Conversely, one study found that treatment with 2 mM 
of oleic acid and palmitic acid in a molar ratio of 2:1 caused cell death in three hepatocytic 
cell lines (HepG2, HuH7, WRL68) (Ricchi, et al., 2009). Furthermore, combination of oleic 
acid and palmitic acid was found to induce greater intracellular lipid accumulation than 
either fatty acid alone.  
The lack of clarity is most likely due to differences in how different cells respond to fatty 
acids under normal conditions, and how these responses are exacerbated under 
pathological changes. There is much debate regarding whether decreased cell viability 
occurs via apoptotic or necrotic processes. The majority of reports support apoptosis, 
although this by no means rules out necrosis (Chavez-Tapia, et al., 2012; Cheon, et al., 
2014; Malhi, et al., 2006; Ricchi, et al., 2009). For example, Yao, et al., (2011) found no 
signs of early apoptosis following treatment of HepG2 cells with free fatty acids. Therefore, 
it was important to perform experiments in this study to tease out the mechanism of cell 
death and to identify the defining factors responsible for differences in toxicity between 
treatments. It was thought the aforementioned differences in toxicity between palmitic acid 
and oleic acid may be due to differing rates of transport across the plasma membrane or 
differing rates of metabolism within the cell. Perhaps, explained by differences in structure 
with palmitic acid being a 16C saturated fatty acid and oleic acid, an 18:1 cis-9 unsaturated 
fatty acid (see Figure 1.4). 
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Therefore, it was important to investigate whether elevated levels of palmitic acid and/or 
oleic acid could induce intracellular lipid accumulation in HepG2 and L6 cells, and 
moreover, evaluate whether an association exists between intracellular lipid accumulation 
and cell viability. Finally, it was considered vital to compare the differential effects of PA and 
OA between HepG2 and L6 cells, to understand whichtissue is potentially more vunerable 
to elevated levels of FFAs, This was important due to potential implications in the 
progression of obesity-associated disorders and may highlight links between obesity and its 
sequelae.  
3.1.1 Aims 
● To ascertain whether palmitic acid and/or oleic acid cause cell death and to identify 
whether death is via apoptotic or necrotic mechanism. 
● To establish whether palmitic acid and/or oleic acid cause intracellular lipid 
accumulation. 
● To understand the correlation, or lack of, between fatty acid-induced intracellular 
lipid accumulation and cell death. 
● To compare the effect of palmitic acid and oleic acid on cell death, lipid 
accumulation and potential association of the two between HepG2 cells and L6 
cells. 
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3.2 Methods 
Refer to Chapter 2 Materials and methods. The minimum number of times an experiment 
was repeated was three, with the exact n number provided in the figure legend.All data is 
expressed as mean ± SEM. *P<0.05 
N.B. The caspase assay was not performed on HepG2 cells, as these cells had a tendency 
to clump in culture which led to marked decreases in viability of the controls in the annexin 
V/PI assay (image in Appendix B). This clumping would, therefore, risk the production of 
artefactual results, especially without access to the sophisticated software used for flow 
cytometric analysis. ImageJ analysis was also not used for HepG2 cells as the 
aforementioned clumping prevented the formation of a monolayer which made ImageJ 
analysis difficult and unreliable. 
 
 
3.2.1 Concentration of fatty acids 
Initial experiments used concentrations of palmitic acid up to 1 mM, oleic acid up to 2 mM 
and combined up to 3 mM, similar to those found throughout the literature (Appendix Dl). 
However, these concentrations were found to be too high to be physiologically relevant both 
in the literature and via meta-analysis conducted in this project (Chapter 5; Abdelmagid, et 
al., 2015). Concentrations up to 1 mM were selected for subsequent experimentation with 
the range chosen to enable direct comparison between treatments of palmitic acid and oleic 
acid alone and in combination (Table 2.1). 
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3.3 Results 
3.3.1 HepG2 Viability in response to fatty acids 
3.3.1.1 Toxicity of the FFA vehicle in HepG2 cells  
Initial experiments were carried out to ensure that methanol, the solvent for FFA, did not 
affect HepG2 cell viability. Methanol at concentrations equivalent to those used in the fatty 
acid solutions did not cause cell death, as assessed by CCK-8 assays (P=0.1343, Figure 
3.1A) and flow cytometric analysis of annexin V/PI staining (P=0.9736, Figure 3.1B).  
As methanol did not affect HepG2 cells adversely, experimentation using methanol as the 
solvent was continued. 
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Figure 3.1 Methanol did not cause cell death in HepG2 cells 
A) Methanol did not affect the viability of HepG2, as assessed by CCK-8 assays (P=0.1343) 
(n=8). B) Flow cytometric analysis of annexin V/PI staining showed that methanol did not 
affect the original percentage of live HepG2 cells (P=0.9736) (n=3). Due to the use of 100 
mM stock solutions, the percentage of methanol equalled that of the fatty acid 
concentrations. The use of % change is described in 3.2.2. 
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3.3.1.2 Cell death in response to palmitic acid and oleic acid 
Section 3.3.1.1. demonstrated that the FFA vehicle, methanol, had no effect on HepG2 cell 
death, the next experiment sought to measure cell death in these cells in response to FAs. 
The CCK-8 assay used to determine the effects of palmitic acid and oleic acid, alone and in 
combination, demonstrated that low concentrations of palmitic acid (0.17-0.33 mM) did not 
affect the viability of HepG2 cells (P=0.9976 and 0.9991, respectively). In contrast, 0.67 mM 
palmitic acid caused significant cell death (P=0.0001), with the highest concentration of 1 
mM palmitic acid causing the greatest decrease in HepG2 viability, resulting in an average 
viability of 31.6 ± 1.86 % following treatment (P=0.0001) (Figure 3.2A). In contrast, 
treatment with oleic acid did not produce a significant decrease in HepG2 viability, however, 
1 mM oleic acid resulted in an average viability of only 89.38 ± 2.53% following treatment 
(P=0.0786). The results for individual treatments of PA and OA were similar to those 
produced by Moravcová, et al., (2015), however the combination of the two was found to be 
far more cytotoxic in this project. At the lowest concentration, 0.17 mM of the combined 
treatment conferred little effect on the viability of HepG2 (P=0.1617). However, treatment 
with higher concentrations (0.33–1 mM) led to significant decreases in cell viability 
(P=0.0467, 0.0145 and 0.0052, respectively). Yet it is worth noting that 1 mM of the 
combination treatment only decreased the viability of HepG2 cells by an average of 15.1 ± 
4.90%, unlike 1 mM of palmitic acid which produced an average reduction of 68.4 ± 1.86%.  
Before assessing whether palmitic acid caused a loss in cell viability via apoptosis or 
necrosis, it was important to validate the CCK-8 results, by studying the percentage of live 
HepG2 cells remaining following treatment. This was achieved via flow cytometric analysis 
of annexin V/PI staining, and was vital as CCK-8 assays measure all cells with functioning 
dehydrogenase activity, and, thus, may include cells that are undergoing cell death 
processes. However, flow cytometric techniques are able to quantify cells that are live and 
not undergoing any cell death processes via the combination of one probe of apoptosis 
(annexin V) and one probe of necrosis (PI), which allows for the gating of apoptosis- and 
necrosis-negative cells (live cells). 
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Analysis of annexin V- and propidium iodide-negative cells following 24 hour treatment 
largely corroborated the CCK-8 results (Figure 3.2B). The three lowest concentrations of 
palmitic acid, 0.17 mM, 0.33 mM and 0.67 mM, had little effect on the percentage of live 
HepG2 cells following treatment as compared to the control (P=0.6499, 0.9084 and 0.2071, 
respectively). However, 1 mM palmitic acid caused an average reduction of 62.84 ± 0.70% 
in live HepG2 cells (P=0.0001). In contrast to the CCK-8 results, the lowest concentrations 
of oleic acid, 0.17 mM, 0.33 mM and 0.67 mM, produced significant reductions in the 
percentage of live cells by up to 35.8 ± 5.42% (P=0.0078, 0.0007 and 0.0001, respectively). 
Whereas, 1 mM oleic acid did not have a significant effect on the percentage of live cells in 
comparison to the control (P=0.1478). Conversely, 0.17-0.33 mM of the combined 
treatment did not cause a decrease in the live cell percentage (P=0.9999 and 0.9983, 
respectively), whilst 0.67 mM resulted in an average reduction of 22.65 ± 4.06% 
(P=0.0077). Interestingly, the highest concentration of 1 mM caused an increase of 14.36 ± 
3.23% in the percentage of live HepG2, however, this was not statistically significant 
(P=0.1293) and not evident in the CCK-8 results. 
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Figure 3.2 Palmitic acid caused cell death in HepG2 cells 
 
A) Changes in cell viability following treatment with palmitic acid and oleic acid, alone and in 
combination were assessed by CCK-8 assay (n=16). Palmitic acid caused significant 
decreases in HepG2 viability (P=0.0001), whilst oleic acid did not (P=0.0786). In 
combination, viability was significantly reduced, but not to the extent caused by palmitic 
acid alone (P=0.0052). B) Flow cytometric analysis of annexin V/PI staining determined the 
percentage change in live cells following treatment (n=3). Palmitic acid produced significant 
reductions in the percentage of live HepG2 cells (P=0.0001). Low concentrations of oleic 
acid had a similar effect (P=0.0001), however, the highest concentration did not cause 
significant reductions in live cells (P=0.1478). The combination treatment (0.67 mM) caused 
a decrease in live cell percentage (P=0.0077), whilst 1 mM produced a non-significant 
increase (P=0.1293). 
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3.3.1.3 Stages of cell death in HepG2 cells 
Results from the cell viability studies found that all treatments reduced the percentage of 
live HepG2 cells, and, thus, further investigations into cell death processes were required. 
Flow cytometric analysis of annexin V/PI staining was performed to ascertain the 
mechanisms involved (Figure 3.3). Annexin V was used as a probe for apoptosis and 
propidium iodide as a probe for necrosis with results broken down into four gates. Annexin 
V- and PI-negative cells were considered to be live, annexin V-positive and PI-negative 
cells were said to be apoptotic, annexin V-negative and PI-positive were judged to be late 
apoptotic/necrotic and annexin V- and PI-positive cells were deemed to be dead. 
At the lowest concentration of 0.17 mM, palmitic acid, oleic acid nor the combination 
treatment caused an increase in percentage of dead cells in comparison to the control 
(P=0.3555, 0.9814 and 0.0575, respectively) (Figure 3.3A). At a concentration of 0.17 mM, 
none of the treatments induced changes in the percentage of apoptotic HepG2 cells 
(P=0.8380, 0.1804, and 0.4674, respectively), nor the percentage of late apoptotic HepG2 
cells (P=0.5476, 0.0736 and 0.7818, respectively). The only treatment to have an effect 
was 0.17 mM, which produced a significant decrease in the percentage of live cells 
(P=0.0078). 
Palmitic acid and oleic acid, alone and in combination at a concentration of 0.33 mM did not 
alter the percentage of apoptotic HepG2 cells (P=0.9169, 0.6660 and 0.9463, respectively) 
(Figure 3.3B). However, at this concentration oleic acid induced an increase of 66.83 ± 
14.30% in late apoptotic cells (P=0.0073), whilst palmitic acid and the combination 
treatment did not significantly alter the percentage of apoptotic HepG2 (P=0.9567 and 
0.4718, respectively). In contrast, 0.33 mM of the combined treatment significantly reduced 
the percentage of dead cells by 47.8 ± 0.61% (P=0.0002), whilst individually palmitic acid 
and oleic acid had little effect (P=0.9999 and 0.5088, respectively). 
Higher concentrations of the treatments (0.67 mM) had greater effects on HepG2 cells 
(Figure 3.3C). 0.67 mM of the combined treatment significantly reduced apoptotic HepG2 
cells by 36.26 ± 3.55% and dead cells by 44.12 ± 1.05% (P=0.0483 and 0.0006, 
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respectively), whilst it increased the percentage of late apoptotic cells by 76.74 ± 7.82% 
(P=0.0019). The same concentration of palmitic acid did not alter the percentages of 
apoptotic, late apoptotic or dead cells significantly (P=0.9999, 0.5887 and 0.9814, 
respectively). On the other hand, 0.67 mM of oleic acid did not cause significant percentage 
change of apoptotic or dead HepG2 (P=0.5647 and 0.9936, respectively), but did induce an 
increase of 70.18 ± 20.94% in late apoptotic cells (P=0.0045). 
Palmitic acid at the highest concentration of 1 mM, increased the percentage of apoptotic 
HepG2 cells by 98.69 ± 10.69%, and the percentage of late apoptotic/necrotic cells by 
114.1 ± 6.16% (P=0.0001 and 0.0001, respectively) (Figure 3.3D). However, the 
percentage of dead cells was not altered by this treatment (P=0.5499). In contrast, 1 mM of 
the combination treatment did not cause changes to the percentages of apoptotic or late 
apoptotic/necrotic HepG2 cells (P=0.8147 and 0.9943, respectively), and yet reduced the 
percentage of dead HepG2 cells by 57.14 ± 0.26% (P=0.0001). Individually, 1 mM oleic 
acid did not significantly affect the percentage of apoptotic cells (P=0.6106), but did 
increase late apoptosis/necrosis by 59.02 ± 6.85% (P=0.0187). Furthermore, 1 mM oleic 
acid significantly decreased the percentage of dead HepG2 cells by 46.61 ± 7.51% 
(P=0.0003). 
It is worth noting that for all concentrations, the combination of oleic acid and palmitic acid 
in a 2:1 ratio caused significantly less cell death than palmitic acid or oleic acid alone 
(Figure 3.3). 
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Figure 3.3 Palmitic acid increased early apoptosis, whilst oleic acid increased late 
apoptosis/necrosis, and the combination treatment decreased the percentage of 
dead HepG2 cells  
   
A, B, C, D) Flow cytometric analysis of annexin V/PI staining identified changes in the 
percentage of live, apoptotic, late apoptotic/necrotic and dead cells. HepG2 cells were 
treated for 24 hours with oleic acid, palmitic acid or a 2:1 combination in the following 
concentrations: 0.17 mM (A), 0.33 mM (B), 0.67 mM (C) and 1 mM (D) (n=3).
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Forward scatter and side scatter of the cells were analysed to aid in the determination of 
the mechanism of fatty acid-induced cell death. The results produced by this analysis were 
by no means prescriptive, but rather enabled the formation of a semi-qualitative overview. 
The lowest concentration of palmitic acid and the combination treatment, 0.17 mM, did not 
cause significant changes to forward scatter (P=0.1245 and 0.9927, respectively) (Figure 
3.4A). However, 0.17 mM oleic acid did induce a significant reduction in forward scatter 
(P=0.0059). At concentrations of 0.33 mM, 0.67 mM and 1 mM, all treatments caused 
statistically significant decreases in forward scatter with 1 mM oleic acid producing the 
largest reduction of 86.61 ± 0.80% (P=0.0001). 
Side scatter produced by HepG2 cells was significantly increased by 30.5 ± 10.74% after 
treatment with 0.17 mM oleic acid and by 31.94 ± 10.05 after treatment with 0.17 mM of the 
combined treatment (Figure 3.4B). Whereas, 0.67 mM oleic acid reduced side scattered 
light by 44.14 ± 6.23% (P=0.0001). Side scatter was further decreased by 1 mM palmitic 
acid which caused a 48.71 ± 2.57% reduction and 1 mM oleic acid which induced a 67.04 ± 
2.56% reduction (P=0.0001 and 0.0001, respectively). 
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Figure 3.4 All treatments caused significant reductions in forward scatter whilst 
palmitic acid and oleic acid caused decreases in side scatter 
     
A) Flow cytometric analysis identified changes in forward scatter (n=3). All treatments 
caused a significant decrease in forward scatter (P=0.0001). B) Flow cytometric analysis 
identified changes in side scatter (n=3). Side scattered light was reduced by 1 mM palmitic 
acid and 1 mM oleic acid (P=0.0001 and 0.0001). 
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3.3.2 Lipid accumulation in HepG2 
Oil red O staining was used to quantify the extent of lipid accumulation in HepG2 cells.  
At even the highest concentration of palmitic acid (1 mM) did not induce significant 
intracellular lipid accumulation with a 37.84 ± 21.79% increase from the control (P=0.1562) 
(Figure 3.5), which contradicts results from Moravcová, et al., (2015). Conversely, the two 
highest concentrations of the combination treatment, 0.67 mM and 1 mM, produced 
significant dose-dependent lipid accumulation up to 105.1 ± 18.13% (P=0.0024 and 0.0001, 
respectively). Oleic acid caused the most intracellular lipid accumulation with 0.33 mM, 0.67 
mM and 1mM producing significant results in a dose-dependent manner (P=0.0072, 0.0001 
and 0.0001, respectively). The largest percentage increase in intracellular lipid 
accumulation, 164.9 ± 8.01% was produced by 1 mM oleic acid. 
Of note is that the combination treatment induced 63.7%, approximately two thirds, of the 
lipid accumulation produced by oleic acid (105.1 ± 18.13% and 164.9 ± 8.01%, 
respectively). This was consistent with the composition of the combined treatment, which 
was composed of 
2
3
 oleic acid and 
1
3
 palmitic acid (Figure 3.5). 
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Figure 3.5 Oleic acid and the combination treatment caused intracellular lipid 
accumulation in HepG2 cells  
 
Oil Red O staining quantified intracellular lipid accumulation following treatment (n=3). Oleic 
acid and the combination treatment induced lipid accumulation in a dose-dependent 
manner (P=0.0001 and 0.0001), whilst even the highest concentration of palmitic acid did 
not (P=0.1562). 
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3.3.3 Correlation between lipid accumulation and viability 
The correlation between intracellular lipid accumulation tested by Oil Red O staining and 
cell viability of HepG2 assessed by CCK-8 (Figure 3.6A, 3.6B, 3.6C) was determined. The 
correlation between intracellular lipid accumulation from ORO experimentation and live cells 
(Figure 3.6D, 3.6E, 3.6F), apoptotic cells (Figure 3.7A, 3.7B, 3.7C), late apoptotic/necrotic 
cells (Figure 3.7D, 3.7E, 3.7F) and dead cells (Figure 3.8) measured by flow cytometric 
analysis of annexin V/PI staining was studied. The data was presented in percentage 
change in viability, live cells, apoptotic cells, late apoptotic cells and dead cell in order to 
standardise the results and enable better visual comprehension. 
The correlation between lipid accumulation and cell viability was assessed by plotting Oil 
Red O results on the X-axis with CCK-8 results on the Y-axis (Figure 3.6A, 3.6B, 3.6C). 
Palmitic acid induced-intracellular lipid accumulation was linked with a decrease in cell 
viability, however, this result was statistically non-significant (r=-0.512, P=0.3778). Oleic 
acid-induced lipid accumulation was significantly correlated with a decrease in the viability 
of HepG2 cells (r=-0.925, P=0.0244), as was lipid accumulation induced by the combined 
treatment (r=-1, P=0.0301). 
Oil Red O results on the X-axis were plotted against annexin V-and PI-negative results on 
the Y-axis, in order to study the correlation between lipid accumulation and the percentage 
of live cells following treatment (Figure 3.6D, 3.6E, 3.6F). Intracellular lipid accumulation 
resulting from treatment with palmitic acid was negatively correlated with live cell 
percentage, yet not significantly (r=-0.7, P=0.2333). A mild, non-significant correlation 
existed between oleic acid-induced lipid accumulation and a decrease in live HepG2 cells 
(r=-0.4, P=0.5167). Conversely, lipid accumulation induced by the combined treatment was 
mildly associated with an increase in live cell percentage, although not significantly (r=0.3, 
P=0.6833). 
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Figure 3.6 Lipid accumulation induced by oleic acid and the combination treatment is 
associated with decreases in cell viability 
 
A, B, C) Analysis of the correlation between intracellular lipid accumulation and the viability 
of HepG2 as determined by CCK-8 assay (ORO n=3, CCK-8 n=16). Combination-and oleic 
acid-induced lipid accumulation was correlated with decreased cell viability (P=0.0301 and 
0.0244, respectively), whilst palmitic acid-induced lipid accumulation was not (P=0.3778). 
D, E, F) Analysis of the correlation between intracellular lipid accumulation and percentage 
of apoptotic HepG2 cells found no significant links following 24h of exposure to any of the 
treatments (ORO n=3, flow cytometry n=3).  
 106 
 
 
On the X-axis, Oil Red O results were plotted against annexin V-positive/PI-negative results 
on the Y-axis, which allowed the correlation between lipid accumulation and the percentage 
of apoptotic cells to be studied (Figure 3.7A, 3.7B, 3.7C). Intracellular lipid accumulation as 
a result of treatment with palmitic acid was linked with a slight increase in apoptotic HepG2 
cells, which was not significant (r=0.3, P=0.6833). Lipid accumulation induced by oleic acid 
was mildly correlated with a decrease in the percentage of apoptotic cells, but not 
significantly (r=-0.3, P=0.6833). Whilst, combination treatment-induced lipid accumulation 
was also slightly associated with a non-significant decrease in apoptotic HepG2 cells (r=-
0.3, P=0.6833). 
Oil Red O results were plotted on the X-axis with annexin V-negative/PI-positive results on 
the Y-axis to analyse the correlation between lipid accumulation and the percentage of late 
apoptotic/necrotic following treatment (Figure 3.7D, 3.7E, 3.7F). Intracellular lipid 
accumulation induced by all three treatments was associated with an elevation in late 
apoptotic/necrotic HepG2 cells, however, none were statistically significant. Oleic acid-
induced lipid accumulation was the most strongly correlated (r=0.7, P=0.2333) followed by 
palmitic acid were (r=0.6, P=0.3500), and the combined treatment (r=0.4, P=0.5167), 
however, these too did not reach significance. 
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Figure 3.7 There was no significant correlation between lipid accumulation and 
apoptosis or late apoptosis/necrosis in HepG2  
 
A, B, C) Analysis of the correlation between intracellular lipid accumulation and percentage 
of apoptotic HepG2 found no significant associations following 24h of exposure to any of 
the treatments (ORO n=3, flow cytometry n=3). D, E, F) Study of the correlation between 
intracellular lipid accumulation and percentage of late apoptotic/necrotic HepG2 cells 
determined no significant links for any of the treatments (ORO n=3, flow cytometry n=3). 
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Oil Red O results on the X-axis were plotted against annexin V-and PI-positive results on 
the Y-axis, to analyse the correlation between lipid accumulation and the percentage of 
dead HepG2 cells (Figure 3.8A, 3.8B, 3.8C). Intracellular lipid accumulation induced by 
palmitic acid was associated with a mild increase in the percentage of dead HepG2 cells, 
yet this associations was non-significant (r=0.5, P=0.4500). On the other hand, oleic acid-
induced lipid accumulation was mildly linked with a non-significant decrease in the 
percentage of dead cells (r=-0.4, P=0.5167). Furthermore, lipid accumulation produced by 
the addition of the combination treatment was strongly correlated with a decrease in the 
dead cell percentage, however, this result was not statistically significant (r=-0.9, 
P=0.0833). 
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Figure 3.8 There was no significant correlation between lipid accumulation and 
percentage of dead HepG2 cells 
 
A, B, C) Statistical analysis uncovered no significant associations between intracellular lipid 
accumulation and percentage of dead HepG2 cells following treatment with palmitic acid 
and oleic acid, alone and in combination (ORO n=3, flow cytometry n=3).
 110 
 
3.3.4 L6 Viability in response to fatty acids 
Following investigations into the differential effects of palmitic acid and oleic acid, alone and 
in combination, on HepG2 hepatocytes, the next study aimed to characterise the effects on 
skeletal myotubes. L6 cells were cultured and allowed to differentiate before the above 
experimentation was replicated in this model (Figure 2.1). 
 
3.3.4.1 Toxicity of the FFA vehicle in L6 cells  
Experiments were performed to confirm that methanol did not adversely affect L6 cells 
(Figure 3.9). Even at the highest volume percentage, methanol did not cause significant 
changes in the viability of L6 cells in CCK-8 assays (P=0.6833). Also, flow cytometric 
analysis of annexin V/PI staining demonstrated that the addition of methanol did not alter 
the percentage of live L6 cells (P=0.9677). 
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Figure 3.9 Methanol did not cause cell death in L6 cells 
A) CCK-8 assays determined that methanol did not alter the viability of L6 cells (P=0.6833) 
(n=15). B) Flow cytometric analysis of annexin V/PI staining found that methanol had no 
effect on the percentage of live L6 cells following treatment (P=0.9677) (n=3). Due to the 
use of 100 mM stock solutions, the percentage of methanol equalled that of the fatty acid 
concentrations. The use of % change is described in 3.2.2. 
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3.3.4.2 Cell death in response to palmitic acid and oleic acid 
The CCK-8 assay used to examine the differential effects of palmitic acid and oleic acid on 
L6 cells demonstrated that a combination of the two fatty acids did not alter cell viability, 
even at the highest concentration of 1 mM (P=0.9311) (Figure 3.10A). At low 
concentrations (0.17-0.33 mM), palmitic acid had little effect on the viability of L6 cells 
(P=0.9990 and 0.9911, respectively). Whilst, 0.67 mM palmitic acid caused a significant 
reduction of 29.01 ± 6.04% in cell viability (P=0.0004), and 1 mM palmitic acid decreased 
cell viability by 87.87 ± 0.37% (P=0.0001). Similarly, the treatment of L6 cells with 0.17 mM 
oleic acid had no significant effect on cell viability (P=0.1426). However, oleic acid at 
concentrations of 0.33 mM, 0.67 mM and 1 mM produced significant decreases in cell 
viability (P=0.0086, 0.0005 and 0.0001, respectively).  
It is worth noting that although palmitic acid and oleic acid both induced significant 
decreases in the viability of L6, reduction caused by palmitic acid was far greater. For 
example, percentage viability following treatment with 1 mM oleic acid was 65.4 ± 2.66%, 
as opposed to 12.13 ± 0.37% following treatment with 1 mM palmitic acid. 
Live cell percentage results from flow cytometric analysis of annexin V/PI staining were 
studied to verify the CCK-8 results as CCK-8 classifies all cells with functioning 
dehydrogenase activity as viable, which may result in the inclusion cells undergoing death 
processes. On the other hand, flow cytometric techniques are able to quantify cells that are 
live without cell death processes initiated. 
Live cell percentage results were similar to the above cell viability results (Figure 3.10B). 
Alone, the lowest concentration of palmitic acid and oleic acid, 0.17 mM, had little effect on 
the percentage of live L6 cells following treatment (P=0.0764 and 0.3700, respectively). 
However, 0.17 mM of the combined treatment caused a small yet significant decrease in 
live cell percentage of 2.38 ± 0.24% (P=0.0159). At a concentration of 0.33 mM, palmitic 
acid, oleic acid and the combined treatment all produced small, but significant reductions in 
the percentage of live L6 (P=0.0001, 0.0001 and 0.0449, respectively). However, 0.67 mM 
of the combination treatment did not alter the live cell percentage (P=0.3548), whilst 0.67 
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mM oleic acid reduced live L6 cells by 8.33 ± 0.39% and 0.67 mM palmitic acid decreased 
the live cell percentage by 84.66 ± 0.48% (P=0.0001 and 0.0001, respectively). All 
treatments at the highest concentration of 1 mM diminished the percentage of live L6 cells. 
However, the percentage change varied wildly from a reduction of 5.22 ± 0.35% produced 
by the combination treatment, to a decrease of 25.95 ± 1.06% by oleic acid, to a 97.64 ± 
0.13% by palmitic acid (P=0.0001, 0.0001 and 0.0001, respectively). 
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Figure 3.10 All treatments caused a reduction in the percentage of live L6 cells 
 
A) CCK-8 assays illustrated that palmitic acid and oleic acid caused significant decreases in 
cell viability (P=0.0001 and 0.0001, respectively) (n=5). B) Flow cytometric analysis of 
annexin V/PI staining determined that all treatments caused significant decreases in live L6 
cells (P=0.0001), with palmitic acid causing the greatest reduction (n=3). 
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3.3.4.3 Stages of cell death in L6 cells 
The above studies determined that all treatments decreased the percentage of live L6 cells, 
and, therefore, further experimentation was required to understand the stage of cell death 
affected by FAs. As for HepG2, flow cytometric analysis of annexin V/PI staining was 
performed to examine the mechanisms responsible (Figure 3.11).  
At the lowest concentration of 0.17 mM, all treatments caused a significant decrease in the 
percentage of apoptotic L6 in comparison to the control (Figure 3.11A). Palmitic acid 
reduced apoptosis by 54.09 ± 7.70%, oleic acid by 68.44 ± 1.37% and the combination 
treatment by 49.93 ± 3.53% (P=0.0001, 0.0001 and 0.0001, respectively). Conversely, all 
treatments caused non-significant increases in late apoptosis/necrosis (P=0.0990, 0.8768 
and 0.1519, respectively). Furthermore, palmitic acid and the combined treatment both 
increased the percentage of dead L6 cells by 79.01 ± 27.2% and 107.8 ± 5.54%, 
respectively (P=0.0002 and 0.0001, respectively). 
At a concentration of 0.33 mM, palmitic acid, oleic acid and the combination treatment all 
significantly reduced the percentage of apoptotic cells, however, to a lesser extent than at 
0.17 mM (P=0.0001, 0.0001 and 0.0003, respectively) (Figure 3.11B). On the other hand, 
all treatments increased late apoptosis/necrosis to a greater and statistically significant 
extent (P=0.0001, 0.0001 and 0.0292, respectively). Palmitic acid continued to cause a 
greater percentage of dead L6 cells than the control (P=0.0043), and oleic acid also caused 
a significant increase of 104.23 ± 5.21% in dead cell percentage (P=0.0001), whilst the 
combined treatment did not (P=0.0646). 
As the concentration of the treatments increased to 0.67 mM, palmitic acid and the 
combined treatment continued to produce decreases in the percentage of apoptotic L6 cells 
by 50.79 ± 2.66% and 53.8 ± 4.1%, respectively (P=0.0001 and 0.0001, respectively), 
whilst reduction caused by oleic acid decreased to 16.36 ± 7.82% (P=0.0642) (Figure 
3.11C). Oleic acid and palmitic acid also continued to increase the percentage of late 
apoptosis/necrosis by 285.27 ± 22.56% and 3234.56 ± 17.85%, respectively (P=0.0001 and 
0.0001, respectively), however, the combination treatment did not induce a significant 
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increase (P=0.5984). Furthermore, oleic acid and palmitic acid continued to cause greater 
percentages of dead L6 cells than the control, whilst the combination treatment did not 
(P=0.0001, 0.0001 and 0.1343, respectively). 
At 1 mM, oleic acid caused small non-significant decreases in apoptosis of 1.15 ± 8.14%, 
whilst the combination treatment caused a small non-significant increase in apoptosis 
(P=0.9991 and 0.1258, respectively) (Figure 3.11D). Only 1 mM palmitic acid caused 
greater percentages in apoptotic cells than the control (P=0.0001). Very high levels of late 
apoptosis/necrosis were induced by 1 mM of all treatments. The combined treatment 
increased the percentage of late apoptotic/necrotic L6 cells by 166.67 ± 15.17%, oleic acid 
by 827.96 ± 40.38% and palmitic acid by 3026.73 ± 8.00% (P=0.0001, 0.0001 and 0.0001, 
respectively). At this concentration, all treatments also caused larger percentages of dead 
L6 cells than the control. The combined treatment increased the dead cell percentage by 
49.74 ± 3.23%, oleic acid by 336.16 ± 8.03% and palmitic acid by 1457.14 ± 14.83% 
(P=0.0173, 0.0001 and 0.0001, respectively). 
It is of note that, in spite of all 1 mM treatments causing significant late apoptosis/necrosis 
and cell death, palmitic acid caused significantly greater levels than oleic acid, and oleic 
acid caused significantly greater levels than the combined treatment.  
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Figure 3.11 Palmitic acid and oleic acid increased late apoptosis/necrosis and cell 
death in L6 
 
A, B, C, D) Flow cytometric analysis of annexin V/PI staining examined changes in the 
percentage of live, apoptotic, late apoptotic/necrotic and dead L6 cells. Experiments were 
performed following 24 hours of treatment with palmitic acid, oleic acid, alone or combined, 
in the following concentrations: 0.17 mM (A), 0.33 mM (B), 0.67 mM (C) and 1 mM (D) 
(n=3).  
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Similar to the HepG2 study, forward scatter and side scatter of L6 were examined as an 
additional tool in understanding the stage of cell death induced by fatty acids. The results 
formed by this experiment were judged holistically to give a qualitative summary, which 
carried little weight in the discussion. 
Neither palmitic acid, oleic acid nor the combination treatment at 0.17 mM induced 
significant alterations to the forward scatter produced by L6 (P=0.3828, 0.0653 and 0.1040, 
respectively) (Figure 3.12A). At 0.33 mM, oleic acid had no significant effect on forward 
scattered light (P=0.9505), however, palmitic acid induced a 13.55 ± 2.5% decrease whilst 
the combined treatment produced a 12.53 ± 1.2% increase (P=0.0179 and 0.0309, 
respectively). Palmitic acid continued to cause reductions to forward scatter at 0.67 mM 
with a decrease of 72.84 ± 0.25%, yet oleic acid and the combination treatment did not 
induce significant changes (P=0.0001, 0.1999, and 0.6876, respectively). Interestingly, 1 
mM of the combined treatment did not produce significant alterations to forward scattered 
light (P=0.8885), but oleic acid caused a 15.62 ± 0.98% decrease and palmitic acid a 60.22 
± 0.16% reduction (P=0.0056 and 0.0001, respectively). 
Side scatter produced by L6 cells remained unchanged by the majority of treatments, but 
0.67 mM oleic acid which caused an increase of 95.49 ± 66.37% (P=0.0023) (Figure 
3.12B). 
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Figure 3.12 Palmitic acid and oleic acid reduced forward scatter 
 
A) Flow cytometric analysis of annexin V/PI staining showed that palmitic acid caused a 
significant decrease in forward scatter (P=0.0001) (n=3). B) None of the treatments had a 
significant effect on side scattered light (n=3). 
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3.3.4.4 Apoptosis in L6 cells 
The results from flow cytometric analysis of annexin V/PI staining were equivocal as the 
cells appeared to bypass early apoptosis with large increases in late apoptosis/necrosis. 
Therefore, additional experiments were performed to determine whether the fatty acid 
treatments induced cell death via apoptosis or necrosis. To investigate this, L6 caspase 3/7 
activity was measured via an assay kit following treatment.  
Results from the caspase assay in L6 corroborated those from the late apoptosis/necrosis 
gate of the annexin V/PI analysis (Figure 3.13). Low concentrations of palmitic acid, 0.17 
and 0.33 mM had little effect on caspase 3/7 activity (P=0.9830 and 0.8817, respectively). 
Whereas, the addition of 0.67 mM palmitic triggered a significant 17811.11 ± 7288.50% 
increase in activity (P=0.0001). At the higher concentration of 1 mM, palmitic acid induced 
caspase activity of only 7288.89 ± 3038.05% (P=0.0753). In contrast, even the highest 
concentration of oleic acid and the combination treatment, 1 mM, did not cause significant 
percentage change in caspase 3/7 activity. Oleic acid induced an increase of 4166.67 ± 
2483.79% and the combined treatment produced an increase of 944.44 ± 309.25% 
(P=0.4753 and 0.9943, respectively). 
It is worth noting that caspase 3/7 activity following treatment with 1 mM palmitic acid was 
lower than following treatment with 0.67 mM palmitic acid. This was likely due to the very 
large increases in late apoptosis/necrosis shown in Figure 3.11C. 
 121 
 
 
 
 
 
 
 
Figure 3.13 Palmitic acid triggered caspase 3/7 activity 
 
A caspase 3/7 assay determined that palmitic acid induced caspase 3/7 activity (P=0.0753), 
whilst oleic acid and the combination treatment did not (n=3). 
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3.3.5 Lipid accumulation in L6 
Oil red O staining was utilised to measure intracellular lipid accumulation in L6 cells and 
ImageJ analysis was used to quantify the number of lipid droplets present. 
Results determined that palmitic acid did not trigger significant intracellular lipid 
accumulation in L6 cells (Figure 3.14A). The highest concentration of palmitic acid, 1 mM 
produced a 41.71 ± 19.33% increase in intracellular lipids (P=0.1113). On the other hand, 
oleic acid and the combination treatment induced lipid accumulation in a dose-dependent 
manner. The lowest concentration, 0.17 mM of the combination treatment did not cause 
significant lipid accumulation (P=0.0878), however, 0.33 mM, 0.67 mM and 1 mM did, with 
a maximal increase of 152.80 ± 9.74% (P=0.0168, 0.0001 and 0.0001, respectively). Oleic 
acid produced the highest levels of intracellular lipid accumulation in L6 cells with all 
concentrations, 0.17 mM, 0.33 mM, 0.67 mM and 1 mM producing statistically significant 
results (P=0.0083, 0.0002, 0.0001 and 0.0001, respectively). Maximal lipid accumulation of 
185.61 ± 22.77% was produced by 1 mM oleic acid. 
Interestingly, the combined treatment induced greater than two thirds of the lipid 
accumulation produced by oleic acid. This was odd as the combination treatment was 
composed of 
2
3
 oleic acid and 
1
3
 palmitic acid. 
Image J analysis examined the number of lipid droplets per field of confluent L6 cells and 
deduced that neither palmitic acid nor the combination treatment caused a significant 
increase in lipid droplet formation (Figure 3.14B). At the highest concentration of 1 mM, 
oleic acid did not induce the formation of any lipid droplets, whilst the combination treatment 
produced 2.33 ± 0.67 lipid droplets per field (P=0.9969). However, 1 mM of oleic acid 
resulted in a marked increase in the number of lipid droplets per field to 106 ± 24.58 
(P=0.0001).  
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Figure 3.14 Oleic acid and the combined treatment induced significant lipid 
accumulation, whilst oleic acid caused the formation of lipid droplets in L6 cells 
 
A) Oil Red O staining showed that oleic acid produced significant intracellular lipid 
accumulation (P=0.0001), as did the combination treatment (P=0.0001) (n=3). B) Analysis 
of lipid droplets via ImageJ showed that oleic acid caused the formation of intracellular lipid 
droplets in L6 (P=0.0001).  
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3.3.6 Correlation between lipid accumulation and viability 
As with the HepG2 study, the correlation between intracellular lipid accumulation and 
varying L6 cell death parameters were analysed. The correlation between intracellular lipid 
accumulation, tested by Oil Red O staining and cell viability of L6 determined by CCK-8 
(Figure 3.15A, 3.15B, 3.15C) was examined. The correlation between intracellular lipid 
accumulation and live cells (Figure 3.15D, 3.15E, 3.15F), apoptotic cells (Figure 3.16A, 
3.16B, 3.16C), late apoptotic/necrotic cells (Figure 3.16D, 3.16E, 3.16F) and dead cells 
(Figure 3.17A, 3.17B, 3.17C) quantified by flow cytometric analysis of annexin V/PI staining 
was studied. The results were presented in percentage change to standardise the data and 
permit better visual understanding. 
On the X-axis, Oil Red O results were plotted against CCK-8 results on the Y-axis, to 
determine the correlation between lipid accumulation and cell viability (Figure 3.15A, 3.15B, 
3.15C). Intracellular lipid accumulation resulting from treatment with palmitic acid was not 
associated with changes in cell viability (r=-0.1, P=0.9500). Oleic acid-induced lipid 
accumulation was moderately, but non-significantly correlated with a reduction in the 
viability of L6 cells (r=-0.7, P=0.2333). On the other hand, lipid accumulation induced by the 
combination treatment was correlated with a moderate increase in cell viability, however, 
this result was not significant (r=0.5, P=0.4500). 
Oil Red O results were plotted on the X-axis against annexin V-and PI-negative results on 
the Y-axis, to examine the association between lipid accumulation and the percentage of 
live cells following treatment (Figure 3.15D, 3.15E, 3.15F). Palmitic acid-induced 
intracellular lipid accumulation was negatively, yet not significantly linked with live cell 
percentage (r=-0.7, P=0.2333). Lipid accumulation produced by treatment with oleic acid 
was strongly associated with a decrease in the percentage of live L6 cells, however, the 
result was not significant (r=-0.9, P=0.0833). Lipid accumulation induced by the 
combination treatment was mildly associated with a non-significant decrease in live cell 
percentage (r=-0.3, P=0.6833). 
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Figure 3.15 Intracellular lipid accumulation was not significantly associated with cell 
viability or the percentage of live L6 cells 
 
A, B, C) Analysis of the correlation between lipid accumulation and cell viability of L6 was 
determined by comparison of ORO and CCK-8 results. There was no significant correlation 
following exposure to any of the treatments (ORO n=3, CCK-8 n=5). D, E, F) Analysis of the 
association between intracellular lipid accumulation and percentage of apoptotic L6 cells 
found no significant links for any of the treatments (ORO n=3, flow cytometry n=3).  
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Correlation between lipid accumulation and the percentage of apoptotic L6 cells was 
determined by plotting ORO results on the X-axis against annexin V-positive and PI-
negative results on the Y-axis (Figure 3.16A, 3.16B, 3.16C). Palmitic acid-induced lipid 
accumulation was moderately linked with a reduction in the percentage of early apoptotic 
L6 cells, yet non-significantly (r=-0.7, P=0.2333). There was no correlation between oleic 
acid-induced lipid accumulation and the percentage of apoptotic L6 cells (r=0, P>0.9999). 
Furthermore, there was no correlation between intracellular lipid accumulation induced by 
the combination treatment and apoptosis in L6 cells (r=0.1, P=0.9500). 
On the X-axis, Oil Red O results were plotted against annexin V-negative and PI-positive 
results on the Y-axis, in order to study the correlation between lipid accumulation and the 
percentage of late apoptotic/necrotic L6 cells (Figure 3.16D, 3.16E, 3.16F). Intracellular lipid 
accumulation produced by palmitic acid was linked with a non-significant increase in late 
apoptotic/necrotic cell percentage (r=0.4, P=0.9500). Oleic acid-induced lipid accumulation 
was significantly linked to an increase in the percentage of late apoptotic/necrotic L6 cells 
(r=1, P=0.0167). Lipid accumulation caused by the combination treatment was also 
moderately associated with an elevation in late apoptotic/necrotic cells, however, this result 
was not significant (r=0.7, P=0.2333). 
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Figure 3.16 Oleic acid-induced intracellular lipid accumulation was associated with 
an increase in late apoptosis/necrosis.  
 
A, B, C) Study of the correlation between intracellular lipid accumulation and percentage of 
early apoptotic L6 found no significant links following exposure to any of the treatments 
(ORO n=3, flow cytometry n=3). D, E, F) Examination of the association between 
intracellular lipid accumulation and late apoptotic/necrotic L6 cells found that oleic acid-
induced lipid accumulation was significantly correlated with an increase in late 
apoptosis/necrosis (P=0.0167), whilst palmitic acid and the combined treatment were not 
(P=0.9500 and 0.2333, respectively) (ORO n=3, flow cytometry n=3).  
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The association between lipid accumulation and the percentage of dead L6 cells was 
examined by plotting ORO results on the X-axis against annexin V- and PI-negative results 
on the Y-axis (Figure 3.17A, 3.17B, 3.17C). Intracellular lipid accumulation as a result of 
palmitic acid treatment was moderately correlated with elevated cell death, yet not 
significantly (r=0.6, P=0.3500). A strong association existed between oleic acid-induced 
lipid accumulation and the percentage of dead L6 cells, however, this correlation was not 
statistically significant (r=0.8, P=0.1333). There was zero correlation between intracellular 
lipid accumulation induced by the combination treatment and the percentage of dead L6 
cells (r=0, P>0.9999). 
 129 
 
 
Figure 3.17 No significant associations between intracellular lipid accumulation and 
L6 cell death existed for any of the treatments  
 
A, B, C) Upon comparison of intracellular lipid accumulation and dead cell percentage, no 
significant associations were found (ORO n=3, flow cytometry n=3). 
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On the X-axis, Oil Red O results were plotted against caspase assay results on the Y-axis, 
to determine the link between lipid accumulation and caspase 3/7 activity (Figure 3.18A, 
3.18B, 3.18C). Intracellular lipid accumulation induced by palmitic acid was mildly, but non-
significantly associated with elevated caspase 3/7 activity in L6 cells (r=0.4, P=0.5167). 
Oleic acid caused significant lipid accumulation, which was strongly correlated with an 
increase in caspase 3/7 activity, however, the result was not statistically (r=0.9, P=0.0833). 
Lipid accumulation induced by the combination treatment was mildly and non-significantly 
linked with increased caspase 3/7 activity (r=0.3, P=0.6833). 
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Figure 3.18 Intracellular lipid accumulation was not linked with caspase 3/7 activity in 
L6 cells.  
 
A, B, C) Examination of the correlation between intracellular lipid accumulation and 
caspase 3/7 activity in L6 cells found no significant links following 24 hours of treatment 
with palmitic acid and oleic acid, individually and in combination (ORO n=3, caspase assay 
n=3). 
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3.3.7 The differential effect of palmitic acid and oleic acid in HepG2 versus L6 
Given the different findings from the two cell types, and the lack of understanding on the 
effect of FA in these two tissues, the final study in this chapter sought to compare the effect 
of PA and OA in HepG2 versus L6 cells. 
Comparison of cell viability data between HepG2 and L6 revealed consistent trends across 
the range of concentrations (Figure 3.19). Palmitic acid caused greater loss in cell viability 
in L6 cells. At the highest concentration, 1 mM palmitic acid reduced the viability of HepG2 
cells to 31.6 ± 1.86%, and L6 cells to the significantly lower 12.13 ± 0.37% (P=0.0086). 
Furthermore, all but the lowest concentration of oleic acid caused significantly greater loss 
in viability in L6 cells. Oleic acid at 1 mM decreased the viability of HepG2 to 89.38 ± 
2.53%, but reduced the viability of L6 to 65.40 ± 2.66% (P=0.0010). In contrast, the 
combination treatment caused a greater loss to the viability of HepG2 cells than L6 cells, 
yet at higher concentrations caused reductions in the viability of HepG2 cells and increases 
in viability in L6 cells. The 1 mM combined treatment decreased the viability of HepG2 cells 
to 82.91 ± 4.90% and yet increased the viability of L6 to 104.20 ± 3.43% (P=0.0095). 
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Figure 3.19 Palmitic acid and oleic acid caused greater viability loss in L6 cells, 
whilst the combined treatment produced the opposite effect 
 
Comparision of HepG2 and L6 viability following FA treatment with results from the CCK-8 
assay. A) 0.17 mM. B) 0.33 mM. C) 0.67 mM. D) 1 mM. 
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Live cell percentage data was compared between HepG2 and L6 cells to identify trends. At 
low concentrations, 0.17 mM and 0.33 mM palmitic acid produced larger, but non-significant 
reductions in live HepG2 cells as opposed to L6 (P=0.7834 and 0.9992, respectively) 
(Figure 3.20). However, at higher concentrations of 0.67 mM and 1 mM this was reversed 
and palmitic acid caused significantly greater reductions in the percentage of live L6 in 
comparison to HepG2. At 1mM, oleic acid decreased live HepG2 percentage by 62.84 ± 
0.70% yet reduced live L6 percentage by 97.64 ± 0.13% (P<0.0001). Oleic acid produced a 
similar trend in that low concentrations caused significantly greater reductions in live HepG2 
cells than L6. For example, 0.67 mM oleic acid decreased the percentage of live HepG2 by 
35.80 ± 5.42% and L6 by only 8.32 ± 0.39% (P=0.0001). However, 1 mM of oleic acid 
caused a reduction in live HepG2 cells by 13.89 ± 0.71% and yet decreased live L6 by 
25.95 ± 1.06%, and, thus, demonstrated the opposite trend (P=0.0002). On the other hand, 
the combination treatment produced little difference between HepG2 and L6 at 0.17 mM 
and 0.33 mM (P=0.9769 and 0.8660, respectively), and yet produced contradictory results 
for 0.67 mM and 1 mM. At 0.67 mM, the combined treatment caused a reduction in live 
HepG2 cells by 22.65 ± 4.06% and a slight increase in live L6 cells of 1.21 ± 0.33% 
(P=0.0005). But conversely at 1 mM, elevated the percentage of live HepG2 cells by 14.36 
± 3.23% and decreased live L6 cells by 5.22 ± 0.35% (P<0.0001). 
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Figure 3.20 Palmitic acid caused greater reductions in the percentage of live L6 cells 
in comparison to HepG2 
 
Comparison of live cell percentage change in HepG2 and L6 following treatment with PA 
and/or OA. Results from flow cytometric analysis of annexin V/PI staining. A) 0.17 mM. B) 
0.33 mM. C) 0.67 mM. D) 1 mM. 
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The comparison of apoptosis data demonstrated that palmitic acid induced greater levels in 
HepG2 than L6 cells (Figure 3.21). Furthermore, palmitic acid consistently decreased 
apoptosis in L6 cells, but had a tendency to increase it in HepG2. At 1 mM, palmitic acid 
induced a 98.69 ± 10.69% increase in the percentage of apoptotic HepG2 cells, yet 
reduced apoptosis by 77.91 ± 1.65% in L6 cells (P<0.0001). Oleic acid produced a similar 
trend at concentrations of 0.17 mM and 0.33 mM (P<0.0001 and P=0.0002, respectively). 
However, there was no significant difference between the effects of higher concentrations 
of oleic acid on HepG2 cells and L6 cells. The combination treatment did not produce a 
trend between HepG2 and L6, but did produce a significant result at 0.33 mM (P=0.0017). 
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Figure 3.21 Palmitic acid induced greater levels of early apoptosis in HepG2 than L6 
cells 
 
Comparison of apoptotic cell percentage change in HepG2 and L6 following FA treatment. 
Results from flow cytometric analysis of annexin V/PI staining. A) 0.17 mM. B) 0.33 mM. C) 
0.67 mM. D) 1 mM. 
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The percentage of late apoptotic/necrotic cells was compared between HepG2 and L6. 
Palmitic acid at concentrations of 0.33mM, 0.67 mM and 1 mM induced significantly higher 
percentages of late apoptosis/necrosis in L6 cells compared to HepG2 cells (P=0.0025, 
P<0.0001 and P<0.0001) (Figure 3.22). At 1 mM, palmitic acid increased late 
apoptotic/necrotic L6 cells by 3026.73 ± 8.00%, whilst the percentage of late/necrotic 
HepG2 cells only increased by 114.11 ± 6.16%. Oleic acid demonstrated the same trend 
and caused significantly greater late apoptosis/necrosis in L6 cells following treatment with 
0.33 mM, 0.67 mM and 1 mM oleic acid (P=0.0006, P<0.0001 and P<0.0001, respectively). 
At 1 mM, oleic acid elevated the percentage of late apoptotic/necrotic HepG2 cells by 59.02 
± 6.85% yet increased late apoptosis/necrosis by 827.96 ± 40.38% in L6 cells. The 
combination treatment also followed the same pattern, however, only1 mM produced a 
significant difference between HepG2 and L6. At 1 mM, the combination treatment 
increased late apoptotic/necrotic HepG2 cells by only 5.95 ± 6.53% yet elevated late 
apoptosis/necrosis by 166.67 ± 15.17% in L6 cells (P=0.0001). 
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Figure 3.22 Palmitic acid and oleic acid induced vastly greater levels of late 
apoptosis/necrosis in L6 cells than HepG2 cells 
  
Comparison of late apoptotic/ necrotic cell percentage change in HepG2 and L6 following 
FA treatment. Results from flow cytometric analysis of annexin V/PI staining. A) 0.17 mM. 
B) 0.33 mM. C) 0.67 mM. D) 1 mM. 
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Comparison of dead cell percentages between HepG2 and L6 demonstrated that all 
treatments induced greater levels of cell death in L6 cells (Figure 3.23). All concentrations 
of palmitic acid produced a significant difference, however, at 0.17 mM and 0.33 mM 
palmitic acid reduced cell death in HepG2 cells, yet increased cell death in L6 (P=0.0004 
and P<0.0001, respectively). At higher concentrations, palmitic acid induced minimal levels 
of cell death in HepG2 cells, but high levels in L6. At 1 mM, cell death was increased by 
12.70 ± 10.17% in HepG2 and 1457.14 ± 14.83% in L6 (P<0.0001). Oleic acid produced 
the same trend except at 0.17 mM, which caused little cell death in either cell line 
(P=0.9938). At 0.33 mM, 0.67 mM and 1mM oleic acid induced greater percentages of cell 
death in L6 than HepG2 (P<0.0001, P=0.0004 and P<0.0001, respectively). The pattern 
was also similar for the combination treatment, however, all concentrations caused a 
reduction in cell death in HepG2. At 1 mM, the combined treatment decreased the dead 
HepG2 percentage by 57.14 ± 0.26% and elevated cell death in L6 by 49.74 ± 2.23% 
(P<0.0001). 
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Figure 3.23 All treatments caused greater cell death in L6 cells as opposed to HepG2 
cells 
 
 
Comparison of late apoptotic/ necrotic cell percentage change in HepG2 and L6 following 
treatment with PA and/or OA. Results from flow cytometric analysis of annexin V/PI 
staining. A) 0.17 mM. B) 0.33 mM. C) 0.67 mM. D) 1 mM. 
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Intracellular lipid accumulation was compared between HepG2 and L6 cells. This section of 
the study was vital to understand whether disparities in lipid accumulation could be a factor 
in the differing effects of palmitic acid and oleic acid between the two cell types. 
Comparisons found that levels of palmitic acid-induced lipid accumulation was equal 
between HepG2 and L6 cells, even at 1 mM (P=0.9994) (Figure 3.24). On the other hand, 
both oleic acid and the combined treatment caused greater lipid accumulation in L6 than 
HepG2, however, this observation was not statistically significant even at the highest 
concentration (P=0.8064 and 0.2190, respectively).
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Figure 3.24 Lipid accumulation induced by any of the treatments did not differ 
between HepG2 and L6 cells 
  
Comparison of intracellular lipid accumulation fold change in HepG2 and L6 following FA 
treatment. Results from analysis of ORO staining. A) 0.17 mM. B) 0.33 mM. C) 0.67 mM. D) 
1 mM. 
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3.4 Discussion  
The aim of experiments in this chapter was to examine the effects of palmitic acid and oleic 
acid, alone and in combination, on cell death and intracellular lipid accumulation in HepG2 
and L6 cells. This extended to the determination of associations between lipid accumulation 
and phase of cell death, and finally to the comparison of all results between the two cell 
lines to clarify contradictory literature in the field and gain a better understanding of the 
differential effects caused by these fatty acids. Results highlighted that palmitic acid 
instigated loss of viability in both HepG2 and L6 cells, whilst oleic acid only reduced cell 
viability in L6 cells. The results from the combination treatment were more interesting when 
compared to results from its constituent parts. The 1 mM combination treatment was 
composed of 0.67 mM oleic acid and 0.33 mM palmitic acid and produced differing effects 
in the two cell lines. In L6, the combination of the two fatty acids abolished the deleterious 
effects of oleic acid, whilst in HepG2 the combination was more toxic than the individual 
treatments alone. These results highlighted the differential effects between the two cell lines 
and indicated potential differences in fatty acid metabolism between HepG2 and L6 cells. 
Further experimentation investigated the stages of viability loss and demonstrated that all 
treatments reduced the percentage of live cells relative to the control in both cell lines. In L6 
cells, low concentrations of palmitic acid and oleic acid, alone and in combination reduced 
early apoptosis. Conversely, at the highest concentration they all elevated late 
apoptotic/necrotic and dead cells. In HepG2 cells, trends were less clear. The highest 
concentration of palmitic acid increased late apoptosis/necrosis, but unlike L6 also 
increased early apoptosis. Oleic acid on the other hand, caused an increase in late 
apoptosis/necrosis, but decreased dead HepG2 cells. In contrast to L6, the combination 
treatment reduced the percentage of dead cells in HepG2. The results indicated that 
palmitic acid was inducing cell death via apoptosis as increases in early and late apoptosis 
were found. However, the mechanism of oleic acid-induced cell death was less certain, 
and, thus, further analysis was required. 
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Forward scatter and side scatter were examined to gain a better insight into the possible 
modes of cell death. In HepG2, palmitic acid, oleic acid and the combination treatment 
decreased forward scattered light. Only palmitic acid and oleic acid alone reduced FSC in 
L6 cells. Palmitic acid and oleic acid alone, also reduced side scatter in HepG2, but no 
treatment altered this parameter in L6 cells. In spite of these results being tentative, they 
added further weight to the theory that palmitic acid was causing cell death via apoptosis. 
However, results for the other treatments were equivocal. Therefore, a caspase assay was 
used to study apoptosis in L6 cells, but not in HepG2 cells due to aforementioned issues 
with clumping in culture. Palmitic acid greatly increased caspase 3/7 activity in L6 cells, 
whilst oleic acid and the combination treatment did not. This confirmed that palmitic acid 
was eliciting its effects via apoptosis, and suggested that oleic acid and the combination 
treatment were causing cell death by another mechanism. 
Intracellular lipid levels were measured to examine the link between intracellular lipid 
accumulation and cell death. In both cell lines, oleic acid and the combination treatment 
induced lipid accumulation. In HepG2, the combined treatment caused an increase in lipid 
accumulation, whilst oleic acid caused maximal accumulation from the control. Slightly 
higher increases were found in L6 with both the combination treatment and oleic acid. 
Further analysis studying the number of lipid droplets was performed in L6. This experiment 
was not performed on HepG2 as in culture the cells clumped rather than grow in a 
monolayer, which made analysis unreliable. This test was important to understand how the 
different treatments altered lipid storage. Only oleic acid caused a significant increase in the 
number of lipid droplets in L6. These results suggested that palmitic acid did not exert its 
deleterious effects through intracellular lipid accumulation, and that oleic acid caused 
intracellular lipid accumulation in the form of lipid droplets. Furthermore, they suggested 
that combination treatment-induced lipid accumulation differed from oleic acid-induced lipid 
accumulation. However, further statistical analysis was performed to fully understand the 
relationships between intracellular lipid accumulation and cell death processes. 
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The correlation between intracellular lipid accumulation and cell viability, percentage of live 
cells, early apoptosis, late apoptosis/necrosis and percentage of dead cells was examined, 
and only three associations found. In HepG2, lipid accumulation induced by oleic acid and 
the combination treatment were both associated with a loss of cell viability. In addition, oleic 
acid-induced lipid accumulation was correlated with late apoptosis/necrosis in L6 cells. 
These results confirmed that palmitic acid was not eliciting its toxicity via intracellular lipid 
accumulation. However, oleic acid-induced lipid accumulation may physically damage cells, 
thus, supporting necrosis as the proposed mechanism of cell death. 
 
3.4.1 Palmitic acid induces cell death in HepG2 and L6 cells 
Many studies have investigated the effects of FFA on cells in vitro (Chavez-Tapia, et al., 
2012; Cheon, et al., 2014; El-Assaad, et al., 2003; Gaster, et al., 2005; Haffar, et al., 2015; 
Listenberger, et al., 2003b; Malhi, et al., 2006; Ricchi, et al., 2009; Shen, et al., 2017; Yao, 
et al., 2011), however, there are a number of contradictions in the literature regarding which 
fatty acids cause cell death, and whether the loss in viability is as a result of intracellular 
lipid accumulation. Furthermore, most papers suggest that unsaturated fatty acids are able 
to prevent the detrimental effects produced by saturated fatty acids (Cheon, et al., 2014; El-
Assaad, et al., 2003; Haffar, et al., 2015; Listenberger, et al., 2003b; Shen, et al., 2017), 
whilst a small number have found these ‘protective’ unsaturated fatty acids to cause cell 
death in their own right (Malhi, et al., 2006). 
Research on pancreatic β-cells is the most abundant possibly due to links between obesity 
and type II diabetes (Halban, et al., 2014; Linnemann, et al., 2014; Tomita, 2016). Studies 
focusing on hepatocytes are less frequent, although due to implications for non-alcoholic 
fatty liver disease are still relatively common (Al Fadel, et al., 2016; Kochan, et al., 2017). 
However, investigations into the effects of FFA on skeletal muscle cells are somewhat 
lacking (Cheon, et al., 2014; Peng, et al., 2011). 
The literature in this area reports that fatty acids have a common effect across cell types. 
Most papers report that palmitic acid causes cell death, whilst oleic acid seems to have little 
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effect, however, this was not always the case. Azevedo-Martins, et al., (2006) found that 
both palmitic acid and oleic acid cause DNA fragmentation leading to apoptosis in RINm5F 
pancreatic β-cells, while Maestre, et al., (2003) found that apoptosis is accelerated in 
β(INS-1)-cells ). One study found that oleic acid causes limited cell death in pancreatic β-
cells, whilst exerting higher toxicity than palmitic acid in non–β islet cells (Cnop, et al., 
2001). Oleic acid has also been shown to induce cell death in AS-30D rat hepatoma cells 
(Dymkowska, et al., 2006), Jurkat human T lymphocytes and Raji B lymphocytes (Cury-
Boaventura, et al., 2006), J774 macrophages (Martins de Lima, et al., 2006) and human 
neuroblastoma SH-SY5Y cells (Zhu, et al., 2005). Other studies report that palmitic acid 
induces apoptosis in hepatocytes, whilst oleic acid induces autophagy (Mei, et al., 2011). 
This discord in the literature highlights the importance of investigating the effects of palmitic 
acid and oleic acid on the viability of hepatocytes and skeletal myocytes. 
The results from this study determined that palmitic acid and oleic acid elicited different 
effects on different cell types. Palmitic acid was highly toxic to HepG2 and L6 cells, causing 
68.4 ± 1.86% and 87.9 ± 0.37% cell death, respectively. Flow cytometric analysis of 
annexin V/PI staining found that palmitic acid caused a significant increase in late 
apoptotic/necrotic cells in both HepG2 and L6 cells (P=0.0001 and 0.0001, respectively. 
Furthermore, 0.67 mM palmitic acid significantly increased caspase 3/7 activity in L6 cells 
(P=0.0001). These results were consistent with previous research in HepG2 that found 
palmitic acid causes mitochondrial dysfunction, by inducing oxidative stress via the 
activation of NADPHox (García-Ruiz, et al., 2015). A study in L6 myocytes determined that 
palmitic acid induces cell death through the loss of mitochondrial membrane potential 
(Cheon & Cho, 2014). However, many mechanisms of action have been proposed; for 
example a study using L6 and C2C12 myocytes found that palmitic acid induces ER stress 
(Peng, et al., 2011).   
It was found that oleic acid, at concentrations of 1 mM caused significant cell death in L6 
cells, (34.6 ± 2.66% of cells), whilst triggering cell death in only 10.6 ±2.53% in HepG2 cells 
(P=0.0010). This finding was confirmed by flow cytometric analysis of annexin V/PI, which 
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highlighted a significant increases in late apoptotic/necrotic cells in L6 (827.96 ± 40.38%), 
and smaller, but still significant elevations in late apoptotic/necrotic HepG2 of 59.02 ± 
6.85% following treatment with oleic acid (P=0.0001 and 0.0187, respectively). This is in 
contrast to research carried out in L6 and C2C12 myocytes, which found that oleic acid 
does not cause ER stress (Peng, et al., 2011), and, thus, does not trigger cell death. 
The combination of palmitic acid and oleic acid appeared to exert protective effects over 
low level toxicity in L6 cells. In HepG2 cells, the combination treatment induced greater 
losses to cell viability than its constituent parts. These results are similar to findings in L6 
and C2C12 myocytes which indicate that a combination the addition of oleic acid relieved 
palmitic acid-induced ER stress (Peng, et al., 2011). Others have found that the effects of 
palmitic acid are completely abolished with the equimolar addition of unsaturated fatty acids 
in mouse L-M fibroblasts (Doi, et al., 1978). However, the combination of palmitic acid and 
oleic acid increasing cell viability in any cell type has not been evidenced in the literature. 
However, this was a small effect, and, thus, within the experimental range.  
There are a number of mechanisms through which oleic acid may protect cells against the 
deleterious effects of palmitic acid. For example, oleic acid may block the uptake of palmitic 
acid into the cells by forming aggregates or via competitive inhibition. However this was 
disproven in C2C12 cells as it was shown that oleic acid recovers Akt phosphorylation by 
relieving palmitic acid-induced ER stress (Peng, et al., 2011).  
A significant number of studies suggest that oleic acid forms neutral lipid droplets within the 
cell which sequesters the palmitic acid, thereby preventing it from eliciting lipotoxic effects 
(Cheon & Cho, 2014; El-Assaad, et al., 2003; Haffar, et al., 2015; Listenberger, et al., 2003; 
Shen, et al., 2017). Results from this study suggested that oleic acid did form lipid droplets, 
however, these were not necessarily neutral as oleic acid caused toxicity in L6 cells. 
Furthermore, these lipid droplets did not appear to sequester palmitic acid.  
There is also some confusion as to whether fatty acids cause cell death via apoptotic or 
necrotic pathways. The majority of papers suggest that fatty acids trigger apoptosis, yet a 
number of papers challenge the dogma, suggesting that lipotoxicity is executed via 
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mitochondrion-dependent necrosis (Rockenfeller, et al., 2010), or via a combination of the 
two (Hoffmann, et al., 2014). Mitochondrion-dependent necrosis is initiated by the formation 
of the mitochondrial permeability transition pore following stress resulting in membrane 
depolarisation and uncoupling of oxidative phosphorylation, which leads to ATP depletion 
and necrotic cell death (Halestrap, 2009; Lemasters, et al., 1998). The results from the 
current study concur with those from Yao, et al., (2011), who found that HepG2 treated with 
a combination of palmitic and oleic acid showed increases in the late apoptotic/necrotic 
quadrant as demonstrated by flow cytometric analysis of annexin V/PI staining. Yao, et al., 
(2011) suggested that these results indicate a combination of apoptosis and necrosis is 
taking place. However, results from this project indicated that palmitic acid was undergoing 
apoptosis. This theory appears to be highly likely as the increase in caspase 3/7 following 
treatment with palmitic acid was a strong indicator of apoptosis. This finding is supported by 
the literature, as palmitic acid causes LDH release in cultured human endothelial cells 
(Zhang, et al., 1992), DNA laddering in neonatal rat ventricular myocytes (de Vries, et al., 
1997), and DNA fragmentation in pancreatic β-cells (Maedler, et al., 2001). It was 
hypothesised that the lapse of time between the initiation of apoptosis and the performance 
of the assay resulted in some cells falling into the late apoptotic/necrotic category. 
However, oleic acid appears to initiate necrotic processes as signs of early apoptosis were 
not evident. 
Despite differences in the mechanism, the evidence strongly supports the concept that 
mitochondria and the ER play a role in fatty acid-induced lipotoxicity (Egnatchik, et al., 
2014; Hauck & Bernlohr, 2016). A number of studies have shown that fatty acids cause 
structural and functional changes to mitochondria (Chan & Higgins, 1978; Penzo, et al., 
2002). One of the most recognised deleterious effects of fatty acids is the uncoupling of 
oxidative phosphorylation through a number of metabolite transporters (Hermesh, et al., 
1998; Samartsev, et al., 2011; Samartsev, et al., 2013). The interaction between fatty acids 
and mitochondrial carrier proteins leads to membrane depolarisation, and/or the 
transformation of the mitochondrial carrier protein into a pore (Penzo, et al., 2002). The 
opening of this permeability transition pore initiates apoptosis (Rial, et al., 2010). Some 
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authors believe that de novo ceramide synthesis following treatment with palmitic acid also 
leads to activation of the apoptotic mitochondrial pathway (Maedler, et al., 2001). Results 
from research investigating effects on the ER indicate that palmitic acid induces the 
production of phospholipids, which cause imbalances in the ER membrane leading to ER 
expansion, disrupting the normal functioning of the ER (Peng, et al., 2011). However, other 
papers suggest that palmitic acid causes the formation of solid lipid deposits in the ER 
membrane (Shen, et al., 2017), which produce cleft-like dilations displacing the normal 
granular contents of the ER (Gordon, 1977). This project did not find significant lipid 
accumulation following treatment with palmitic acid which could favour the theory of 
incorporation into the ER membrane, leading to ER stress and ultimately cell death. 
However, further investigations would be required to confirm this hypothesis. 
 
3.4.2 Oleic acid induces lipid accumulation 
Yao, et al., (2011) showed that as the concentration of fatty acid solution increases, so 
does intracellular lipid accumulation (P<0.01), which is implicated in triggering cell death 
and alterations to intracellular signalling. There is much debate regarding intracellular lipid 
accumulation and the mechanisms by which it damages cell viability, if at all. Some studies 
have linked the accumulation of intracellular lipids with cell death (Lee, et al., 1994; Unger, 
1997). However, other studies have found an inverse relationship between TAG 
accumulation and lipotoxicity in pancreatic β-cells (Cnop, et al., 2001). 
Results from study determined that palmitic acid did not induce intracellular lipid 
accumulation in either cell line. Furthermore, palmitic acid-induced intracellular lipid 
accumulation was not correlated with cell death or any of its processes in either cell line, yet 
palmitic acid was the most toxic treatment tested. Therefore, this project found that lipid 
accumulation was not inherently responsible for cell death. Many authors agree that 
palmitic acid treatment results in minimal lipid accumulation, however, some studies have 
found it to accumulate in primary neonatal cardiomyocytes (Haffar, et al., 2015), jejunal 
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epithelial cells (McKay, et al., 1967) and C2C12 myocytes (Chavez, et al., 2003; Peng, et 
al., 2011).  
The presence of increasing concentrations of oleic acid resulted in significant intracellular 
lipid accumulation in both HepG2 and L6 cells. This lipid accumulation was correlated with 
the loss of HepG2 viability and associated with late apoptosis/necrosis in L6 cells. There is 
a strong body of evidence that suggests that oleic acid causes intracellular lipid 
accumulation in lipid droplets (Cheon & Cho, 2014; Cnop, et al., 2001; Gordon, 1977; 
Haffar, et al., 2015; Hawley & Gordon, 1976; Listenberger, et al., 2003; Peng, et al., 2011; 
Rosenthal, 1981). However, most studies did not find a link between intracellular lipid 
accumulation and cell death. The common consensus is that palmitic acid and oleic acid 
cause the intracellular accumulation of different lipid species in different structures, and, 
thus, trigger very different consequences. The results from treatment with palmitic acid and 
oleic acid individually, highlighted that cell death occurred regardless of lipid accumulation. 
Therefore, it was hypothesised that intracellular lipid metabolites were formed following 
treatment, and it was those lipid species that resulted in differential toxic effects. 
The combination treatment of 2:1, oleic acid to palmitic acid also resulted in significant 
intracellular lipid accumulation, but to a lesser extent than oleic acid alone. In HepG2 cells, 
lipid accumulation induced by the combination treatment appeared to be relative to the ⅔ 
oleic acid composition, and was correlated with a loss of viability. Whereas, lipid 
accumulation induced in L6 by the combination treatment was greater than could be 
accounted for by the ⅔ oleic acid composition. However, there were no associations 
between lipid accumulation and any cell death process. It was theorised that in HepG2 the 
lipid droplets formed by oleic acid did not sequester palmitic acid, thus, leading to lower lipid 
accumulation and higher toxicity than in L6 cells. On the other hand, the larger percentage 
of lipid accumulation cause by 1 mM of the combination treatment than 0.67 mM oleic acid 
alone indicated that palmitic acid was partially sequestered. 
It is thought that the disparity in toxicity between palmitic acid and oleic acid is because 
oleic acid is stored in neutral TAG lipid droplets within the cell, whilst palmitic acid leads to 
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the production of toxic lipid species such as ceramide and DAG (Itami, et al., 2018; 
Listenberger, et al., 2003; Lu, et al., 2016). One study (Gordon, 1977), measured 
intracellular triglycerides in L mouse fibroblasts using the colorimetric methods of Soloni 
(1971) and found that unsaturated FFAs increased intracellular TAG concentrations over 
2000%, whilst maintaining normal cell growth (Gordon, 1977). On the other hand, saturated 
FFAs increased intracellular TAG by 800%, markedly less than caused by unsaturated 
FFAs (Gordon, 1977). Treatment with palmitic acid causes an increase in intracellular DAG 
in human skin fibroblasts (Rosenthal, 1981), HeLa cervical epithelial cells (Shen, et al., 
2017), and C2C12 myocytes (Chavez, et al., 2003; Peng, et al., 2011). In addition, 
increases in intracellular ceramide levels have been shown in H4IIE liver cells (Wei, et al., 
2006), pancreatic β-cells (Maedler, et al., 2001; Shimabukuro, et al., 1998; Unger, 1997), 
HeLa cervical epithelial cells (Shen, et al., 2017), haematopoietic cell lines (Paumen, et al., 
1997), and C2C12 myocytes (Chavez, et al., 2003). However, palmitic acid-induced ER 
stress is not prevented by inhibition of de novo ceramide synthesis, demonstrating that 
palmitic acid disrupts cells and induces apoptosis independently of ceramide accumulation 
(Wei, et al., 2006).  
Many studies suggest that whilst oleic acid accumulates in neutral lipid droplets in the 
cytoplasm (Cheon & Cho, 2014; Cnop, et al., 2001; Gordon, 1977; Haffar, et al., 2015; 
Hawley & Gordon, 1976; Leamy, et al., 2014; Listenberger, et al., 2003; Peng, et al., 2011; 
Rosenthal, 1981), palmitic acid accumulates in other forms. A study by Cnop, et al., (2001) 
showed that oleic acid caused the formation of large spherical lipid droplets, whilst palmitic 
acid forms small crescent-like particles. Haffar, et al., (2015) also found that the pattern of 
lipid accumulation differs between treatments. Oleic acid resulted in the formation of 
spherical lipid droplets, whilst palmitic acid triggers the formation of irregular shaped 
deposits. The generation of larger spherical droplets by oleic acid in contrast to those 
produced by palmitic acid may suggest differences in converting fatty acids into neutral lipid 
species (Peng, et al., 2011). Interestingly, co-administration of oleic acid with palmitic acid 
causes the formation of smaller spherical lipid droplets than oleic acid on its own (Haffar, et 
al., 2015). One study found that arachidonic acid generates considerable neutral TAG lipid 
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droplets, which are able to limit the lipotoxic effects of palmitic acid by sequestering it. Oleic 
acid may act through the same mechanism, but to a lesser extent (Cheon & Cho, 2014; 
Leamy, et al., 2014). 
A number of papers take this hypothesis further by claiming that these palmitic acid 
deposits cause alterations to the ER membrane. Scarpelli, et al., (1974) found that feeding 
trout a diet of cyclopropenic fatty acids led to damage of ER membranes in their 
hepatocytes. Palmitic acid specifically has been shown to cause alterations to ER 
morphology, namely ER expansion in C2C12 myocytes (Peng, et al., 2011). This ER 
expansion occurred after 3 hours of PA treatment, whereas ER stress does not become 
significant until 6 hours after PA treatment, indicating the morphological changes may be 
responsible for inducing ER stress (Peng, et al., 2011). It is thought that an imbalance of 
phospholipids in the ER membrane may disrupt the normal functioning of the ER as 
approximately 22% of palmitic acid applied is incorporated into phospholipids in primary 
hepatocytes (Leamy, et al., 2014) and C2C12 myocytes (Peng, et al., 2011). However, 
many studies suggest that it isn’t the incorporation of phospholipids in the ER membrane 
that induces ER stress, but the formation of seemingly solid lipid deposits that physically 
damages the membrane. Hawley & Gordon (1976) report that human neutrophils incubated 
in vitro with oleic acid develop neutral lipid droplets within the cytoplasm, whilst those 
exposed to palmitic acid form elongated cleft-like dilations in the ER. In L mouse fibroblasts, 
Gordon (1977) also demonstrated that saturated FFAs cause deposits of lipid species in 
elongated needle-like dilations to form in the ER without the production of intracellular lipid 
droplets. These dilations displace the normal granular contents of the ER and appear as 
angular, electron-translucent spaces (McKay, et al., 1967). An explanation of these 
structural alterations is that crystallisation of the lipids may be occurring due to the high 
melting point of palmitic acid (Gordon, 1977). This hypothesis is confirmed by Shen, et al., 
(2017) who report that palmitic acid causes accumulation of TAG, DAG, phosphatidic acid 
(PA), phosphatidylinositol (PI), phosphatidylcholine (PC) and ceramide, in structures other 
than lipid droplets (Borradaile, et al., 2006). These lipid structures are not readily stained by 
Nile Red and are more widely distributed in size than lipid droplets. However, they exhibit 
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weaker, more uniform intensity, suggesting a lamellar organisation indicative of new 
membrane (Shen, et al., 2017). This may explain why lipid droplets were not found via 
ImageJ analysis in this study. Further investigations found palmitic acid was being 
incorporated into membrane lipids, and in fact developing new ER membrane in the form of 
lamellar cisternae, distinct from native ER membrane (Borradaile, et al., 2006; Deguil, et al., 
2011; Shen, et al., 2017). However, the lipids synthesised and incorporated into the new 
membrane as a result of palmitic acid treatment are high melting temperature lipids that 
drive phase separation from the ‘normal’ fluid phase membrane to a solid phase 
membrane. The result is a highly ordered acyl chain packing and ultraslow lateral motion. 
The addition of oleic acid is able to channel palmitic acid into lipid droplets and reduce solid 
domains (Shen, et al., 2017). 
 
3.4.3 Comparison of findings from HepG2 and L6 cells 
Both palmitic acid and oleic acid were more toxic to L6 than HepG2 cells. However, in 
combination the opposite was true, perhaps indicating different processing or metabolic 
pathways in the two cell types. It is also worth noting that not only was the combination 
treatment more damaging to HepG2 cells, but in contrast, it increased the viability of L6 
cells, although not significantly. Higher levels of lipid accumulation were found in L6 cells as 
opposed to HepG2 cells, with oleic acid causing the highest degree of intracellular lipid 
accumulation in both cell lines. Lipid accumulation in HepG2 was negatively correlated with 
viability for all treatments, however, individually palmitic acid and oleic acid were positively 
correlated with viability in L6.  
Hepatocytes and skeletal myocytes have vastly different roles within the body, which may 
cause them to respond differently to FFAs. The major functions of hepatocytes are bile 
production, toxin removal, lipid synthesis, carbohydrate metabolism and storage, and 
protein synthesis and storage, whilst skeletal myocytes are mainly involved in muscle 
contraction. However, both liver and skeletal muscle are important in fat storage and fatty 
acid metabolism (Frayn, et al., 2006).  
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Skeletal muscle is the second main site for triacylglycerol storage after adipose tissue, 
containing ~300g. However, there are two sites of storage in muscle, in adipocytes between 
muscle fibres and within the muscle cells themselves (intramyocellular). Liver is the third 
main tissue in triacylglycerol storage, containing ~100g (Frayn, et al., 2006). Liver and 
muscle both hydrolyse the stored triaclyglycerol to release fatty acids (Akie & Cooper, 2015; 
Jensen, 2002). Skeletal muscle uses fatty acids as a substrate for oxidation whilst the liver 
uses them as a substrate for re-esterification to make triacylglycerol for the secretion of 
very-low-density lipoproteins (VLDL). 
The normal triacylglycerol content of the liver is up to 10% by weight, however, this can 
expand significantly in non-alcoholic fatty liver disease (NAFLD). The liver receives fatty 
acids from the plasma, from the uptake of remnant particles of lipoproteins and from the 
hydrolysis of plasma triglyceride. The liver can also synthesise fatty acids from glucose and 
and other precursors in a process called de novo lipogenesis (Akie, et al., 2015; Clark, et 
al., 1974; Goodridge, 1973).  
Skeletal muscle receives fatty acids from the plasma and from the hydrolysis of plasma 
triglycerides. Muscle lipolysis is unaffected by insulin, but is affected by catecholamines, 
whilst FFA uptake and oxidation is increased by vigourous exercise (Jensen, 2002).  
The ability of the liver to store excess fat and its advanced role in lipid metabolism in 
comparison to skeletal muscle, could explain why HepG2 had a greater tolerance to FFAs 
than L6 cells. This may also explain why the earliest detectable abnormality of T2DM is 
insulin resistance in skeletal muscle (Petersen, et al., 2012), and why exercise has a 
positive effect on type II diabetes independent of its weight loss effects (Ansari, 2009; Zou, 
et al., 2016). 
  
   
4 The effects of palmitic acid and oleic acid on platelet 
function 
4.1 Introduction 
Platelets are crucial in haemostasis, but have also been shown to play a key role in 
atherosclerosis and its sequelae by adhering and aggregating on exposed vascular 
surfaces leading to activation of the clotting cascade in a process called 
atherothrombosis (Huo, et al., 2003; Karshovska, et al., 2015; Massberg, et al., 2002; 
Murphy, et al., 2013). Platelets perpetuate inflammation in atherosclerosis by recruiting 
inflammatory cells towards sites of plaque formation, and release a variety of 
inflammatory mediators (Lievens & Hundelshausen, 2011). Furthermore, they have 
been shown to transport regulatory molecules which drive the inflammatory response 
and mediate atherosclerotic progression (Badimon, et al., 2012). Platelets are in 
constant contact with fatty acids within the plasma and at sites of atherosclerotic 
plaque formation. Therefore, it is important to understand the effects fatty acids may 
have on platelets in populations with elevated circulating FFA levels. 
Atherosclerosis is a progressive, systemic inflammatory disease characterised by the 
accumulation of lipids, macrophages and lymphocytes within the intima of large 
arteries, in formations otherwise known as plaques (Badimon, et al., 2012). The 
formation of plaques often compromises the integrity of the arterial walls leading to 
ischaemic events distal to the arterial stenosis, and is thereby the underlying cause of 
most cases of coronary artery disease, peripheral arterial disease and many cases of 
stroke (Badimon, et al., 2012).  
The formation of atherosclerotic plaques is multifaceted and combines interactions 
between cells of the arterial intima and leukocytes, with disturbances in local blood flow 
and lipids. Once formed, plaques display a fibrous cap surrounding a central core of 
extracellular lipids and debris, otherwise known as the atheroma. The fibrous tissue 
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provides structural integrity to the plaque as the atheroma is soft and highly 
thrombogenic (van der Wal & Becker, 1999). Atherosclerotic plaques are high in 
extracellular lipids and are bordered by macrophages. These macrophages 
phagocytose vast quantities of oxidised LDL resulting in the formation of foam cells, the 
death of which perpetuates the formation and growth of the atheroma, in combination 
with extracellular binding of lipids to collagen fibres and proteoglycans (van der Wal, et 
al., 1999). 
In addition to LDL, atherosclerotic plaques accumulate cholesterol esters which are 
hydrolysed in the later stages of plaque development to release cholesterol and free 
fatty acids (Lundberg, 1985; Smith, et al., 1967). As plaques advance they become 
unstable and susceptible to erosion and rupture. This damage not only initiates platelet 
activation exacerbating atherosclerotic plaque formation, but also exposes platelets to 
additional levels of free fatty acids. The hydrolysis of cholesterol esters specifically 
causes an increase in palmitic acid (Smith, et al., 1967) with palmitic acid accounting 
for 20.64% of total fatty acids within atherosclerotic plaques, whilst oleic acid accounts 
for 29.85% (Stachowska, et al., 2004). Free fatty acids are also released into the 
plasma following carotid artery stenting, where they could contribute to the higher rate 
of periprocedural stroke (Abe, et al., 2012). Furthermore, saturated fatty acids are 
taken up more readily than other fatty acids by macrophages in cell culture and could 
lead to greater lipid accumulation within arteries (De Pascale, et al., 2006). However, it 
is unknown whether free fatty acids play a role in platelet aggregation at sites of plaque 
damage, and moreover, the specific effects of palmitic acid and oleic acid on platelets 
in general has yet to be fully elucidated. 
Research into the influence of free fatty acids on the behaviour of platelets is 
surprisingly limited. Interactions between platelets and FFAs may occur either in the 
plasma (where levels of FFA are raised in populations with obesity and/ or diabetes), or 
as a consequence of plaque rupture, or both. Exposure to elevated levels of plasma 
FFAs may contribute to sensitisation of circulating platelets, resulting in heightened 
 158 
 
reactivity at sites of plaque rupture. In fact, a study by Connor, et al., (1963) found that 
infusion of FFAs into canines results in mortality from extensive thrombosis, thus, 
indicating a pro-thrombotic effect in vivo. Light transmission aggregometry revealed 
increases in light transmission of washed human platelet suspensions following 
treatment with 0.35 mM stearic acid or oleic acid (Hoak, et al., 1967). In platelet-rich 
plasma (PRP), stearic acid increases light transmission whilst oleic acid does not 
(Srivastava & Awasthi, 1983). This possibly reflects a buffering effect by plasma 
proteins such as albumin on plasma FFAs. Furthermore, elevated plasma FFA levels 
induced by heparin injected intravenously results in increased platelet sensitivity to 
ADP and collagen (Burstein, et al., 1978). Other studies suggest an inhibitory role for 
oleic acid during platelet activation by ADP and collagen in PRP (Srivastava, et al., 
1983). 
Early work found that most free fatty acids have the ability to initiate platelet 
aggregation, with reports suggesting that saturated fatty acids are more potent than 
unsaturated fatty acids (Hoak, et al., 1967; Mahadevan, et al., 1966). The majority of 
studies found that oleic acid evoked a robust aggregatory response in washed platelets 
(Miles et al.,. 1988; Hashimoto, et al., 1985; Zentner, et al., 1981; Connor, et al., 1969; 
Hoak, et al., 1967). Similarly, it was reported that palmitic acid caused platelet 
aggregation (Zentner, et al., 1981, Connor, et al., 1969), yet this was disputed by the 
minority of studies (Hashimoto, et al., 1985). Additionally, oleic acid was found to 
activate protein kinase C (PKC), whilst palmitic acid did not (Yoshida, et al., 1992). The 
activation of PKC is a critical event in platelet aggregation as it modulates granule 
secretion, synthesis of thromboxane A2 and integrin αIIbβ3 activation (Bye, et al., 2016; 
Konopatskaya, et al., 2011; Yacoub, et al., 2006). 
The role that these interactions may play in atherosclerosis and the obese population, 
and the lack of consensus regarding the effects of palmitic acid and oleic acid on 
platelets, highlights the importance of investigating this further. 
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Owing to the contradictory reports highlighted above, experiments were designed to 
establish whether exposure to oleic acid or palmitic acid results in platelet activation 
and/or aggregation. This study is one of the few to investigate this effect in detail; it 
was, therefore, important to characterise these effects further by comparing the effects 
of FFAs to responses triggered by physiological agonists to investigate the 
mechanisms involved. In particular, it was important to dissect platelet activation into its 
component signalling pathways and study the influence of these pathways in the 
aggregatory response to fatty acids.  
Initial light transmission aggregometry experiments were performed to establish the 
potential of oleic acid and palmitic acid to induce aggregation in washed platelet 
suspensions. These experiments provided the foundation for future studies, to 
determine 1) whether aggregation was triggered via known pathways, 2) whether 
aggregation was mediated by secondary signalling, and 3) whether aggregation 
exhibited conventional characteristics of platelet activation. In order to fully understand 
the platelet-aggregating properties of fatty acids, responses to two conventional platelet 
agonists (thrombin and CRP-XL) were studied. Analyses included the quantification of 
maximum aggregation, minimum aggregation, derived from aggregometry traces. This 
approach ensured that the washed platelet suspensions were functional, and acted as 
points of comparison for typical platelet activation. Thrombin and collagen-related 
peptide (CRP-XL), are widely used in platelet researchand function through different 
signalling pathways. Thrombin utilises G protein-mediated signalling, whilst CRP-XL 
triggers tyrosine kinase-based signalling via engagement of the Ig superfamily 
member, GpVI. The two signalling pathways converge on PLC isoforms, resulting in 
PKC activation. PKC regulates many downstream activatory responses, including 
integrin activation, granule release and PS exposure. 
Maximum aggregation was measured as it is probably the most important analysis in 
LTA, as it measures the maximum aggregation achieved during the period of analysis 
regardless of time point. In typical agonist-induced aggregation the measure of 
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maximum aggregation would be very similar to final aggregation. However, in cases of 
platelet dissociation, maximum aggregation would produce a meaningful result whilst 
final aggregation would not. Minimum aggregation was analysed as an important 
measure of platelet shape change, considered to be the first measurable physiological 
response to agonists (Kim and Kunapuli, 2011), detectable in the first seconds of 
platelet activation (Redondo, et al., 2006). Shape change is the transition that platelets 
undergo from flat, concave discs to spherical forms with pseudopodial and lamellipodial 
protrusions, which occur as a result of actin reorganisation (Hartwig 2006; Bearer, et 
al., 2002). Upon addition of an agonist, the initial shape change results in an increase 
in optical density, and hence decrease in light transmittance during aggregometry 
(Aslan, 2017). The extent of the decrease is quantified as the minimum aggregation.  
PS exposure on the outer surface of the platelet was analysed as platelet activation 
causes its translocation from the inner leaflet of the platelet membrane to the outer 
surface (Bonomini, et al., 2004). The reason for this remains unclear, however, it is 
thought to be a major regulatory event in coagulation as it binds to discrete regulatory 
sites on factors V(a) and X(a), thereby allosterically changing their proteolytic activities 
(Lentz, 2003). Furthermore, PS exposure is correlated with an increase in thrombin 
generation (Lentz, 2003; Monroe, et al., 2002). 
 
4.1.1 Aims 
 To determine whether palmitic acid and oleic acid cause platelet aggregation 
o If so, to understand the mechanism by which they elicit a response 
o To compare fatty acid- induced responses with those of known agonists 
 To establish whether exposure to palmitic acid and oleic acid initiates apoptosis 
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4.2 Methods 
Refer to Chapter 2 Materials and methods. The minimum number of times an 
experiment was repeated was three, with the exact n number provided in the figure 
legend. All data is expressed as mean ± SEM. *P<0.05 
 
4.3 Results 
4.3.1 Interpretation of platelet aggregation in washed platelets 
4.3.1.1 Platelet aggregation in response to thrombin and collagen-related 
peptide 
Initial experiments were performed to ensure that platelet activity following preparation 
of washed suspensions from PRP was retained for subsequent investigation. Washed 
platelets suspensions at a concentration of 2x106/mL were stimulated with collagen-
related peptide (CRP-XL) and thrombin. Both agonists were used to verify the platelet 
aggregation response via light transmission aggregometry to ensure washed platelets 
were functional following processing and as a control. Only thrombin was used in 
subsequent experiments to confirm platelet activation.  
Once responses of the platelet suspensions to agonist stimulation were established, 
effects of palmitic acid and oleic acid on platelet aggregation were investigated 
The addition of CRP-XL (0.03-1 μg/ml) to washed platelet suspensions evoked a 
concentration-dependent increase in light transmission, consistent with platelet 
aggregation (Figure 4.1). While 0.03-0.1 μg/ml induced only a partial aggregatory 
response, 0.3 μg/ml caused 77.2 ± 13.7% aggregation and 1 μg/ml induced maximal 
aggregation of 85.7 ± 7.9%. Thrombin evoked a similar concentration-dependent 
increase in platelet aggregation with 0.03-0.1 U/ml producing little aggregation, whilst 
0.3 U/ml induced 70.8 ± 32.5% and 1 U/ml caused maximal aggregation of 88.7 ± 2.2% 
(Figure 4.1A).  
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Thrombin (1U/ml) caused minimum aggregation of -7.7 ± 3.9%, whilst CRP-XL (1μg/ml) 
caused minimum aggregation of -8.7 ± 5.0%, both demonstrating shape change typical 
of platelet activation (Figure 4.1D). 
The time-to-half maximum aggregation and the gradient at 25% aggregation were 
analysed and used in combination with the aggregation traces to assess the overall 
progression of the aggregatory response. Thrombin (1 U/ml) produced a very short lag 
phase, the time immediately following stimulation until shape change has changed to 
the start of platelet aggregation. CRP-XL (1 μg/ml) produced a longer lag phase 
initially, however, there was no significant difference between the time-to-half maximum 
aggregation for thrombin (1 U/ml) and CRP-XL (1 μg/ml), of 44.9 ± 23s and 46.6 ± 
10.2s, respectively (P=8468) (Figure 4.1E). Similarly, the aggregation traces and 
gradient at 25% of completion show that both agonists achieved the majority of their 
aggregatory response rapidly, within the first couple of minutes following addition of the 
agonists (Figure 4.1F). These results are typical of agonists causing full platelet 
activation. 
These results established the functionality of the platelet preparations. Thrombin 
(1U/ml) was selected as a control for subsequent experiments as it demonstrated 
maximum aggregation (Figure 4.1C) and typical aggregations traces (Figure 4.1B) 
produced by a full aggregatory response. 
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Figure 4.1 Platelet preparations were responsive to physiological agonists 
The functionality of the washed platelet preparations were confirmed via LTA (n=6). A) 
CRP-XL and thrombin induced platelet aggregation in a dose-dependent manner. B) 
Representative traces of aggregation induced by CRP-XL and thrombin at 
concentrations of 1 mM. C, D, E, F) At 1 mM, the agonists produced similar maximum 
aggregation (C), minimum aggregation (D), time to half maximum (E) and gradient at 
25% of completion (F). All of which were indicative of a full aggregatory response.
  
   
4.3.1.2 Maximum aggregation in response to oleic acid and palmitic acid 
The aggregatory response of platelets to a range of concentrations of PA and OA was 
exmined in order to select a concentration for subsequent experimentation. Maximum 
aggregation and traces were analysed and compared with responses to CRP-XL and 
thrombin. 
The addition of palmitic acid (0.001-1 mM) caused aggregation in a concentration-
independent manner. While 0.001-0.3 mM palmitic acid had little effect on platelet 
aggregation, 1 mM caused maximal aggregation of 32.2 ± 6.5% (P=0.0028) (Figure 
4.2A). Similarly, the addition of oleic acid (0.001-1 mM) induced aggregation in a 
concentration-independent manner. Low concentrations (0.001-0.003 mM) caused little 
aggregation, whilst 0.01 mM OA evoked partial aggregation of 28.8 ± 8.1%, and 0.1 
mM induced maximal aggregation of 73.0 ± 2.0%.  
The 1 mM concentration of both palmitic acid and oleic acid caused significant platelet 
aggregation, 32.1 ± 6.5% and 29.8 ± 7.2%, respectively (P=0.0028 and 0.0052, 
respectively) (Figure 4.2). Maximal aggregation produced by palmitic acid (32.2 ± 
6.5%) did not resemble aggregation induced by thrombin or CRP, in that the period of 
shape change was elongated, thereby delaying the log phase of aggregation (Figure 
4.2B). This profile was not consistent with full platelet activation as the trace indicated 
that palmitic acid did not initiate secondary aggregation as shown by the trace 
gradually evened out before full aggregation.  
Aggregation caused by 1 mM oleic acid showed a swift, but small log phase, possibly 
caused by primary activation, then dissociation where the platelets separated from their 
aggregates. This was followed by a gradual increase to maximal aggregation of 29.8 ± 
7.2% (Figure 4.2C). In a similar manner to PA, the profile was also not consistent with 
full platelet activation. The gradual increase to maximum aggregation could have been 
caused by a delay in secondary aggregation, however, similar traces have not been 
found in the literature. 
 165 
 
A concentration of 1 mM was selected for further use in this study, because at this 
concentration both PA and OA induced significant aggregation. 
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Figure 4.2 Platelet aggregation in response to varying concentrations of fatty 
acids. 
The aggregatory responses of washed platelets to a range of concentrations of PA and 
OA were examined via LTA (n=6). Aggregation was measured every 0.5 seconds to 
produce representative aggregation traces. A) Comparision of maximum aggregation 
caused by PA and OA found that oleic acid produced greater responses. B) 
Representative traces of PA-induced aggregation. C) Representative traces of OA-
induced aggregation. 
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4.3.1.3 Platelet aggregation in response to 1 mM of palmitic acid or oleic acid  
As mentioned above, 1 mM palmitic acid caused maximal aggregation of 32.2 ± 6.5% 
and 1 mM oleic acid 29.8 ± 7.2% (Figure 4.3B). These levels of aggregation were 
significantly different from the vehicle control (1.2 ± 0.2%, P=0.0028 and 0.0052, 
respectively); and were also significantly lower than maximal aggregation induced by 
thrombin (90.1 ± 1.3%, P<0.0001). 
Oleic acid (1 mM) caused minimum aggregation of -3.2 ± 2.5%. This is consistent with 
minimal aggregation induced by thrombin (1 U/ml, values) and CRP-XL (1 μg/ml, 
values, Figure 4.3C). Thereby, indicating that OA induced a similar shape change 
response to that seen following activation with conventional agonists. Conversely, 
palmitic acid (1mM) caused minimum aggregation of -17.4 ± 8.7%, which was 
significantly different from that produced by thrombin (1 U/ml) and CRP-XL (1 μg/ml) 
(P=0.0084 and 0.0216, respectively). The shape change results produced by palmitic 
acid were not representative of platelet activation and may have indicated structural 
changes to the platelet membrane, perhaps expansion from necrotic process. 
Alternatively, palmitic acid-induced aggregation may be elicited via mechanisms other 
than platelet activation. 
The representative aggregation traces evoked by palmitic acid and oleic acid (1mM) 
showed partial aggregation in comparison to that caused by thrombin (Figure 4.3A). 
The palmitic acid trace appeared to show activation of the primary wave of aggregation 
without secondary mediated signalling to produce the second wave, seen as the trace 
gradually evens out before full aggregation. Additionally, the time-to-half maximum 
(138.2 ± 104.6s) was significantly greater than that of thrombin or CRP-XL (P=0.0128 
and 0.0151, respectively), which further suggested the lack of secondary signalling to 
perpetuate activation (Figure 4.3D). The oleic acid aggregation trace also showed a 
lack of full platelet activation, and instead indicated activation of the primary wave of 
aggregation, followed by disaggregation before initiation of the secondary wave of 
aggregation. Gradient at 25% of completion was negative and, thus, showed the 
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disaggregation (-3.7 ± 4.4) (Figure 4.3E). However, the reliability of gradient at 25% of 
completion was questioned as the result produced by 1 U/ml thrombin was not 
significantly different from the untreated control. 
It is also worth noting the high variability of maximal aggregation between platelet 
donors. A range of 9 - 81% maximum aggregation was observed across 6 individual 
platelet donors for the 0.03 mM dose of oleic acid.  
However, whilst performing experiments, it was observed that the fatty acids may not 
have been fully dissolving in the platelet suspension at concentrations of 1mM, as 
shown in Figure 4.4A. This was of consequence, as if correct, it may have caused 
artefactual aggregation traces and enhanced maximum aggregation readings. This 
observations was examined in the test section with testing performed to ascertain 
whether this observation was correct.  
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Figure 4.3 Platelet aggregation in response to 1 mM of PA or OA 
The aggregatory responses of washed platelets to 1 mM of PA or OA were established 
via LTA (n=6). A) Aggregation was measured every 0.5 seconds to produce 
representative aggregation traces. B) At 1 mM, PA and OA induced significant 
maximum aggregation, but only PA produced significant minimum aggregation (C). (D) 
Time for PA to produce half maximal results was significantly different to unstimulated 
platelets, but neither PA nor OA induced a significant change in gradient at 25% of 
completion (E).   
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4.3.1.4 Palmitic acid induced platelet aggregation is an artefact of insolubility in 
platelet preparations 
To ascertain whether the fatty acids were coming out of solution following their addition 
to washed platelet preparations, as mentioned before, the samples were removed from 
the aggregometer immediately prior to analysis and placed into a spectrophotometer, 
and their absorbance read at 600 nm. An unstirred, untreated platelet preparation was 
used to blank the spectrophotometer, and an untreated platelet preparation processed 
in the same way as the treated samples was used as a control. At concentrations of 1 
mM, both oleic acid and palmitic acid samples displayed significant turbidity (P=0.0075 
and P=0.0001, respectively), whilst at 0.1 mM, neither were significantly different from 
the control (P=0.9999 and P=0.9997, respectively) (Figure 4.4B). Thus, the anecdotal 
observation was judged to be correct.  
These results invalidated the aggregometry data for both 1mM oleic acid and 1mM 
palmitic acid, as the accuracy of the data produced could not be reliably proven. 
Therefore, the aggregation results for 1 mM of PA and OA were disregarded and this 
concentration was not used for subsequent experiments. Lower concentrations of 
palmitic acid were unable to evoke statistically significant platelet aggregation, 
however, analysis was initially continued with 0.1 mM in order to study the potential of 
PA inducing platelet shape change. On the other hand, 0.1 mM of oleic acid caused 
significant maximal aggregation without affecting turbidity, therefore, this treatment was 
selected for the remainder of the study. 
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Figure 4.4 1 mM fatty acid treatments were insoluble in CFT buffer 
A) A photograph of the perceived lack of solubilisation shows cloudiness and the 
presence of grains stuck to the cuvettes in both 1 mM fatty acid solutions. B) 
Spectrophotometric analysis determined that 1 mM solutions of both PA and OA in 
CFT were significantly more turbid that CFT alone. 
 
   0.1mM       1mM        0.1mM        1mM 
        Palmitic acid             Oleic acid 
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4.3.1.5 Changes in light transmission of platelet suspensions by OA represents 
conventional platelet aggregation 
As with 1 mM oleic acid, 0.1 mM oleic acid produced a biphasic aggregation trace 
suggestive of activation of the primary wave of aggregation, followed by disaggregation 
before the initiation of secondary messenger-mediated signalling to perpetuate the 
aggregatory response (Figure 4.5A). Biphasic traces are frequently indicative of weak 
agonists. Furthermore, minimum aggregation (-12.0 ± 5.9%) was consistent with that 
produced by thrombin (P=0.1213), which suggested a similar shape change (Figure 
4.5C). Time-to-half maximum (57.1 ± 9.6s) produced by 0.1mM oleic acid was 
significantly different from that of the control (P<0.0001), but was not statistically 
different from that caused by thrombin (P=0.2478) (Figure 4.5D). This indicated that 
oleic acid may have been caused primary activation including shape change in a less 
rapid manner than thrombin. There were no significant differences between the 
gradient at 25% of control compared to thrombin or oleic acid (Figure 4.5E).  
As 1 mM of PA did not induce changes in maximum aggregation (P=0.3704), minimum 
aggregation (P=0.7363), time to half maximum aggregation (P=0.2292) or gradient at 
25% of completion (P=0.1664), its use was discontinued. 
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Figure 4.5 Oleic acid induced aggregation comparable to physiological agonists 
The aggregatory responses of washed platelets to 0.1 mM of PA or OA were examined 
via LTA (n=6). A) Aggregation was measured every 0.5 seconds to produce 
representative aggregation traces. B) 0.1 mM OA induced significant maximum 
aggregation, and time to half maximum (D), but did not cause significant mimum 
aggregation (C) or gradient at 25% of completion (E) in comparision to unstimulated 
platelets.   
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4.3.2 Characterisation of platelet activation in washed platelets 
4.3.2.1 Oleic acid induced aggregation was not reliant on secondary signalling 
via granule secretion and thromboxane release  
Following platelet activation, second messengers enhance the platelet aggregation 
response through the release of ADP from dense granules, the generation of 
thromboxane A2 (TxA2) and the release of zinc, sometimes causing a biphasic 
aggregation trace in the process. Therefore, it was important to establish whether oleic 
acid-induced aggregation was dependent on second messenger-mediated signalling 
and to understand the biphasic aggregation trace produced by 0.1mM oleic. To study 
this, the platelets were treated with 1 mM aspirin, 2 µM prostaglandin E1 (PGE1) or 50 
µM N,N,N',N'-tetrakis(2-pyridylmethyl)ethane-1,2-diamine (TPEN) prior to stimulation 
with oleic acid. Aspirin is an irreversible inhibitor of the enzyme cyclooxygenase, 
preventing the generation of TxA2, whilst PGE1 increases cyclic AMP (cAMP) levels, 
which in turn inhibits ADP signalling. TPEN is a chelating agent with high affinity for 
Zn2+, without which secondary aggregation is reduced. 
The ability for these reagents to evoke platelet aggregation on their own without an 
agonist was examined to ensure results seen were produced by oleic acid alone 
(Figure 4.6B). None of the reagents was found to cause platelet aggregation in the 
absence of agonists. 
To establish the effectiveness of these reagents in the presence of agonists, 
aggregation was observed in response to thrombin following incubation (Figure 4.6A). 
Aspirin, PGE1 and TPEN all caused a significant reduction in thrombin-stimulated 
platelet aggregation, reducing maximum aggregation to 8.00 ± 3.86%, 5.43 ± 4.05%, 
and 1.74 ± 0.32%, respectively (P=0.0001, 0.0001 and 0.0001, respectively). 
Therefore, these reagents were confirmed to inhibit second messenger-mediated 
signalling and were used to examine the mechanism of oleic acid-induced aggregation. 
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Following inhibition of second messenger signalling with aspirin, PGE1 or TPEN, 
platelets were treated with 0.1 mM oleic acid. OA alone induced aggregation of 71.4 ± 
4.5%. Aspirin decreased aggregation to 60.54 ± 9.14%, PGE1 reduced aggregation to 
63.76 ± 12.99%, and TPEN decreased aggregation to 68.55 ± 6.9%. However, neither 
aspirin nor PGE1 nor TPEN significantly inhibited oleic acid-induced aggregation 
(P=0.6822, 0.8250 and 0.9564, respectively) (Figure 4.6C). However, these molecules 
did have different effects on the shape of the aggregation traces produced (Figure 
4.6D). Aspirin caused very little shape change and went straight into a gradual log 
phase. PGE1 significantly increased shape change and doubled the period of shape 
change. It also caused a biphasic response. TPEN significantly increased the period of 
shape change and resulted in a very gradual log phase. These results strongly suggest 
that although oleic acid-induced aggregation is not reliant on second messengers, they 
may play a small role in mediating signalling responses. 
4.3.2.2 Oleic acid induced aggregation is not mediated by PKC  
In order to understand the pathway through which oleic acid elicits platelet aggregation, 
a further experiment was performed. Here, platelets were incubated with 10 µM 
GF109203X prior to stimulation with oleic acid. GF109203X is an inhibitor of protein 
kinase C (PKC). PKC is an important enzyme, with a number of platelet activation 
pathways converging on this target downstream of integrin ɑIIbβ3. Inhibition of PKC by 
GF109203X prevents collagen- and thrombin-induced aggregation, in addition to 
collagen-triggered ATP secretion, without affecting ADP-induced, reversible 
aggregation. Initially, aggregation in response to thrombin was studied to establish the 
effectiveness of the reagent. 
The effectiveness of GF109203X to inhibit aggregation was examined in response to 
thrombin (Figure 4.6A). It reduced aggregation to 7.16 ± 3.80% (P=0.0001), and, thus, 
was confirmed to inhibit PKC-mediated aggregation. 
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The ability of GF109203X to induce platelet aggregation without the addition of an 
agonist was also tested to ensure the presence of no background aggregation (Figure 
4.6B). GF109203X alone did not cause platelet aggregation. 
OA alone induced aggregation of 71.4 ± 4.5%. The addition of oleic acid to GF109203X 
pre-treated platelets produced 67.39 ± 12.29% aggregation, and thereby did not 
significantly inhibit oleic acid-induced aggregation, P=0.7671 (Figure 4.6C). However, 
the trace showed that GF109203X slightly increased the period of shape change and 
significantly altered the gradient of the log phase, making it far less steep than that 
produced by oleic acid alone. These results indicate that oleic acid-induced 
aggregation is not reliant on PKC signalling, although PKC is likely to play a role in the 
process. 
 
4.3.2.3 Oleic acid induced aggregation is not integrin dependent  
To verify that aggregatory responses induced by oleic acid were indeed a result of 
platelet activation and integrin-dependent aggregation, as opposed to platelet 
agglutination, additional experiments were performed. Platelets were stimulated in the 
presence of 10 µM GR144053, and 20 µM of the Ca2+ chelator, BAPTA. GR144053 is 
a peptidomimetic antagonist of integrin ɑIIbβ3, containing the amino acid sequence, 
arginine, glycine and aspartic acid, mimicking the sequence on the fibrinogen Aɑ chain, 
which binds to integrin ɑIIbβ3, the point at which all platelet activatory pathways 
converge. It thereby blocks interactions between fibrinogen and the receptor, 
preventing all known pathways of aggregation through competitive inhibition. BAPTA is 
a chelating agent with high affinity for Ca2+; increases in intracellular calcium are 
essential for the activation of integrin ɑIIbβ3, without which aggregation would be 
inhibited. 
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Aggregation following the addition of GR144053 or BAPTA was measured to confirm 
that these reagents did not cause aggregation on their own (Figure 4.6B). Neither 
GR144053 nor BAPTA induced platelet aggregation. 
Firstly, the effectiveness of the reagents was confirmed with the use of the known 
agonist, thrombin (Figure 4.6A). GR144053 reduced maximum aggregation to 2.36 ± 
1.08%, whilst BAPTA decreased it to 4.75 ± 2.70% (P=0.0001 and 0.0001, 
respectively). Therefore, the effectiveness of these reagents to inhibit the activation of 
integrin ɑIIbβ3 was established. 
OA alone induced aggregation of 71.4 ± 4.5%. The addition of 0.1 mM oleic acid to 
platelets incubated with GR144053 or BAPTA produced aggregation of 60.50 ± 5.73% 
and 56.36 ± 11.41%, respectively (P=0.1739 and 0.3509, respectively). Therefore, 
inhibition of the activation of integrin ɑIIbβ3 did not significantly affect oleic acid-induced 
aggregation (Figure 4.6C). The traces revealed that GR144053 greatly increased oleic 
acid-induced shape change and severely elongated the period of shape change. 
Furthermore, the integrin ɑIIbβ3 antagonist altered the usual log phase from a steep 
curve to a gradual increase in aggregation. BAPTA had no effect on the magnitude of 
shape change, but did increase the period of shape change, and reduced the gradient 
of the log phase. These results suggested that although oleic acid-induced platelet 
aggregation was not dependent on the activation of integrin ɑIIbβ3, this signalling step 
may be involved in the aggregatory process. However, all known pathways of platelet 
activation resulting in platelet aggregation culminate in the activation and expression of 
integrin ɑIIbβ3, therefore, these results indicate that oleic acid is not eliciting a response 
via platelet activation. 
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Figure 4.6 Inhibitors of vital components of platelet activation were unable to 
prevent oleic acid-induced aggregation 
Platelets pre-treated with inhibitors for a range of vital activatory signalling events were 
stimulated and their responses measured via LTA (n=5). A) All inhibitors were effective 
against thrombin stimulation. B) None of the inhibitors displayed an ability to activate 
platelets themselves. C) None of the inhibitors could significantly reduced OA-induced 
platelet aggregation, however, they did alter the traces produced. 
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4.3.2.4 Oleic acid-induced aggregation is reliant on intracellular signalling 
Further experiments were required to understand the results produced via 
aggregometry. It was important to distinguish whether oleic acid-induced platelet 
activation led to typical platelet aggregation, or whether oleic acid resulted in superficial 
clumping and platelet agglutination. To investigate this, formalin was used to fix 
platelets prior to stimulation in order to establish whether the effects of oleic acid were 
dependent on intracellular signalling. 
Aggregation through integrin ɑIIbβ3/ fibrinogen interactions, as a consequence of 
platelet activation, is only one way in which platelets are able to aggregate. 
Agglutination is a process by which platelets can aggregate through interactions 
between surface receptors and molecules, independent of intracellular signalling. 
Agglutination is typically used to refer to aggregate formation caused by interactions 
between antibodies and surface antigens. To ascertain whether oleic acid-induced 
platelet aggregation is reliant on intracellular signalling, or is alternatively a result of 
agglutination, washed platelets were fixed with formalin prior to stimulation. Formalin 
contains formaldehyde, a reactive electrophilic species, which reacts readily with 
various functional groups of macromolecules in order to form cross-links (Thavarajah, 
et al., 2012). This cross-linking prevents molecules performing their function, whilst 
preserving their structure and spatial relationship to the cell, thereby preventing 
intracellular signalling (Thavarajah, et al., 2012). To confirm the effectiveness of 
fixation, aggregation was observed in response to thrombin and CRP-XL. 
Fixation significantly reduced the aggregatory responses produced by thrombin and 
CRP-XL, producing maximal aggregation of 6.6 ± 6.5% and 9.0 ± 4.6%, respectively (P 
<0.0001) (Figure 4.7A). The aggregation traces following fixation showed no shape 
change or aggregation, and, thus, established that neither agonist elicited a response 
(Figure 4.7C). This confirmed that fixation with formalin blocked the intracellular 
signalling required for activation-dependent platelet aggregation, and could be used to 
understand the mechanism of oleic acid-induced aggregation. 
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Formalin fixation significantly reduced oleic acid-induced aggregation, producing 
maximal aggregation of 3.3 ± 1.4% (P<0.0001) (Figure 4.7A). Furthermore, the 
aggregation trace was visually the same as those produced by thrombin and CRP-XL 
following fixation without shape change or aggregation (Figure 4.7C). This strongly 
suggested that oleic acid-induced aggregation was dependent on intracellular 
signalling and was, therefore, not a result of agglutination. However, previous 
experiments were unable to identify the pathway through which oleic acid evoked its 
response, possibly suggesting a novel pathway of platelet activation or a novel 
mechanism of aggregation, independent of platelet activation. 
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Figure 4.7 Fixation of platelets with formalin prevents OA-induced aggregation  
A) Formalin fixation of washed platelets prevented physiological agonist-induced 
platelet aggregation and OA-induced aggregation. B) Representative traces prove the 
function of unfixed cells to agonist stimulation. C) Representative traces show a 
complete lack of response in fixed platelets. 
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4.3.2.5 Oleic acid does not cause activation marker expression 
In order to establish whether oleic acid was eliciting a response via a pathway of 
platelet activation or not, antibodies against markers of platelet activation were 
employed. Platelets were incubated with fluorescently labelled anti-PAC1, anti-CD62P 
and anti-CD63 prior to stimulation and the fluorescence was measured on a flow 
cytometer. PAC1 antibody is directed against activated integrin ɑIIbβ3, the product of all 
known pathways of aggregation as a result of platelet activation. Anti-CD62P is an 
antibody against P-selectin, which is expressed on the membrane of α-granules in 
resting platelets, but, translocates to the surface of the platelet following activation 
(Berman, et al., 1986; Stenberg, et al., 1985). Anti-CD63 is directed against CD63, a 
protein present in the membrane of dense granules and lysosomes (Nishibori, et al., 
1993), which translocates to the outer platelet membrane upon release of dense 
granules, associating with the integrin αIIbβ3-CD9 complex, and with the actin 
cytoskeleton in an αIIbβ3-dependent manner, following platelet activation (Hamamoto, et 
al., 1994). To confirm functionality of the antibodies and to understand levels of 
activation markers present on activated platelets, the response following stimulation 
with a known agonist, thrombin, was observed. 
Thrombin evoked a significant increase in the expression of all three markers of 
activation, activated integrin ɑIIbβ3, CD62P and CD63 (P=0.0021, 0.0001, and 0.0012, 
respectively) (Figure 4.8). These results confirmed the functionality of the antibodies, 
and established that all three markers were significantly increased by platelet activation 
via known pathways.  
Oleic acid did not cause a significant increase in the expression any of the markers of 
activation (Figure 4.8). Therefore, it was determined that oleic acid did not cause the 
release of ɑ- or dense granules, both of which are vital to all known pathways of 
platelet activation. Moreover, oleic acid did not cause platelets to aggregate via binding 
of activated integrin ɑIIbβ3 to fibrinogen, currently the only known mechanism through 
which activated platelets aggregate. These results strongly suggested that oleic acid 
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did not cause platelet activation, but rather acted through another mechanism of 
aggregation, independent of platelet activation. 
 
 
 
 
Figure 4.8 Oleic acid does not increase the expression of markers of platelet 
activation 
 
Platelet activation markers were probed with fluorescence conjugated antibodies and 
analysed in real-time for 5 minutes with unstimulated platelets as a control (n=4). 
Expression change was measured at the 5 minute time point. Thrombin vastly 
increased the expression of all three markers of activation; integrin ɑIIbβ3, P-seletin and 
CD6, whilst oleic acid did not. 
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4.3.2.6 Oleic acid induced phosphatidylserine exposure 
Exposure of phosphatidlyserine (PS) on the outer platelet membrane is another marker 
of platelet activation. However, unlike the previously investigated markers, PS 
exposure can also be regulated by signalling pathways independent of platelet 
activation (Schoenwaelder, et al., 2009). At rest, phosphatidylserine (PS) is distributed 
asymmetrically across the plasma membrane of platelets, with the majority on the 
cytoplasmic face (Chap, et al., 1977; Schick, et al., 1976; Verkleij, et al., 1973). This 
asymmetry is maintained through ATP-dependent aminophospholipid translocase 
activity (Devaux, 1991). However, upon activation or cellular damage, PS is 
translocated the outer surface of the platelet membrane through a currently unknown 
mechanism. To study the notion that oleic acid may be inducing platelet aggregation 
via signalling independent of the activatory pathways, annexin V-FITC, a fluorescent 
phosphatidylserine-binding protein was employed to measure PS exposure. In order to 
establish functionality of the probe, and to understand levels of PS exposure present 
on activated platelets, the response following stimulation with thrombin was assessed. 
Thrombin caused an increase in external PS exposure of 71.1 ± 31.8% in comparison 
to the control, although, this increase was not significant, and, thus, indicated that 
platelet activation led to small increases in PS exposure (P=0.4968) (Figure 4.9).  
On the other hand, oleic acid, induced significant PS exposure of 291.2 ± 203.8%, 
(P=0.0014) (Figure 4.9). These results indicated that oleic acid mediated platelet 
aggregation via intracellular signalling linked to PS exposure. PS exposure is also 
associated with cell death processes, which in turn have been linked with platelet 
aggregation, and, thus, it was vital to investigate whether oleic acid induced platelet 
death. 
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Figure 4.9 Oleic acid induced high levels of PS exposure 
Flow cytometric analysis of annexin V stained platelets determined PS exposure 
following stimulation with unstimulated platelets as a control (n=6).Thrombin induced 
small, non-significant PS translocation, whilst oleic acid induced significant PS 
exposure. 
 
 
4.3.3 Investigation of the effect of oleic acid on other platelet functions 
4.3.3.1 Oleic acid caused significant cell death 
To ascertain whether cell death signalling was involved in oleic acid-induced PS 
exposure, a lactate dehydrogenase (LDH) assay and a calcein AM experiment were 
performed following platelet stimulation. LDH absorbance is inversely proportional to 
cell viability, and, thus, were converted from absorbance to percentage viability, theory 
can be found in Appendix C .Calcein AM is a cell-permeant, non-fluorescent dye that is 
converted to green-fluorescent calcein by esterases in live cells, and leaks from dead 
cells or cells with damaged membranes, thereby acting as a measure of platelet 
 186 
 
viability. In order to understand differences between platelet activation and platelet 
death, the known agonist thrombin was used as a model of typical aggregation. 
Thrombin did not cause significant alterations to platelet viability as measured by the 
LDH assay (P=0.5177) (Figure 4.10A). The calcein AM experiment also found that 
thrombin had no effect on the viability of washed platelets (P=0.7039) (Figure 4.10B). 
These results determined that typical platelet activation and aggregation did not cause 
a decrease in platelet viability. 
The addition of 0.1 mM oleic acid to washed platelets caused a significant increase in 
LDH release, which represented a final viability of 59.62 ± 6.27% (P=0.0011) (Figure 
4.10A). Flow cytometric analysis of calcein AM leakage found that oleic acid 
significantly decreased platelet viability to 49.79 ± 4.76% (P<0.0001) (Figure 4.10B). 
These results determined that oleic acid evoked platelet death, and, thus, suggested 
that intracellular signalling in oleic acid-induced aggregation was important in cell death 
processes, not platelet activation. However, these results enabled further 
understanding of platelet signalling and PS exposure following treatment with oleic 
acid, but did not explain how the platelets were aggregating, or in fact whether they 
were aggregating at all. Aggregometry relies on a rudimentary measure of optical 
density to measure aggregation, which is liable to a wide range of artefactual results 
from anything that alters the turbidity of the solution. For example, platelet lysis and 
crystallisation of a solution can both lead to convincing aggregation results and traces. 
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Figure 4.10 Oleic acid decreased platelet viability 
Two experiments to assess platelet viability following stimulation were employed, LDH 
assay and calcein-AM staining with unstimulated platelets as a control (n=6 and 5, 
respectively. A) Oleic acid-induced loss in platelet viability measured by LDH assay. B) 
Oleic acid-induced reduction in platelet viability measure by calcein-AM staining. 
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4.3.4 The formation of oleic acid-induced platelet aggregates was 
confirmed 
It was important to establish whether platelets were indeed aggregating following 
stimulation with oleic acid. Therefore, confocal microscopy was used to view the 
washed platelets at a range of time points throughout the aggregometry experiment.  
As shown in Figure 4.11, oleic acid did induce the formation of platelet aggregates, and 
thereby indicated that the results produced during the aggregometry experiments were 
not artefactual. Close examination of the images indicated that oleic acid appeared to 
cause platelet shrinkage, however, this could not be measured using the confocal 
software as the magnification was too low. This observation contradicted platelet 
activation, as this would cause platelets to increase surface area through the extension 
of pseudopodia. It also contradicted a loss in platelet viability via necrosis, as this 
would have caused expansion and blebbing. Therefore, it was important to measure 
the size of platelets following treatment to gain a better understanding of aggregation 
and platelet death processes. 
  
   
 
 
Figure 4.11 Oleic acid-induced aggregates were visualised via confocal 
microscopy 
Platelets were removed from the aggregometer at time points of 0, 1, 2, 5, 10 and 15 
minutes and images taken at 600x magnification. These confirmed that physical 
aggregation of platelets was occurring following OA stimulation rather than an artefact. 
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4.3.4.1 Oleic acid caused platelet shrinkage 
The relative size of platelets following treatment in comparison to their size before 
treatment can be indicative of a number of different processes. The confocal 
microscopy images were qualitatively analysed and it was observed that platelets were 
shrinking (Figure 9). However, a more robust technique was required for quantitative 
analysis. Flow cytometric analysis was employed to measure relative cell size following 
platelet stimulation. To understand alterations in platelet size caused by activation, 
forward scattered light was analysed following stimulation with thrombin to act as a 
comparison for oleic acid treated samples. 
Thrombin caused significant platelet enlargement of 47.69 ± 17.06%, P=0.0127 (Figure 
4.12). These results were consistent with the literature and are explained by the 
cytoskeletal reorganisation induced by platelet activation that facilitates platelet-platelet 
interactions via increased surface area.  
Oleic acid, on the other hand, induced significant platelet shrinkage of 48.81 ± 7.52%, 
P=0.0032 (Figure 4.12). These results further indicated that oleic acid was not inducing 
platelet activation. In combination with the platelet viability results, the significant 
platelet shrinkage was a potential indicator of apoptotic processes at play. This was 
also consistent with the significant PS exposure found. 
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Figure 4.12 Oleic acid caused a decrease in platelet size 
Forward scatter, indicative of platelet size, was measured flow cytometry (n=6). 
Thrombin induced small, non-significant increases in FSC as shown in the literature. 
Oleic acid caused significant decreases in FSC. 
 
 
4.3.5 Analysis of competing hypotheses 
The interpretation of results from this chapter was complex due to their novelty and 
conflicting nature. In order to view the results objectively and make unbiased 
conclusions, a methodology called analysis of competing hypotheses (ACH) was 
utilised. ACH was developed for the Central Intelligence Agency to overcome cognitive 
bias. 
Primary data from this study was combined with a couple of key pieces of literature in 
the ACH matrix (Table 4.1). Each piece of evidence was listed on the left hand side 
and its credibility and relevance assessed. The credibility of each piece of evidence 
was rated on the accuracy and precision of the methodology, and the relevance of the 
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evidence was rated on how important that result was in reaching a conclusion. The 
evidence was then rated for each hypothesis on a five-point-scale of inconsistency.  
CC = very consistent, C = consistent, N = neutral, I = inconsistent and II = very 
inconsistent. 
The ACH software was used to form weighted inconsistency scores, taking the 
credibility and relevance of evidence into consideration (Figure 4.13). These scores 
were used to objectively assess each hypothesis and draw conclusions about this 
study. The theory that inconsistency outweighs consistency was used in this analysis. 
The hypothesis that oleic acid was causing platelet activation produced the highest 
weighted inconsistency score of 30. This strongly indicated that this hypothesis should 
be rejected due to a number of large flaws in the argument. The theory of platelet 
agglutination also received a high weighted inconsistency score of 19, which also 
suggested the rejection of this hypothesis based on a lack of support in the data. On 
the other hand, hypotheses of oleic acid-induced platelet death produced low weighted 
inconsistency scores. Necrosis received a score of 3, whilst apoptosis was favoured 
with a score of 0. Only the determination that oleic acid caused platelet shrinkage was 
contradictory to the necrosis theory, whilst none of the results produced in this study 
could discount the possibility that apoptosis was the mechanism of action of oleic acid. 
These results, therefore, strongly indicate that oleic acid does not cause platelet 
activation or agglutination, but does in fact induce platelet death via the probable 
mechanism of apoptosis. 
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Table 4.1 Analysis of competing hypotheses matrix 
 Type Credibility Relevance Activation Agglutination Necrosis Apoptosis 
Aggregation trace 1ary Low Medium CC CC N N 
Oleic acid produces maximum platelet aggregation of 61.4 ± 22.5% 1ary Low Medium C C N N 
Oleic acid-induced aggregation is not reliant on secondary-
mediated signalling 
1ary High Low N C C C 
Ol ic acid-induced aggregation is not mediated by PKC 1ary High High II C C C 
Oleic acid-induced aggregation is not integrin dependent 1ary High High II C C C 
Oleic acid-induced aggregation is reliant on intracellular signalling 1ary High High CC II N CC 
Oleic acid does not activate integrin ɑIIbβ3 1ary High High II CC CC CC 
Oleic acid does not cause α-granule release 1ary High High II CC CC CC 
Oleic acid does not cause dense granule release 1ary High High II CC CC CC 
Oleic acid induces PS exposure 1ary Medium High C II CC CC 
Oleic acid evokes platelet death 1ary High High I II CC CC 
Oleic acid causes platelet shrinkage 1ary Medium High II II II CC 
Inhibitors of platelet activation and chelators of calcium were 
unable to inhibit PS exposure in platelets undergoing apoptosis 2ary High High II II C CC 
Amphipathic molecules can induce aggregation of PS along with 
leakage of cellular content 2ary High High II II CC CC 
Objective analysis of evidence 
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Figure 4.13 Analysis of competing hypotheses rejects platelet activation 
Weighted inconsistency scores were produced by ACH software to indicate the strength of 
the proposed hypotheses. Platelet activation was the theory least supported by the data in 
this chapter, whilst apoptosis was the most supported. 
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4.4 Discussion 
The objective of this study was to characterise the effect of palmitic acid and oleic acid on 
platelet aggregation, and specifically platelet activation. This extended from aggregometry 
to the analysis of activation markers, and finally the analysis of LDH release to clarify 
contradictions in the literature regarding fatty acid-induced aggregation, and to gain a better 
understanding of the mechanisms through which fatty acids may elicit their response. 
Results confirmed that oleic acid induced platelet aggregation, in contrast to palmitic acid. 
Furthermore, oleic acid-induced aggregation was found to be reliant on intracellular 
signalling, but independent of traditional activation pathways. This potentially indicated the 
action of a novel mechanism that may or may not be related to oleic acid-induced platelet 
death, established in this study. 
 
4.4.1 Oleic acid induces platelet aggregation via an unknown mechanism 
In this study, oleic acid was shown to evoke a robust aggregatory response in washed 
platelets, which is supported by the majority of literature (Miles et al.,. 1988; Hashimoto, et 
al., 1985; Zentner, et al., 1981; Connor, et al., 1969; Hoak, et al., 1967), and contradicted 
by a small minority (Nunez, et al., 1990). In contrast, palmitic acid did not induce significant 
aggregation, which is both supported (Hashimoto, et al., 1985) and contradicted by the 
literature (Zentner, et al., 1981, Connor, et al., 1969).  
Oleic acid-induced aggregation appeared to be biphasic due to the presence of two waves, 
as seen on the aggregation trace, suggesting a lag between primary and secondary 
signalling, and, thus, indicating that 0.1mM oleic was not as potent as the physiological 
agonists used in this study (Huang, 1989). Additionally, it suggested an important role for 
secondary mediators of signalling such as ADP and TxA2, in oleic acid- induced 
aggregation. However, inhibitors of secondary signalling pathways did not significantly 
reduce the aggregation response to oleic acid, indicating that it is not perpetuated by ADP 
or the generation of TxA2. These results suggest another mechanism may be responsible 
for the secondary wave of aggregation, seen on the biphasic aggregation traces.  
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The observations that the inhibition of PKC also had little effect on oleic acid-induced 
aggregation, suggested that oleic acid does not act through the P2Y1, thromboxane-
prostanoid (TP), PAR1/ 4, GPVI or α2β1 receptors. This left P2Y12 as a possible candidate 
for the signal transduction receptor, as P2Y12 has been found to activate integrin ɑIIbβ3 
concomitantly with P2TAC, and is vital for ADP-induced aggregation (Kauffenstein, et al., 
2001; Jin and Kunapuli, 1998). The inability of integrin ɑIIbβ3 inhibition to reduce platelet 
aggregation as a result of oleic acid caused swift dismissal of this possibility, and strongly 
suggested that oleic acid caused aggregation independently of platelet activation. However, 
the possibility of a novel mechanism of aggregation, or a novel pathway of activation could 
not be ruled out until the lack of CD62P, CD63, and most importantly activated integrin 
ɑIIbβ3 on the outer platelet membrane following stimulation with oleic acid, contradicted the 
latter.  
The result that oleic acid-induced responses were resistant to a broad spectrum of 
inhibitors was surprising yet not inconsistent with some forms of agglutination. For example, 
some snake venom proteins such as echicetin, ristocetin and botrocetin induce 
agglutination and intracellular signalling via GpIb (Kini & Evans, 1990; Navdaev, et al., 
2001). Conventional agglutination requires activation of von Willebrand’s factor (vWF), 
either via biochemical interactions or by exposure to elevated shear rates. Activated vWF 
subsequently binds to GpIb/V/IX, which crosslinks platelets and form aggregates. However, 
the changes invoked in light transmission aggregometry in response to oleic acid were 
apparent in washed platelets, from which plasma vWF had been removed. This strongly 
indicated that vWF-dependent agglutination was also unlikely to be the mechanism through 
which oleic acid induced responses. 
 
4.4.2 Oleic acid as a signalling molecule 
A number of studies have suggested that oleic acid may have signalling properties in a 
range of nucleated cell types (Siafaka-Kapadai, et al., 1997). Oleic acid activates soluble 
protein kinase C (Khan, et al., 1992). In rat β islet cells, OA evokes Ca2+ signalling via 
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interaction with GPCRs of the FFAR family (Alvarez-Curto & Milligan, 2016; Fujiwara, et al., 
2005). Additionally, OA interacts with CD36 (GpIV) to induce foam cell formation and 
enhance atherosclerotic lesion development in smooth muscle cells (Ma, et al., 2011). 
Interestingly, CD36 is also expressed on platelet membranes, where it contributes to 
platelet activation (Nergiz-Unal, et al., 2011). Furthermore, oleic acid regulates the activity 
of α- and β-adrenergic receptors during blood pressure regulation (Terés, et al., 2008).  
Oleic acid is an omega-9 monounsaturated C18 fatty acid. The oleoyl- group is common 
amongst numerous signalling molecules in both nucleated cells and platelets. For example, 
1-oleoyl lysophosphatidic acid (LPA) is a phospho-oleoyl ester which evokes platelet 
aggregation via interactions with LPA receptors (Haserück, et al., 2004; Lin, et al., 2010). 
Additionally, 1-oleoyl-2-acetyl-sn-glycerol (OAG) is regularly employed in platelet research 
as a diacylglycerol (DAG) analogue to induce platelet aggregation (Albarran, et al., 2014; 
Ilkan, et al., 2017; Kroll, et al., 1988; Marumo & Wakabayashi, 2017). N-oleoyl-dopamine 
(OLDA) is a vanilloid receptor agonist which inhibits platelet aggregation in response to 
ADP and collagen (Almaghrabi, et al., 2016; Almaghrabi, et al., 2014). In nucleated cells, 
oleoyl-ethanolamide (OEA) activates the nuclear receptor PPAR-α (Chen, et al., 2015; Fu, 
et al., 2005; Guzmán, et al., 2004). Furthermore, OEA activates GPR119, a Gαs-coupled 
GPCR leading to enhanced insulin secretion in pancreatic β cells (Moran, et al., 2014) and 
increased glucagon-like peptide-1 (GLP-1) secretion from intestinal L-cells (Lauffer, et al., 
2009). Other lipids containing the oleoyl- group also activate the GPR119 receptor, 
including oleoyl-lysophosphatidylcholine (LPC), 2-oleoyl-glycerol (2OG) and N-oleoyl-
dopamine (ODA) (Hansen, et al., 2012; Ning, et al., 2009). N-oleoyl-glycine (OLGly) is an 
endocannabinoid receptor ligand associated with activation of Akt signalling in 3T3-L1 
adipocytes (Wang, et al., 2015). Other compounds containing the oleoyl group with 
signalling roles in nucleated cells include oleoyl-CoA, oleamide and oleoyl-glycerol (Bell, et 
al., 2007; Hsu & Powell, 1975; Liu, et al., 2001).  
These studies provide substantial evidence of roles for FFAs, and more specifically oleoyl-
group containing compounds as signalling molecules in a variety of cells via heterogeneous 
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mechanisms, and, thus, it is plausible that oleic acid activates signalling pathways in 
platelets other than those of activation. Additionally, a mounting body of evidence suggests 
that many characteristics of platelet activation may be mimicked by the initiation of cell 
death signalling within platelets. 
 
4.4.3 Oleic acid causes platelet death 
A number of studies have found a link between procoagulant platelet activity and apoptosis 
(Zhu, et al., 2016; Cohen, et al., 2007; Cohen, et al., 2004). Procoagulant platelets exhibit 
key characteristics of apoptotic cells, including phosphatidylserine (PS) exposure, 
membrane blebbing and microvesiculation (Schoenwaelder, et al., 2009). One study 
demonstrated that there is often overlap between activation and cell death when platelets 
are stimulated with known agonists (Schoenwaelder, et al., 2009). It was determined that 
PS exposure on the surface of agonist-stimulated platelets is associated with the proteolytic 
cleavage of a number of cellular substrates present in cell death processes. Furthermore, 
inhibitors of platelet activation and chelators of calcium were unable to inhibit the cleavage 
of these proteins in platelets undergoing apoptosis, in contrast to agonist-stimulated 
platelets (Schoenwaelder, et al., 2009). Consistent with this, studies have also 
demonstrated that caspase inhibitors do not prevent the procoagulant function of activated 
platelets (Kulkarni & Jackson, 2004; Schoenwaelder, et al., 2009; Zauli, et al., 1997). 
Results produced by this study are consistent with the literature in that a vast range of 
inhibitors could not reduce oleic-acid induced aggregation, and two assays measuring cell 
death found that oleic acid caused significant loss in platelet viability. However, this does 
not explain the physical aggregation of oleic acid stimulated platelets, but may indicate that 
signalling other than platelet activation is responsible for this process or at least partially 
involved. 
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4.4.4 Oleic acid may cause aggregation via changes to the platelet 
membrane and/ or via platelet fusion 
The mechanism responsible for OA-induced changes in platelet behaviour is not known. 
Conventional receptor-ligand mediated responses might provide the best explanation. 
However, a number of other possible mechanisms may also play a role. 
The incubation of nucleated cells with oleoyl-group compounds has previously been shown 
to alter cell signalling. For example, fusion of cells with dioleoyl-phosphatidylcholine 
(DOPC) liposomes resulted in a loss of β-adrenergic receptor sites, in comparison to cells 
treated with dipalmitoyl-phosphatidylecholine (DPPC) liposomes (Bakardjieva, et al., 1979). 
This loss in function was associated with a decrease in adenylate cyclase activity and a 
reduction in cAMP. In platelets, if a similar effect were to occur, the reduction in cAMP 
would potentiate platelet activation.  
A second potential mechanism of oleic acid-induced platelet aggregation is through 
modulation of membrane fluidity and anisotropy of membrane lipids (Feijge, et al., 1990; 
Mateo, et al., 1991; Vélez, et al., 1995). Oleic acid has been demonstrated to incorporate 
into the plasma membrane (Rao, et al., 1994) and Miles, et al., (1988) found that high 
concentrations of oleic acid produced changes in membrane fluidity that caused cellular 
damage. Additionally, membrane fluidity is often cited as a contributing factor in a range of 
disorders such as leukaemia (Popov, et al., 2014), Alzheimer’s disease (Yang, et al., 2011) 
and obesity (Cazzola, et al., 2004). 
Another potential explanation for the effects of oleic acid on platelets is fusogenicity, in 
which the phospholipid bilayers of adjacent cells merge via interactions with membrane 
lipids and proteins. Cell fusion is a familiar phenomenon in the differentiation of some 
nucleated cells, although a role in platelet function has not been reported. Ahkong, et al., 
(1973b) found that oleic acid and oleoyl-glycerol induced fusion in erythrocytes and 
erythrocyte ghosts in physiological time periods of 5-10 minutes at 37oC. Interestingly, 
palmitic acid did not produce the same response and was shown to possess no fusogenic 
properties (Ahkong, et al., 1973b). The mechanism by which lipids with fusogenic properties 
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induce cell fusion remains unclear. It has been proposed that oleoyl-induced erythrocyte 
fusion occurs due to increased membrane fluidity, which is likely caused by an elevated 
percentage of hydrocarbons with low melting points. Lipids with melting points below body 
temperature exist in a relatively liquid state and, thus, their incorporation into the membrane 
would alter fluidity (Ahkong, et al., 1973a; Ahkong, et al., 1973b). Alternatively, the 
incorporation of exogenous lipids into the plasma membrane may create protein–free 
regions that can interact with similar regions of opposing cells. Contact of these regions 
causes fusion via the formation of a multi-lamellar lipid membrane (Tsivion & Sharon, 
1981). Throughout the literature search, only one paper confirmed platelet-platelet fusion. 
The study incidentally observed platelet fusion in response to the cholinergic agent, 
carbachol in vitro (White, 1999). However, this was independent of time and concentration, 
and, thus, the pathophysiological significance of this observation is unclear. 
Thus, oleoyl-induced changes in membrane fluidity or fusion of platelets may be a 
contributing factor to occlusive thrombi formation at sites of plaque rupture. If so, such 
effects may explain correlations between plasma FFA levels and pathogenicity of stroke, 
cardiovascular disease and diabetes and may be a significant contributing factor for platelet 
thrombus formation during plaque rupture. 
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5 Meta-analysis of plasma lipid composition: implications for 
pathologies 
5.1 Background 
Lipid transport, storage and metabolism is complex, with the involvement of lipoproteins, 
formation of large plasma lipid and protein complexes, and involvement of the digestion 
system, liver and target tissues of muscle and adipose tissue. Most lipids (about 90%) are 
carried in the form of fatty acid esters in the form of triacylglycerol (TAG), cholesterol esters 
and phospholipids, contained in circulating lipoprotein particles. A smaller proportion of 
lipids (up to10%) are transported as non-esterified (NEFA) fatty acids (also called free fatty 
acids -FFA) that circulate in the plasma, the functions of which were largely elucidated by 
Vincent Dole (1956) and Robert Gordon (1956; 1957), at the Rockefeller Institute and the 
National Institutes of Health respectively. FFAs are an important source of energy via fatty 
acid β-oxidation (Janssen & Stoffel, 2002). They also play a role in signalling, interacting 
with nuclear peroxisome proliferator-activated receptors (PPARs) to maintain lipid 
homeostasis (Varga, et al., 2011). Furthermore, they are vital in the production of plasma 
membranes (Abbott, et al., 2012). 
As they diffuse easily across cell membranes, circulating FFA are the primary fuel source in 
the body, as well as having a number of other important functions, with significant 
involvement in oxidative stress, cell signalling and membrane stability. Being hydrophobic, 
free fatty acids bind to plasma albumin for transport in the circulatory system, and are the 
vehicle by which triacylglycerol is transported from storage in the adipose tissue to sites of 
utilisation. Turnover of FFA is rapid, with a plasma half-life of 1.8-3.9 minutes (Eaton, et al., 
1969). 
In the normal overnight fasting state, FFA are almost entirely produced by the hydrolysis of 
triacylglycerol within adipocytes of abdominal subcutaneous fat, with small amounts arising 
from leg adipose tissue and intra-abdominal adipose tissue (Nielsen, et al., 2004), thereby 
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maintaining a steady-state reported to be approximately 300-600 µmol/L, with levels higher 
in woman than in men (Abdelmagid, et al., 2015; Frayn, et al., 1996). Levels of circulating 
FFA can also be altered by physiological states; for example, extended fasting of 72 hours 
increases levels of plasma FFA up to ∼1800 μmol/L (Gjesdal, et al., 1976). States of 
increased stress as found in racing drivers before a race are associated with elevated 
circulating FFA, up to 1 720 μmol/L (Taggart, et al., 1971).  
In addition, varied dietary habits generate a wide variation in intake of amounts of fat, and 
the proportions of different types of fatty acids. Different countries and ethnicities have 
significantly varying diets, for instance palm oil producing island nations such as Samoa 
and Kiribati consume high levels of saturated fat (27.5% and 27% of total energy intake, 
respectively). Other island nations consume high levels of omega-3 such as the Maldives, 
whilst unsurprisingly sub-Saharan Africa have a very low intake (Micha, et al., 2014). In 
addition, the daily nutritional intake recommendations vary between men and women, which 
may lead to differences in circulating FFA.  
It is also hypothesised that disparities in circulating plasma FFA exist between different BMI 
groups. As plasma FFA mainly arises from adipose tissue in the fasting state, and adipose 
tissue mass is increased in obesity, it has been hypothesised that circulating concentrations 
of FFA are elevated in these individuals (Björntorp, et al., 2009; Karpe, et al., 2011; 
Lafontan & Langin, 2009). Increased circulating FFAs may trigger peripheral insulin 
resistance, as well as inhibiting production and release of insulin from pancreatic beta cells 
(Boden, 1999; Sears & Perry, 2015). Furthermore, increases in circulating FFAs has also 
been linked with the devlopment and progression of cardiovascular disease (Breitling, et al., 
2011; Pilz, et al., 2006; Roy, et al., 2013). 
Elevated plasma FFA in obese individuals was found in early research (Opie & Walfish, 
1963), however, more recent studies have shown that the difference in fasting circulating 
FFA between obese and non-obese patients is highly variable and equivocal (Arner, et al., 
2015; Frias, et al., 2000; Horton, et al., 1995; Jocken, et al., 2008). One meta-analysis of 43 
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articles showed that FFA levels in obese patients were elevated only by an average of 70 
µmol/L, with no direct association with BMI. The range of increase across the studies, 
however, was highly variable, ranging from a slight decrease, to an increase of over 500 
µmol/L. Another study following this meta-analysis conducted on obese vs non-obese 
subjects involved in a genetic trial found a level in FFA in obese subjects 30% higher than 
non-obese (Arner, et al., 2015).  
As elevated plasma FFA concentrations are possibly associated with a number of diseases, 
it is essential to understand whether we can distinguish groups within the population with 
increased total circulating FFA, which may predispose to specific pathologies. Moreover, it 
is important to understand whether changes in plasma FFA profiles are evident in the 
population, and more importantly whether these are linked to unfavourable health 
outcomes. Small-scale studies lack enough statistical power to overcome within-person 
variation. It is, therefore, important to aggregate studies in a meta-analysis, in order to 
compute the relationship between such complex variables more reliably.  
An essential aspect in developing our understanding is to know what a ‘normal’ lipid and 
FFA profile looks like, and be able to compare this to an ’abnormal’ one. However, robust 
normal reference ranges for plasma lipids and FFA do not currently exist, thereby hindering 
this line of clinical investigation. In this study, we aimed to aggregate data in order to 
produce a robust set of reference ranges. Studies often rely upon the literature as a 
foundation for continuing research, using previously reported values as fact in new 
investigations. However, reported values are commonly produced from experimentation 
with small sample sizes and differing methodology, leading to an unstable foundation for 
future work. Therefore, it is important to draw together results and information from 
systematic reviews to create more accurate values for future research. 
Furthermore, with focus shifting towards lipids, FFAs, and their roles in health and disease, 
it is vital to create reference ranges of certain key lipid species to be used in healthcare 
settings. 
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Plasma triglycerides are one of the most commonly measured lipid species within plasma, 
and are measured within the National Health Service (NHS) as an indicator of different 
disease states such as type II diabetes, nephrosis and liver obstruction. Average plasma 
triglyceride concentrations and NHS reference ranges are ‘common knowledge’ (Table 5.1). 
This study aimed to determine whether variability in results exists between multiple 
sources, even for the most common of lipid species. 
Like plasma triglycerides, plasma free fatty acids are also tested within the NHS and have 
established reference ranges. However, their testing is not as common, but may possibly 
more be important as triglycerides are deemed to be inert lipids (Sørensen, 2011), while 
free fatty acids are biologically active and potentially toxic (Carpentier, et al., 2000; Masi, et 
al., 2011; Plötz, et al., 2017). 
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Table 5.1 Plasma triglyceride reference ranges across NHS Trusts 
NHS Trust Reference range (mmol/L) 
South Tees Hospitals NHS Foundation Trust <40 years old: 0.3 – 1.8 
>40 years old: 0.3 – 2.1 
Leeds Teaching Hospitals NHS Trust <1.7 
Southend University Hospital NHS Trust 0.6 – 2.3 
North Bristol NHS Trust 0.5 – 1.7 
Gloucestershire Hospitals NHS Foundation 
Trust 
0.6 – 1.9 
Southern Health NHS Foundation Trust <1.7 
The Newcastle upon Tyne Hospitals NHS Trust 0.8 – 1.9 
University Hospitals of North Midlands NHS 
Trust 
0.8 – 1.8 
Epsom and St. Helier University Hospitals NHS 
Trust 
0.5 – 2.0 
East Sussex Healthcare NHS Trust 0.0 – 1.7 
Homerton University Hospital NHS Trust <1.8 
Warrington and Halton Hospitals NHS 
Foundation Trust 
0.2 – 2.0 
University Hospitals Birmingham NHS 
Foundation Trust, 2018 
<1.7 
Barking Havering and Redbridge University 
Hospitals NHS Trust 
0.5 – 2.3 
Tameside and Glossop Integrated Care NHS 
Foundation Trust 
<1.8 
Bedford Hospital NHS Trust 0.4 – 1.8 
Kingston Hospital NHS Foundation Trust 0.2 – 1.7 
Sheffield Children’s NHS Foundation Trust Neonate: <1.8 
Infant: 0.3 – 1.7 
Child: 0.4 – 2.1 
Adult: <2.5 
The Ipswich Hospital NHS Trust 0.3 – 2.3 
University Hospital Southampton NHS 
Foundation Trust 
<2.3 
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Table 5.1 continued 
St. George’s University Hospitals NHS 
Foundation Trust 
0.8 – 2.0 
University College London Hospitals NHS 
Foundation Trust 
<2.3 
Coventry and Warwickshire Partnership NHS 
Trust 
0.4 -1.9 
London North West Healthcare NHS Trust <2.3 
University Hospitals of Leicester NHS Trust 0.0 – 2.0 
North Cumbria University Hospitals NHS Trust <2.3 
Nottingham University Hospitals NHS Trust  Female: 0.4 – 1.53 
Male: 0.45 – 1.81 
Lewisham and Greenwich NHS Trust 0.5 – 1.5 
Derby Teaching Hospitals NHS Foundation 
Trust 
0.5 – 2.0 
Hampshire Hospitals NHS Foundation Trust 0.28 – 2.20 
Dartford and Gravesham NHS Trust <1.7 
Portsmouth Hospitals NHS Trust <2.3 
Mid Cheshire Hospitals NHS Foundation Trust 0.4 – 1.7 
Wirral University Teaching Hospital NHS 
Foundation Trust 
0.8 – 1.8 
Salford Royal NHS Foundation Trust & Wigan 
and Leigh NHS Foundation Trust 
<1.7 
Whittington Health NHS Trust 0.0 – 2.2 
NHS Borders <1.7 
NHS Greater Glasgow and Clyde <2.3 
York Teaching Hospital NHS Foundation Trust <1.7 
Royal Liverpool and Broadgreen University 
Hospitals NHS Trust 
<2.3 
Worcestershire Acute Hospitals NHS Trust 0.0 – 1.8 
Surrey and Sussex Healthcare NHS Trust <2.3 
Royal Berkshire NHS Foundation Trust Female: 0.4 -1.54 
Male : 0.45 -1.82 
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Table 5.1 continued 
 
 
This table illustrates the disparity between plasma triglyceride references ranges across 
NHS Trusts 
 
 
 
 
5.1.1 Aims 
 To establish the normal levels and reference ranges for different circulating lipid 
species in different subpopulations  
 To establish the relationship between different lipid species in different populations 
 To establish the relationship between different lipid species and diseased states
County Durham and Darlington NHS 
Foundation Trust 
<2.0 
Countess of Chester Hospital NHS Foundation 
Trust 
0.6 – 1.7 
NHS Fife 0.85 – 2.0 
Frimley Health NHS Foundation Trust <1.8 
Royal Cornwall Hospitals NHS Trust 0.5 – 1.86 
Manchester University NHS Foundation Trust <1.7 
Central Manchester University Hospitals NHS 
Foundation Trust 
<1.7 
St. Helens and Knowsley Teaching Hospitals 
NHS Trust 
<2.0 
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5.2 Methods 
Refer to Chapter 2 Materials and methods. The number of studies and participants per 
analysis is provided in the figure legend or text. The number of participants per study is also 
indicated on each graph by the size of the circle symbol used (Table 4.2). 
 
Table 5.2 Key to indicate the number of participants in each study 
 
All data is expressed as mean ± SD.  
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5.3 Results 
5.3.1 Average molecular weight of plasma free fatty acids 
To measure the concentration of fatty acids within plasma lipid species, both mg/dL and 
mmol/L are equally acceptable. However, one source states mg/L as the SI unit for free 
fatty acids (Young, 1988), whilst another states µmol/L for plasma free fatty acids and 
mmol/L for total serum fatty acids (Lehmann, 1976) and another g/L (American Diabetes 
Association, 1991).  
An average molecular weight (MW) for free fatty acids in plasma was required for 
conversion between these units to collate data from studies and to provide a consistent 
reference range to healthcare providers. A search of literature revealed that most studies 
do not convert units, whilst online calculators and kit inserts use the molecular weight of 
oleic acid as the average molecular weight for total free fatty acids (DIALAB, 2008; DiaSys 
Diagnostic Systems GmbH, 2017).  
The literature was searched for reports with the most comprehensive profiling of plasma 
lipids and with a large number of participants. One study was found, and the data extracted 
to create a weighted average molecular weight for plasma free fatty acids (Abdelmagid, et 
al., 2015). Results show that oleic acid is not the most abundant FFA in circulation (Figure 
5.1), but rather that polyunsaturated fatty acids, 18 carbons in length with 2 double bonds 
(18:2) such as linoleic acid are, making up 33.07% of total plasma FFAs. The most frequent 
monounsaturated fatty acids are 18:1, which includes oleic acid and accounts for 21.83% of 
total plasma FFAs, whilst palmitic acid (16:0) is the most abundant saturated fatty acid at 
23.38%. Therefore, the use of the molecular weight of oleic acid (282.47g/mol) as the 
average molecular weight of plasma FFA is inaccurate. 
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Figure 5.1 Relative percentage of each free fatty acid in plasma  
Data for this graph was calculated from comprehensive plasma FFA profiling published by 
Abdelmagid, et al., (2015). n=826 
 
 
An average molecular weight for total plasma FFA was calculated by weighting the 
molecular weight of each individual fatty acid based on their abundance within the 
plasma (Table 5.3). The sum of the weighted averages was divided by 100 to 
compute the result. 
Average MW = 
∑%14 × 𝑀𝑊14 + %14:1 × 𝑀𝑊14:1 + %15 × 𝑀𝑊15 + %15:1 × 𝑀𝑊15:1 …
100
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Table 5.3 Weighted compositions (abundance x MW) of plasma FFA used in the 
calculation of an average FFA MW 
Fatty acid (C:D) Abundance (%) MW (g/mol) 
Weighted 
composition 
14 0.911 228.378 2.082 
14:1 0.039 226.378 0.088 
15 0.255 242.405 0.618 
15:1 0.001 240.405 0.003 
16 23.376 256.432 59.942 
16:1 2.150 254.432 5.469 
17:1 0.150 268.459 0.404 
18 7.015 284.486 19.957 
18:1 21.828 282.486 61.660 
18:2 33.072 280.486 92.762 
18:3 1.116 278.486 3.109 
18:4 0.003 276.486 0.008 
19 0.062 298.513 0.184 
19:1 0.007 296.513 0.021 
20 0.070 312.540 0.219 
20:1 0.205 310.540 0.636 
20:2 0.188 308.540 0.579 
20:3 1.088 306.540 3.334 
20:4 5.632 304.540 17.152 
20:5 0.578 302.540 1.747 
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Table 5.3 continued 
 
 
Carbon:double bond – ratio of number of carbons in the hydrocarbon chain to the number 
of double (unsaturated) bonds. Data for this table was calculated from a plasma FFA profile 
published by Abdelmagid, et al., (2015). n=826 
 
 
The average molecular weight of plasma FFA was found to be 277.454 g/mol. This 
new value was 1.79% different from the molecular weight of oleic acid, which in turn 
can create disparities of up to ~20 µmol/L in the conversion of FFA from mg/dL to 
µmol/L. 
 
 
21 0.021 326.567 0.070 
22 0.096 340.594 0.327 
22:1 0.056 338.594 0.189 
22:2 0.044 336.594 0.150 
22:3 0.009 334.594 0.029 
22:4 0.221 332.594 0.734 
22:5 0.457 330.594 1.511 
22:6 1.273 328.594 4.182 
24 0.020 368.648 0.074 
24:1 0.057 366.648 0.210 
Average MW                 277.454 g/mol 
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5.3.2 Average plasma triglyceride levels 
This study collated 139 sets of data from 87 studies with n=52,128 (Appendix F). All data 
was converted to mmol/L. All BMIs were included, but diseased states were excluded. 
Although not perfect with the risk of large variance, this was assessed to be the best way to 
capture data representative of the general population.  
The results (Figure 5.2) showed a vast range of average plasma triglyceride concentrations; 
the lowest reported value was 0.7 mmol/L (Jocken, et al., 2008) whilst the highest was 5-
fold greater at 3.5 mmol/L (Stojiljkovic, et al., 2002). The average plasma triglyceride 
concentration was 1.424 ± 0.476 mmol/L, which was significantly different to the weighted 
average based on the number of participants per study (1.578 ± 0.409 mmol/L) (p=0.0002).  
The Gaussian qualities of the data were examined to assess whether it could be 
representative of the general population for the calculation of reference ranges. Analysis 
was achieved by fitting a non-linear regression line of best fit with confidence intervals onto 
a histogram of the data (Figure 5.3A). The adjusted R2=0.8305 indicated a relatively good fit 
for the bell curve. However, visual inspection of the line of best fit found that it could not 
predict low concentrations of plasma triglycerides. Furthermore, two intervals of the 
histogram were outliers, 0.6 mmol/L and 1.8 mmol/L. Analysis of the residuals initially 
showed a random spread, which indicated a good fit of the non-linear regression model 
(Figure 5.3B). However, as values of plasma triglyceride concentrations increased, the 
residuals became more regular and formed a sigmoidal curve, indicating flaws in the fit of 
the bell curve. In all, the data was perfectly normally distributed, which prevented the 
modelling of a high quality bell curve, but was adequate for the calculation of references 
ranges.  
A standard 95% reference range was calculated using the equation in section 5.2.8. The 
reference range included values between the 2.5 percentile and the 97.5 percentile, leaving 
5% of ‘normal’ results outside of the range. The reference range for plasma triglycerides 
was 0.47 - 2.38 mmol/L. 
 214 
 
This systematic review uncovered a wide range of reported average plasma triglyceride 
concentrations, which may be explained by natural variation, differences in methodology or 
due to influencing factors such as BMI. The correlation between plasma triglycerides and 
BMI was analysed and a moderate, but statistically significant positive correlation was 
found (r=0.5608, P<0.0001) (Figure 5.28). Differences in plasma triglyceride concentrations 
between different subpopulations such as non-obese vs. obese vs. type II diabetic and men 
vs. women were studied later in this chapter (Section 5.3.15 and 5.3.16, respectively). 
Furthermore, a reference range was calculated that could be used to better inform NHS 
trusts, as many use ranges that are significantly different (Table 5.3).  
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Figure 5.2 Average plasma triglyceride levels from systematic review 
Black circles indicate mean plasma triglycerides published by the study. The size of the 
circle is representative of the number of participants in the study (Table 5.2). Black dots 
mark the average of the datasets. Red dots mark the weighted average of the dataset. A 
table of the data can be found in Appendix F. n=52,128
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Figure 5.3 Plasma triglyceride frequency histogram with Gaussian curve shows 
passable normal distribution 
A) % frequency histogram showing the distribution of data amongst brackets of 0.2 mmol/L. 
The Gaussian curve was fitted to test normality. Confidence intervals show where the 
Gaussian curve falls with a 95% certainty. The blue dashed lines indicate the calculated 
reference range. B) Residuals plot was used to assess the fit of the Gaussian distribution 
curve. n=52,128
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5.3.3 Average plasma free fatty acid levels 
This study analysed 125 sets of data across 71 studies with n=8847 (Appendix F). All BMIs 
were included, but diseased states were excluded. The results, illustrated in Figure 5.4, 
show a wide range of average plasma FFA concentrations, with the highest value at 990 
µmol/L (Xiao, et al., 2006), over 4-fold more than the lowest average value of 223 µmol/L 
(Sundell, et al., 2003). The unweighted average plasma FFA concentration was found to be 
562.1 ± 172.881 µmol/L, whilst the calculated weighted average was significantly lower, at 
397.9 ± 134.7µmol/L (p<0.0001). 
The adjusted R2 value was examined to assess the fit of the non-linear regression model 
and found a relatively good fit (adjusted R2=0.8234), with no outliers (Figure 5.5A). 
However, visual inspection showed that the model was not adequate at predicting low 
concentrations of plasma free fatty acids. Analysis of residuals found a random spread, 
which further indicated a normal distribution (Figure 5.5B). Therefore, it was concluded that 
this dataset could be used to calculate reference ranges, although there was room for 
improvement. 
A 95% reference range was computed using the equation in section 5.2.8. The reference 
range included values between the 2.5 and the 97.5 percentile, leaving 2.5% of ‘normal’ 
results above this range and 2.5% below this range. The reference range for plasma free 
fatty acids was 216.3 - 907.9 µmol/L. 
This systematic review unearthed a range of average plasma free fatty acid concentrations, 
which could be accounted for by differences in methodology used in each study, natural 
variation and/or by influencing factors such as BMI. Unfortunately, the correlation between 
FFA and BMI could not be computed in this project as BMI was a controlled variable in this 
study. However, further analyses of plasma FFA concentrations between different 
subpopulations were studied later in this chapter (Section 5.3.15 and 5.3.16, respectively). 
Furthermore, a relatively robust reference range was calculated for plasma FFAs that could 
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be used in a clinical setting to identify those at risk of obesity-related sequelae. Additionally, 
it could be used as a foundation upon which to base research in this field. 
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Figure 5.4 Average plasma FFA from systematic literature review 
Black circles indicate mean plasma triglycerides published by the study. The size of the 
circle is representative of the number of participants in the study (Table 5.2). Black dots 
mark the average of the datasets. Red dots mark the weighted average of the dataset. A 
table of the data can be found in Appendix F. n=8847 
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Figure 5.5 Plasma FFA frequency histogram with Gaussian curve reveals normal 
distribution 
A) % frequency histogram showing the distribution of data amongst brackets of 50 µmol/L. 
The Gaussian curve was fitted to test normality. Confidence intervals show where the 
Gaussian curve falls with a 95% certainty. The blue lines indicate the computed reference 
range. B) Residuals plot was used to assess the fit of the Gaussian distribution curve. 
n=8847
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5.3.4 Plasma phospholipid composition – molar percentage of palmitic and 
oleic acids 
The fatty acid fractions of plasma phospholipids are the most commonly analysed lipid 
species in the literature. Therefore, one would assume a consensus amongst studies as to 
average concentrations found in the circulation. Changes to plasma phospholipid 
composition, especially increases in palmitic acid incorporation, have been associated with 
a number of diseases including prostate cancer (Crowe, et al., 2008) and coronary heart 
disease (Simon, et al., 1996).  
Molar percentage is the most common measurement of fatty acid composition of 
phospholipids (mol % -percentage of total moles of a particular component), which is more 
susceptible to error than absolute concentration measurements as it is related to the other 
fractions (Schwertner & Mosser, 1993). Therefore, it is important to collate multiple sources 
of data to calculate averages in the general population.  
This study examined 74 datasets over 31 studies with n=41,288 for palmitic acid and 73 
datasets across 30 studies with n=26,124 for oleic acid (Appendix F).  
Results in Figure 5.6A showed the spread of data for palmitic acid with a range of 15 mol%. 
However, the average and weighted average of palmitic acid in plasma phospholipids were 
remarkably similar at 27.24 ± 3.51 mol% and 27.62 ± 2.62 mol%, respectively (p=0.3603). 
The fit of the Gaussian distribution curve to the palmitic acid in phospholipids (mol%) data 
was not ideal (adjusted R2 =0.7603) (Figure 5.7A). Furthermore, examination of the 
residuals showed that predictions calculated by the model were consistently too low (Figure 
5.7B). Therefore, distribution of the data was not deemed adequately normal for the 
computation of reference ranges. 
The range of oleic acid data (Figure 5.6B) was just less than 11 mol%. However, the 
average and weighted average were significantly different, measuring 10.56 ± 1.94 mol% 
and 11.20± 2.03 mol%, respectively (p<0.0001). The fit of the Gaussian distribution curve to 
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the oleic acid in phospholipids (mol%) data was good, even with an outlier in the 10 mol% 
bracket (adjusted R2 =0.8715) (Figure 5.7C). Furthermore, analysis of the residuals plot 
showed a random spread, which suggested a good fit of the bell curve (Figure 5.7D). In all, 
this dataset was adequately Gaussian to enable the calculation of reference ranges, 
however, due to small underestimations of the model more of the population fell outside the 
upper limit of the reference range than the lower limit. 
An equation in section 5.2.8 was used to calculate the 95% reference range for oleic acid in 
phospholipids (mol%). The reference range included values between the 2.5 and the 97.5 
percentile, leaving 5% of ‘normal’ results outside this range. The reference range was 6.68 
– 14.44 mol%. 
This systematic review highlighted that molar percentage is the most common measure of 
palmitic acid and oleic acid in plasma phospholipids. A reference range was calculated for 
oleic acid in phospholipids (mol%), but not palmitic acid. The use of such reference ranges 
could be important in the measurement of risk factors as mol% of fatty acids in 
phospholipids have been linked to prostate cancer risk with a high mol% of palmitic acid in 
phospholipids being positively associated and oleic acid being inversely associated 
(Bassett, et al., 2013). 
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Figure 5.6 Average molar percentage of palmitic and oleic acid in phospholipids  
Black circles indicate mean plasma triglycerides published by the study. The size of the 
circle is representative of the number of participants in the study (Table 5.2). Black dots 
mark the average of the datasets. Red dots mark the weighted average of the dataset. A 
table of the data can be found in Appendix F. A) n=41,288 B) n=26,124
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Figure 5.7 Frequency histogram with Gaussian curve established normality of oleic 
acid in phospholipids, but not palmitic acid in phospholipids (mol%) 
A, C) % frequency histogram showing the distribution of data amongst brackets of 1 mol%. 
The Gaussian curve was fitted to test normality. Confidence intervals show where the 
Gaussian curve falls with a 95% certainty. The blue dashed lines indicate the calculated 
reference range. B, D) Residuals plot was used to assess the fit of the Gaussian distribution 
curve. A, B) n=41,288 C, D) n=26,124
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5.3.5 Palmitic acid in phospholipids 
This study examined 5 datasets over 4 studies with n=316 for mass%, 9 sets of data across 
8 studies with n=901 for mg/dL and 3 datasets in 3 studies with n=8,480 for mmol/L 
(Appendix F).  
The mass% results found a small range of 4.59 % across data points with similar average 
and weighted average of 27.94 ± 2.20 mass% and 26.49 ± 1.90 mass%, respectively 
(p=0.2147) (Figure 5.8A). A Gaussian distribution curve could not be fitted to the palmitic 
acid in phospholipids (mass%) data, and hence reference ranges could not be calculated 
(Figure 5.9A and 5.9B). The data was not convergent, probably due to the small sample 
size. 
The spread of data was very large for mg/dL of palmitic acid in phospholipids with a range 
of 126.21 mg/dL. This caused a significant disparity between the average and weight 
average, 47.08 ± 39.46 mg/dL and 36.40 ± 14.46 mg/dL, respectively (p<0.0001) (Figure 
5.8B). The Gaussian distribution curve for the palmitic acid in phospholipid (mg/dL) data 
produced a high adjusted R2 value (0.9169) (Figure 5.9C). However, two of the histogram 
intervals were outliers, 80 mg/dL and 140 mg/dL, and visual inspection of the curve showed 
that it did not adequately fit the datat. Examination of the residuals revealed a lack of 
random scatter around zero, which further indicated the inadequacy of the model, and 
hence the inability to use this dataset for the computation of reference ranges (Figure 
5.9D).  
The spread of data was also large for mmol/L with a range of 0.83 mmol/L (Figure 5.8C). 
The difference between the average and weighted average was 50%, 0.88 ± 0.42 mmol/L 
and 1.22 ± 0.13 mmol/L, respectively. However, this difference was not significant 
(p=0.3010). The Gaussian curve did not fit the palmitic acid in phospholipids (mmol/L) data 
whatsoever (adjusted R2 =-0.1111) (Figure 5.9E). The inadequacy of the model was further 
shown by the lack of random scatter of residuals, and hence the data could not be used to 
calculate reference ranges (Figure 5.9F). 
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In summary, few studies analysed the mass%, mg/dL or mmol/L of palmitic acid in plasma 
phospholipids, even though links have been found with diseased states such as prostate 
cancer (Bassett, et al., 2013; Crowe, et al., 2008) and metabolic dysfunction (Lemaitre, et 
al., 2015). This small volume of data prevented in-depth analysis and computation of 
reference ranges, but did highlight gaps in the literature. The mg/dL and mmol/L data was 
not interconverted and presented together as this approach had the potential to introduce 
error into some of the values. However, the average and weighted average of the mg/dL 
data was converted to mmol/L in order run statistical analysis. The converted average of 
1.84 ± 1.54 was significantly higher than the average of the mmol/L data at 0.38 ± 0.42 
(P=0.0144). On the other hand, the converted weighted average of 1.42 ± 0.61 was not 
significantly different to the unconverted weighted average of 1.22 ± 0.13 (P=0.3504). 
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Figure 5.8 Palmitic acid in phospholipids in literature 
Black circles indicate mean plasma triglycerides published by the study. The size of the 
circle is representative of the number of participants in the study (Table 5.2). Black dots 
mark the average of the datasets. Red dots mark the weighted average of the dataset. A 
table of the data can be found in Appendix F. A) n=316 B) n=901 C) n=8,480
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Figure 5.9 Frequency histograms with Gaussian curves demonstrated the lack of 
normality of palmitic acid in phospholipids (mass%, mg/dL, mmol/L) 
A, C, E) % frequency histogram showing the distribution of data amongst brackets of 1 
mass%, 20 mg/dL and 0.2 mmol/L. The Gaussian curve was fitted to test normality. 
Confidence intervals show where the Gaussian curve falls with a 95% certainty. B, D, F) 
Residuals plot was used to assess the fit of the Gaussian distribution curve. 
A, B) n=316 C, D) n=901 E, F) n=8,480
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5.3.6 Oleic acids in phospholipids 
This study analysed 5 sets of data across 4 studies with n=316 for mass%, 9 datasets in 8 
studies with n=901 for mg/dL and 3 datasets across 3 studies with n=8,480 for mmol/L 
(Appendix F). 
The results showed a range of 4.1 % for mass% data with a non-significant difference 
between the average and weighted average, 11.06 ± 1.80 mass% and 9.76 ± 1.19 mass%, 
respectively (p=0.1816) (Figure 5.10A). The Gaussian curve fitted to the oleic acid in 
phospholipids (mass%) data did not fit at all (adjusted R2=-0.7241), which was further 
illustrated by the lack of random scatter of the residuals (Figure 5.11A and 5.11B). 
Therefore, this dataset could not be used to compute reference ranges. 
The spread of data for mg/dL was small except for one data point that was over 5.5-fold 
greater than the weighted average (Schwertner, et al., 1993); including this point the range 
was 66.09 mg/dL and excluding this point the range was 17.39 mg/dL (Figure 5.10B). This 
data point in question was produced by TLC, an outdated technique, for the measurement 
of the lipid species, which may explain the anomalous result. The average and weighted 
average were 20.50 ± 21.53 mg/dL and 13.79 ± 8.59 mg/dL respectively, which were not 
significantly different (p=0.3769). The normal distribution curve fitted to the oleic acid in 
phospholipids data (mg/dL) had a high adjusted R2 value (0.9315), which indicated a good 
fit of the model (Figure 5.11C). However, visual examination of the curve and residuals plot 
found that the curve did not fit the data and two outliers were present at 30 mg/dL and 80 
mg/dL intervals (Figure 5.11D). Therefore, references ranges could not be calculated from 
this dataset. 
 The range of data for mmol/L of oleic acid in plasma phospholipids was 0.21 mmol/L 
(Figure 5.10C). The average and weighted average were 0.39 ± 0.11 mmol/L and 0.47 
±0.02 mmol/L, respectively, and were not significantly different (p=0.3495). The adjusted R2 
value for the bell curve fitted to the oleic acid in phospholipids (mmol/L) data was low, which 
suggested a poor fit of the model (0.5238) (Figure 5.11E). Examination of the histogram 
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and lack of random spread of residuals further indicated the inadequacy of the model, and 
hence, this dataset could not be used to calculate reference ranges (Figure 5.11F). 
In summary, the study of mass%, mg/dL or mmol/L of oleic acid in plasma phospholipids 
was not particularly common, in spite of research inversely associating it with the risk of 
developing prostate cancer (Bassett, et al., 2013; Crowe, et al., 2008). The lack of data did 
not enable the calculation of reference ranges or detailed statistical analysis, but did 
illustrate the need for further research in this field. The conversion of data points from 
mg/dL to mmol/L was not performed as this would have introduced undue error. However, 
the average and weighted average of the mg/dL data was converted to mmol/L to compare 
them statistically. The converted average of 0.73 ± 0.76 was not statistically different to the 
unconverted average of 0.39 ± 0.11 (P=0.2027). Additionally, the converted weighted 
average of 0.49 ± 0.30 was similar to the unconverted weighted average of 0.47 ± 0.02 
(P=0.8443). 
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Figure 5.10 Oleic acid in phospholipids from systematic review 
Black circles indicate mean plasma triglycerides published by the study. The size of the 
circle is representative of the number of participants in the study (Table 5.2). Black dots 
mark the average of the datasets. Red dots mark the weighted average of the dataset. A 
table of the data can be found in Appendix F.A) n=316 B) n=901 C) n=8,480
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Figure 5.11 Frequency histograms with Gaussian curves demonstrated the lack of 
normality of oleic acid in phospholipids (mass%, mg/dL, mmol/L) 
A, C, E) % frequency histogram showing the distribution of data amongst brackets of 1 
mass%, 10 mg/dL and 0.05 mmol/L. The Gaussian curve was fitted to test normality. 
Confidence intervals show where the Gaussian curve falls with a 95% certainty. B, D, F) 
Residuals plot was used to assess the fit of the Gaussian distribution curve. A, B) n=316 C, 
D) n=901 E, F) n=8,480 
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5.3.7 Palmitic acid in cholesterol esters 
Cholesterol esters and their fractions are the second most frequently investigated lipid 
species in the literature. Long chain cholesterol esters have been linked to Alzheimer’s 
disease (Proitsi, et al., 2015), whilst increased esterification rates predict coronary heart 
disease (Tanaka, et al., 2013). Furthermore, the fatty acid composition of cholesterol esters 
has been associated with visceral and subcutaneous fat deposition, which in turn is a 
predictor of cardiometabolic disease (Rosqvist, et al., 2017). 
This study collated 29 datasets from 20 studies with n=20,294 for molar percentage, 5 
datasets across 4 studies with n=185 for mg/dL and 5 sets of data from 3 studies with 
n=146 for mmol/L (Appendix F). 
The mol% data produced a range of 5.73 % with an average and weighted average of 
11.63 ± 1.30 mol% and 10.92 ± 0.97 mol%, respectively. This small difference between 
averages was statistically significant (p=0.0068) (Figure 5.12A). The fit of the Gaussian 
distribution curve to the palmitic acid in cholesterol esters (mol%) data was assessed to be 
poor due to a low adjusted R2 value (0.4401) (Figure 5.13A). Further examination found 
one outlier at the 10 mol% interval, but a good random spread of residuals (Figure 5.13B). 
Once the results were amalgamated, the model was considered inadequate for the 
calculation of reference ranges. 
The range for mg/dL was 3.37 mg/dL when excluding a data point that was over 4.4-fold 
greater than the weighted average (Schwertner, et al., 1993) (Figure 5.12B). This outlier 
was likely due to the TLC methodology utilised in the study. Including this point the range 
was 52.44 mg/dL. The average and weighted average were not significantly different, 
measuring 20.28 ± 22.42 mg/dL and 13.82 ± 13.75 mg/dL, respectively (p=0.5547) (Figure 
7B). The adjusted R2 value (0.8991) for the bell curve fitted to the palmitic acid in 
cholesterol esters (mg/dL) data was high and no outliers were found, which indicated a 
good fit of the model (Figure 5.13C). However, visual examination found that the curve did 
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not fit the wide spread of data, and the residuals were not randomly spread (Figure 5.13D). 
Thus, the dataset was deemed inadequate for the creation of reference ranges. 
The range of data for mmol/L was large, spanning 11.46 mmol/L (Figure 5.12C). 
Unfortunately, the two very small values were from the same paper, whilst the two large 
values were also from the same paper. The average and weighted average were 4.42 ± 
6.00 mmol/L and 2.57 ± 5.20 mmol/L, respectively. The difference between the two 
averages was not statistically significant (p=0.5290). The normal distribution curve to the 
palmitic acid in cholesterol esters (mmol/L) data produced a moderately low adjusted R2 
value (0.5962) (Figure 5.13E). Visual analysis of the histogram revealed that the model did 
not fit the data and the residuals plot showed a lack of random spread (Figure 5.13F). 
Therefore, the dataset was determined to be unsuitable for the computation of reference 
ranges. 
In summary, mol% was the most common measure of palmitic acid in plasma cholesterol 
esters with mg/dL and mmol/L included in only a few studies. A good volume of data 
existed for mol%, however, no reference ranges could be calculated as none of the 
datasets were adequately normally distributed. Furthermore, the mg/dL individual data 
points were not converted to mmol/L as this would have included error. However, the 
average and weighted average of the mg/dL data was converted to mmol/L to enable 
statistical analysis. The converted average of 0.79 ± 0.87 was not statistically smaller than 
the average of the mmol/L dataset, 4.42 ± 6.00 (P=0.2174). Additionally, the converted 
weighted average of 0.54 ± 0.54 was not significantly smaller than the unconverted 
weighted average of 2.57 ± 5.20 (P=0.4105). These statistical observations were due to the 
large standard deviations.  
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Figure 5.12 Palmitic acid in cholesterol esters in literature 
Black circles indicate mean plasma triglycerides published by the study. The size of the 
circle is representative of the number of participants in the study (Table 5.2). Black dots 
mark the average of the datasets. Red dots mark the weighted average of the dataset. A 
table of the data can be found in Appendix F. A) n=20,294 B) n=185 C) n=146 
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Figure 5.13 Frequency histograms with Gaussian curves demonstrated the lack of 
normality of palmitic acid in cholesterol esters (mol%, mg/dL, mmol/L) 
A, C, E) % frequency histogram showing the distribution of data amongst bands of (0.5 
mol%, 10 mg/dL and 2 mmol/L. The Gaussian curve was fitted to test normality. Confidence 
intervals show where the Gaussian curve falls with a 95% certainty. B, D, F) Residuals plot 
was used to assess the fit of the Gaussian distribution curve. A, B) n=20,294 C, D) n=185 
E, F) n=146
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5.3.8 Oleic acid in cholesterol esters 
This investigation analysed 29 datasets from 20 studies with n=20,294 for molar 
percentage, 5 datasets from 4 studies with n=185 for mg/dL and 5 sets of data across 3 
studies with n=146 for mmol/L (Appendix F). 
The range of mol% data was large, measuring 10.77 %, and the average and weighted 
average were significantly different, at 18.67 ± 2.40 mol% and 17.26 ± 1.88 mol%, 
respectively (p=0.0037) (Figure 5.14A). The normal distribution curve fitted to the oleic acid 
in cholesterol esters (mol%) data was assessed to be poor due to a low adjusted R2 value 
(0.4707) (Figure 5.15A). Further analysis found one outlier at the 16 mol% interval, and an 
inadequate spread of residuals around zero (Figure 5.15B). All of which indicated that the 
dataset was not suitable for the creation of reference ranges. 
The mg/dL range of data was 3.2 mg/dL when excluding a data point that was 4.65-fold 
greater than the weighted average (Schwertner, et al., 1993) (Figure 5.14B). This outlier 
may be explained by the use of TLC, an outdated technique, for the measurement of the 
lipid species. Including this point the range was 81.35 mg/dL. With inclusion of this 
anomalous data point, the difference between the average and weighted average was not 
statistically significant, measuring 32.19 ± 35.76 mg/dL and 20.68 ± 22.25 mg/dL, 
respectively (p=0.5116). The adjusted R2 value (0.8701) for the Gaussian distribution curve 
fitted to the OA in cholesterol esters (mg/dL) data was moderately high with no outliers, 
which suggested an adequate fit of the model (Figure 5.15C). However, visual analysis of 
the histogram found that the bell curve was vastly inadequate. The residuals were also not 
spread randomly, and hence the dataset was considered inadequate for the calculation of 
reference ranges (Figure 5.15D). 
The data for mmol/L was very widely spread with a range of 28.15mmol/L (Figure 5.14C). 
Even though the range of data was large the difference between the two averages was 
non-significant (p=0.5353). The average and weighted average were 9.89 ± 13.67 mmol/L 
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and 5.75 ± 11.77 mmol/L, respectively. The bell curve for the oleic acid in cholesterol esters 
(mmol/L) data was deemed to be inadequate due to its low adjusted R2 value (0.5962) 
(Figure 5.15E). Examination of the histogram identified that the model did not fit the data 
and the lack of random spread of residuals further confirmed flaws in the model (Figure 
5.15F). Thus, it was concluded that the dataset was unsuitable for the creation of reference 
ranges. 
In summary, mol% was the most common measure of oleic acid in plasma cholesterol 
esters, whilst few studies used mg/dL and mmol/L. Despite the good volume of mol% data, 
no reference range could be calculated as it wasn’t adequately Gaussian. Data for the other 
units was also inadequately normally distributed due to the smll number of studies, and, 
thus, no reference ranges could be calculated. Furthermore, the mg/dL data was not 
converted to mmol/L and presented together as this would have introduced undue error. 
However, the average and weighted average of the mg/dL data was converted to mmol/L to 
enable an overall comparison. The difference between the converted average of 1.14 ± 
1.26 and unconverted average of 9.89 ± 13.67 was not statistically significant (P=0.1919). 
The difference between the converted weighted average of 0.73 ± 0.79 and the 
unconverted weighted average of 5.75 ± 11.77 (P=0.3692) was also not significant. These 
statistical observations were most probably due to the large standard deviations of the 
unconverted mmol/L data. 
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Figure 5.14 Oleic acid in cholesterol esters from systematic review 
Black circles indicate mean plasma triglycerides published by the study. The size of the 
circle is representative of the number of participants in the study (Table 5.2). Black dots 
mark the average of the datasets. Red dots mark the weighted average of the dataset. A 
table of the data can be found in Appendix F. A) n=20,294 B) n=185 C) n=146
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Figure 5.15 Frequency histograms with Gaussian curves established the absence of 
normality of oleic acid in cholesterol esters (mol%, mg/dL, mmol/L) 
A, C, E) % frequency histogram showing the distribution of data amongst bands of 1 mol%, 
20 mg/dL and 5 mmol/L. The Gaussian curve was fitted to test normality. Confidence 
intervals show where the Gaussian curve falls with a 95% certainty. B, D, F) Residuals plot 
was used to assess the fit of the Gaussian distribution curve. A, B) n=20,294 C, D) n=185 
E, F) n=146 
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5.3.9 Palmitic acid in triglycerides 
Although the analysis of total plasma triglycerides is common, the study of the fatty acid 
composition of plasma triglycerides is not as frequently published. Research in this area is 
important as a reduction in some long chain plasma triglyceride species has been found to 
preceed cardiovascular disease (Fernández-Real, et al., 2003). 
This analysis studied 18 sets of data from 12 studies with n=2797 for molar percentage, 3 
datasets across 2 studies with n=144 for mg/dL and 3 datasets over 2 studies with n=43 for 
mmol/L (Appendix F). 
The spread of mol% data was large with a range of 18.02%. The average and weighted 
average were significantly different, measuring 26.12 ± 4.21 mol% and 29.11 ± 1.52 mol%, 
respectively (p=0.0077) (Figure 5.16A). The adjusted R2 value for the bell curve fitted to the 
palmitic acid in triglycerides mol% data was moderately good (0.7518) with no outliers 
found (Figure 5.17A). Furthermore, the spread of residuals was deemed adequate (Figure 
5.17B). However, visual examination of the curve found that the fit at the upper and lower 
concentration limits were not good. In all, these results suggested the data could be used 
for rough references ranges.  
A 95% reference range for palmitic acid in plasma triglycerides (mol%) was calculated 
using the equation in section 5.2.8. The reference range included values between the 2.5 
and the 97.5 percentile, leaving 2.5% of ‘normal’ results above the range and 2.5% below 
the range. The reference range was 17.71 – 34.53 mol%. 
The range of data for mg/dL was 9.17 mg/dL, whilst the average and weighted average 
were 23.28 ± 4.79 mg/dL and 20.14 ± 4.48 mg/dL, respectively, and were not significantly 
different (p=0.3740) (Figure 5.16B). A bell curve could not be fitted to the palmitic acid in 
triglycerides (mg/dL) data as it was not convergent, and hence, reference ranges could not 
be calculated (Figure 5.17C and 5.17D). Non-convergence was due to separation of the 
data, likely a result of the small sample size. 
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The mmol/L data points were vastly spread with the range measuring 25.53 mmol/L (Figure 
5.16C). However, the difference between the average and weighted average was not 
statistically significant, at 15.96 ± 13.86 mmol/L and 18.92 ± 12.01 mmol/L, respectively 
(p=0.7474). The fit of the Gaussian distribution curve to the palmitic acid in triglycerides 
(mmol/L) data was assessed as poor due to a low adjusted R2 value (0.125 (Figure 5.17E). 
Furthermore, one outlier in the 0 mmol/L interval was found, and the residuals did not vary 
from zero (Figure 5.17F). Therefore, the dataset was considered unsuitable for the 
calculation of reference ranges. 
In summary, mol% was the most common measure of palmitic acid in plasma triglycerides 
with a good number of studies found. On the other hand, limited studies were found to 
report mg/dL and mmol/L. The mol% data was confirmed to be adequately Gaussian, which 
enabled the calculation of a reference range. However, reference ranges could not be 
calculated for the other datasets. Moreover, individual mg/dL and mmol/L data points were 
not interconverted as this would have included error. Yet, the average and weighted 
average of the mg/dL data was converted to mmol/L to identify differences through 
statistical analysis. Although much smaller, the difference between the converted average 
of 0.91 ± 0.19 and the unconverted average of 15.96 ± 13.86 was not statistically different 
(P=0.1332). Also, the converted weighted average of 0.79 ± 0.17 was not significantly 
smaller than the unconverted weighted average of 18.92 ± 12.01 (P=0.0591). These results 
were likely due to that large standard deviations of the unconverted averages. 
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Figure 5.16 Palmitic acid in triglycerides from literature review 
Black circles indicate mean plasma triglycerides published by the study. The size of the 
circle is representative of the number of participants in the study (Table 5.2). Black dots 
mark the average of the datasets. Red dots mark the weighted average of the dataset. A 
table of the data can be found in Appendix F. A) n=2797 B) n=144 C) n=43
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Figure 5.17 Frequency histograms with Gaussian curves revealed the normal 
distribution of palmitic acid in triglycerides (mol%) 
A, C, E) % frequency histogram showing the distribution of data amongst bands of 2 mol%, 
2 mg/dL and 5 mmol/L. The Gaussian curve was fitted to test normality. Confidence 
intervals show where the Gaussian curve falls with a 95% certainty. The blue lines indicate 
the computed reference range. B, D, F) Residuals plot was used to assess the fit of the 
Gaussian distribution curve. A, B) n=2797 C, D) n=144 E, F) n=43 
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5.3.10 Oleic acid in triglycerides 
This comparison examined 18 datasets across 12 studies with n=2798 for molar 
percentage, 3 datasets across 2 studies with n=144 for mg/dL and 3 sets of data from 2 
studies with n=43 for mmol/L (Appendix F). 
The range of mol% data was 9.00%, whilst the difference between the two averages was 
statistically significant (p=0.0003). The average and weighted average were 38.02 ± 2.95 
mol% and 34.90 ± 1.90%, respectively (Figure 5.18A). The Gaussian distribution curve for 
the oleic acid in triglycerides (mol%) data was not an adequate fit due to an adjusted R2 
value below zero (-0.5198) (5.19A). Furthermore, the residuals were skewed which caused 
an under prediction of many data points (Figure 5.19B). Therefore, the dataset was not 
suitable for the creation of reference ranges. 
The spread of data points for mg/dL was large with a range of 18.98 mg/dL (Figure 5.18B). 
The average and weighted average were 31.74 ± 10.25 mg/dL and 24.89 ± 9.70 mg/dL, 
respectively. The difference between the two averages was not statistically significant 
(p=0.3667). The low adjusted R2 value for the curve fitted to the oleic acid in triglycerides 
(mg/dL) data indicated a poor fit (Figure 5.19C). Furthermore, three outliers were identified 
at the intervals 20 mg/dL, 34 mg/dL and 40 mg/dL and the residuals lacked a random 
spread about zero (Figure 5.19D). Thus, the dataset was inadequate for the calculation of 
reference ranges. 
The mmol/L range of data was vast, measuring 47.56 mmol/L (Figure 5.18C). But, this large 
spread of data did not confer a statistically significant difference between the two averages 
(p=0.7846). The average and weighted average was 28.61 ± 25.10 mmol/L and 33.13 ± 
22.51 mmol/L, respectively. The normal distribution curve on the oleic acid in triglycerides 
(mmol/L) data was a poor fit by an adjusted R2 value below zero (-0.1111) (Figure 5.19E). 
Furthermore, there was one outlier in the 0 mmol/L interval, and the residuals were not 
randomly distributed about zero (Figure 5.19F). Thus, the dataset was inadequate for the 
computation of reference ranges. 
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In summary, a good number of studies measuring the mol% of oleic acid in plasma 
triglycerides were uncovered, but papers using mg/dL and mmol/L were limited. Despite a 
good volume of data for mol%, no reference range could be calculated as it was not 
normally distributed. Reference ranges could not be computed for mg/dL or mmol/L either 
as the number of dtata points was too small to produce a Gaussian distribution. Also, 
individual data points for mg/dL were not converted to mmol/L in order to limit errors. But, 
the average and weighted average of the mg/dL data was converted to mmol/L and their 
difference analysed. The converted average of 1.12 ± 0.36 was much smaller than the 
average of the mmol/L dataset, 28.61 ± 25.10 (P=0.1307), however, the difference was not 
statistically significant due to a large standard deviation for the original mmol/L data. This 
was also true for the difference between the converted weighted average of 0.88 ± 0.34 and 
the unconverted weighted average of 33.13 ± 22.51 (P=0.0681).  
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Figure 5.18 Oleic acid in triglycerides in literature 
Black circles indicate mean plasma triglycerides published by the study. The size of the 
circle is representative of the number of participants in the study (Table 5.2). Black dots 
mark the average of the datasets. Red dots mark the weighted average of the dataset. A 
table of the data can be found in Appendix F. A) n=2798 B) n=144 C) n=43
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Figure 5.19 Frequency histograms with Gaussian curves demonstrated the lack of 
normality of oleic acid in triglycerides (mol%, mg/dL, mmol/L) 
A, C, E) % frequency histogram showing the distribution of data amongst bands of 1 mol%, 
2 mg/dL and 10 mmol/L. The Gaussian curve was fitted to test normality. Confidence 
intervals show where the Gaussian curve falls with a 95% certainty. B, D, F) Residuals plot 
was used to assess the fit of the Gaussian distribution curve. A, B) n=2798 C, D) n=144 E, 
F) n=43 
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5.3.11 Free palmitic acid levels 
Whilst numerous studies have been published regarding high levels of plasma FFAs on 
health and disease, far fewer have studied the effects of the composition of plasma FFAs. 
Studies that have found palmitic acid to be directly correlated with coronary heart disease 
(Simon, et al., 1995) and increases in systolic blood pressure (Simon, et al., 1996). 
Whereas low plasma oleic acid levels have been found in colorectal cancer patients (Butler, 
et al., 2017). 
Data for three comparisons was collated from 14 sets of data across 8 studies with n=1039 
for molar percentage, 7 datasets from 6 studies with n=8256 for mg/dL and 6 datasets over 
6 studies with n=169 for mmol/L (Appendix F).  
The mol% data had a range of 12.07 %, whilst the difference between the two averages 
was non-significant (p=0.0528). The average and weighted average were 24.53 ± 3.30 
mol% and 26.41 ± 1.45 mol%, respectively (Figure 5.20A). The fit of the Gaussian 
distribution curve for the free palmitic acid (mol%) data was considered poor due to a 
moderate adjusted R2 value (0.5948) (Figure 5.21A). Furthermore, visual examination of 
the histogram revealed that the model did not account for low molar percentages of palmitic 
acid. The spread of residuals was also skewed, which showed a consistent underestimation 
of the data (Figure 5.21B). In combination these results indicated that the dataset was not 
suitable for the calculations of references ranges.  
The mg/dL data spread was substantial with a range of 73.71 mg/dL (Figure 5.20B), 
however, this was not due to a single anomalous data point. The average and weighted 
average were significantly different, measuring 33.54 ± 23.36 mg/dL and 73.73 ± 8.32 
mg/dL, respectively (p=0.0039), meaning the larger studies found higher concentrations of 
palmitic acid. The bell curve fitted to the free palmitic acid (mg/dL) data was a poor fit with a 
low adjusted R2 value (0.1345) (Figure 5.21C). Visually the curve did not fit the lower and 
upper limits, even though the residuals were randomly distributed (Figure 5.21D). 
Therefore, reference ranges could not be reliably calculated from this dataset. 
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The range of data for mmol/L was small at 0.124 mmol/L, and the two averages were not 
significantly different (p=0.7712) (Figure 5.20C). The average and weighted average was 
0.124 ± 0.047 mmol/L and 0.118 ± 0.041 mmol/L, respectively. The adjusted R2 value for 
the fit of the Gaussian distribution curve to the free palmitic acid (mmol/L) data was 
moderate (0.6267) (Figure 5.21E). However, the dataset contained two outliers at the 
intervals of 0.16 mmol/L and 0.20 mmol/L. Furthermore, visual examination found that the 
curve did not adequately fit the data and the residuals were not random about zero (Figure 
5.21F). Thus, the dataset was inadequate for the creation of reference ranges. 
In summary, a moderate number of studies used mol%, mg/dL and mmol/L to measure free 
palmitic acid in the plasma, but too few used mass% for analysis. No reference ranges 
could be computed as the datasets were not normally distributed. Furthermore, individual 
mg/dL data points were not converted to mmol/L or vice versa as this would have 
introduced undue error. However, the average and weighted average of the mg/dL data 
was converted to mmol/L to allow for statistical analysis. The converted average was 
significantly larger than unconverted average (1.308 ± 0.91 and 0.124 ± 0.047, respectively) 
(P=0.0049). Additionally, the difference between the converted weighted average and the 
weighted average of the mmol/L dataset was also statistically significant (2.876 ± 0.32 and 
0.118 ± 0.041, respectively) (P<0.0001).  
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Figure 5.20 Free palmitic acid concentrations from the literature 
Black circles indicate mean plasma triglycerides published by the study. The size of the 
circle is representative of the number of participants in the study (Table 5.2). Black dots 
mark the average of the datasets. Red dots mark the weighted average of the dataset. A 
table of the data can be found in Appendix F. A) n=1039 B) n=8256 C) n=169
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Figure 5.21 Frequency histograms with Gaussian curve established the absence of 
normality of free oleic acid (mol%, mg/dL, mmol/L) 
A, C, E) % frequency histogram showing the distribution of data amongst bands of 2 mol%, 
10 mg/dL and 0.02 mmol/L. The Gaussian curve was fitted to test normality. Confidence 
intervals show where the Gaussian curve falls with a 95% certainty. B, D, F) Residuals plot 
was used to assess the fit of the Gaussian distribution curve. A, B) n=1039 C, D) n=8256 E, 
F) n=169
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5.3.12 Free oleic acid levels 
Three groups of data looking at free oleic acid levels were obtained: 13 sets of data from 7 
studies with n=233 for molar percentage, 7 datasets over 6 studies with n=8256 for mg/dL 
and 5 sets of data across 5 studies with n=163 for mmol/L (Appendix F).  
The range of mol% data was 14.06 %. The average and weighted average measured 33.44 
± 4.27 mol% and 33.90 ± 3.85 mol%, respectively, and were not significantly different 
(p=0.7091) (Figure 5.22A) 12A). The fit of the bell curve for the free oleic acid (mol%) data 
was assessed as poor by a low adjusted R2 value (0.1406) (Figure 5.23A). Visual analysis 
of the curve further confirmed the poor fit of the model, even though residuals were 
randomly spread about zero (Figure 5.23B). It was concluded that this dataset was 
inadequate for the creation of references ranges.  
The spread of data for mg/dL was substantial with a range of 68.63 mg/d, however, this 
was not due to an outlying data point (Figure 5.22B). The difference between the average 
and weighted average was statistically significant (p=0.0066), with the two measuring 32.86 
± 22.93 mg/dL and 68.06 ± 7.96 mg/dL, respectively. A Gaussian distribution curve could 
not be fitted to the free oleic acid (mg/dL) data as it was not converged, and hence could 
not be used to calculate reference ranges (Figure 5.23C and 5.23D). This was likely due to 
separation of the data, resulting from the small sample size. 
The mmol/L data had a range of 0.28 mmol/L. The average and weighted average were 
0.192 ± 0.112 mmol/L and 0.151 ± 0.073 mmol/L (Figure 5.22C), respectively. The 
difference between the two was not statistically significant (p=0.7712). The adjusted R2 
value for the fit of the normal distribution curve to the free oleic acid (mmol/L) data was low 
(0.2844), which indicated a poor fit (Figure 5.23E). Additionally, visual analysis of the curve 
revealed a poor fit that did not account for high concentrations of oleic acid, whilst the 
residuals showed a skew in under predicting the data (Figure 5.23F). Hence, reference 
ranges were not computed from the data. 
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In summary, a moderate number of studies measured free oleic acid in all three units, 
mol%, mg/dL or mmol/L, however, too few were found using mass% for analysis. This 
made analysis and the calculation of reference ranges difficult. Reference ranges could not 
be produced as the datasets were not normally distributed. Additionally, mg/dL and mmol/L 
were not presented on the same graph as conversion would have introduced error into 
some values. Yet, the average and weighted average of the mg/dL data was converted to 
mmol/L to enable statistical analysis. The converted average of 1.63 ± 0.81 was 
significantly larger than the unconverted average, 0.192 ± 0.112 (P=0.0085). The converted 
weighted average of 2.409 ± 0.28 was also significantly higher than the average of the 
mmol/L dataset, 0.157 ± 0.073 (P<0.0001).  
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Figure 5.22 Free oleic acid concentrations from the literature 
Black circles indicate mean plasma triglycerides published by the study. The size of the 
circle is representative of the number of participants in the study (Table 5.2). Black dots 
mark the average of the datasets. Red dots mark the weighted average of the dataset. A 
table of the data can be found in Appendix F. A) n=233 B) n=8256 C) n=163
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Figure 5.23 Frequency histograms with Gaussian curve demonstrated the lack of 
normality of free oleic acid (mol%, mg/dL, mmol/L) 
A, C, E) % frequency histogram showing the distribution of data amongst bands of 2 mol%, 
10 mg/dL and 0.05 mmol/L). The Gaussian curve was fitted to test normality. Confidence 
intervals show where the Gaussian curve falls with a 95% certainty. B, D, F) Residuals plot 
was used to assess the fit of the Gaussian distribution curve. A, B) n=233 C, D) n=8256 E, 
F) n=163
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5.3.13 Total palmitic acid in plasma lipids  
Total palmitic acid in plasma lipids is the sum of palmitic acid across all plasma lipid species 
including phospholipids, cholesterol esters, triglycerides and free fatty acids. Despite a 
moderate number of studies and datasets uncovered, there is very little research available 
of the effect of total plasma lipid composition on disease. Most studies included in this 
research were fatty acid profiles. 
This research analysed 26 datasets across 13 studies with n=1687 for molar percentage, 
15 datasets from 4 studies with n=392 for mass%, 3 sets of data from 2 studies with n=160 
for mg/dL and 9 sets of data across 4 studies with n=1162 for mmol/L (Appendix F).  
The mol% data had a range of 8.9% and the average and weighted average were not 
statistically different, measuring 21.63 ± 2.53 mol% and 21.18 ± 2.65 mol%, respectively 
(p=0.3803) (Figure 5.24A). The fit of the Gaussian distribution curve to the total palmitic 
acid (mol%) data was poor with a low adjusted R2 value (0.3449) (Figure 5.25A). 
Furthermore, visual examination found that the curve did not account for high molar 
percentages of total palmitic acid and the positive residuals were quite large (Figure 5.25B). 
Hence this dataset was deemed unsuitable for the calculation of references ranges.  
The range for mass% data was 7.9% with no significant difference between the average 
and weighted average, 21.67 ± 2.84 mass% and 22.29 ± 2.67 mass%, respectively 
(P=0.5373) (Figure 5.24B). The bell curve fitted to total palmitic acid (mass%) data as 
deemed to be inadequate due to a moderate adjusted R2 value (0.6044) (Figure 5.25C). 
Further examination found that the curve did not visually fit the data and the residuals were 
not random about zero (Figure 5.25D). Therefore, it was concluded that the dataset was not 
adequate for the formation of reference ranges. 
The data spread for mg/dL was large with a range of 68.54 mg/dL (Figure 5.24C). However, 
this did not confer statistical significance to the difference between the averages 
(p=0.4723). The average and weighted average measure 46.35 ± 34.81 mg/dL and 28.70 ± 
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34.68 mg/dL, respectively. A normal distribution curve could not be fitted to the total palmitic 
acid (mg/dL) data as it was not converged, and hence could not be used to calculate 
reference ranges (Figure 5.25E and 5.25F). This was due to separation of the data, a result 
of the small sample size. 
The range of mmol/L data was 1.27 mmol/L. The difference between the average and 
weighted average was statistically significant, measuring 2.41 ± 0.52 mmol/L and 1.92 ± 
0.50 mmol/L, respectively (p=0.0222) (Figure 5.24D). The adjusted R2 value for the fit of the 
Gaussian distribution curve to the total palmitic acid (mmol/L) data was low (0.3476), which 
suggested a poor fit (Figure 5.25G). This was supported by visual analysis, which revealed 
a poor fitting curve, in addition to large residuals over double figures (Figure 5.25H). Thus, 
reference ranges could not be calculated from the data. 
In summary, mol% was the most common unit for the measurement of total palmitic acid in 
plasma lipids, whilst mass%, mg/dL and mmol/L were only used in a few studies. A good 
number of studies existed for mol%, however, no reference ranges could be calculated as 
none of the datasets were Gaussian in their distribution. Moreover, individual mg/dL data 
points were not converted to mmol/L as this would have incorporated error. But, the 
average and weighted average of the mg/dL data was converted to mmol/L to allow 
statistical comparison. The converted average of 1.81 ± 1.36 was similar to the unconverted 
average of 2.41 ± 0.52 (P=0.5148). Additionally, the converted weighted average of 0.89 ± 
1.35 was not significantly smaller than the unconverted weighted average of 1.92 ± 0.50 
(P=0.2830), probably due to the large standard deviation of the converted average. 
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Figure 5.24 Total plasma palmitic acid from systematic review 
Black circles indicate mean plasma triglycerides published by the study. The size of the 
circle is representative of the number of participants in the study (Table 5.2). Black dots 
mark the average of the datasets. Red dots mark the weighted average of the dataset. A 
table of the data can be found in Appendix F. A) n=1687 B) n=392 C) n=160 D) n=1162
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Figure 5.25 Frequency histograms with Gaussian curve established the absence of 
normality of palmitic acid in total plasma lipids (mol%, mass%, mg/dL, mmol/L) 
A, C, E, G) % frequency histogram showing the distribution of data amongst bands of 1 
mol%, 1 mass%, 10 mg/dL and 0.2 mmol/L. The Gaussian curve was fitted to test 
normality. Confidence intervals show where the Gaussian curve falls with a 95% certainty. 
B, D, F, H) Residuals plot was used to assess the fit of the Gaussian distribution curve. A, 
B) n=1687 C, D) n=392 E, F) n=160 G, H) n=1162
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5.3.14 Total oleic acid in plasma lipids  
This research examined 26 datasets from 13 studies with n=1687 for molar percentage, 15 
datasets from 4 studies with n=392 for mass%, 3 datasets across 2 studies with n=160 for 
mg/dL and 8 datasets over 3 studies with n=1156 for mmol/L (Appendix F). 
The range of mol% data was 10.64 %. The difference between the two averages was 
statistically significant (p=0.0152). The average and weighted average were 22.51 ± 2.79 
mol% and 21.08 ± 2.29 mol%, respectively (Figure 5.26A). The adjusted R2 value for the fit 
of the bell curve to the total oleic acid (mol%) data was moderately low (0.4334), which 
suggested a poor fit (Figure 5.27A). Further analysis revealed that the curve did not 
account for high molar percentages even though the residuals were well distributed about 
zero (Figure 5.27B). Therefore, reference ranges could not be calculated for this dataset.  
The range for mass% data was 5.0% with similar average and weighted average, 19.26 ± 
1.57 mass% and 19.16 ± 1.65 mass%, respectively (P=0.8662) (Figure 5.26B).The normal 
distribution curve fitted to total oleic acid (mass%) data was inadequate as the adjusted R2 
value was below zero (-0.02229) (Figure 5.27C). This was corroborated by visual 
examination of the histogram, which found that the curve did not account for high mass 
percentages of total oleic acid. Furthermore, analysis of the residuals found a pattern that 
was not completely random with one large residual (Figure 5.27D). It was concluded that 
the dataset was unsuitable for the calculation of reference ranges. 
The mg/dL data had a range of 39.51 mg/dL with an average and weighted average of 
13.46 ± 20.62 mg/dL and 19.57 ± 2.79 mg/dL, respectively (Figure 5.26C). The difference 
between these two averages was non-significant (p=0.4570). The adjusted R2 value for the 
Gaussian distribution curve fitted to the total oleic acid (mg/dL) data was below zero, which 
deemed the curve unsuitable (-0.241) (Figure 5.27E). Visual analysis found that it did not 
account for low concentrations of total oleic acid, and the residuals were not initially 
random, both conferring the poor fit of the curve (Figure 5.27F). Thus, references ranges 
could not be formulated for this dataset. 
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The range of mmol/L data was 2.15 mmol/L. The average and weighted average measured 
2.35 ± 0.77 mmol/L and 1.71 ± 0.75 mmol/L, respectively, the difference between which 
was non-significant (p=0.0516) (Figure 5.26D). The normal distribution curve fitted to the 
total oleic acid (mmol/L) data was a poor fit with a very low adjusted R2 (0.008014) (Figure 
5.27G). Visual examination confirmed this, as did the residuals, which were not random 
below zero, and hence the dataset was inadequate for the calculation of reference ranges 
(Figure 5.27H). 
In summary, mol% was the most common measure of total oleic acid in plasma lipids with 
mass%, mg/dL and mmol/L used in only a few studies. Unfortunately, no reference ranges 
could be computed as the datasets were not normally distributed, in spite of the good 
volume of data for mol%. The mg/dL data was not converted to mmol/L and presented on 
the same graph as this would have introduced error. However, the average and weighted 
average of the mg/dL data was converted to mmol/L for statistical analysis. The converted 
average was significantly smaller than the average of the mmol/L dataset (0.48 ± 0.73 and 
2.35 ± 0.77, respectively) (P=0.0379). Conversely, the difference between the converted 
weighted average and the unconverted weighted average was not significant (0.69 ± 0.74 
and 1.71 ± 0.75) (P=0.1689).  
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Figure 5.26 Total plasma oleic acid in literature 
Black circles indicate mean plasma triglycerides published by the study. The size of the 
circle is representative of the number of participants in the study (Table 5.2). Black dots 
mark the average of the datasets. Red dots mark the weighted average of the dataset. A 
table of the data can be found in Appendix F. A) n=1687 B) n=392 C) n=160 D) n=1156
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Figure 5.27 Frequency histograms with Gaussian curve revealed the lack of 
normality of oleic acid in total plasma lipids (mol%, mass%, mg/dL, mmol/L) 
A, C, E, G) % frequency histogram showing the distribution of data amongst bands of 1 
mol%, 0.5 mass%, 5 mg/dL and 0.2 mmol/L). The Gaussian curve was fitted to test 
normality. Confidence intervals show where the Gaussian curve falls with a 95% certainty. 
B, D, F, H) Residuals plot was used to assess the fit of the Gaussian distribution curve. A, 
B) n=1687 C, D) n=392 E, F) n=160 G, H) n=1156
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Table 5.4 Summary of average concentrations 
 
Mol% Mass% mg/dL mmol/L mg/dL converted to mmol/L 
Average 
Weighted 
average 
Average 
Weighted 
average 
Average 
Weighted 
average 
Average 
Weighted 
average 
Average 
Weighted 
average 
Phospholipid 
 
PA 27.24 ± 3.51 27.62 ± 2.62 27.94 ± 2.20 26.49 ± 1.90 47.08 ± 39.46 36.40 ± 15.65 0.38 ± 0.42 1.22 ± 0.13 1.84 ± 1.54* 1.42 ± 0.61 
OA 10.56 ± 1.94 11.20 ± 2.03 11.06 ± 1.80 9.76 ± 1.19 20.50 ± 21.53 13.79 ± 8.59 0.39 ± 0.11 0.47 ± 0.02 0.73 ± 0.76 0.49 ± 0.30 
Cholesterol 
esters 
 
PA 11.63 ± 1.30 10.92 ± 0.97   20.28 ± 22.42 13.82 ± 13.75 4.42 ± 6.00 2.57 ± 5.20 0.79 ± 0.87 0.54 ± 0.54 
OA 18.67 ± 2.40 17.26 ± 1.88   32.19 ± 35.57 20.68 ± 22.25 9.89 ± 13.67 5.75 ± 11.77 1.14 ± 1.26 0.73 ± 0.79 
Triglycerides 
 
PA 26.12± 4.21 29.11 ± 1.52   23.28 ± 4.79 20.14 ± 4.48 15.96 ± 13.86 18.92 ± 12.01 0.91 ± 0.19 0.79 ± 0.17 
OA 38.02 ± 2.95 34.90 ± 1.90   31.74 ± 10.25 24.89 ± 9.70 28.61 ± 25.10 33.13 ± 22.51 1.12 ± 0.36 0.88 ± 0.34 
Free 
PA 25.53 ± 3.31 26.41 ± 1.45   33.54 ± 23.36 73.73 ± 8.32 0.124 ± 0.047 0.118 ± 0.041 1.308 ± 0.91* 2.876 ± 0.32* 
OA 33.44 ± 4.27 33.90 ± 3.85   32.86 ± 22.93 68.06 ± 7.96 0.192 ± 0.112 0.157 ± 0.073 1.163 ± 0.81* 2.409 ± 0.28* 
Total 
PA 21.63 ± 2.53 21.18 ± 2.65 21.67 ± 2.84 22.29 ± 2.67 46.35 ± 34.81 22.70 ± 34.68 2.41 ± 0. 52 1.92 ± 0.50 1.81 ± 1.36 0.89 ± 1.35 
OA 22.51 ± 2.79 21.08 ± 2.29 19.26 ± 1.57 19.16 ± 1.65 13.46 ± 20.62 19.57 ± 20.79 2.35 ± 0.77 1.71 ± 0.75 0.48 ± 0.73 0.69 ± 0.74 
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5.3.15 Ratio of palmitic acid: oleic acid in lipid species 
 
This research examined 90 datasets from 45 studies with n=35821 for PA:OA in 
phospholipids, 41 datasets from 29 studies with n=20852 for PA:OA in cholesterol esters, 
24 datasets from 16 studies with n=2985 for PA:OA in triacylglycerol, 27 datasets from 22 
studies with n=8675 for PA:OA in free fatty acids, and 52 datasets from 22 studies with 
n=3395 for PA:OA in total plasma lipids. 
The range of ratios of PA:OA in phospholipids was 3.27. The difference between the two 
averages was not statistically significant (p=0.0806). The average and weighted average 
were 2.62 and 2.52, respectively (Figure 5.28A). The adjusted R2 value for the fit of the 
Gaussian distribution curve to the data was high (0.9640), which suggested a very good fit 
suitable for the creation of a reference range (Figure 5.28B). Analysis of the residuals 
confirmed that this dataset could be used for the calculation of a reference range as points 
were randomly distributed around zero (Figure 5.28C).  
A 95% reference range was calculated using the equation in section 5.2.8, leaving 2.5% of 
results above this range and 2.5% below this range. The reference range for the ratio of 
PA:OA in phospholipids was 1.51 – 3.73. 
The range for ratios of PA:OA in cholesterol esters was 0.47 with similar average and 
weighted average, 0.62 and 0.63, respectively (P=0.1300) (Figure 5.29A).The bell curve 
fitted to the data was more than adequate as the adjusted R2 value was high (0.9053) 
(Figure 5.29B), and the residuals were close to zero and randomly distributed (Figure 
5.29C). It was concluded that the dataset was suitable for the calculation of reference 
ranges. 
Using the equation in section 5.2.8, a 95% reference range was computed. The reference 
range including ratios of PA:OA in cholesterol esters between the 2.5 and the 97.5 
percentile was 0.45 – 0.78. 
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The ratios of PA:OA in TAG data had a range of 0.57 with an average and weighted 
average of 0.68 and 0.83, respectively (Figure 5.30A), and the difference between the two 
averages statistically significant (p<0.0001). The adjusted R2 value for the Gaussian 
distribution curve was moderate, but not adequate for the creation of reference ranges 
(0.7620) (Figure 5.30B). Analysis of the residuals found a persistent underestimation of the 
data (Figure 5.30C). Thus, references ranges could not be calculated for this dataset. 
The range of ratios of PA:OA in free fatty acids was 1.88. The average and weighted 
average measured 0.91 and 1.1, respectively, the difference between which was 
statistically significant (p=0.0473) (Figure 5.31A). The normal distribution curve was a 
relatively good fit with an R2 (0.8989) (Figure 5.31B). Visual examination found a tail of data 
that had been excluded from the curve, and residuals showed a lack of randomness about 
zero. The non-liner regression systematically underestimated then overestimated the 
dataset (Figure 5.31C). Therefore, this dataset was inadequate for the creation of reference 
ranges. 
The ratios of PA:OA in total plasma lipids had a range of 0.93 with an average and 
weighted average of 1.1 and 1.1, respectively (Figure 5.32A). The difference between these 
two averages was non-significant (p=0.1061). The normal distribution curve had moderate 
fit but did not account for data on the lower end of the scale. The adjusted R2 value was 
0.7548 (Figure 5.32B). The residuals were randomly distributed around zero, however, the 
fit of the curve was too poor to be used in the calculation of reference ranges (Figure 
5.32C).  
In summary, calculating the ratio of palmitic acid: oleic acid values published in the collated 
studies was an effective way of combining data regardless of measurement unit. This 
increased the number of participants per analysis and in turn increased the quality of the 
results, which led to the calculation of two reference ranges.   
 268 
 
 
Figure 5.28 Ratio of PA:OA in phospholipids 
 
A) Black circles indicate the ratio of PA:OA published by the study. Black dots mark the 
average of the datasets. Red dots mark the weighted average of the dataset. B) % 
frequency histogram showing the distribution of data amongst bands of 0.2. The Gaussian 
curve was fitted to test normality. Confidence intervals show where the Gaussian curve falls 
with a 95% certainty. C) Residuals plot was used to assess the fit of the Gaussian 
distribution curve. n=35821
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Figure 5.29 Ratio of PA:OA in cholesterol esters 
 
A) Black circles indicate the ratio of PA:OA published by the study. Black dots mark the 
average of the datasets. Red dots mark the weighted average of the dataset. B) % 
frequency histogram showing the distribution of data amongst bands of 0.05. The Gaussian 
curve was fitted to test normality. Confidence intervals show where the Gaussian curve falls 
with a 95% certainty. C) Residuals plot was used to assess the fit of the Gaussian 
distribution curve. n=20852
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Figure 5.30 Ratio of PA:OA in triacylglycerol 
 
A) Black circles indicate the ratio of PA:OA published by the study. Black dots mark the 
average of the datasets. Red dots mark the weighted average of the dataset. B) % 
frequency histogram showing the distribution of data amongst bands of 0.05. The Gaussian 
curve was fitted to test normality. Confidence intervals show where the Gaussian curve falls 
with a 95% certainty. C) Residuals plot was used to assess the fit of the Gaussian 
distribution curve. n=2985
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Figure 5.31 Ratio of PA:OA in fatty acids 
 
A) Black circles indicate the ratio of PA:OA published by the study. Black dots mark the 
average of the datasets. Red dots mark the weighted average of the dataset. B) % 
frequency histogram showing the distribution of data amongst bands of 0.2. The Gaussian 
curve was fitted to test normality. Confidence intervals show where the Gaussian curve falls 
with a 95% certainty. C) Residuals plot was used to assess the fit of the Gaussian 
distribution curve. n=8675
 272 
 
 
Figure 5.32 Ratio of PA:OA in total plasma lipids 
 
A) Black circles indicate the ratio of PA:OA published by the study. Black dots mark the 
average of the datasets. Red dots mark the weighted average of the dataset. B) % 
frequency histogram showing the distribution of data amongst bands of 0.1. The Gaussian 
curve was fitted to test normality. Confidence intervals show where the Gaussian curve falls 
with a 95% certainty. C) Residuals plot was used to assess the fit of the Gaussian 
distribution curve. n=3395
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5.3.16 Comparison of lipid profiles in men vs. women  
As concentrations of plasma lipids have been linked with the prediction and development of 
a range of diseases it is important to understand which subpopulations may be at risk. For 
example, research suggests that plasma triglycerides are a risk factor for the development 
of coronary heart disease (Iso, et al., 2001), and that there is a higher and earlier incidence 
of coronary heart disease in the male population (Sanchis-Gomar, et al., 2016). Therefore, 
its important to establish whether the male population has higher plasma triglyceride levels 
than the female population, however, research to date has been rather contradictory 
(Ebbesson, et al., 2015; Glew, et al., 2010; Svanborg, et al., 2009; Yamagishi, et al., 2008). 
For this study all BMIs were included, whilst diseased states were excluded. This approach 
aimed to capture data representative of the general population. 
 
5.3.17 Plasma triglyceride levels in males vs females 
The average plasma triglyceride concentrations from 12 studies were compared between 
male and female subjects, n=5051 and n=5943, respectively.  
Meta-analysis of the data (Table 5.5) demonstrated that men had significantly higher 
concentrations of plasma triglycerides than women (p=0.003) with the average triglyceride 
concentration in men being almost 3 SD greater than in women (Z=2.95).  
 
 274 
 
Table 5.5 Plasma triglycerides - men vs. women 
 
Chi2 =86.80 was much greater than the degrees of freedom (11), which indicated heterogeneity. However, the number of studies included was too small to 
produce a reliable result. I2 =87% estimated high levels of variation amongst study results. Tau2 =0.03 found small levels of between-study variance. In 
combination, these results point to a level of heterogeneity greater suited to the use of a random-effects model.  
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5.3.18 Total palmitic acid and oleic acid levels in men vs. women 
The average molar percentage of palmitic acid and oleic acid across plasma lipids from 3 
studies between male and female participants (n=277 and n=266, respectively). 
Results (Table 5.6 and 5.7) showed that men had significantly higher molar percentages of 
total plasma palmitic acid than women (p=0.006), however, there was no significant 
difference between men and women for molar percentages of total plasma oleic acid 
(p=0.31). Average mol% of total plasma palmitic acid was over 2 SD higher in men than 
women (Z=2.73). 
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Table 5.6 Total palmitic acid (mol%) - men vs. women 
 
Chi2 =5.18 was slightly greater than the degrees of freedom (4), which confers acceptable levels of heterogeneity. However, in this instance Chi2 was not 
reliable due to the small number of samples. I2 =23% estimated small amounts of inconsistency amongst study results, which was acceptable. Tau2 =0.07 
also indicated small levels of heterogeneity. However, these results were not significant (p=0.27), and, therefore, not reliable. A random-effects model was 
used as a precaution to diminish the impact potential heterogeneity, especially as all studies included had a similar number of subjects, thereby reducing 
small sample bias. 
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Table 5.7 Total oleic acid (mol%) – men vs. women 
 
For the comparison of total plasma oleic acid in men vs. women (Figure 20B), Chi2 =14.52 was greater than the degrees of freedom (4), and thereby 
indicated heterogeneity. However, the sample size in this study was too small to produce reliable results. I2 =72% estimated moderate variability amongst 
study results. Whilst, Tau2 =1.54 was greater than 1, which confirmed definite heterogeneity. Therefore, a random-effects model was used. 
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5.3.19 Molar percentage of palmitic acid in phospholipids in men vs. women 
The average molar percentage of palmitic acid in plasma phospholipids between male and 
female subjects was compared, n=3173 and n=3383, respectively. 17 datasets across 3 
studies were analysed. 
The results, shown in Table 5.8, demonstrated that men had significantly higher molar 
percentages of palmitic acid in plasma phospholipids than women (p<0.00001). The 
average mol% of palmitic acid in plasma phospholipids was over 5 SD greater in male 
participants than female participants (Z=5.56). 
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Table 5.8 Palmitic acid in plasma phospholipids (mol%) - men vs. women 
 
Chi2 =353.35 was much greater than the degrees of freedom (16) and, thus, suggested heterogeneity. However, the number of studies included was too 
small to produce a reliable result. I2 =95% which strongly suggested variation amongst study results. Tau2 =0.8 was close to 1, which also strongly indicated 
heterogeneity. Therefore, a random-effects model was utilise to diminish the impact of between-study variance. Multiple values from Saadatian-Elahi, et al., 
(2008) represent datasets from different countries. 
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5.3.20 Molar percentage of oleic acid in phospholipids in men vs. women 
The next comparison looked at the average molar percentage of oleic acid in plasma 
phospholipids between male and female participants, n=3173 and n=3382, respectively. 17 
datasets were analysed from 3 studies. 
The meta-analysis (Table 5.9) found that men had significantly higher molar percentages of 
oleic acid in plasma phospholipids than women (p=0.0007) with the average mol% of the 
male subjects over 3 SD higher than the average mol% of the female subjects (Z=3.41).
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Table 5.9 Oleic acid in plasma phospholipids (mol%) - men vs. women 
 
Chi2 =47.47 was much larger than the degrees of freedom (16) and consequently indicated heterogeneity. However, the result was unreliable due to the 
small number of studies included. I2 =66% which indicated moderate variability amongst study results. Tau2 =0.07 suggested small levels of heterogeneity. 
In combination these results suggested levels of heterogeneity which were better suited to a random-effects model in order to combat the impact of 
between-study variance. Multiple values from Saadatian-Elahi, et al., (2008) represent datasets from different countries. 
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5.3.21 Lipid profiles in non-obese vs overweight/obese vs type II diabetic 
subjects 
5.3.22 Plasma triglyceride levels in non-obese vs. obese subjects 
Having established concentration ranges of triglycerides and fatty acids in their various 
plasma constituents, the next step was to compare average total plasma triglyceride 
concentrations in non-obese versus overweight/obese subjects without medical conditions. 
Data was extracted from 21 studies with non-obese and overweight/obese participants, 
n=692 and n=658, respectively.  
Meta-analysis of the data demonstrated that overweight/obese subjects had significantly 
higher concentrations of plasma triglyceride than non-obese subjects (p<0.00001) (Table 
5.10). The average plasma triglyceride concentration of overweight/obese participants was 
over 6 SD greater than the average plasma triglyceride concentration of non-obese 
participants (Z=6.78). 
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Table 5.10 Plasma triglyceride levels – non-obese vs. overweight/obese 
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The Chi2 was calculated at 55.22, which was much larger than the degrees of freedom (20), indicating heterogeneity. However, the number of studies 
included was not large enough to produce a reliable Chi2. I2 was equal to 64%, indicating moderate inconsistency in study results. Tau2 is the most reliable 
measure of heterogeneity, and a value of 0.06 was derived, which suggested that small amounts of between-study variance existed. Together, these 
measures indicated that samples of the population used in each study varied between studies, producing heterogeneity, therefore, a random-effects model 
was used. 
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The forest plot in Table 5.10 demonstrated that obese subjects had higher plasma 
triglyceride concentrations than non-obese subjects, however, it was important to identify 
whether a direct correlation between BMI and plasma triglyceride levels existed. 
Results found a moderate, statistically significant positive correlation between BMI and 
plasma triglyceride concentrations (r=0.5608, P<0.0001).   
 
 
 
Figure 5.33 Correlation between BMI and plasma triglycerides 
Analysis of the correlation between BMI and plasma triglycerides found a positive 
correlation between the two (r=0.5608, P<0.0001) (n=100).  
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5.3.23 Plasma free fatty acid levels in non-obese vs. obese subjects 
This study compared average plasma free fatty acid concentrations from 44 studies 
between non-obese and overweight/obese participants, n=864 and n=854, respectively.  
Results of the meta-analysis are shown in Table 5.11, and showed that overweight/obese 
subjects had significantly higher concentrations of plasma free fatty acids than non-obese 
subjects (p<0.00001). The average plasma FFA concentration of overweight/obese 
participants was over 7 SD higher than the average plasma FFA concentration of non-
obese participants (Z=7.06). 
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Table 5.11 Plasma free fatty acids – non-obese vs. overweight/obese 
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Table 5.11 continued 
 
Chi2 =188.87 was much larger than the degrees of freedom (43) and, thus, indicated heterogeneity. I2 =77% indicated moderate inconsistency in study 
results. Tau2 =11869.91 was far greater than 1, thereby confirming definite heterogeneity between the included studies, therefore, a random-effects model 
was selected. 
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The forest plot in Table 5.11 found that obese subjects had higher plasma free fatty acid 
concentrations than non-obese subjects. But, it was imperative to study the relationship 
BMI and plasma free fatty acid concentrations. 
The study revealed a small, yet statistically significant positive correlation between BMI and 
plasma free fatty acid concentrations (r=0.3734, P=0.0001).   
 
 
 
 
Figure 5.34 Correlation between BMI and plasma free fatty acids 
Analysis of the correlation between BMI and plasma free fatty acids found a positive 
correlation between the two (r=0.3734, P=0.0001) (n=103).  
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5.3.24 Plasma triglyceride levels in non-obese and obese subjects vs. type II 
diabetics 
Following on from the comparison of triglyceride levels in non-obese vs. obese subjects 
(Table 5.10), this study compared average plasma triglyceride concentrations from 11 
studies between non-obese participants without medical conditions and participants with 
type II diabetes regardless of BMI, n=8688 and n=1093, respectively. Average plasma 
triglyceride concentrations were also compared across 11 studies between 
overweight/obese participants without medical conditions and participants with type II 
diabetes regardless of BMI, n=2646 and n=2069, respectively.  
The meta-analysis (Table 5.12) found that subjects with type II diabetes had significantly 
higher concentrations of plasma triglyceride than both non-obese and overweight/obese 
controls without type II diabetes (p<0.00001). The average concentrations of plasma 
triglyceride in participants with type II diabetes was over 5 SD greater than both control 
groups (Z=5.27 non-obese, Z=5.97 overweight/obese). 
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Table 5.12 Plasma triglycerides – non-obese vs. type II diabetes 
 
Chi2 =74.23 was much greater than the degrees of freedom (11), which indicated heterogeneity. However, the number of studies included was too small to 
produce a reliable result. I2 =85% indicated high levels of inconsistency amongst study results. Tau2 =0.05 suggested a small level of heterogeneity, 
however, in combination these results indicated the presence of between-study variance and hence a random-effects model was chosen. 
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Table 5.13 Plasma triglycerides – overweight/obese vs. type II diabetes 
 
Chi2 =32.18 was greater than the degrees of freedom (10), which suggested heterogeneity. However these results were unreliable in a sample of this size. 
I2 =69% which suggested moderate variability amongst study results. Tau2 =0.06 indicated small amounts of between-study variance, however, when 
amalgamated these results indicated a level of heterogeneity that was greater suited to the use of a random-effects model. 
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5.3.25 Plasma free fatty acid levels in non-obese and obese subjects vs. type 
II diabetics 
Following on from the comparison of FFA levels in non-obese vs obese subjects, this study 
compared average free fatty acid concentrations from 14 studies between non-obese 
participants and participants with type II diabetes, n=178 and n=152, respectively. Average 
plasma FFA concentrations were also compared across 13 studies between 
overweight/obese subjects and participants with type II diabetes, n=153 and n=151, 
respectively.  
The results (Table 5.14 and 5.15) showed that participants with type II diabetes had 
significantly higher concentrations of plasma FFA than non-obese participants without type 
II diabetes (p<0.00001). Furthermore, subjects with type II diabetes also had significantly 
higher concentrations of plasma FFA than overweight/obese participants without type II 
diabetes (p=0.003).The average concentration of plasma FFA in participants with type II 
diabetes was almost 3 SD more than the average plasma FFA concentration for the 
overweight/obese controls (Z=2.99), and over 5 SD greater than the average of the non-
obese control group (Z=5.37). 
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Table 5.14 Plasma free fatty acids – non-obese vs. type II diabetes 
 
Chi2 =143.28 was much larger than the degrees of freedom (13), which strongly suggested heterogeneity. However, the number of studies included was 
not large enough to produce a dependable result. I2 =91% indicated very high levels of inconsistency amongst study results. Tau2 =36924.47 was vastly 
greater than 1, which confirmed definite heterogeneity. 
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Table 5.15 Plasma free fatty acids – overweight/obese vs. type II diabetes 
 
Chi2 =62.06 was greater than the degrees of freedom (12), which suggested heterogeneity. However, these results were unreliable in a sample of this size. 
I2 =81% showed moderate variability amongst study results. Tau2 =18525.69 was significantly larger than 1, which identified definite heterogeneity. 
Therefore, a random-effects model was selected in both instances. 
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5.3.26 Molar percentage of palmitic acid and oleic acid in cholesterol esters in 
control and type II diabetic subjects 
A further comparison was made comparing the average molar percentage of palmitic acid 
and oleic acid in cholesterol esters between control subjects regardless of BMI and 
participants with type II diabetes across 3 studies, n=4735 and n=358, respectively. 
Results found that participants with type II diabetes had significantly higher molar 
percentages of palmitic acid in plasma cholesterol esters than the control group 
(p<0.00001) (Table 5.16 and 5.17). Furthermore, subjects with type II diabetes also had 
significantly higher molar percentages of oleic acid in plasma cholesterol esters than the 
control subjects (p=0.02). The average mol% of palmitic acid in plasma cholesterol esters 
was over 5 SD higher in type II diabetics than in the control group (Z=5.32), whilst the 
average mol% of oleic acid in cholesterol esters was over 2 SD greater in type II diabetics 
than in the control participants (Z=2.38). 
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Table 5.16 Palmitic acid in cholesterol esters (mol%) – control vs. Type II diabetes 
 
Chi2 =2.87 was slightly greater than the degrees of freedom (2), which provided marginally acceptable levels of heterogeneity. However, in this study Chi2 
was unreliable due to the small number of samples. I2 =30% estimated small to moderate levels of inconsistency amongst study results, which was just 
outside the realms of acceptable. Tau2 =0.01 was small, which indicated low levels of between-study variance, however, when combined these results 
indicated an unacceptable level of heterogeneity for the assumptions in a fixed-effects model. Therefore, a random-effects model was selected. 
 
 
 
 
 
 298 
 
Table 5.17 Oleic acid in cholesterol esters (mol%) – control vs. Type II diabetes 
 
For the comparison of oleic acid plasma cholesterol esters in men vs. women (Figure 23B), Chi2 =2.19 was just larger than the degrees of freedom (2), and 
thereby suggested a low and acceptable level of between-study variance. I2 =9% estimated a very small amount of inconsistency amongst study results. 
Tau2 =0.01 was small and, thus, indicated acceptably low levels of heterogeneity, therefore, a fixed-effects model was selected. 
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5.3.27 Molar percentage of palmitic acid in plasma phospholipids between 
control and type II diabetic subjects  
This research examined the average molar percentage of palmitic acid in plasma 
phospholipids between control subjects and subjects with type II diabetes across 4 studies, 
n=21396 and n=12929, respectively.  
Results (Table 5.18) showed that participants with type II diabetes had significantly higher 
molar percentages of palmitic acid in plasma phospholipids than the control subjects 
(p=0.002). The average mol% of palmitic acid in plasma phospholipids was over 2 SD 
higher in the type II diabetes group than in the control group (Z=2.40). 
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Table 5.18 Palmitic acid in phospholipids (mol%) - control vs. type II diabetes 
 
Chi2 =93.50 was much greater than the degrees of freedom (3), which strongly suggested between-study variance. However, the small number of studies 
produced an unreliable result. I2 =97% estimated very high levels of variability amongst study results. Tau2 =0.14 suggested moderate levels of 
heterogeneity. When studied in combination, these results demonstrated levels of heterogeneity unsuitable for a fixed-effects model, hence the selection of 
a random-effects model. 
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5.3.28 Lipid profile in patients with cardiovascular disease 
5.3.29 Plasma triglyceride concentrations between control participants and 
subjects with cardiovascular disease 
Because of the expected involvement of lipids in the development of cardiovascular 
disease, this research examined the average plasma triglyceride concentrations between 
control participants and subjects with cardiovascular disease. This analysis collated 7 
studies including 12151 control subjects and 3259 subjects with cardiovascular disease. 
Results (Table 5.19) found that subjects with cardiovascular disease had significantly 
higher concentrations of plasma triglyceride than participants in the control group 
(p<0.00001). The average plasma triglyceride concentration of the cardiovascular disease 
group was over 6 SD higher than the average for the control subjects (Z=6.25). 
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Table 5.19 Plasma triglycerides - control vs. cardiovascular disease 
 
Chi2 =20.14 was greater than the degrees of freedom (7), and, thus, indicated heterogeneity. However, this result was unreliable due to the small number of 
studies included. I2 =65% predicted moderate levels of inconsistency amongst study results. Tau2 =0.01 was small and suggested small amounts of 
between-study variance. However, once combined these results indicated moderate heterogeneity, and, thus, a random-effects model was performed. 
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5.3.30 Plasma free fatty acid concentrations between control subjects and 
participants with cardiovascular disease  
This study compared average plasma free fatty acid concentrations between control 
subjects and participants with cardiovascular disease across 3 studies, n=5216 and n=336, 
respectively. 
The meta-analysis (Table 5.20) showed that there was no significant difference between 
average plasma FFA in subjects with cardiovascular disease and participants in the control 
group (p=0.31). 
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Table 5.20 Plasma free fatty acids - control vs. cardiovascular disease 
 
 
Chi2 =4.84 was greater than the degrees of freedom (2) and suggested heterogeneity. However, the Chi2 was unreliable due to the small number of studies 
included. I2 =59% which suggested moderate inconsistencies amongst study results. Tau2 =1547.42 was vastly greater than 1, and, thus, confirmed 
heterogeneity. Therefore, a random-effects model was selected to take between-study variance into account. 
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5.3.31 Molar percentage of palmitic acid and oleic acid in cholesterol esters 
between control and cardiovascular disease subjects 
The next step was to compare the average molar percentage of palmitic acid and oleic acid 
in cholesterol esters between control subjects and participants with cardiovascular diseases 
across 3 studies, n=5209 and n=495, respectively.  
The meta-analysis (Table 5.21 and 5.22) demonstrated that there was no difference 
between the molar percentage of palmitic acid in cholesterol esters in participants with 
cardiovascular disease compared to the control group (p=0.99). However, subjects with 
cardiovascular disease did have a significantly higher molar percentage of oleic acid in 
plasma cholesterol esters than the control participants (p=0.02). The average mol% of oleic 
acid in plasma cholesterol esters was over 2 SD higher in the cardiovascular disease group 
than in the control group (Z=2.37), whilst the average mol% of palmitic acid in cholesterol 
esters was marginally greater in the cardiovascular group versus the control group 
(Z=0.02). 
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Table 5.21 Palmitic acid in cholesterol esters (mol%) - control vs. cardiovascular disease 
 
Chi2 =350.51 was significantly greater than the degrees of freedom (2), which demonstrated unacceptable levels of heterogeneity. I2 =99% estimated large, 
unacceptable levels of inconsistency amongst study results. Tau2 =1.51 was large, and, thus, suggested high levels of between-study variance. Therefore, 
a random-effects model was selected. 
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Table 5.22 Oleic acid in cholesterol esters (mol%) - control vs. cardiovascular disease 
 
Chi2 =0.59 was smaller than the degrees of freedom (2), which conferred an acceptable level of heterogeneity. I2 =0% estimated no variability amongst 
study results. Tau2 =0.00 also suggested no between-study variance, and, thus, a fixed-effects model was performed. N.B. the heterogeneity results 
produced a large non-significant p value (p=0.75), however, the results were deemed strong enough to use a fixed-effects model regardless. 
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5.4 Discussion 
A comprehensive systematic review of the literature revealed that many papers stated 
average plasma lipid concentrations obtained from small samples or from niche 
populations. Further primary studies have then used these averages as a baseline for 
subsequent work, thereby creating an unstable and inaccurate foundation for research in 
this field.  
The rationale behind this study was that with the amalgamation of results collected through 
systematic review, robust averages and reference ranges of total lipids, free fatty acids, and 
levels of palmitic acid and oleic acid in different plasma lipid species could be derived, 
thereby informing future studies in this field. Furthermore, this study aimed to assess the 
levels of different lipid species in subpopulations and diseased states, in order to 
understand the potential of a clinical relationship between palmitic and oleic acid levels and 
disease. The majority of this was achieved with the exception of reference ranges for all 
lipid species; only four could be calculated reliably. 
 
5.4.1 Units of measurement and average molecular weight of plasma free 
fatty acids 
A systematic review of the literature found that two units of measurement are commonly 
used for plasma free fatty acids. The majority of papers used the SI unit mmol/L, although 
many used mg/dL. However, not one paper converted between the two units. This result 
was surprising, as instead of pooling research for the advancement of knowledge in the 
field, researchers are continuing down one of the two separate paths.  
It was important for this systematic review to pool data in order to give a better overview, 
and calculate more robust averages. Therefore, the literature was interrogated for a 
conversion factor between the two units, however, one could not be found. A number of 
online calculators exist that use the molecular weight of oleic acid as the average molecular 
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weight for plasma free fatty acids (DIALAB, 2008; DiaSys Diagnostic Systems GmbH, 
2017). None of the websites included references evidencing the validity of this conversion 
factor, and, therefore, it was important to calculate the average molecular weight of plasma 
free fatty acids for subsequent use in this study.  
Systematic review identified one comprehensive lipid profiling study with a large sample 
size (n=826) (Abdelmagid, et al., 2015). From this study data was extracted and an average 
molecular weight calculated based on the fatty acid percentage composition of plasma in 
the study. This study calculated the average molecular weight of plasma free fatty acids to 
be 277.454 g/mol as opposed to 282.47 g/mol, the MW of oleic acid. This difference can 
create disparities of ~2% in the conversion from mg/dL to mmol/L. We recommend the use 
of the lower value in future conversions.  
 
5.4.2 Average concentrations of plasma lipids 
Systematic review identified and collated data on total plasma triglycerides and total free 
fatty acids levels. In addition, palmitic acid and oleic acid content in phospholipids, 
cholesterol esters, and triglycerides were calculated, as well as free palmitic acid and oleic 
acid levels. The range of available data varied hugely from plasma triglycerides with 139 
datasets included to palmitic acid and oleic acid in phospholipids with only 3 datasets.  
Plasma triglycerides are the most frequently measured plasma lipid, and are measured by 
the NHS to evaluate risk factors of coronary heart disease and pancreatitis (Southend 
University Hospital NHS Trust, 2018). As such, average plasma triglyceride concentrations 
are widely published and reference ranges have been calculated (Table 5.1). This study 
considered it important to check for any disparities between published averages for the 
most common lipids in order to illustrate the vast range in data that existed, and to highlight 
the need for greater standardisation. Results from plasma triglyceride data found that the 
average concentration across the 139 datasets was significantly different compared to the 
average when weighted for the number of participants per study. A reference range was 
 
 
310 
 
calculated to be 0.47 - 2.38 mmol/L, which was quite different to many being used by the 
NHS (Table 5.1). This new reference range could be used nationwide, across the NHS to 
standardise results, as currently reference ranges are used on a trust by trust basis (Table 
5.1). 
Plasma free fatty acid levels are also commonly measured, however, few reference ranges 
exist. The difference between the average plasma FFA concentration across datasets and 
the weighted average was very large. However, the data was assessed to be normally 
distributed and a reference range of 216.3 - 907.9 µmol/L was calculated. This could also 
be used by the NHS to standardise patient results. 
The data available for palmitic acid and oleic acid in different lipid fractions was scarce and 
not helped by the existence of four different seemingly acceptable units of measurement 
that were found in the literature. The majority of analyses contained too few datasets to 
compute reliable statistics and most were not normally distributed, and hence could not be 
used to form reference ranges. However, reference ranges could be calculated for oleic 
acid in phospholipids (mol%) and palmitic acid in triglycerides, 6.68 – 14.44 mol% and 
17.71 – 34.53 mol%, respectively. 
Many studies chose to report palmitic acid and oleic acid in different lipid fractions as a 
percentage of the total moles or total weight, instead of absolute concentrations. However, 
inaccuracy in the measurement of one fraction via this method can have substantial knock-
on effects on the percentages of the other fatty acids measured. 
Most importantly, for the analysis of palmitic acid and oleic acid in different plasma lipid 
fractions, none of the units of individual data points were converted, as conversion would 
have introduced error. However, the average and weighted average were converted to 
mmol/L to enable statistical analysis, which highlighted vast disparities. For example, the 
converted weighted average of free palmitic acid was significantly larger than the 
unconverted weighted average (P<0.0001) (Table 5.4). However, ratios of palmitic acid to 
oleic acid were calculated for all lipid species in order to amalgamate data from all sources 
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regardless of unit. This effectively increased the amount of usable data per analysis, 
thereby, increasing the quality of the output. Furthermore, this analysis was performed as 
the previous two chapters indicated the importance of measuring the ratio of saturated to 
unsaturated fatty acids. 
This study strongly highlighted the need for larger scale studies to act as a foundation for 
future research, and standardisation of units and measurements across the field.  
5.4.3 Lipid species amongst the population 
There is much contradiction in the literature regarding lipid species in different populations. 
For example, most studies report that men have higher plasma triglyceride concentrations 
than women (Abdelmagid, et al., 2015; Fernandez-Real, et al., 2005; Hotta, et al., 2000; 
Khaw, et al., 2012; Kuriki, et al., 2003; Vognild, et al., 1998; Yamagishi, et al., 2008) , but 
many authors have published results contradicting this (Baylin, et al., 2005; Ebbesson, et 
al., 2015; Glew, et al., 2010; Svanborg, et al., 2009). Therefore, taken individually studies 
could be misleading with the possibility of negatively influencing future research. We felt it 
important to conduct a systematic review and meta-analysis to view the data as a whole 
and draw more informed conclusions. 
Results found that most lipid species are higher in men. Men have ~3 SD higher levels of 
plasma triglycerides, ~2 SD higher total palmitic acid (mol%), ~5 SD higher palmitic acid in 
phospholipids (mol%) and ~ 3 SD higher oleic acid in phospholipids (mol%) than women. 
For total oleic acid (mol%) the values from men and women were the same. 
Overweight/obese, non-diabetic subjects have significantly higher levels of plasma 
triglycerides and plasma free fatty acids than non-obese subjects, ~6 SD and ~7SD, 
respectively. Furthermore, there was a positive correlation between BMI and plasma 
triglyceride concentration, and BMI and plasma FFA. Previous studies have reported similar 
results, but in smaller, niche populations. For example, one study found a correlation 
between BMI and blood triglycerides in 208 South Korean subjects (Kim, et al., 2012), 
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whilst another in 155 Iraqi diabetic premenopausal women during their pre ovulatory period 
(Ali & Al-Zaidi, 2011). 
 
5.4.4 Lipid species in disease 
In the past couple of decades an increasing number of studies have examined the 
relationship between different lipid species and a range of diseases including cancer 
(Butler, et al., 2017; Crowe, et al., 2008), cardiovascular diseases (Fernández-Real, et al., 
2003), cardiometabolic diseases (Rosqvist, et al., 2017), and even Alzheimer’s disease 
(Proitsi, et al., 2015). However, studies are often small and don’t utilise meta-analyses 
which can enhance statistical power. Therefore, this study considered it to be important to 
study the relationship between lipids and prominent diseased states by collating data. 
Participants with type II diabetes had significantly higher concentrations of plasma 
triglycerides and plasma FFAs than non-obese and overweight/obese participants without 
the disease. Furthermore, participants with type II diabetes also had higher molar 
percentages of palmitic acid and oleic acid in cholesterol esters, and palmitic acid in 
phospholipids than control subjects. 
Participants with cardiovascular disease had significantly higher concentrations of plasma 
triglycerides and a higher molar percentage of oleic acid in cholesterol esters than control 
subjects. On the other hand, subjects with cardiovascular diseases did not have 
significantly higher concentrations of plasma free fatty acids or higher molar percentage of 
palmitic acid in cholesterol esters. 
There was, however, no significant difference between the molar percentages of palmitic 
acid or oleic acid in phospholipids in control subjects and participants with cancer, which 
was contradictory to research by Crowe, et al., (2008) who found a positive association 
between palmitic acid in phospholipids and prostate cancer.  
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This study worked with the available resources to generate the results above. The 
systematic review process highlighted the lack of data available in this field and established 
the need for more large scale studies to act as a foundation for future research. 
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6 General discussion 
This project took a multifactorial approach with an aim to better understanding the 
pathophysiological effects of elevated plasma FFA throughout the body and in different 
populations in order to clarify contradictions in the literature. Originally the aim of this 
project was to study the effects of FFA on insulin sensitive cells and platelets in depth as 
many scientists believe that plasma FFAs are elevated in the obese community. If true, 
research into their effects are vital in the process of understanding how to prevent the 
deleterious effects of the obesity, which are pandemic across the whole and cause 
significant strain on global healthcare services. However, throughout the course of research 
large disparities and contradictions started to appear in the foundations of the literature, 
which caused questions as to the importance of FFAs in obesity. For example, many 
papers have been published regarding the measurement of lipid species in different 
subpopulations without coming to a common consensus on average plasma levels of lipid 
species in the normal population. Even the NHS uses vastly different reference ranges for 
the normal population across the country. Furthermore, researchers also disagree about 
whether certain lipids are elevated in certain subpopulations or not, and use different 
measurement units which cannot be directly converted. Additionally, many disagree about 
lipid risk factors for CVD, CHD, mortality etc. Therefore, it was deemed important to try to 
debunk this area of research before continuing with the cellular research. 
The final project and thesis was achieved via in vitro studies on hepatocyte, skeletal 
myocyte and washed platelet models to determine whether fatty acids accumulate 
intracellularly and induce lipotoxicty. In addition to a systematic review and meta-analysis to 
determine whether certain plasma lipid fractions are in fact associated with obesity and 
diseased states. 
Initially this project investigated the effects of physiological levels of free palmitic acid and 
oleic acid on hepatocyte, skeletal myocyte and platelet models in order to understand the 
potential effects elevated plasma FFAs may have at a cellular level. The selection of fatty 
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acid concentrations for cell and platelet studies was difficult as there was a limited 
consensus regarding normal physiological levels and levels in obesity, yet after consulting 
the literature, concentrations up to 1 mM were selected. In the hepatocyte and skeletal 
muscle cell models, palmitic acid was found to cause cell death, probably via apoptotic 
mechanisms, whilst oleic acid induced intracellular lipid accumulation. These results were in 
agreement with the most common theory that lipotoxicity occurs when fatty acids cannot be 
stored intracellularly as neutral lipid species. This is highly dependent on fatty acid 
structure, and the cell’s storage capacity. It is thought that due to their higher melting 
temperatures, saturated fatty acids are less capable of forming neutral lipids intracellularly 
so are more lipotoxic individually, however, unsaturated fatty acids are able to sequester 
them into neutral lipid storage thereby ameliorating their deleterious effects in combination. 
This leads to thinking that the physiological combination of plasma fatty acids within the 
circulation would not cause cellular damage unless potentially highly elevated, or the ratio 
of saturated to unsaturated fatty acids was abnormal. 
Conversely, palmitic acid had no effect on washed platelets whilst oleic acid induced 
platelet aggregation. Attempts to reduce oleic acid-induced aggregation via the inhibition of 
vital signalling events in platelet activation failed. Additionally, no markers of platelet 
activation were found following stimulation, except the exposure of PS which is also a 
hallmark of apoptosis. Two separate experiments were performed to examine cell death; 
oleic acid caused significant loss of platelet viability, giving credence to the hypothesis that 
oleic acid evokes platelet aggregation via apoptotic mechanisms. Due to the rapid response 
of platelets upon stimulation with oleic acid, it is likely that apoptosis is occurring due to 
alterations to the platelet membrane. The mechanisms are likely to be different to those 
initiated by palmitic acid in HepG2 and L6 cells. However, the three cells studied in this 
project do share common signalling pathways, such as caspase activation in apoptosis 
(Mutlu, et al., 2012). These results are produced in isolation, and would not be present if 
treated with the physiological combination of fatty acids found within the blood. However, 
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once again it is possible that these results would be seen in vivo in the presence of an 
abnormal ratio of saturated to unsaturated fatty acids. 
 
Systematic review and meta-analysis was firstly used to analyse circulating lipids in healthy 
subjects. The aim was to find average values and reference ranges, and produce average 
PA:OA ratios for different lipid species. Results confirmed that 1 mM of fatty acids was 
appropriate for the laboratory experiments, and suggested averages and reference ranges 
for future use by the wider community including researchers and the NHS. Systematic 
review uncovered the usage of four different measurement units across the literature that 
could not be accurately converted, which caused confusion when trying to ascertain a 
congruent answer for average circulating lipids. Analysis found that 25% of the converted 
values were statistically different to the values originally measured in mmol/L. This finding 
was worrying and unexplained, hence the recommendation that the research community 
favours one unit and does not convert between the two. Furthermore, there is not always a 
good correlation between the relative (mol% and mass%) and absolute (mg/dL and mmol/L) 
metrics (Song, et al., 2016). This may not affect the interpretation of all results in studies of 
association between a lipid species and disease outcomes, especially if a covariate of total 
lipids is provided. However, for lipid species with low correlation between the two 
measures, choosing which to draw inferences from may significantly affect the outcome 
(Song, et al., 2016). 
Fortunately, following analysis from the cellular and platelet work in this project it was 
identified that the ratio of PA:OA was potentially more important that the absolute values, 
and all data regardless of units could be used for these calculations. The results produced 
had a smaller variance and effectively amalgamated all of the data in addition to producing 
reliable average ratios and reference ranges. 
The main point highlighted by the research was the vastly differing results for all lipid 
species studied. Even without the additional issue of units, the range of data in the literature 
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varied massively and as such affected results. Often there was a statistical difference 
between the average and weighted average, suggesting outliers or study bias, where the 
weight of small studies is overestimated or the weight of large studies is underestimated. 
This, and a lack of available data for some lipid fractions led to data that was not Gaussian 
with no improvement upon log transformation, therefore, many reference ranges could not 
be calculated. The wide range of data published throughout the literature was believed to 
be due to a number of factors. Firstly, there is no gold-standard for the measurement of 
lipids in the blood or plasma, so different approaches were used across published works. 
Secondly, the inclusion and exclusion criteria for ‘healthy subjects’ were not only widely 
different across research articles, but failed to identify the effects characteristics such as 
age, obesity and menopause may have upon the validity of the results. For example, most 
researchers did not consider asking female participants about whether they had started the 
menopause even though they included women of pre- and post- menopausal age. 
Furthermore, none included in this study asked whether post-menopausal women were 
taking hormone replacement therapy. This could have significant effects on the results as 
hormone levels have been shown to alter the lipid profile (Bade, et al., 2014). 
Regardless of the issue with the data, reliable reference ranges for the general population 
were calculated for plasma FFA, plasma triglyceride, oleic acid in phospholipids (mol%) and 
palmitic acid in triglycerides (mol%). The reference range for plasma triglycerides could be 
adopted across the NHS to standardise testing, as currently reference ranges vary greatly 
between trusts. In spite of being a niche test in the NHS, the plasma FFA reference range 
could also be utilised. Unfortunately, the other two mean little as stand-alone reference 
ranges.  
The levels of lipid species in different subpopulations were then studied to identify groups 
with elevated lipids such as obese and type II diabetic patients. Many studies linked 
elevated levels of plasma FFA with the development of a range of cardiovascular and 
metabolic diseases. In the 1960s, individuals classified as obese with a BMI over 30 kg/m2 
were found to have greater levels of circulating FFA (Opie, et al., 1963). However, as more 
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studies have been published and the analysis widened to include more and more subsets 
of the population the results have become variable. More recently, a number of studies 
have been published that show no difference in plasma FFA levels between obese and 
non-obese subjects, which contradicted the results of this study (Arner, et al., 2015; Frias, 
et al., 2000; Horton, et al., 1995; Jocken, et al., 2008; Johns, et al., 2014). And yet, 
research continues to be published based on the assumption that FFAs are raised in 
obesity, without further large scale systematic review and meta-analysis.  
The meta-analysis confirmed that circulating levels of plasma TG and FFAs are indeed 
raised in the obese population, but furthermore, that they are even more elevated in type II 
diabetics. This could be due to systemic insulin resistance leading to hyperinsulinaemia 
which in turn leads to reduced TG synthesis and storage, and increased lipolysis in the 
adipose tissue, thereby, causing increased circulating levels (Czech, et al., 2013; Shah, et 
al., 2003). However, it could also be due to a causal effect. In order to qualify as a 
physiological link between obesity and insulin resistance, the substance should be elevated 
in the blood of obese people; increasing plasma levels (within physiologic limits) should 
enhance insulin resistance, and reducing plasma levels should ameliorate insulin 
resistance. FFAs have been found to meet all three criteria (Boden, 2008; Boden, et al., 
1994; Reaven, et al., 1988; Santomauro, et al., 1999).  
In contradiction to this literature suggests that plasma TG is rarely elevated in well 
controlled diabetics (Fisher, 1991), which may indicate that type II diabetics, in general, 
have poor glycaemic control. Glycated haemoglobin (HbA1c), the gold-standard test for 
glycaemic control should be lower than 7% in diabetics. However, numerous systematic 
reviews found that over half of type II diabetics had HbA1c readings higher than 7% across 
a range of interventions (Li, et al., 2018; Srinivasan, et al., 2008). Additionally, type II 
diabetics have higher molar percentages of palmitic acid in phospholipids and cholesterol 
esters than the non-diabetic population. This is directly contradicted by Chuang, et al., 
(2012) who found that palmitic acid in phospholipids was decreased in the type II diabetic 
population, yet, supported by Salomaa, et al., (1990) who discovered that palmitic acid in 
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cholesterol esters increased with increasing glucose intolerance. Subjects with 
cardiovascular disease had greater levels of plasma triglyceride, which is not surprising as 
high circulating TG levels are a risk factor in the development of cardiovascular diseases 
(Han, et al., 2016; Harchaoui, et al., 2009; Yuan, et al., 2007). The molar percentage of 
oleic acid in cholesterol esters is also increased in subjects with cardiovascular disease, 
whilst plasma FFA is not. However, many studies have found that elevated FFA is a risk 
factor for cardiovascular diseases (Djoussé, et al., 2013; Pirro, et al., 2002), and is linked to 
the progression of CVD (Jin, et al., 2017).  
In summary, this project provides insights into the pathophysiological effects of fatty acid on 
hepatocytes, skeletal myocytes and platelets. In addition to providing average plasma 
triglyceride and free fatty acid levels, and palmitic acid and oleic acid content of plasma lipid 
species, in the general population and subpopulations. It was established that palmitic acid 
caused cell death in hepatocytes and skeletal muscle cells, whilst oleic acid caused 
intracellular lipid accumulation. Oleic acid also caused platelet death, likely via apoptosis. 
These results highlighted the physiological importance of the saturated:unsaturated fatty 
acid ratio in the blood. 
Results from the meta-analysis showed that men have greater concentrations of plasma 
FFA. Furthermore, they confirmed that circulating levels of FFAs are indeed raised in the 
obese population, and even more so in type II diabetics. This has large implications as high 
levels of FFA are associated with a variety of acute and chronic conditions in cells and 
tissues across the body.  
In addition to understanding basic processes involved in lipotoxicity. This study highlights 
gaps in the foundations of research in this field and suggests that more work goes into 
understanding differing levels of lipid species amongst the population in order to better 
understand subpopulations at risk of developing cardiovascular and/or metabolic disease. 
All of this should be with the aim of reducing obesity and its comorbidities in order to lessen 
the burden on healthcare services across the world. 
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8 Appendices 
8.1 Appendix A 
8.1.1 Establishing an adipocyte model 
8.1.2 Chemically-induced Differentiation of 3T3-L1 
3T3-L1 cells were seeded at approximately 3 x 103 cells per cm2 of the culture flask. The 
culture was subcultured before reaching 70% confluence using trypsin. Prior to 
differentiation pre-adipocyte expansion medium (PEM) was used to maintain the cells. PEM 
consists of DMEM supplemented with 10% foetal bovine serum (FBS) and 1% penicillin-
streptomycin. 
For differentiation the cells were subcultured and seeded into the appropriate vessels at the 
following densities: 
Table 8.1 Cell density used in different cell culture vessel 
Culture Vessel Cell Density 
6 well plate 8 x 104 cells per well 
96 well plate 2 x 103 cells per well 
 
Subcultures were maintained with PEM until reaching 100% confluence. The fully confluent 
cells were incubated for 48 hours, then the PEM was replaced with differentiation medium 
(DM) and incubated for a further 48 hours. DM consists of DMEM supplemented with 10% 
FBS, 1.0 µM dexamethasone, 0.5 mM methylisobutylxanthine, 1.0 µg/ml of bovine insulin 
and 1% penicillin-streptomycin. After 48 hours DM was replaced with adipocyte 
maintenance medium (AMM) and maintained as per the usual protocol. AMM consists of 
DMEM supplemented with 10% FBS, 1.0 µg/ml of bovine insulin and 1% penicillin-
streptomycin. The cells were incubated between 7 and 20 days until fully differentiated, as 
evidenced by the formation of lipid droplets. 
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8.1.3 Measurement of GLUT4 translocation 
The 3T3-L1 cells were serum starved overnight. They were trypsinised and seeded in to a 
24 well-plate at 1 x 105 cells/well in serum-free medium. The cells were placed into the 
incubator for 2 hours to recover from trypsinisation.  
5 µl of primary anti-GLUT4 was mixed with 1 µl of secondary goat anti-mouse IgG 
(conjugated to Alexa Fluor 488) for every well used. The antibodies were incubated in the 
dark, at room temperature for 10 minutes. A 2X working stock of insulin was prepared by 
diluting it in DMEM. 
6 µl of the antibody mix and 500 µl of insulin solution were added to each well. The well-
plates were then incubated in an incubator with 5% CO2 at 37°C for 30 minutes. Halfway 
through incubation 15 nM insulin solution was added to the positive samples. 
The cells were fixed by the addition of 500 µl of 1% paraformaldehyde/PBS solution to each 
well and incubated in the dark, at room temperature for 20 minutes. 
The cell suspension was transferred to 1.5 ml Eppendorf tubes and centrifuged at 1000 rpm 
for 5 minutes. The pellet was washed twice and recentrifuged at 1000 rpm for a further 5 
minutes each. After washing, the pellet was resuspended in 400 µl of 1% 
paraformaldehyde/PBS solution. The samples were run through the BD Accuri™ C6 flow 
cytometer and data was acquired from 10,000 events per tube.
  
8.1.4 Results from adipocytes 
This study was conducted to evaluate the differentiation of 3T3-L1 from fibroblasts into 
adipocytes following a differentiation procedure. GLUT4 translocation was tested to assess 
the feasibility of the differentiated cells as an adipocyte model for following research. 
Differentiation of 3T3-L1 from fibroblasts into adipocytes was attempted three times 
following the recommended ATCC chemically-induced differentiation procedure (2011). 
Twice the adherent cell layer detached due to the fragility of the cell line and a pH 
imbalance. The process reached completion on one attempt. Throughout the procedure 
differentiation was assessed via the formation of intracellular lipid droplets visualised by 
inverted microscopy. Following 20 days of differentiation, 5 more than the stated 
requirement, lipid droplets were only visibly apparent in ~50% of 3T3-L1 cells as evidenced 
by photographs (Figure 8.1). The effectiveness of differentiation was not in keeping with the 
reference material from ATCC (Figure 1d). This indicates incomplete differentiation from 
fibroblasts to adipocytes, as upwards of 85% of cells were expected to undergo the 
transformation. 
  
 
 
Figure 8.1 Progression of 3T3-L1 differentiation following treatment with 
differentiation and maintenance medium. 
a) Cells were subcultured into 6 well plates at approximately 30% confluence. b) After 3 
days cell reached 100% confluence and the differentiation process began. c) Intracellular 
lipid droplets were visible after 15 days of differentiation. d) An example of fully 
differentiated 3T3-L1 cells from ATCC (2011). 
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The success of differentiation was measured by GLUT4 translocation studies. The rationale 
behind this was that only cells sensitive to insulin, thereby causing GLUT4 translocation 
upon its presence, were fully differentiated and hence a feasible adipocyte model in this 
research. Results from these studies show GLUT4 translocation occurred in a maximum of 
6% of cells with no significant difference between basal and insulin-induced levels of 
GLUT4 translocation (P=0.8422) (Figure 8.2). Therefore, the differentiation process was 
ineffective, with the vast majority of cells not acquiring the insulin sensitive mechanisms of 
adipocytes, rendering the 3T3-L1 cells an inadequate adipocyte model for further 
investigations in this research. 
 
Figure 8.2 Insulin stimulation of differentiated 3T3-L1 cells caused no significant 
GLUT4 translocation. 
A maximum of 6% of cells exhibited GLUT4 translocation following insulin activation, with 
no significant difference between the negative and positive control (P=0.8422, n=3). 
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8.2 Appendix B 
 
Figure 8.3 Inverted microscope image of HepG2 clumping at 400x magnification 
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8.3 Appendix C 
8.3.1 Background of methods  
8.3.1.1 Cell Counting Kit 8  
A number of assays can be employed to assess the viability of cells including the Cell 
Counting Kit-8 (CCK-8), which measures the proportion of viable cells in a sample. CCK-8 
utilises a colourless, water-soluble tetrazolium salt-8 (WST-8), which is oxidised by 
intracellular NADH, NADPH and dehydrogenases to form an orange water-soluble WST-8 
formazan dye (Dojindo, 2009). Enzyme action only occurs in cells with their dehydrogenase 
activity intact, hence the correlation between absorbance at 450 nm and viable cells. A 
standard curve was obtained to check for the assay’s limits of detection. 
8.3.1.2 Flow cytometry theory 
Flow cytometry utilises fluidics, lasers, filters and detectors to measure a range of 
characteristics of individual cells. Flow cytometers employ hydrodynamic focusing to create 
a single file stream of cells by injecting them into the core of sheath fluid being pumped 
through a laminar flow chamber. This flow of single file cells is transported to the 
interrogation point, where the laser intersects the sample, causing light scatter and/or the 
excitation of fluorescence tagged antibodies, which is measured by different detectors 
(Figure 8.4). 
The two main characteristics measured by the detection of scattered light upon 
interrogation are cell size, measured by forward scatter (FSC), and cell granularity, 
measured by side scatter (SSC). However, these measurements are only reliable for 
regular shaped cells. In order to measure other characteristics, fluorescent dyes and 
fluorescently labelled antibodies against a target of interest can be incubated with cells prior 
to analysis to investigate the presence of specific antigens within the cell or on the cell 
surface. Lasers appropriate for the excitation wavelengths of the fluorophores being used 
are directed at cells passing through the interrogation point. Upon contact, the fluorophore 
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is excited and emits a different wavelength of light, which are measured separately to FSC 
and SSC by a range of detectors. 
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Figure 8.4 Representation of the internal workings of a flow cytometer 
Cells are passed single file through a laser beam at the interrogation point. Upon contact 
with the cell, light scatters based on the cell’s properties. Lasers are also able to excite 
fluorophores conjugated to bound antibodies, which emit different wavelengths of 
fluorescent light. 
 
Forward scattered light 
Side scattered light 
Fluorescence 
Laser light 
source 
Interrogation 
point 
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8.3.1.3 Light transmission aggregometry theory 
First described by Born (1962), light transmission aggregometry (LTA) is now the ‘gold 
standard’ technique for in vitro platelet function testing. LTA is a turbidimetric assay that 
measures the decrease in intensity of transmitted light due to the scattering effect of 
particles suspended in the solution. The technique relies on platelets being distributed 
evenly throughout the suspension, forming an optically dense medium that significantly 
refracts the passage of light (Figure 8.5A). This enables a suspension of resting platelets to 
be set as a representative of 0% aggregation and platelet-free CFT to represent 100% 
aggregation (ie. full light transmission as all platelets are assumed to be aggregated). 
 
Washed platelet preparation is dispensed into a glass cuvette and placed into the 
aggregometer, where it rests between a light source and a photometer, under stirring 
conditions at 37°C. Upon the addition of an agonist, platelet activation is initiated and they 
undergo rapid cytoskeletal reorganisation causing the extension of filopodia and 
lamellipodia, resulting in a dramatic increase in surface area, otherwise referred to as 
platelet shape change. This shape change causes an increase in turbidity due to the 
increased surface area of the platelets, which results in a decrease in light transmission 
from the resting platelet baseline (Figure 8.5B). After shape change, activatory signalling 
continues via a number of different pathways until integrin ɑIIbβ3 receptors on the platelet 
surface are activated to a high-affinity state. Active integrin ɑIIbβ3 binds fibrinogen released 
from α-granules of other activated platelets. As fibrinogen can bind to two activated integrin 
receptors simultaneously, this leads to a cascade of platelet binding that initially forms 
microaggregates, and later forms macroaggregates. As aggregates start to form, the 
turbidity of the platelet suspension decreases, allowing increased light transmission through 
the sample. Therefore, following an initial dip in light transmission, it increases past 0% 
towards 100%, with the rate of aggregation and maximal aggregation being influenced by 
the potency of the agonist. The photometer measures the amount of light transmitted 
through the platelet suspension periodically, and the computer software plots this data on a 
graph, otherwise known as an aggregation trace (Figure 2.11B).  
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The formation of platelet aggregates upon stimulation transforms the solution from one 
containing a vast number of small particles to one containing a smaller number of larger 
particles. This increases the space between particles, thus, light transmission increases 
(Cardinal & Flower, 1980; Cattaneo, et al., 2012). As the platelets form larger and larger 
aggregates, the space between them continues to increase, thereby, allowing greater and 
greater transmission of light through the solution. When agonist stimulated sample is 
compared to the platelet-free CFT sample, there is a correlation between the amount of 
light transmission and the extent of platelets aggregation.  
The potency of the agonist dictates which of three types of aggregation the platelets 
undergo. Weak agonists induce primary aggregation, which is reversible, allowing platelets 
to return back to a resting state. Stronger agonists can evoke either biphasic or secondary 
wave of aggregation, both of which are irreversible and result from the release of mediators 
of secondary signalling, however, there is a lag between primary and secondary signalling 
in biphasic aggregation. Biphasic aggregation may be caused by agonists with medium 
potency. The representative trace in Figure 2.11B is biphasic. 
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Figure 8.5 Light transmission aggregometry of washed platelets 
A) An illustration of aggregation of washed platelets in an aggregometer. B) Aggregation 
trace of biphasic aggregation with an explanation of trace analysis. Upon addition of an 
agonist, platelets undergo shape change that increases turbidity, before a rapid decrease in 
turbidity as a result of platelet activation. 
 
8.3.1.4 Lactate dehydrogenase assay theory 
Lactate dehydrogenase (LDH) is a stable oxidoreductase enzyme present in nearly all living 
cells that is released upon damage to the plasma membranes. The LDH assay determines 
LDH activity via a two-step enzymatic reaction (Figure 8.6). Firstly, LDH catalyses the 
 
 
420 
 
oxidation of lactate to pyruvate while reducing NAD+ to NADH and H+. Then, diaphorase 
uses NADH and H+ to catalyse the reduction of the tetrazolium salt to a formazan dye, 
which changes colour from pale yellow to red. The magnitude of this reaction depends on 
the quantity of LDH released, which is proportional to the quantity of cells with damaged 
plasma membranes. The formazan salt is water-soluble with a broad absorbance spectrum 
and maxima at 500 nm, whereas the tetrazolium salt produces minimal absorbance at 
these wavelengths, making it ideal for experimental use (abcam, 2016; Cayman chemical, 
2012; Thermo Scientific, 2016).  
 
Figure 8.6 Diagram of reactions involved in the LDH assay 
Cellular damage releases LDH which catalyses the production of NADH and H+, which are 
used in the production of a formazan dye. The absorbance of this dye is proportional to 
LDH release. 
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8.4 Appendix D 
 
 
 
Figure 8.7 Loss of HepG2 viability following treatment with fatty acids upto 3 mM 
 
Figure 8.8 Loss of L6 viability following treatment with fatty acids upto 3 mM 
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8.5 Appendix E 
8.5.1 Molar percentage of palmitic acid and oleic acid in phospholipids 
between control participants and subjects with cancer  
This research studied the average molar percentage of palmitic acid and oleic acid in 
phospholipids between control participants and subjects with cancer across 4 studies, 
n=540 and n=379, respectively. 
The meta-analysis (Table 8.2 and 8.3) demonstrated that there were no significant 
differences in the molar percentages of palmitic acid and oleic acid in plasma phospholipids 
in cancer patients versus the control group (p=0.22 and 0.94, respectively). 
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Table 8.2 Palmitic acid in phospholipids (mol%) - control vs. cancer 
 
Chi2 =56.36 was far larger than the degrees of freedom (3), which suggested significant heterogeneity. However, Chi2 was unreliable due to the small number 
of studies included. I2 =95% estimated very high levels of variability amongst study results. Tau2 =0.99 was very close to 1, which confers definite 
heterogeneity. Therefore, between-study variance was present and a random-effects model was chosen. 
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Table 8.3 Oleic acid in phospholipids (mol%) - control vs. cancer 
 
Chi2 =4.05 was far greater than the degrees of freedom (3), and, thus, suggested between-study variance. However, the result was unreliable as number of 
studies included was too small to produce reliable results. I2 =26% predicted moderate variability amongst study results. However, Tau2 =0.02 was fairly small. 
However, when analysed in combination, the results showed the heterogeneity within the study that required the use of a random-effects model. 
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8.6 Appendix F 
Table 8.4 Full list of search terms 
Search terms 
fatty acids, FA, free fatty acids, FFA, non-esterified fatty acids, NEFA, palmitic acid, 
oleic acid, plasma, serum, phospholipids, PL, cholesterol esters, CE, triglycerides,TG, 
triacylglycerol, TAG, circulating, composition, fractions, levels, concentrations, 
percentages, proportions 
 
A combination of theses search terms were used to find studies for this project 
 
Table 8.5 Plasma triglyceride data 
 Study n 
TAG 
(mmol/L) SD 
1 Yli-Jama, et al., 2002 103 1.74 0.67 
2 Yli-Jama, et al., 2002 104 1.39 0.58 
3 Baylin, et al., 2005 99 1.21 0.65 
4 Baylin, et al., 2005 101 1.21 0.62 
5 Forsythe, et al., 2008  20 2.38 0.65427 
6 Forsythe, et al., 2008  20 2.11 0.65088 
7 Rise, et al., 2007 10 0.79 0.23617 
8 Ebbesson, et al., 2015 419 1.51 0.87914 
9 Ebbesson, et al., 2015 337 1.42 0.80004 
10 Fernandez-Real, et al., 2005 76 1.33 0.791 
11 Fernandez-Real, et al., 2005 40 0.79 0.2712 
12 Itakura, et al., 2010 8076 2.15 0.17402 
13 Kim et al., 2013 159 0.97 0.23 
14 Kim et al., 2013 331 1.51 0.35 
15 Kim et al., 2013 103 2.33 0.85 
16 Jouven, et al., 2001 91 1.69 1.3673 
17 Jouven, et al., 2001 145 1.59 1.3221 
18 Jouven, et al., 2001 5014 1.41 1.1639 
19 Raatz, et al., 2001 8 1.57 0.32 
20 Raatz, et al., 2001 8 0.91 0.18 
21 Talreja, et al., 2014 76 1.15 0.678 
22 Mayneris-Perxachs et al., 2014 112 0.98 0.37742 
23 Khaw, et al., 2012 1595 2.22 1.23 
24 Khaw, et al., 2012 2246 2.01 1.15 
25 Khaw, et al., 2012 776 2.1 1.15 
26 Khaw, et al., 2012 2684 1.64 1.07 
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27 Yamagishi, et al., 2008 1667 1.57 1.0622 
28 Yamagishi, et al., 2008 1908 1.31 0.8249 
29 Glew, et al., 2010 22 1.03 0.3955 
30 Glew, et al., 2010 29 1.13 0.5085 
31 Lee, et al., 2000 60 1.13 0.53 
32 Lee, et al., 2000 133 1.05 0.58 
33 Kuriki, et al., 2003 15 1.09 0.44 
34 Kuriki, et al., 2003 79 0.89 0.43 
35 Vognild, et al., 1998 124 1.1 0.1 
36 Vognild, et al., 1998 149 1.5 0.1 
37 Vicario, et al., 1998 10 0.96 0.9486832981 
38 Simon, et al., 1996 156 2.19 1.83 
39 Ferdandz-Real, et al., 2003 64 1.1 0.5085 
40 Ferdandz-Real, et al., 2003 70 1.59 0.9831 
41 Yerlikaya, et al., 2011 45 1.02 0.50285 
42 Tholstrup, et al., 2004 17 0.8 0.3 
43 Woods, et al., 2009 13 0.79 0.29493 
44 Woods, et al., 2009 18 1.88 1.0848 
45 Kawashima, et al., 2009 27 1.08 0.5198 
46 Kawashima, et al., 2009 43 1.59 0.6215 
47 Kim, et al., 2010 30 1.65 0.6870084039 
48 Jocken, et al., 2008 13 0.701 0.2379663842 
49 Jocken, et al., 2008 10 0.648 0.1328156617 
50 Buemann, et al., 2006 269 1.41 0.87 
51 Buemann, et al., 2006 174 1.91 1.55 
52 Wuesten, et al., 2005 17 1.06 0.6 
53 Wuesten, et al., 2005 16 1.66 0.99 
54 Abdelmagid, et al., 2015 327 1 0.5 
55 Abdelmagid, et al., 2015 499 0.8 0.3 
56 Chrisholm, et al., 1998 21 1.91 0.75 
57 Manning, et al., 2008 15 1.45 0.75 
58 Manning, et al., 2008 14 1.07 0.42 
59 Pollare, et al., 1991  7 1.42 0.59 
60 Pollare, et al., 1991  7 2.14 1.51 
61 van der Merwe, et al., 2001 10 0.7 0.06 
62 van der Merwe, et al., 2001 10 1.1 0.4110960958 
63 Frias, et al., 2000 9 1.9 0.93 
64 Frias, et al., 2000 9 1.11 0.24 
65 Goodpaster, et al., 2002 7 1.26 0.476235236 
66 Goodpaster, et al., 2002 7 1.99 1.243503116 
67 Stefan, et al., 2008 54 1.08 0.4409081537 
68 Stefan, et al., 2008 133 1.38 1.037930634 
69 Stefan, et al., 2008 31 1.6 1.893039883 
70 Sundell, et al., 2003 10 1.3 0.7 
71 Sundell, et al., 2003 10 1.1 0.5 
72 Ranganath, et al., 1999 7 1.99 1.322875656 
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73 Ranganath, et al., 1999 7 1.03 0.6878953409 
74 Stojiljkovic, et al., 2002 10 3.5 3.794733192 
75 Vanttinen, et al., 2005  72 1.03 0.54 
76 Vanttinen, et al., 2005  52 1.34 0.94 
77 de Jongh, et al., 2004  16 0.8 0.3 
78 de Jongh, et al., 2004  12 1.4 0.8 
79 Kruszynska, et al., 2003  15 0.95 0.3872983346 
80 Kruszynska, et al., 2003  15 2.06 1.00697567 
81 Riedel, et al., 1995  5 1.86 1.25 
82 Riedel, et al., 1995  5 1.93 0.48 
83 Manco, et al., 2004 5 1.1 0.2236067977 
84 Manco, et al., 2004 5 1.55 0.201246118 
85 Straczkowski, et al., 2006 33 1.02 0.52 
86 Straczkowski, et al., 2006 30 1.64 0.93 
87 Laaksonen, et al., 2002 806 1.17 0.21 
88 Vessby, et al., 1994 1753 2.06 1.14 
89 Kashyap, et al., 2003 8 1.38 0.24 
90 Kashyap, et al., 2003 13 1.28 0.11 
91 Carpentier, et al., 2000 7 1.17 0.4233202098 
92 Ferrannini, et al., 1993 6 1.08 0.6 
93 Diraison, et al., 2003 6 0.85 0.171464282 
94 Grundy, et al., 1986 11 1.9 0.6633249581 
95 Friday, et al., 1989 8 2.29 0.3111269837 
96 Tripathy, et al., 2003 10 0.85 0.18 
97 Kelley, et al., 2004 17 2.33 0.29 
98 Kelley, et al., 2004 22 1.85 0.16 
99 Herrero, et al., 2006 11 1.5 0.69 
100 Svanborg, et al., 2009 30 0.94 0.39 
101 Abbey, et al., 1994 16 1.41 0.52 
102 Judd, et al., 1994 29 1.26 0.655 
103 Judd, et al., 1994 29 1.34 0.802 
104 Ramirez-Tortosa, et al., 2010 30 1.63 0.876356092 
105 Ramirez-Tortosa, et al., 2010 26 1.04 0.6628725368 
106 De Almeida, et al., 2002 6 0.8 0.4 
107 Jacobsen, et al., 1983 22 2.16 0.775 
108 Jacobsen, et al., 1983 20 2.31 0.66 
109 Ducimetiere, et al., 1980 7246 1.23 1.16 
110 DeFronzo and Goodman, 1995 146 2.09 1.208304597 
111 Couillard, et al., 2001 62 0.94 0.22 
112 Drexel, et al., 1994 105 1.51 1.024695077 
113 Schaefer, et al., 1978 1088 0.98 0.49 
114 Hotta, et al., 2000 54 1.76 1.763632615 
115 Hotta, et al., 2000 28 1.31 0.7408103671 
116 Chen, et al., 2006 59 1.3 0.8 
117 Rijzewijk, et al., 2008 28 1 0.6614378278 
118 Isomaa, et al., 2001 1988 1.29 0.8 
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119 Liu, et al., 2013 60 1.17 0.69 
120 Nappo, et al., 2002 20 0.8 0.2 
121 Prior, et al., 2005 19 0.75 0.3 
122 Brancati, et al., 2000 1316 1.08 0.7255342859 
123 Brancati, et al., 2000 4621 1.29 0.679779376 
124 Pirro, et al., 2002 98 1.7 0.66 
125 Logan, et al., 1978 107 1.82 1.06 
126 Logan, et al., 1978 82 1.28 0.67 
127 Després, et al., 1990 25 0.79 0.35 
128 Després, et al., 1990 10 1.47 0.79 
129 Després, et al., 1990 10 2.57 2.41 
130 Esposito, et al., 2003 60 1.6 0.5 
131 Esposito, et al., 2003 60 1.6 0.6 
132 Bonanome and Grundy, 1988 11 1.64 0.4974937186 
133 Vessby, et al., 1994b 215 1.45 0.9 
134 Salomaa, et al., 1990 325 1.5 0.84 
135 Miettinen, et al., 1982 64 1.9 0.8 
136 Harper, et al., 2006 27 1.5 0.4 
137 Harper, et al., 2006 22 1.4 0.4 
138 Baer, et al., 2004 50 1.149 0.5727564928 
139 Öhrvall, et al., 1996 1836 2.03 1.14 
     
  
n= 
52128 
Average = 
1.424158273  
     
   
Weighted 
average = 
1.577840757  
 
Table 8.6 Plasma FFA data 
 Study n 
FFA 
(µmol/L) SD 
1 Sundell, et al., 2003  10 610 948.6832981 
2 Sundell, et al., 2003  10 500 474.341649 
3 Ranganath, et al., 1999  7 575 158.7450787 
4 Ranganath, et al., 1999  7 720 142.8705708 
5 Stefan, et al., 2008  54 710 238.3843418 
6 Stefan, et al., 2008  164 645 276.9991545 
7 Stojiljkovic, et al., 2002 12 707 207.8460969 
8 Stojiljkovic, et al., 2002 10 669 290.9295447 
9 Jocken, et al., 2008 13 661 147.8276023 
10 Jocken, et al., 2008 10 638 132.8156617 
11 Pincelli, et al., 2001 6 433.6 164.8751546 
12 Pincelli, et al., 2001 10 703.7 187.1435919 
13 Reyna, et al., 2008  7 351 97.89279851 
 
 
429 
 
14 Reyna, et al., 2008  8 479 166.8772004 
15 Mari, et al., 2006  22 230 60 
16 Mari, et al., 2006  12 410 90 
17 Manco, et al., 2004 5 540 156.5247584 
18 Manco, et al., 2004 5 580 156.5247584 
19 Buemann, et al., 2006  269 359 142 
20 Buemann, et al., 2006  174 393 161 
21 Owen, et al., 1992 5 402 138.6362146 
22 Owen, et al., 1992 5 495 125.2198067 
23 Wuesten, et al., 2005  17 540 250 
24 Wuesten, et al., 2005  16 460 150 
25 Vanttinen, et al., 2005  72 530 190 
26 Vanttinen, et al., 2005  52 630 220 
27 de Jongh, et al., 2004  16 550 190 
28 de Jongh, et al., 2004  12 690 210 
29 Iannello, et al., 1998 10 373 139.140217 
30 Iannello, et al., 1998 25 721 260 
31 Adams, et al., 2004 10 621 22.13594362 
32 Adams, et al., 2004 10 860 22.13594362 
33 Kruszynska, et al., 2003  15 445 209.1411007 
34 Kruszynska, et al., 2003  15 404 170.4112672 
35 Horton, et al., 1995  9 320.8 140.55 
36 Horton, et al., 1995  7 299.1 143.0293159 
37 Goodpaster, et al., 2002  7 474 132.2875656 
38 Goodpaster, et al., 2002  7 599 171.9738352 
39 Allick, et al., 2004  6 540 97.97958971 
40 Allick, et al., 2004  6 650 171.464282 
41 Golay, et al., 2002  15 630 174.2842506 
42 Golay, et al., 2002  12 732 214.7743001 
43 Soriguer, et al., 2008 12 315 103.9230485 
44 Soriguer, et al., 2008 9 605 147 
45 Gautier, et al., 2000 11 920 340 
46 Gautier, et al., 2000 11 640 360 
47 Straczkowski, et al., 2006  33 347 116 
48 Straczkowski, et al., 2006  30 504 155 
49 Belfiore, et al., 2001  34 359 216.1533867 
50 Belfiore, et al., 2001  27 713 242.6083566 
51 Reeds, et al., 2006  5 408 162.1149284 
52 Reeds, et al., 2006  5 383 103.7535542 
53 Frias, et al., 2000  9 240 0.15 
54 Frias, et al., 2000  9 360 0.24 
55 Morin‐Papunen, et al.,2000  17 460 907.0832376 
56 Morin‐Papunen, et al.,2000  17 550 948.3142939 
57 Jansson, et al., 1998 15 494 174.2842506 
58 Jansson, et al., 1998 9 696 153 
59 Sbraccia, et al., 2002 10 223 51.86135363 
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60 Sbraccia, et al., 2002 14 738 277.6309781 
61 Solini, et al., 1997  9 575 111 
62 Solini, et al., 1997  11 728 102.8153685 
63 Macor, et al., 1997  9 434 105 
64 Macor, et al., 1997  26 747 229.4558781 
65 Paquot, et al., 2002  10 430 411.0960958 
66 Paquot, et al., 2002  6 850 489.8979486 
67 Riedel, et al., 1995  5 940 210 
68 Riedel, et al., 1995  5 920 170 
69 van der Merwe, et al., 2001  10 463 151.7893277 
70 van der Merwe, et al., 2001  10 870 132.8156617 
71 Groop, et al., 1992 11 642 129.3483668 
72 Groop, et al., 1992 7 793 113.7673064 
73 Robertson, et al., 1992  14 770 190 
74 Robertson, et al., 1992  16 970 210 
75 Manning, et al., 2008 14 410 19 
76 Manning, et al., 2008 15 420 14 
77 Pollare, et al., 1991  7 410 180 
78 Pollare, et al., 1991  7 500 140 
79 Yli-Jama, et al., 2002 103 420 370 
80 Yli-Jama, et al., 2002 104 380 280 
81 Smedman, et al., 1999 62 500 170 
82 Mougios, et al., 2003 13 303 53 
83 Jouven, et al., 2001 91 384 334 
84 Jouven, et al., 2001 145 310 123 
85 Jouven, et al., 2001 5014 313 144 
86 Lopes, et al., 1991 12 435 11 
87 Hagenfeldt, 1971 25 640 239 
88 Kim, et al., 2010 30 618.2 38.3 
89 Abdelmagid, et al., 2012 327 457.5 252.5 
90 Abdelmagid, et al., 2012 499 485.9 250.8 
91 Gautier, et al., 2001 10 990 250 
92 Gautier, et al., 2001 12 850 130 
93 Kashyap, et al., 2003 8 607 243.2447327 
94 Kashyap, et al., 2003 13 575 169.4609099 
95 Boden, et al., 1998 7 597 222.2431101 
96 Santomauro, et al., 1999 9 329 84 
97 Santomauro, et al., 1999 13 560 187.4886663 
98 Blaak, et al., 2000 8 724 66 
99 Carpentier, et al., 2000 7 510 185.2025918 
100 Ferrannini, et al., 1993 6 670 80 
101 Diraison, et al., 2003 6 426 107.7775487 
102 Diraison, et al., 2003 5 608 116.2755348 
103 Fraze, et al., 1985 15 306 81.33265027 
104 Tripathy, et al., 2003 10 352 62 
105 Chen, et al., 1987 6 572 108 
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106 Chen, et al., 1987 6 782 184 
107 Kelley, et al., 2004 17 691 98.95453501 
108 Kelley, et al., 2004 22 705 164.1645516 
109 Cusi, et al., 2007 9 498 84 
110 Mensink, et al., 2001 7 727 182.5568405 
111 Swislocki, et al., 1987 6 533 36.74234614 
112 Svanborg, et al., 2009 47 750 233 
113 Svanborg, et al., 2009 15 781 174 
114 Rich, et al., 1959 7 855 243 
115 Felber, et al., 1987 6 580 134.7219359 
116 Felber, et al., 1987 9 383 78 
117 Felber, et al., 1987 7 575 259.2836285 
118 Rijzewijk, et al., 2008 28 450 211.6601049 
119 Prior, et al., 2005 19 620 95.89577676 
120 Pirro, et al., 2002 98 750 280 
121 Esposito, et al., 2003 60 581 102 
122 Esposito, et al., 2003 60 562 0.6 
123 Carlsten, et al., 2009 9 854 205.5 
124 Vessby, et al., 1994b 215 500 180 
125 Xiao, et al., 2006 7 460 211.6601049 
     
  
n= 
8847 
Average = 
562.1344  
     
   
Weighted 
average = 
397.8530688  
 
Table 8.7 Palmitic acid in phospholipids (mol%) data 
 Study n 
Palmitic acid in 
phospholipids 
(mol%) SD 
1 Bradbury, et al., 2011 2416 31.73 4.22 
2 Clemmesen, et al., 2000 11 31.5 2 
3 Forouhi, et al., 2014 15164 29.93 1.74 
4 Raatz, et al., 2001 10 27.32 0.64 
5 Raatz, et al., 2001 10 25.26 0.62 
6 Clarke, et al., 2009 239 29.1 1.3 
7 Skeaff, et al., 2006 19 33.14 1.54 
8 Saadatian-Elahi, et al., 2009 91 25.2 1.4 
9 Saadatian-Elahi, et al., 2009 100 23.8 1.7 
10 Saadatian-Elahi, et al., 2009 93 24.7 1.6 
11 Saadatian-Elahi, et al., 2009 100 22.8 1.5 
12 Saadatian-Elahi, et al., 2009 96 25 1.4 
13 Saadatian-Elahi, et al., 2009 100 22.8 1.6 
14 Saadatian-Elahi, et al., 2009 94 25.2 1.8 
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15 Saadatian-Elahi, et al., 2009 100 23.1 1.8 
16 Saadatian-Elahi, et al., 2009 90 26.1 1.7 
17 Saadatian-Elahi, et al., 2009 99 24 1.7 
18 Saadatian-Elahi, et al., 2009 94 25.9 1.3 
19 Saadatian-Elahi, et al., 2009 99 24.5 1.7 
20 Saadatian-Elahi, et al., 2009 96 25.5 1.3 
21 Saadatian-Elahi, et al., 2009 100 24.6 1.5 
22 Saadatian-Elahi, et al., 2009 96 24.8 1.9 
23 Saadatian-Elahi, et al., 2009 95 26.4 1.6 
24 Saadatian-Elahi, et al., 2009 96 25.6 1.4 
25 Saadatian-Elahi, et al., 2009 96 26.5 1.6 
26 Saadatian-Elahi, et al., 2009 99 25.3 2.2 
27 Saadatian-Elahi, et al., 2009 95 26.1 2 
28 Saadatian-Elahi, et al., 2009 100 24.6 1.9 
29 Saadatian-Elahi, et al., 2009 95 25.8 1.4 
30 Saadatian-Elahi, et al., 2009 100 24.9 2.1 
31 Saadatian-Elahi, et al., 2009 95 24.2 2.2 
32 Saadatian-Elahi, et al., 2009 100 22 2.1 
33 Saadatian-Elahi, et al., 2009 96 26.9 1.6 
34 Saadatian-Elahi, et al., 2009 100 25.1 1.9 
35 Saadatian-Elahi, et al., 2009 100 25.5 1.6 
36 Saadatian-Elahi, et al., 2009 95 26.3 1.8 
37 Saadatian-Elahi, et al., 2009 94 26.6 1.5 
38 Saadatian-Elahi, et al., 2009 99 25.3 1.6 
39 Kim, et al., 2013 159 31.858 0.415 
40 Kim, et al., 2013 331 32.544 0.29 
41 Kim, et al., 2013 103 33.235 0.519 
42 Hodge, et al., 2007 3391 25.23 1.54 
43 Hodge, et al., 2007 346 25.24 1.44 
44 Yeh et al., 1994 104 37 0.44 
45 Simon, et al., 1996 156 28.12 1.77 
46 Harvei, et al., 1997 282 26.1 1.46 
47 Harvei, et al., 1997 141 27.9 2.36 
48 Vicario, et al., 1998 10 29.75 0.41 
49 Agren, et al., 1995 8 28.4 1.4 
50 Agren, et al., 1995 11 30.3 1.7 
51 Okuno, et al., 2013 61 29.69 1.73 
52 Lopes, et al., 1991 12 24.7 0.72 
53 Thiebaut, et al., 2009 1114 25.1 1.66 
54 Saadatian-Elahi, et al., 2002 91 25.1 1.6 
55 Saadatian-Elahi, et al., 2002 106 25 1.3 
56 Saadatian-Elahi, et al., 2002 91 24.9 1.5 
57 Saadatian-Elahi, et al., 2002 106 24.9 1.6 
58 Yamagishi, et al., 2008 3575 25.41 1.64 
59 Zeleniuch-Jacquotte, et al., 2000 46 24.04 1.63 
60 Nikkari, et al., 1995 41 28.4 1.77 
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61 Nikkari, et al., 1995 41 28.25 1.33 
62 Sabel, et al., 2009 30 34.1 1.3 
63 Kim, et al., 2010 30 34.6 
2.464751
509 
64 Woods, et al., 2009 13 36.5 3.6 
65 Woods, et al., 2009 18 34.4 2.7 
66 Wang, et al., 2003 2657 25.3 1.6 
67 Patel, et al., 2010 184 26.84 0.87 
68 Folsom, et al., 1996 3403 25.4 1.6 
69 Ma, et al., 1995 1712 25.5 1.6 
70 Ma, et al., 1995 1858 25.3 1.7 
71 Caren and Corbo, 1966 20 32.4 
4.919349
55 
72 Manku, et al., 1984 60 25.89 1.69 
73 Manku, et al., 1984 41 30.14 1.86 
74 Miettinen, et al., 1982 64 35.17 2.24 
     
  
n= 
41288 
Average = 
27.24036486  
     
   
Weighted 
average = 
27.61610761  
 
Table 8.8 Oleic acid in phospholipids (mol%) data 
 Study n 
Oleic acid in 
phospholipids 
(mol%) SD 
1 Bradbury, et al., 2011 2416 6.53 2.51 
2 Clemmesen, et al., 2000 11 6.699 1.1 
3 Raatz, et al., 2001 10 7.003 0.36 
4 Raatz, et al., 2001 10 7.269 0.27 
5 Clarke, et al., 2009 239 7.73 2.1 
6 Skeaff, et al., 2006 19 8.14 0.86 
7 Saadatian-Elahi, et al., 2009 91 8.5 2.1 
8 Saadatian-Elahi, et al., 2009 100 8.59 2.4 
9 Saadatian-Elahi, et al., 2009 93 8.6 2.1 
10 Saadatian-Elahi, et al., 2009 100 8.6 2 
11 Saadatian-Elahi, et al., 2009 96 8.6 2.2 
12 Saadatian-Elahi, et al., 2009 100 8.6 2.3 
13 Saadatian-Elahi, et al., 2009 94 8.66 2.3 
14 Saadatian-Elahi, et al., 2009 100 8.67 2.3 
15 Saadatian-Elahi, et al., 2009 90 8.7 2 
16 Saadatian-Elahi, et al., 2009 99 8.7 1.8 
17 Saadatian-Elahi, et al., 2009 94 9.3 1.5 
18 Saadatian-Elahi, et al., 2009 99 9.4 2 
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19 Saadatian-Elahi, et al., 2009 96 9.4 1.8 
20 Saadatian-Elahi, et al., 2009 100 9.5 1.5 
21 Saadatian-Elahi, et al., 2009 96 9.6 1.5 
22 Saadatian-Elahi, et al., 2009 95 9.6 1.4 
23 Saadatian-Elahi, et al., 2009 96 9.6 1.4 
24 Saadatian-Elahi, et al., 2009 96 9.69 1.6 
25 Saadatian-Elahi, et al., 2009 99 9.8 1.4 
26 Saadatian-Elahi, et al., 2009 95 10 1.8 
27 Saadatian-Elahi, et al., 2009 100 10 1.4 
28 Saadatian-Elahi, et al., 2009 95 10 1.4 
29 Saadatian-Elahi, et al., 2009 100 10 1.4 
30 Saadatian-Elahi, et al., 2009 95 10.1 1.6 
31 Saadatian-Elahi, et al., 2009 100 10.1 1.5 
32 Saadatian-Elahi, et al., 2009 96 10.15 1.7 
33 Saadatian-Elahi, et al., 2009 100 10.3 1.3 
34 Saadatian-Elahi, et al., 2009 100 10.3 1.3 
35 Saadatian-Elahi, et al., 2009 95 10.3 1.3 
36 Saadatian-Elahi, et al., 2009 94 10.4 1.2 
37 Saadatian-Elahi, et al., 2009 99 10.4 1.4 
38 Kim, et al., 2013 159 10.4 0.147 
39 Kim, et al., 2013 331 10.4 0.095 
40 Kim, et al., 2013 103 10.5 0.159 
41 Hodge, et al., 2007 3391 10.6 1.48 
42 Hodge, et al., 2007 346 10.6 1.51 
43 Yeh et al., 1994 104 10.9 1.8 
44 Simon, et al., 1996 156 11 1.99 
45 Harvei, et al., 1997 282 11.16 1.6 
46 Harvei, et al., 1997 141 11.2 1.78 
47 Vicario, et al., 1998 10 11.2 0.24 
48 Agren, et al., 1995 8 11.2 1.5 
49 Agren, et al., 1995 11 11.2 0.8 
50 Okuno, et al., 2013 61 11.4 1.35 
51 Lopes, et al., 1991 12 11.44 0.29 
52 Thiebaut, et al., 2009 1114 11.47 1.45 
53 Saadatian-Elahi, et al., 2002 91 11.5 1.7 
54 Saadatian-Elahi, et al., 2002 106 11.5 1.1 
55 Saadatian-Elahi, et al., 2002 91 11.5 1 
56 Saadatian-Elahi, et al., 2002 106 11.5 1.4 
57 Yamagishi, et al., 2008 3575 11.5 1.17 
58 Zeleniuch-Jacquotte, et al., 2000 46 11.7 1.6 
59 Nikkari, et al., 1995 41 12 1.38 
60 Nikkari, et al., 1995 41 12.1 1.12 
61 Sabel, et al., 2009 30 12.14 1.2 
62 Kim, et al., 2010 30 12.2 
0.51107
72936 
63 Woods, et al., 2009 13 12.48 1.7 
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64 Woods, et al., 2009 18 12.6 2.4 
65 Wang, et al., 2003 2657 12.6 1.17 
66 Patel, et al., 2010 184 12.7 0.5275 
67 Folsom, et al., 1996 3403 13 1.2 
68 Ma, et al., 1995 1712 13.2 1.2 
69 Ma, et al., 1995 1858 13.5 1.2 
70 Caren and Corbo, 1966 20 13.53 
2.23606
7977 
71 Manku, et al., 1984 60 14.11 2.21 
72 Manku, et al., 1984 41 15.65 1.31 
73 Miettinen, et al., 1982 64 17.52 2.4 
     
  
n= 
26124 
Average = 
10.5579589  
     
   
Weighted 
average = 
11.20448434   
 
Table 8.9 Palmitic acid in phospholipids (mass%) data 
 Study n 
Palmitic acid in 
phospholipids 
(mass%) SD 
1 Glew, et al., 2010 22 30.1 1.95 
2 Glew, et al., 2010 29 30.2 1.86 
3 Hjartaker, et al., 1997 234 25.61 1.21 
4 Conquer, et al., 2000 19 27.9 0.4 
5 Dyerberg, 1968 12 25.9 1.7 
     
  
n= 
316 
Average =  
27.942  
     
   
Weighted 
average = 
26.49253165  
 
Table 8.10 Palmitic acid in phospholipids (mg/L) data 
 Study n 
Palmitic acid in 
phospholipids 
(mg/L) SD 
1 Durieu, et al., 2007 29 222.86 45.29 
2 Schwertner and mosser, 1993 12 1485 212 
3 Forsythe, et al., 2008 20 266.2 16.4 
4 Forsythe, et al., 2008 20 264.6 15.9 
5 Yeh, et al., 1994 104 368 83 
6 Harvei, et al., 1997 423 353.1 66.8 
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7 Hjartaker, et al., 1997 234 311.76 54.37 
8 Cunnane, et al., 2012 10 380 98 
9 Begin, et al., 1989 49 586 142 
     
  
n= 
901 
Average = 
470.8355556  
     
   
Weighted 
average = 
364.0378246   
 
Table 8.11 Palmitic acid in phospholipids (mmol/L) data 
 Study n 
Palmitic acid in 
phospholipids 
(mmol/L) SD 
1 Lopes, et al., 1991 12 0.424 
0.08660
254038 
2 Thiebaut, et al., 2009 1114 0.9577 0.2575 
3 Khaw, et al., 2012 7354 1.256 0.3323 
     
  
n= 
8480 
Average = 
0.8792333333  
     
   
Weighted 
average = 
1.21563559   
 
Table 8.12 Oleic acid in phospholipids (mass%) data 
 Study n 
Oleic acid in 
phospholipids 
(mass%) SD 
1 Glew, et al., 2010 22 10.4 1.36 
2 Glew, et al., 2010 29 9.7 1.13 
3 Hjartaker, et al., 1997 234 9.3 1.23 
4 Conquer, et al., 2000 19 12.5 0.4 
5 Dyerberg, 1968 12 13.4 1.2 
     
  
n= 
316 
Average =  
11.06  
     
   
Weighted 
average = 
9.761392405  
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Table 8.13 Oleic acid in phospholipids (mg/L) data 
 Study n 
Oleic acid in 
phospholipids 
(mg/L) SD 
1 Durieu, et al., 2007 29 100.14 24.7 
2 Schwertner and mosser, 1993 12 761 87 
3 Forsythe, et al., 2008 20 109.5 16 
4 Forsythe, et al., 2008 20 113.8 9.4 
5 Yeh, et al., 1994 104 105 34 
6 Harvei, et al., 1997 423 131.1 36.5 
7 Hjartaker, et al., 1997 234 113.36 25.68 
8 Cunnane, et al., 2012 10 137 20 
9 Begin, et al., 1989 49 274 72 
     
  
n= 
901 
Average = 
204.9888889  
     
   
Weighted 
average = 
137.8463929   
 
Table 8.14 Oleic acid in phospholipids (mmol/L) data 
 Study n 
Oleic acid in 
phospholipids 
(mmol/L) SD 
1 Lopes, et al., 1991 12 0.267 
0.03464
101615 
2 
3 Khaw, et al., 2012 7354 0.474 0.1849 
     
  
n= 
8480 
Average = 
0.3916666667  
     
   
Weighted 
average = 
0.4684523585  
 
Table 8.15 Palmitic acid in cholesterol esters (mol%) data 
 Study n 
Palmitic acid in 
cholesterol 
esters (mol%) SD 
1 Bradbury, et al., 2011 2393 12.12 2.86 
2 Raatz, et al., 2001 9 11.03 0.24 
3 Raatz, et al., 2001 9 10.01 0.27 
4 Skeaff, et al., 2006 19 11.23 0.97 
5 Yeh et al., 1994 104 15.2 2.2 
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6 Melchert, et al., 1987 5 13.21 2.01 
7 Melchert, et al., 1987 5 12.64 1.93 
8 Melchert, et al., 1987 5 10.79 0.9 
9 Melchert, et al., 1987 5 13.04 2.99 
10 Simon, et al., 1996 156 12.16 1.09 
11 Vicario, et al., 1998 10 12.91 0.52 
12 Agren, et al., 1995 8 10.4 1.1 
13 Agren, et al., 1995 11 11.5 0.7 
14 Lopes, et al., 1991 12 9.47 0.45 
15 Wang, et al., 2003 3309 11.6 1 
16 Wang, et al., 2003 282 10.2 0.8 
17 Yamagishi, et al., 2008 3575 10.02 0.81 
18 Nikkari, et al., 1995 41 12.08 0.83 
19 Nikkari, et al., 1995 41 11.99 0.7 
20 Abel, 2005 27 12.24 1.1 
21 Abel, 2005 43 12.46 1.02 
22 Wang, et al., 2003 2657 9.95 0.8 
23 Vessby, et al., 1994 1753 11.65 0.98 
24 Ma, et al., 1995 1712 10.2 0.8 
25 Ma, et al., 1995 1858 9.9 0.8 
26 Caren and Corbo, 1966 20 12.4 
1.34164
0786 
27 Salomaa, et al., 1990 325 11.85 0.92 
28 Miettinen, et al., 1982 64 13.24 1.04 
29 Öhrvall, et al., 1996 1836 11.65 0.97 
     
  
n= 
20294 
Average = 
11.62551724  
     
   
Weighted 
average = 
10.91811028  
 
Table 8.16 Palmitic acid in cholesterol esters (mg/L) data 
 Study n 
Palmitic acid in 
cholesterol 
esters (mg/L) SD 
1 Durieu, et al., 2007 29 78.62 16.57 
2 Schwertner and mosser, 1993 12 603 84 
3 Forsythe, et al., 2008 20 112.3 11.3 
4 Forsythe, et al., 2008 20 107.9 10.3 
5 Yeh, et al., 1994 104 112 26 
     
  
n= 
185 
Average = 
202.764  
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Weighted 
average = 
138.2052973  
 
Table 8.17 Palmitic acid in cholesterol esters (mmol/L) data 
 Study n 
Palmitic acid in 
cholesterol 
esters (mmol/L) SD 
1 Sansone, et al., 2016 50 0.0018 
0.00031112
69837 
2 Sansone, et al., 2016 50 0.001453 
0.00026162
9509 
3 Lopes, et al., 1991 12 0.114 
0.04156921
938 
4 Tholstrop, et al., 2004 17 10.53 0.2 
5 Tholstrop, et al., 2004 17 11.46 0.21 
     
  
n= 
146 
Average = 
4.4214506  
     
   
Weighted 
average = 
2.570963356  
 
Table 8.18 Oleic acid in cholesterol esters (mol%) data 
 Study n 
Oleic acid in 
cholesterol 
esters (mol%) SD 
1 Bradbury, et al., 2011 2393 19.36 4.54 
2 Raatz, et al., 2001 9 17.3 0.58 
3 Raatz, et al., 2001 9 14.54 0.65 
4 Skeaff, et al., 2006 19 19.24 2.32 
5 Yeh et al., 1994 104 18 2.6 
6 Melchert, et al., 1987 5 17.98 4.3 
7 Melchert, et al., 1987 5 20.6 1.62 
8 Melchert, et al., 1987 5 17.66 3.49 
9 Melchert, et al., 1987 5 20.53 3.86 
10 Simon, et al., 1996 156 20.15 2.98 
11 Vicario, et al., 1998 10 18.97 0.8 
12 Agren, et al., 1995 8 15.9 2.2 
13 Agren, et al., 1995 11 18.3 2 
14 Lopes, et al., 1991 12 20.19 0.58 
15 Wang, et al., 2003 3309 16 2.1 
16 Wang, et al., 2003 282 16.2 2 
17 Yamagishi, et al., 2008 3575 15.95 2.07 
18 Nikkari, et al., 1995 41 22 2.19 
 
 
440 
 
19 Nikkari, et al., 1995 41 21.09 1.9 
20 Abel, 2005 27 17.66 2.62 
21 Abel, 2005 43 18.82 2.06 
22 Wang, et al., 2003 2657 16 2.1 
23 Vessby, et al., 1994 1753 20.04 3.13 
24 Ma, et al., 1995 1712 16.3 2.1 
25 Ma, et al., 1995 1858 15.7 2 
26 Caren and Corbo, 1966 20 20.3 
2.2360679
77 
27 Salomaa, et al., 1990 325 21.98 2.57 
28 Miettinen, et al., 1982 64 25.31 3.92 
29 Öhrvall, et al., 1996 1836 19.38 2.77 
     
  
n= 
20294 
Average = 
18.67068966  
     
   
Weighted 
average = 
17.25613925  
 
Table 8.19 Oleic acid in cholesterol esters (mg/L) data 
 Study n 
Oleic acid in 
cholesterol 
esters (mg/L) SD 
1 Durieu, et al., 2007 29 147.52 30.43 
2 Schwertner and mosser, 1993 12 961 209 
3 Forsythe, et al., 2008 20 177.7 28.9 
4 Forsythe, et al., 2008 20 175.2 17.7 
5 Yeh, et al., 1994 104 148 39 
     
  
n= 
185 
Average = 
321.884  
     
   
Weighted average 
= 206.8112432  
 
Table 8.20 Oleic acid in cholesterol esters (mmol/L) data 
 Study n 
Oleic acid in 
cholesterol 
esters (mmol/L) SD 
1 Sansone, et al., 2016 50 0.003207 
0.00076
3675323
7 
2 Sansone, et al., 2016 50 0.002111 
0.00050
2045814
6 
3 Lopes, et al., 1991 12 0.236 0.05888
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972746 
4 Tholstrop, et al., 2004 17 28.15 0.62 
5 Tholstrop, et al., 2004 17 21.07 0.48 
     
  
n= 
146 
Average = 
9.8922636  
     
   
Weighted 
average = 
5.752314384  
 
Table 8.21 Palmitic acid in triglycerides (mol%) data 
 Study n 
Palmitic acid in 
triglycerides 
(mol%) SD 
1 Bradbury, et al., 2011 2402 29.22 5.77 
2 Raatz, et al., 2001 8 25.08 1.43 
3 Raatz, et al., 2001 8 24.25 1.19 
4 Skeaff, et al., 2006 19 30.59 3 
5 Yeh et al., 1994 104 32.9 3.6 
6 Melchert, et al., 1987 5 22.95 3.34 
7 Melchert, et al., 1987 5 27.55 2.91 
8 Melchert, et al., 1987 5 26.38 3.7 
9 Melchert, et al., 1987 5 29.46 2.17 
10 Vicario, et al., 1998 10 26.43 0.54 
11 Agren, et al., 1995 8 19.4 2.4 
12 Agren, et al., 1995 11 25 4.5 
13 Lopes, et al., 1991 9 14.88 0.82 
14 Nikkari, et al., 1995 41 28.87 3.39 
15 Nikkari, et al., 1995 41 27.02 2.14 
16 Caren and Corbo, 1966 20 26.6 
4.02492
2359 
17 Miettinen, et al., 1982 64 29.49 3.44 
18 Simpson, et al., 1982 32 24 5.8 
     
  
n=  
2797 
Average =  
26.115  
     
   
Weighted 
average = 
29.11078298  
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Table 8.22 Palmitic acid in triglycerides (mg/L) data 
 Study n 
Palmitic acid in 
triglycerides 
(mg/L) SD 
1 Forsythe, et al., 2008 20 270.7 41.4 
2 Forsythe, et al., 2008 20 248.6 23.1 
3 Yeh, et al., 1994 104 179 135 
     
  
n= 
144 
Average = 
232.7666667  
     
   
Weighted 
average = 
201.4027778  
 
Table 8.23 Palmitic acid in triglycerides (mmol/L) data 
 Study n 
Palmitic acid in 
triglycerides 
(mmol/L) SD 
1 Lopes, et al., 1991 9 0.08 0.042 
2 Tholstrop, et al., 2004 17 22.2 0.74 
3 Tholstrop, et al., 2004 17 25.61 0.61 
     
  
n= 
43 
Average = 
15.96333333  
     
   
Weighted 
average = 
18.91837209  
 
Table 8.24 Oleic acid in triglycerides (mol%) data 
 Study n 
Oleic acid in 
triglycerides 
(mol%) SD 
1 Bradbury, et al., 2011 2402 34.36 5.9 
2 Raatz, et al., 2001 8 35.73 0.82 
3 Raatz, et al., 2001 8 35.21 0.81 
4 Skeaff, et al., 2006 19 34.71 3.92 
5 Yeh et al., 1994 104 33.8 3.7 
6 Melchert, et al., 1987 5 35.74 7.92 
7 Melchert, et al., 1987 5 40.77 2.99 
8 Melchert, et al., 1987 5 36.47 6.23 
9 Melchert, et al., 1987 5 41.76 4.18 
10 Vicario, et al., 1998 10 39.68 0.69 
11 Agren, et al., 1995 8 36.4 6 
12 Agren, et al., 1995 11 37.2 2.7 
 
 
443 
 
13 Lopes, et al., 1991 10 36.64 2.27 
14 Nikkari, et al., 1995 41 40.03 3.3 
15 Nikkari, et al., 1995 41 40.92 2.6 
16 Caren and Corbo, 1966 20 42.8 
3.13049
5168 
17 Miettinen, et al., 1982 64 41.96 3.28 
18 Simpson, et al., 1982 32 40.2 9 
     
  
n= 
2798 
Average = 
38.02111111  
     
   
Weighted 
average = 
34.90315225  
 
Table 8.25 Oleic acid in triglycerides (mg/L) data 
 Study n 
Oleic acid in 
triglycerides 
(mg/L) SD 
1 Forsythe, et al., 2008 20 363.1 31.8 
2 Forsythe, et al., 2008 20 389.1 27.5 
3 Yeh, et al., 1994 104 200 135 
     
  
n = 
144 
Average =  
317.4  
     
   
Weighted 
average = 
248.9166667  
 
Table 8.26 Oleic acid in triglycerides (mmol/L) data 
 Study n 
Oleic acid in 
triglycerides 
(mmol/L) SD 
1 Lopes, et al., 1991 10 0.191 
0.07589
466384 
2 Tholstrop, et al., 2004 17 47.75 1.23 
3 Tholstrop, et al., 2004 17 37.88 0.82 
     
  
n= 
44 
Average =  
28.607  
     
   
Weighted 
average = 
33.12772727  
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Table 8.27 Free palmitic acid (mol%) data 
 Study n 
Free palmitic 
acid (mol%) SD 
1 Raatz, et al., 2001 8 25.67 1.11 
2 Raatz, et al., 2001 8 24.61 0.53 
3 Melchert, et al., 1987 5 18.75 4.37 
4 Melchert, et al., 1987 5 27.25 4.16 
5 Melchert, et al., 1987 5 24.46 5.46 
6 Melchert, et al., 1987 5 26.41 2 
7 Yli-Jama, et al., 2002 104 26.98 2.28 
8 Agren, et al., 1995 8 22.9 2.3 
9 Agren, et al., 1995 11 29 1.9 
10 Lopes, et al., 1991 12 16.93 0.29 
11 Laaksonen, et al., 2002 806 26.7 2.4 
12 Caren and Corbo, 1966 20 25.6 
4.02492
2359 
13 Jacobsen, et al., 1983 22 22.7 2.77 
14 Jacobsen, et al., 1983 20 25.4 3.01 
     
  
n= 
1039 
Average = 
24.52571429  
     
   
Weighted 
average = 
26.40757459  
 
Table 8.28 Free palmitic acid (mg/L) data 
 Study n 
Free palmitic 
acid (mg/L) SD 
1 Yerlikaya, et al., 2011 45 10.9 5.7 
2 Itakura, et al., 2010 8076 748 313 
3 Schwertner and mosser, 1993 5 200.2 36.6 
4 Cunnane, et al., 2012 10 470 250 
5 Teubert, et al., 2013 45 264.29 183.52 
6 Teubert, et al., 2013 45 398.62 241.02 
7 Han, et al., 2011 30 256 46 
     
  
n= 
8256 
Average =  
335.43  
     
   
Weighted 
average = 
736.9852774   
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Table 8.29 Free palmitic acid (mmol/L) data 
 Study n 
Free palmitic 
acid (mmol/L) SD 
1 Hadj Ahmed, et al., 2017 13 0.107 0.017 
2 Yli-Jama, et al., 2002 104 0.102524 
0.06475
2 
3 Lopes, et al., 1991 12 0.074 
0.01039
230485 
4 Lankinen, et al., 2015 25 0.198 0.087 
5 De Almeida, et al., 2002 6 0.0972 
0.04188
62746 
6 Carlsten, et al., 2009 9 0.1657 0.0795 
     
  
n= 
169 
Average = 
0.1240706667  
     
   
Weighted 
average = 
0.1181419882  
 
Table 8.30 Free oleic acid (mol%) data 
 Study n 
Free oleic acid 
(mol%) SD 
1 Raatz, et al., 2001 8 31.33 1.68 
2 Raatz, et al., 2001 8 31.79 0.88 
3 Melchert, et al., 1987 5 33.62 9.35 
4 Melchert, et al., 1987 5 27.04 4.65 
5 Melchert, et al., 1987 5 32.56 9.24 
6 Melchert, et al., 1987 5 35.35 4.35 
7 Yli-Jama, et al., 2002 104 32.2 4.16 
8 Agren, et al., 1995 8 30 3.7 
9 Agren, et al., 1995 11 27.1 4 
10 Lopes, et al., 1991 12 36.27 0.34 
11 Caren and Corbo, 1966 20 37.5 
3.57770
8764 
12 Jacobsen, et al., 1983 22 38.9 3.97 
13 Jacobsen, et al., 1983 20 41.1 3.45 
     
  
n= 
233 
Average = 
33.44307692  
     
   
Weighted 
average = 
33.89592275  
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Table 8.31 Free oleic acid (mg/L) data 
 Study n 
Free oleic acid 
(mg/L) SD 
1 Yerlikaya, et al., 2011 45 4.69 2.6 
2 Itakura, et al., 2010 8076 691 370 
3 Schwertner and Mosser, 1993 5 267.7 92.5 
4 Cunnane, et al., 2012 10 450 350 
5 Teubert, et al., 2013 45 144.81 93.97 
6 Teubert, et al., 2013 45 262.76 153.53 
7 Han, et al., 2011 30 479 90 
     
  
n= 
8256 
Average = 
328.5657143  
     
   
Weighted 
average = 
680.6293847  
 
Table 8.32 Free oleic acid (mmol/L) data 
 Study n 
Free oleic acid 
(mmol/L) SD 
1 Hadj Ahmed, et al., 2017 13 0.09 0.019 
2 Yli-Jama, et al., 2002 104 0.12236 0.09016 
3 Lopes, et al., 1991 12 0.153 
0.01732
050808 
4 Lankinen, et al., 2015 25 0.222 0.097 
5 Carlsten, et al., 2009 9 0.372 0.1179 
     
  
n= 
163 
Average = 
0.191872  
   
Weighted 
average = 
0.1511008589   
 
 
Table 8.33 Palmitic acid in total plasma lipids (mol%) data 
 Study n 
Palmitic acid in 
total plasma 
lipids (mol%) SD 
1 Mayneris-Perxachs, et al., 2014 62 21.4 2 
2 Mayneris-Perxachs, et al., 2014 49 20.4 1.5 
3 Sun, et al., 2007 306 19.31 2.41 
4 Marangoni, et al., 2004 6 21.03 0.96 
5 Fernandez-Real, et al., 2005 76 20.1 2.2 
6 Fernandez-Real, et al., 2005 40 19.4 4.1 
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7 Yeh et al., 1994 104 24.8 2.6 
8 Baylin, et al., 2005 63 22.78 2.24 
9 Melchert, et al., 1987 38 20.02 1.9 
10 Melchert, et al., 1987 37 21.48 2.26 
11 Melchert, et al., 1987 62 20.08 2.07 
12 Melchert, et al., 1987 70 20.96 2.91 
13 Kuksis, 1978 64 20.13 2.2 
14 Kuksis, 1978 70 19.63 1.88 
15 Kuksis, 1978 45 18.94 3.27 
16 Kuksis, 1978 57 18.9 2.95 
17 Solakivi, et al., 2010 32 23.6 2.4 
18 Lee, et al., 2000 60 19 2.4 
19 Lee, et al., 2000 133 17.8 3.9 
20 Wheeler, et al., 2011 142 25.9 
2.02578
3799 
21 Wheeler, et al., 2011 91 24.8 
1.71709
0563 
22 Wheeler, et al., 2011 32 25.4 
2.03646
753 
23 Wheeler, et al., 2011 18 26.7 
1.73948
2682 
24 Faas, et al., 1988 5 21.3 0.6 
25 Faas, et al., 1988 5 24.6 1.3 
26 Caren and Corbo, 1966 20 23.8 
3.57770
8764 
     
  
n= 
1687 
Average = 
21.62538462  
     
   
Weighted 
average = 
21.18267931  
 
Table 8.34 Palmitic acid in total plasma lipids (mass%) data 
 Study n 
Palmitic acid in 
total plasma 
lipids (mass%) SD 
1 Rise, et al., 2007 10 22.66 1.72 
2 Vognild, et al., 1998 35 23.8 
1.77482
3935 
3 Vognild, et al., 1998 25 23.4 1.5 
4 Vognild, et al., 1998 29 24.3 
2.15406
5923 
5 Vognild, et al., 1998 38 23.7 
2.46576
5601 
6 Vognild, et al., 1998 31 24 
1.11355
2873 
7 Vognild, et al., 1998 36 23.4 1.2 
8 Vognild, et al., 1998 33 23.7 1.72336
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8794 
9 Parkinson, et al., 1994 20 18.45 2.3 
10 Parkinson, et al., 1994 20 16.61 2.34 
11 Parkinson, et al., 1994 20 18.46 3.06 
12 Parkinson, et al., 1994 20 16.38 3.12 
13 Parkinson, et al., 1994 13 21.34 2.01 
14 Parkinson, et al., 1994 13 20.8 1.91 
15 Begin, et al., 1989 49 23.98 2.25 
     
  
n= 
 392 
Average = 
21.66533333  
     
   
Weighted 
average = 
22.29397959  
 
Table 8.35 Palmitic acid in total plasma lipids (mmol/L) data 
 Study n 
Palmitic acid in 
total plasma 
lipids (mmol/L) SD 
1 Abdelmagid, et al., 2015 327 1.6486 0.4879 
2 Abdelmagid, et al., 2015 499 1.62 0.4405 
3 Kuksis, 1978 64 2.837 0.954 
4 Kuksis, 1978 70 2.853 0.825 
5 Kuksis, 1978 45 2.875 0.996 
6 Kuksis, 1978 57 2.064 1.171 
7 Kuriki, et al., 2003 15 2.36 0.43 
8 Kuriki, et al., 2003 79 2.5 0.63 
9 De Almeida, et al., 2002 6 2.8907 
0.71133
18213 
     
  
n= 
1162 
Average = 
2.405366667  
     
   
Weighted 
average = 
1.915677625   
 
Table 8.36 Oleic acid in total plasma lipids (mol%) data 
 Study n 
Oleic acid in 
total plasma 
lipids (mol%) SD 
1 Mayneris-Perxachs, et al., 2014 62 26.7 4.1 
2 Mayneris-Perxachs, et al., 2014 49 23.8 3.6 
3 Sun, et al., 2007 306 18.6 2.43 
4 Marangoni, et al., 2004 6 29.24 3.31 
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5 Fernandez-Real 76 20.8 3.7 
6 Fernandez-Real 40 22.9 9 
7 Yeh et al., 1994 104 19.2 2.6 
8 Baylin, et al., 2005 63 20.74 2.72 
9 Melchert, et al., 1987 38 19.73 3.89 
10 Melchert, et al., 1987 37 22.86 3.25 
11 Melchert, et al., 1987 62 18.87 2.73 
12 Melchert, et al., 1987 70 22.08 3.03 
13 Kuksis, 1978 64 20.69 3.37 
14 Kuksis, 1978 70 20.98 3.58 
15 Kuksis, 1978 45 20.95 3.53 
16 Kuksis, 1978 57 22.36 8.72 
17 Solakivi, et al., 2010 32 26.6 2.5 
18 Lee, et al., 2000 60 22.3 3.7 
19 Lee, et al., 2000 133 18.8 4.5 
20 Wheeler, et al., 2011 142 22.2 4.766550115 
21 Wheeler, et al., 2011 91 22.1 2.575635844 
22 Wheeler, et al., 2011 32 23.8 2.093036072 
23 Wheeler, et al., 2011 18 22.2 1.697056275 
24 Faas, et al., 1988 5 25.4 4.2 
25 Faas, et al., 1988 5 27.6 3.2 
26 Caren and Corbo, 1966 20 23.7 2.236067977 
     
  
n= 
1687 
Average = 
22.50769231  
     
   
Weighted 
average = 
21.08078838   
 
Table 8.37 Oleic acid in total plasma lipids (mass%) data 
 Study n 
Oleic acid in 
total plasma 
lipids (mass%) SD 
1 Rise, et al., 2007 10 19.38 2.61 
2 Vognild, et al., 1998 35 17.9 
2.958039
892 
3 Vognild, et al., 1998 25 18.2 1.5 
4 Vognild, et al., 1998 29 18.8 
4.308131
846 
5 Vognild, et al., 1998 38 17.8 
3.698648
402 
6 Vognild, et al., 1998 31 19.6 
2.227105
745 
7 Vognild, et al., 1998 36 18.4 2.4 
8 Vognild, et al., 1998 33 17.3 
3.446737
588 
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9 Parkinson, et al., 1994 20 19.8 3.26 
10 Parkinson, et al., 1994 20 18.22 1.57 
11 Parkinson, et al., 1994 20 20.08 3.03 
12 Parkinson, et al., 1994 20 17.88 2.66 
13 Parkinson, et al., 1994 13 21.98 3.44 
14 Parkinson, et al., 1994 13 21.25 2.33 
15 Begin, et al., 1989 49 22.26 3.01 
     
  
n= 
392 
Average = 
19.25666667  
     
   
Weighted 
average = 
19.1584949   
 
Table 8.38 Oleic acid in total plasma lipids (mmol/L) data 
 Study n 
Oleic acid in 
total plasma 
lipids (mmol/L) SD 
1 Abdelmagid, et al., 2015 327 1.3327 0.4545 
2 Abdelmagid, et al., 2015 499 1.275 0.3908 
3 Kuksis, 1978 64 2.791 1.165 
4 Kuksis, 1978 70 3.424 5.047 
5 Kuksis, 1978 45 2.825 1.29 
6 Kuksis, 1978 57 2.853 1.209 
7 Kuriki, et al., 2003 15 2.17 0.6 
8 Kuriki, et al., 2003 79 2.1 0.53 
     
  
n=  
1156 
Average = 
2.3463375  
     
   
Weighted 
average = 
1.711520675   
 
